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In June 2018 Minister for Mental Health Martin Foley appointed me to chair a panel to review and 
provide a report on the trial of Victoria’s medically supervised injecting room (MSIR). Over the 
almost two years of this review there have been five panel members.  
The establishment of the MSIR has been challenging for many: North Richmond Community Health 
(NRCH) (the licensee), local residents and businesses in the area, government officials responsible 
for implementing and overseeing the trial and other health and emergency services, and housing, 
legal and social support services in the area including the Yarra City Council. It has required police 
to adapt and attend to law enforcement in the context of a novel service.  
This report describes the background of the government’s decision to respond to an increasing 
number of heroin overdose deaths in Victoria by trialling a medically supervised injecting facility. 
We are aware from media and Hansard records that, prior to the trial, supporters were hopeful that 
the facility would save lives and reduce harms associated with overdose. We also understand there 
were concerns raised, largely focusing on the location of the facility adjacent to a primary school, 
perceived risks of allowing injection of methamphetamine in the facility and the impact of the 
facility on existing NRCH service users.  
I congratulate NRCH and others associated with establishing the MSIR on getting the facility 
operational in a relatively short time. Many people have taken the opportunity to tour the facility, 
including health and support service professionals and local residents, businesspeople and 
interested bystanders, and almost all have commented positively on the professionalism, care, 
knowledge and skill of the staff and the quality of their delivery of a safe and supportive service.  
People who inject drugs are typically suspicious of government service systems, so it surprised even 
staff that so many began attending on the first day the MSIR opened. This is likely a tribute to the 
relationship that the NRCH had built with the target population over many years, especially through 
its harm reduction services.  
The operations and impact of the MSIR is the principal focus of this review, but it is only one part of 
the response to drug use in North Richmond. My experience in the alcohol and drug sector over 
many years has shown me the complexity of such an endeavour and the requirement to attend to 
the needs and sensitivities of the local community.  
During this review, panel members regularly walked around North Richmond, consulted with local 
groups and attended and observed community gatherings of people interested in the MSIR. 
Reactions to its establishment have been mixed. There were high expectations that the opening of 
the MSIR would resolve previously identified problems linked to the sale and use of drugs in the 
area. Attitudes and understandings have fluctuated among local people over the time of our 
review, influenced by people’s direct observation and experience of living and working in the 
vicinity and possibly also by media reporting of activity associated with the MSIR. It is likely that this 
coverage has also acted as an advertisement for people seeking heroin.  
Local people, businesses and other services have provided valuable insights. They have presented 
their stories, data, experience, thoughts and suggestions. These local people care about and want 
the best for their locality and their community.  
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Almost all the community groups that have engaged with the Panel have supported the intent to 
provide a safer place for people who inject drugs, even though many have expressed concerns 
about troubling incidents or about people congregating in the area. Some residents have proudly 
invited Panel members to visit the cleaned-up areas of their housing estate. Some residents have 
said it is worse. Sorting the different perspectives has been a challenge for the Panel. 
Further plans and actions of government and the local council including the precinct and social 
housing initiative to address amenity began in a visible way sometime after the opening of the 
original facility. The Department of Health and Human Services reports improvements to security, 
lighting, drug outreach services, cleaning, sweeps and collection of used needles, along with a 
more visible police presence. However, by the end of 2019 these initiatives were not especially 
evident. It will require more time to sort out whether the negative impacts of an active drug market 
in this local area can be ameliorated. 
As detailed in the terms of reference for this review (Appendix A), the Panel was required to 
develop the review scope, structure and data and evidence collection requirements with the 
Department of Health and Human Services and to: 
▪ review data and evidence to closely monitor the objects of the Drugs, Poisons and Controlled 
Substances Act 1981, Part IIA  
▪ provide the Secretary to the department with a draft copy of the review to inform a decision 
on whether the trial should be extended 
▪ provide an endorsed review to the Minister for Mental Health before the end of the two-year 
trial. 
This is the report of our findings on the first 18 months of the MSIR project implementation. We have 
been supported in this by a team of skilled evaluators from the Centre for Evaluation, Research and 
Evidence in the department. I thank all who have supported the Panel’s efforts to better 
understand the experience of those in the area and beyond. I especially recognise and thank the 
staff of the MSIR for the care they provide to service users. Many service users talked with us about 
their positive experiences. A small number of other people who inject drugs have explained their 
reasons for not using the MSIR. These stories have been confronting at times for Panel members and 
yet important in contributing to the views of the Panel expressed in this report. 
It has been a privilege to work with my fellow Panel members: Associate Professor Alex Cockram, 
who contributed especially to the approach to our review (until her resignation early in 2019 to 
allow her to take up a role as Commissioner in the Royal Commission into Victoria’s Mental Health 
System); Mr John Ryan, with experience of drug-related harm to communities and harm reduction 
services that included a perspective on overseas injecting facilities; Mr Ken Lay AO, APM, the 
former Chief Commissioner of Police, who was an active member of the Panel from May 2019 until 
late January 2020, contributing his experience and insights into crime, law enforcement and 
emergency services relevant to the operation of the MSIR (Ken resigned to take up the Chair of 
Bushfire Recovery Victoria in January this year); and Associate Professor Ruth Vine, an experienced 
senior psychiatrist and health service leader, who joined as a member in January 2020 to provide a 
medical and mental health perspective. All members participated in site visits, consultations with 
staff, service providers, community groups and facility users. I have appreciated their engagement, 
wise counsel and sharing of ideas through debate and discussion. 
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In October 2017 a trial of a medically supervised injecting room (MSIR) was announced for 
Melbourne. This followed growing concern about the number of heroin-related deaths, two 
parliamentary inquiries and coronial findings that an injecting room would reduce the risk of death 
from heroin overdose. The location selected was 23 Lennox Street, Richmond, the site of North 
Richmond Community Health (NRCH), which was licensed to operate the MSIR for two years 
starting 30 June 2018. 
The review was conducted by an independent panel of experts comprising Professor Margaret 
Hamilton (chair), Mr John Ryan and Associate Professor Ruth Vine (since January 2020). Associate 
Professor Alex Cockram and Mr Ken Lay were on the Panel for the earlier part of the review. The 
review has considered relevant research, surveys of the local community and service users, direct 
observation and communication with a range of stakeholders.  
The focus of this review is the first 18 months of the MSIR’s operation (June 2018 to December 2019), 
which includes one year in a transitional facility and six months in a larger facility.  
Key findings and recommendations 
After the first 18 months of the trial, the Panel found that NRCH successfully implemented a 
medically supervised injecting room noting that implementation remains a work in progress. 
The objectives of the Drugs, Poisons and Controlled Substances Act 1981 Part IIA were ambitious 
because, unlike other trials, the legislation underpinning this trial requires improvement in amenity as 
well as saving lives and reducing harms for people who inject drugs. The trial succeeded in most of 
the objectives:  
▪ The MSIR had more than 119,000 visits in the first 18 months, making it one of the busiest in the 
world.  
▪ There have been no overdose deaths in the MSIR, despite 271 extremely serious overdoses.  
▪ While it is not possible to say with certainty how many people would have died without the 
MSIR, international approaches to modelling suggest at least 21–27 deaths have been 
avoided. 
▪ There has been a reduction in ambulance attendances due to overdoses. 
▪ There has been a reduction in reports of public injecting. 
▪ Many MSIR service users have accessed other health and support services. 
▪ The MSIR has provided screening, assessment and treatment initiation for blood-borne 
infections. 
Some of the objectives had not been achieved by the end of 2019:  
▪ Amenity had not improved. 
▪ Local people reported no change in their experience of seeing discarded injecting 
equipment.  
Given that North Richmond has long been a major site of heroin use and related harms in Victoria, 
and that the trial has successfully reduced harms for service users, the Panel call on the 
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government to continue the trial of the Medically Supervised Injecting Room at North Richmond 
Community Health for a further three years.  
Given also that there are other parts of the state with high concentrations of injecting drug use and 
related harms, the Panel recommends that the government expands the current trial to include 
another supervised injecting service. One site cannot effectively address all the needs for such a 
service in a city the size of Melbourne. Based on analyses of available data, the Panel recommends 
that the government considers an appropriate location within the City of Melbourne.  
Ongoing government implementation needs to focus on community safety and amenity in 
partnership with local government and the community.  
The full list of findings and recommendations is provided at the end of this executive summary.  
Recent historic context for the trial 
North Richmond has been the main site for heroin use and related harms in Victoria for the past 
decade. A cohort study (Burnet Institute 2019) following more than 1,000 people who inject drugs 
identified a noticeable increase in people coming to North Richmond several months before the 
trial began, reflecting the reputation of North Richmond as a place to access heroin. 
The trial occurred in the context of increasing heroin use and increased visibility of people who 
inject drugs in North Richmond and a high number of overdose deaths. 
Operation and use of the licenced MSIR  
Establishing any medically supervised injecting facility is a complex, highly visible and challenging 
endeavour, particularly where there is a requirement for accelerated implementation. The 
Department of Health and Human Services has had significant input including initial licensing 
and the usual responsibility for central policy and performance oversight. Government has also had 
considerable input in approving information about the MSIR for media and community information 
purposes. In establishing the MSIR, the department has benefited from contributions from a large 
number of stakeholders including Victoria Police, Ambulance Victoria, the Metropolitan Fire 
Brigade, the Yarra City Council, the Department of Education and Training, Richmond West Primary 
School, many local service providers, local residents and people who inject drugs.  
Once announced, the trial had a rapid establishment period, reflecting escalating public health 
and safety concerns about public injecting in North Richmond.  
The project greatly benefited from the almost 20 years of experience of Sydney’s medically 
supervised injecting centre (MSIC), including documentation and protocols, especially regarding 
treatment guidelines, data collection and reporting. There are some important distinctions: the 
Sydney MSIC operates from a shopfront location with links to local service providers rather than 
being co-located within a broader community health service. The Melbourne MSIR, unlike Sydney, 
has the explicit aim of improving amenity and reducing attendance by ambulance services, 
paramedic services and emergency services and attendances at hospitals. 
Implementation of the trial was phased, with an initial focus on the supervision of injecting drug use 
in a transitional facility, then a move to a larger facility on the same site with longer operating hours 
and additional client capacity (from 11 to 20 injecting booth positions). This provided better access 
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for people with an increase in the number of supervised injections alongside additional capacity to 




Operationally, the initial focus was:  
▪ getting the service operational to provide an accessible place for injecting and other services 
to people who inject drugs 
▪ attracting the target service users to do their injecting in the facility 
▪ ensuring a safe and appropriate response to anyone who experienced an overdose.  
These goals have all been achieved. 
The service has been well used by the intended client group.  
In the first 18 months of the trial, 3,936 people registered to use the service, associated with 119,223 
visits. Thirty people were refused entry, most commonly because they had not previously injected. 
Some people who inject their drugs in North Richmond choose not to use the MSIR. Efforts to 
describe and explain the experience, attitudes or beliefs of these people suggest that the reasons 
are diverse and include discomfort with people watching and the exclusion requirements of the 
licence. People who inject their drugs elsewhere in public remain highly vulnerable to overdose 
and other harms.  
The service is attracting a group of people who inject drugs with high health and support needs, 
many with recent experiences of overdose.  
The facility is attracting a group of people who inject drugs and have particularly high needs for first 
aid and other health services, including mental health and drug dependence treatment and social 
care such as housing and legal services. Those attending the service have higher support needs, 
even compared with other people who inject drugs in Richmond. They are more likely to be 
unemployed, homeless or recently released from prison than other people injecting drugs in 
Richmond. More than 10 per cent of the people using the service are Aboriginal. It may be that 
these characteristics mean that this group is less likely to have access to private space to inject 
such as in their own home. People who use the MSIR are injecting, on average, 14 times a week, 
compared with an average of three times a week for other people who inject drugs, suggesting 
this cohort would otherwise be more likely to experience higher rates of drug-related harms. Many 
(56 per cent) who have attended the MSIR report having previously experienced an overdose. 
The model of care could be further considered to examine options regarding matters such as 
staffing, optimum opening hours and the ways of providing additional services, recognising that 
many service users require navigation to connect to systems of care. 
A range of models in different settings with a variety of included or linked services operate in other 
countries. Various attempts have been made to scale operations to need and context in these 
other jurisdictions. 
The legislation establishing the MSIR provides for a highly clinically oriented model of injecting 
service, directed at facilitating access to and delivery of services beyond supervision of injecting. 
NRCH’s clinical model relies on nursing staff alongside harm reduction practitioners. The 
requirement for a medical director has been beneficial; however, the service has found that 
nursing and other staff can safely manage most clinical incidents without the additional role of a 
medical supervisor.  
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Advancement of the objects of the legislation 
This review considered the extent to which the trial has contributed to advancing the aims of the 
medically supervised injecting centre legislation. The results of the Panel’s consideration and 
findings are presented in a summary table at the end of this executive summary. 
(a) Advancing a reduction in the number of avoidable deaths and the harm 
caused by overdoses of drugs of dependence  
The MSIR has prevented overdoses and further harm and has saved lives.  
The MSIR trial has supervised 116,802 injections (96.6 per cent of which involved heroin) and 
responded to 2,657 overdoses, with no fatalities. Compared with other people who inject drugs, 
MSIR clients are significantly more likely to have recently injected in high-risk settings, as well as to 
have recently experienced a non-fatal overdose, a known predictor of fatal overdose. Prior to 
registering, more than half of MSIR clients had overdosed and nearly half had witnessed an 
overdose. 
Of those who do attend the service, the nature of the overdoses is significant, and without 
intervention it is likely that many would have died or been permanently injured. 
In the first 18 months of operating, there were 271 extremely serious incidents that required the 
opioid reversal agent naloxone. Many more required oxygen and measures to keep the airways 
open, potentially saving additional lives and avoiding harms associated with lack of oxygen to the 
brain. Advice provided to the Panel from an experienced medical practitioner consulted for the 
review was that ‘the [overdoses] are at least as acute an emergency as those we receive in an 
[emergency department]’. Of those who attend the service, the nature of the overdoses is 
significant, and, without intervention, it is likely that some would have died or been permanently 
injured. 
The harms associated with overdoses can be profound; some are permanent. The facility has the 
appropriate equipment and MSIR staff are well trained and clearly demonstrate the capacity to 
respond, manage and administer interventions required to avoid death or further harm. Staffing 
levels ensure timely responses.  
The MSIR has advanced its critical objective to save lives. While these results are not observable in 
coronial data, the Panel assesses that without responses to overdoses provided by the MSIR, the 
number of deaths could have increased during the trial period. 
Modelling allows an estimate of the number of lives that the MSIR may have saved and, while there 
are different ways to model this, using conservative estimates, these data suggest that between 21 
and 27 deaths were avoided over the 18 months of this review. This does not include the prevention 
of permanent disability including acquired brain injury.  
(b) Advancing delivery of more effective health services for clients of the MSIR by 
providing a gateway to health and social assistance 
NRCH and MSIR staff have made significant progress in delivering additional services and 
developing referral pathways to other service providers.  
With the move to the larger facility, the range and number of services is expanding. 
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The MSIR provided or referred MSIR service users to many additional services during the trial period 
(most commonly to health promotion, wound dressing, medication provision and first aid) as well as 
providing specialist services such as diagnosis and treatment of infectious diseases, oral health 
services and opioid substitution treatment. Primary health clinics have been offered by general 
practitioners.  
Since the move to the larger facility, the original services have been extended and additional 
services are increasingly being offered, many by organisations other than NRCH but from within the 
MSIR, enabling better potential connection between this client group and available services such 
as drug dependence treatment, additional infectious disease diagnosis and treatment, housing 
support and more mental health interventions.  
Although many are now being delivered, the potential benefits of these services have not yet been 
fully realised as the take-up is still growing and the full complement of services is still being 
implemented. 
An ongoing trial would provide the opportunity to develop and assess ongoing integration of 
services and possible different ways of achieving this. 
The legislation provides for the delivery of integrated services, expecting that this would be a more 
effective way of attending to the perceived needs of people who inject drugs.  
There have been challenges and benefits with service integration for this client group. Not all 
people who inject drugs seek or want other services and not all take up services when they are 
offered. Some are clear that they attend the MSIR only to use their drugs in a safe place and then 
leave. Some prefer to access more extensive services elsewhere.  
Given the phased implementation of the service and the ongoing efforts to facilitate referral and 
connection with services, including through the Gateway Services Reference Group of local 
service providers, it is too soon to say that the full potential for integrated services has been 
realised. As at 1 July 2019 there was not yet evidence of a difference in health service use between 
MSIR service users and other people who use drugs; however, the MSIR has facilitated access to 
services including hepatitis C and drug treatment. It is not possible to say whether they would have 
received these services otherwise.  
It is not yet possible to fully assess alternative models of providing integrated care, including 
whether there are advantages of co-locating within a community health service. The work of the 
Gateway Services Reference Group is promising and could be used as a pilot of an approach to 
timely and coordinated linking of people with multiple services.  
(c) Reducing attendance by emergency services and attendances at hospitals 
due to overdoses 
There has been a reduction in ambulance attendances involving naloxone in the vicinity of the 
facility during opening hours.  
Ambulance attendances involving naloxone have reduced by 25 per cent within 1 km of the MSIR 
since it opened. This decline was greater for attendances during MSIR opening hours, with the 
number reducing by 36 per cent. Frequent users of the MSIR trial have had fewer ambulance 
attendances involving naloxone since the MSIR opened. The MSIR has called an ambulance in only 
30 of the 2,657 overdoses responded to in the MSIR. 
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There have been no observable changes in emergency department presentations that can be 
attributed to the MSIR. 
There has been a small increase in the number of drug-related emergency department 
presentations during the trial. Interpretation of hospital emergency department data is challenging 
because of very small numbers of events that could reflect broader changes as well as specific 
interventions.  
(d) Reducing the number of discarded needles and syringes in public places and 
the incidence of injecting of drugs in the vicinity 
There has been a reduction in reports of public injecting. Local people report no difference in 
seeing discarded injecting equipment. There has been an increase in collected injecting 
equipment (noting also an increase in collection activity later in the trial). 
There was very little change in the proportion of people who reported seeing discarded needles 
and syringes (16 per cent in the year before and 17 per cent during the trial). Resident reports of the 
median number of discarded needles and syringes did not change (four per month), but local 
businesspeople reported seeing more (from six to then 10 per month) in the first year of the trial. The 
importance of these reports is linked to earlier research in North Richmond that found that the 
largest impact on the perception of amenity was from seeing discarded needles and syringes and 
other drug-related paraphernalia. There has, however, been a decrease in the proportion of 
people (residents and businesses) who report witnessing public injecting at the time of the second 
wave of the MSIR Review Survey conducted in July/August 2019. 
(e) Improving the amenity of the neighbourhood 
Amenity has not improved during the review assessment period. 
Improvement in amenity has been the most vexed issue during the trial to date and remains to be 
successfully achieved. Stakeholders were strongly divided on the extent to which there had been a 
change in amenity. Due to the illegal nature of drug trafficking and use, it is extremely difficult to 
accurately identify how many people are buying or consuming drugs in Richmond, with data 
suggesting that the numbers were increasing before the MSIR opened.  
While most MSIR service users are not from Richmond, they were coming to the area before the 
MSIR opened because the area was already an established drug marketplace. Victoria Police 
members who had worked in the area were surveyed during 2019, and they reported seeing more 
drug-related activity. The perceptions of people associated with the neighbouring school were 
mixed. However, enrolments have increased and the school reports that incidents involving 
discarded injecting equipment or overdoses have decreased, and indicators of both parent and 
staff satisfaction with the school have remained stable.  
There are conflicting results in relation to perceptions of safety. While the Yarra City Council annual 
surveys suggest that this has not significantly changed, this review found that significantly fewer 
residents and businesspeople reported feeling safe walking alone during the day and after dark. 
Reasons offered included concerns about violence and crime, public visibility of drug use and drug 
deals, safety concerns for their own children and schoolchildren, aggressiveness and 
unpredictability among people who use drugs and discarded syringes in public places.  
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It has been difficult to assess the impact on usual clients’ use of the community health centre. 
Concern has certainly been expressed by local people and some staff about the congregation of 
people, often assumed to be MSIR users, in the entrance and immediate vicinity of NRCH, with a 
possible reduction in use of some services such as maternal and child health support.  
Further evidence suggestive of local people’s perception of amenity is that, overall, the community 
survey conducted by this review of local residents and businesspeople immediately before the trial 
and again after a year of operation indicates that support for the injecting room in North Richmond 
reduced in that period (from 61 to 44 per cent among residents and from 48 to 41 per cent among 
businesses).  
The legislated objective of improved amenity had not been achieved by the end 2019. Drug 
trafficking and antisocial behaviour has significantly affected the local community. Much of the 
focus of complaint and concern has centred on the MSIR. While aspects of the community 
concern are beyond the focus of this review, addressing amenity issues in the neighbourhood 
remains a priority.  
During implementation of the MSIR, there have been increasing efforts to engage with and seek to 
address longstanding issues in the local community, requiring the cooperation of several agencies 
and organisations and agreement on complex issues. The renewed focus on ways of responding to 
the concern of local people are more apparent in recent months. Additional changes, such as 
actions identified through the Crime Prevention Through Environmental Design assessment led by 
Victoria Police and the recent implementation of the Richmond Community Capacity Building 
Initiative and planned longer term actions, could help to improve local wellbeing, safety and 
amenity for locals.  
The Panel also notes that the August 2018 Victorian Government Response to the Parliamentary 
Inquiry into Drug Law Reform provided for a broad set of measures structured around three themes: 
better, earlier treatment; saving lives and preventing harm; and safer communities. The anticipated 
responses relevant to this review are those in the saving lives and preventing harm domain, 
specifically relating to the MSIR. A review of other aspects of the government response is beyond 
the scope of the review, but it would be prudent to consider the progress of both the MSIR and 
these commitments insofar as there are interactions if the trial is extended.  
Implementation of a necessary suite of responses to local amenity is still in its early stages. 
Expectations or hopes that the MSIR would solve all problems in the area are unrealistic. Negative 
impacts of the drug market have been experienced for many years including on Victoria Street 
and in the housing estate adjacent to the MSIR. While the reduction of overdoses in the housing 
estate carpark to the east of the community health centre suggests less use of this area, there are 
still reports of visitors congregating around the housing estate and of trafficking and consumption of 
drugs. This is an important priority to address so that residents can peacefully enjoy their 
neighbourhood.  
International reviews suggest that the principal criteria for establishing such a service are the 
location and co-location of the program and whether people who use drugs will trust the program 
and therefore access the service. European experience suggests that in establishing these facilities 
there is a need to consider: proximity to illicit-drug markets; closeness to places of drug purchase 
where they can be embedded in a wider network of services; compatibility with the needs of 
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people who inject drugs; and compatibility with the needs and expectations of local residents. It is 
the last of these that remains contentious. 
Given the priority of amenity as a key object of the legislation, there should be an increased 
emphasis by all service providers and local and state governments to address community safety 
and amenity. This especially relates to improved coordination of these entities and NRCH and more 
visible community policing of offensive or inappropriate behaviour.  
Noting the relatively rapid uptake of the service, the Panel has reflected on the extent to which 
one service with one injecting room can manage this increase in numbers and the potential risks 
associated with any potential further increase in capacity within the same service, were this 
physically possible. 
While no other location provides a perfect blueprint, extensive international experience suggests 
that consideration should be given to opening more than one medically supervised injecting 
service in a city the size of Melbourne.  
(f) Reduce the spread of blood-borne diseases among MSIR trial clients 
The MSIR has provided screening, assessment and treatment initiation and monitoring of blood-
borne infections. 
The most effective means of avoiding the spread of blood-borne infections among people who 
inject drugs is to avoid sharing injecting equipment. This sits behind the extensive provision of sterile 
injecting equipment through needle and syringe programs (NSP) that were established in Australia 
in the 1980s to prevent HIV/AIDS. Most people who inject drugs in the Richmond area reported not 
sharing needles and syringes prior to the MSIR opening.  
The MSIR is directly providing services to people at high risk of blood-borne infections. In the first 18 
months, more than a third of people screened tested positive and a quarter had begun treatment 
for hepatitis C. The provision of an NSP, and testing, assessment, counselling and treatment of these 
infections in conjunction with an injecting room, is clearly warranted. While screening, assessment 
and referral is an (almost) universal provision where such facilities exist, the MSIR is valuably able to 
offer treatment on site. These services have been available since the early operation of the MSIR 
and have been extended with the opening of the larger facility and further development of 
partnerships with other service providers such as St Vincent’s Hospital Melbourne. 
How the legislation and regulations have operated and 
whether they require amendment 
The Drugs, Poisons and Controlled Substances Act 1981, Part IIA – Trial of Medically Supervised 
Injecting Centre provides for this trial. The regulations of this Part prescribe the drugs of 
dependence and the permitted quantities of those drugs that can be used at the MSIR and the 
content required to be included in the internal management protocols of the licensed medically 
supervised injecting centre. 
Some aspects of the legislation, regulations and policy may require further consideration. The 
specificity of the legislation makes important aspects of the trial difficult to adapt during the trial, 
and the exclusion of vulnerable groups through regulation and policy decisions have been raised 
as concerns by a number of stakeholders.  
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The specificity of the legislation has made it difficult to adapt or innovate during the trial period. 
The operating exclusion criteria limit access for vulnerable people who are likely to nevertheless 
inject their drugs.  
Government may wish to monitor the impact of exclusions to the service on vulnerable cohorts if 
the trial is extended. 
Findings 
▪ North Richmond has been the main site for heroin use and related harms in Victoria for the 
past decade.  
▪ The trial occurred in the context of increasing heroin use and increased visibility of people 
who inject drugs in North Richmond and a high number of overdose deaths.  
▪ The service has been well utilised by the intended client group.  
▪ The service is attracting a group of people who inject drugs with high health and support 
needs, many with recent experiences of overdose. 
▪ The model of care could be further considered to examine options regarding matters such as 
staffing, optimum opening hours and the ways of providing additional services, recognising 
that many of the service users require navigation to connect to systems of care.  
▪ The establishment of the MSIR has prevented overdoses and further harm and has saved lives.  
▪ Of those who do attend the service, the nature of the overdoses is significant, and without 
intervention it is likely that many would have died or been permanently injured.  
▪ Modelling allows an estimate of the number of lives that the MSIR may have saved and, while 
there are different ways to model this, using conservative estimates, these data suggest that 
between 21 and 27 deaths were avoided over the 18 months of this review. This does not 
include the prevention of permanent disability including acquired brain injury.  
▪ NRCH and MSIR staff have made significant progress in delivering additional services and 
developing referral pathways to other service providers. 
▪ With the move to the larger facility, the range and number of services is expanding. 
▪ An ongoing trial would provide the opportunity to develop and assess ongoing integration of 
services and alternative ways of achieving this. 
▪ There has been a reduction in ambulance attendances in the vicinity of the facility during 
opening hours. 
▪ There have been no observable changes in emergency department presentations that can 
be attributed to the MSIR.  
▪ There has been a reduction in reports of public injecting. Local people report no difference in 
seeing discarded injecting equipment. There has been an increase in collected injecting 
equipment (noting also an increase in collection activity later in the trial). 
▪ Amenity has not improved during the review assessment period. 
▪ Implementation of a necessary suite of responses to local amenity is still in its early stages.  
▪ The MSIR has provided screening, assessment and treatment initiation and monitoring of 
blood-borne infections.  
▪ The specificity of the legislation makes any adaption or innovation of the trial elements 
difficult.  
▪ The operating exclusion criteria limit access for vulnerable people who are likely to 
nevertheless inject their drugs  
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Conclusion  
The implementation of this service and associated responses remains a work in progress.  
It has clearly been possible to establish a medically supervised injecting service that has attracted 
people who are at high risk of overdoses associated with injecting drugs. NRCH has managed a 
complex challenge that has included a significant increase in its budget, staffing levels and 
external attention. The MSIR has been responsive and able to oversee many people injecting drugs 
within the facility. There have been no overdose deaths in the MSIR, and a number of people have 
been assisted to access health and support services.  
The trial has shown that the concept of a medically supervised injecting service in Victoria can be 
implemented successfully.  
The expectations detailed as objects in the Act are ambitious and completed assessment of their 
achievement is premature. Considerable detail has been provided in this report. Most of the 
objects of the Act have been advanced during the first 18 months of the trial.  
This review has used many sources of data. Findings relating to illicit drug availability, use and 
associated harm must always consider diverse and often incomplete data in order to draw any 
conclusions that, at the end of the day, must sometimes rely on inference through the weight of a 
mix of evidence. There are benefits to using the unique mix of data Victoria has available, and the 
continued collection of these is warranted. This includes data that provides some insight and 
opportunity to monitor the drug market for heroin and other injectable drugs, the movement of 
people who use these drugs as well as their service seeking, and changes to patterns of use and 
harm as well as uptake of additional services. 
The location of the MSIR in a health service should provide benefits of ensuring access to broader 
health and other support services. Many NRCH staff were already trusted by people who have 
been injecting drugs in Richmond, evidenced by the very rapid take-up of the MSIR upon opening. 
However, ongoing efforts to assess changing dynamics in the area including possible shifts in the 
location of trafficking and consumption will be important as well as monitoring the success of the 
various ways that the MSIR approaches provision of integrated responses, particularly if additional 
services are opened. 
With only six months of operation in the purpose-built, larger facility, there has not been sufficient 
data or experience to allow a considered comparison of the two different locations of the MSIR, 
albeit they have been on the same designated land and physically close. It is too early in 
implementation to determine if the MSIR should be terminated or made permanent. More time and 
the possibility of further supervised injecting services in an additional three-year trial period could 
provide greater experience and an opportunity to explore other means of responding to demand. 
It would also allow for the measures directed at amenity and precinct renewal that are only now 
emerging to be actioned in the vicinity of the MSIR.  





Based on these findings, the Panel recommends that:  
1. The medically supervised injecting room (MSIR) trial at North Richmond Community Health 
(NRCH) continues in order to allow it to operate for the possible full duration of the licence (three 
further years).  
2. The MSIR operates with no more than 20 injecting booth positions to ensure ongoing effective 
management in this high-acuity health setting for the duration of the trial.  
3. Based on demand and international experience, the Victorian Government expands the current 
trial to include another supervised injecting service in an appropriate location within the City of 
Melbourne.1 Trialling further services in this period could help manage demand, potentially save a 
greater number of lives and would allow an opportunity to test effectiveness in different locations 
as well as trial another model of supervised injecting facility in Victoria. 
4. The Department of Health and Human Services continues to lead the MSIR trial as a health 
response with coordination support from the Department of Justice and Community Safety to 
ensure that both health and community needs are considered as the trial evolves to improve real 
and perceived levels of community safety.  
5. The Victorian Government works with local government and the community to continue to 
develop local safety and amenity, including formalising the role of the existing roundtable to be 
responsible for community engagement, community safety and coordination of relevant services. 
This should include representatives from at least the Department of Health and Human Services, 
Victoria Police, Yarra City Council, local service providers (including the MSIR) and the local 
community.  
6. The licensee of any supervised injecting service be proactive in engaging and communicating 
with the local community and key stakeholders on issues that may potentially affect the 
community.  
7. There be more emphasis on place management, including in the vicinity of the MSIR, with a clear 
understanding among staff, service users and community members that disturbing and antisocial 
behaviour will not be tolerated. Visible community policing is required in areas of active drug 
trafficking to increase the experience and perception of community safety.  
8. The model of care be further considered, including:  
▪ the requirement for medical supervision since clinical (nursing) oversight could achieve the 
same level of safety more efficiently    
▪ the current hours of operation to best match demand for the service    
▪ enhancing the access to and availability of care coordination in areas such as mental health, 
housing and drug dependence treatment.  
 
1 This recommendation is based on the international research and experience described in this report, patterns of overdose-
related deaths in non-residential locations, ambulance attendance involving the provision of naloxone, publicly available 
crime data and the Panel’s own knowledge and insights into street-based injecting activity in Victoria (see addendum). 
Consideration of a local government area for another service was not originally part of the terms of reference for this review; 
however, in recommending another supervised injecting service, the Panel agreed to provide additional advice regarding 
location.  
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9. The Victorian Government continues to monitor the implementation of the recommendations of 
the NRHC Alcohol and Other Drug Review, recognising that further refinement in policy or practice 
may be required.  
10. Further reviews associated with establishing any MSIRs be conducted, with a report to be 
submitted at least six months before the potential expiry of any licence. This should draw on 
performance monitoring data from within the service and focus particularly on local amenity 
planning and implementation, and the experience and perception of local community members.  
11. Funding is provided to enable ongoing provision of services that meet the needs of injecting 
room users.  
12. Statewide drug-related patterns of use and harms continue to be monitored through analyses 
of data such as ambulance attendance, the provision of naloxone and deaths involving heroin 
and other injectable drugs. This could usefully include use of qualitative research methodologies in 
locations where evidence indicates high levels of activity related to injecting drugs.  
13. Harm reduction initiatives continue to be provided to those areas and people experiencing 
most harm, such as by expanding overdose response training and the direct provision of naloxone 
including through needle and syringe programs and in prisons, detoxification and rehabilitation 
settings and other relevant services.  
14. The Victorian Government monitors the impact of current exclusion criteria on access for 
vulnerable populations with a view to reviewing their suitability for an MSIR.  
Table 1 summarises the review findings against the legislative objects. 
Table 1: Summary of review findings against the legislative objects 
Object Extent to which the trial has advanced that object 
Part 55A(a): Reduce the 
number of avoidable 
deaths and the harm 
caused by overdoses of 
drugs of dependence 
To assess this object, the Panel considered: 
• Coroner’s Court of Victoria data on fatalities involving 
heroin  
• MSIR data on the volume and nature of overdose 
interventions provided  
• staff and service user consultation. 
The finding of this review is that the trial has advanced this 
object and has saved lives. 
This is based on the following evidence: 
• The MSIR attracts people who are at high risk of 
overdose. 
• The MSIR has supervised 116,802 injections. 
• There have been no fatalities. 
• Of the 2,657 overdoses, the MSIR responded to 271 
extremely serious overdoses with naloxone, which, 
based on existing modelling, avoided between 21 and 
27 deaths. 
• Of the 2,657 overdoses the MSIR responded to 2,615 
overdoses with oxygen and other measures to keep the 
airways open, potentially saving additional lives and 
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Object Extent to which the trial has advanced that object 
avoiding harms associated with lack of oxygen to the 
brain. 
• However, as at the end of September 2019, coronial 
data show no observable difference in the number of 
people who have died from heroin overdoses before 
and after the establishment of the MSIR, either in the 
City of Yarra or across Victoria.  
Part 55A(b): Deliver more 
effective health services 
for clients of the licensed 
medically supervised 
injecting centre by 
providing a gateway to 
health and social 
assistance which includes 
drug treatment, 
rehabilitation support, 
health care, mental 
health treatment and 
support and counselling 
To assess this object, the Panel considered: 
• MSIR data on health needs and services provided  
• emergency department and hospital data 
• the results of a cohort study of people who inject drugs 
linked with Victorian and national health datasets  
• consultations with professional stakeholders, staff and 
service users. 
The finding of this review is that the trial has advanced the 
object of providing a gateway to health and social assistance 
but has not yet demonstrated significantly higher levels of 
service take-up for MSIR users as compared with other people 
who inject drugs in the first year of operation (from within the 
transitional facility).  
This is based on the following evidence:  
• The MSIR attracts and provides services to people with 
high health and other support needs. 
• MSIR clients are significantly less likely to be on opioid 
substitution therapy at registration than other people 
who inject drugs. 
• The MSIR provided or referred 10,540 additional services 
beyond supervision of injecting during the trial period, 
as well as providing specialist clinics. 
• Since the move into the larger facility, additional 
services are increasingly being provided by other 
organisations from within the MSIR, enabling better 
connection between this client group and available 
services. 
• As at 1 July 2019 there was not yet evidence of a 
difference in health service use between MSIR clients 
and other people who inject drugs. 
• Given the increased focus on providing services other 
than supervising injections, and the recent 
commencement of trialling a new, longer acting drug 
therapy from within the facility, monitoring health 
outcomes will be helpful to understand progress 
against this object if the trial is extended.  
Part 55A(c): Reduce 
attendance by 
To assess this object, the Panel considered: 
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Object Extent to which the trial has advanced that object 
ambulance services, 
paramedic services and 
emergency services and 
attendances at hospitals 
due to overdoses of drugs 
of dependence 
 
• Ambulance Victoria data for attendances involving 
naloxone 
• the results of a cohort study of people who inject drugs 
linked with Victorian health datasets  
• analyses of emergency department presentations and 
hospital admissions data  
• consultations with professional stakeholders, staff and 
service users. 
The review found that the trial has advanced this object for 
ambulance attendances, noting there is not yet evidence of 
an impact of the service on broader health service use or 
outcomes. 
• The MSIR attracts people who inject drugs who have 
had more ambulance attendances involving naloxone 
than other people who inject drugs. 
• Frequent users of the MSIR have had fewer ambulance 
attendances involving naloxone since the MSIR trial 
opened but a small increase in the number of drug-
related emergency department presentations during 
the trial. 
• Ambulance Victoria data show a trend towards a 
reduction in ambulance attendances after the MSIR 
opened that just failed to reach statistical significance 
(p < 0.10).  
• There have been no observable changes in 
emergency department presentations overall that can 
be attributed to the MSIR. 
Part 55A(d): Reduce the 
number of discarded 
needles and syringes in 
public places and the 
incidence of injecting of 
drugs of dependence in 
public places in the 
vicinity 
To assess this object, the Panel considered:  
• surveys of residents and businesses immediately prior to 
the trial and after one year of operations (within the 
transitional facility) 
• needle and syringe collection data. 
The findings of this review are mixed regarding the extent to 
which the trial has advanced this object. 
There has been a decrease in the proportion of local 
community members reports of witnessing public injecting (to 
the time of the MSIR Review Survey in July/August 2019), with: 
• a decrease in the proportion of residents and business 
respondents who saw public injecting (24 per cent to 
20 per cent of residents; 27 per cent to 22 per cent of 
business respondents)  
• no change in the number of injections seen by 
residents (three per month) and an increase for 
business respondents (from four to five).  
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Object Extent to which the trial has advanced that object 
There has been no change in local community members 
reporting seeing discarded needles and syringes (to the time 
of the MSIR Review Survey in July/August 2019), with: 
• the proportion of people seeing discarded needles 
and syringes relatively unchanged (16 per cent in the 
year before and 17 per cent during the trial) 
• no change in the median number of discarded 
needles and syringes seen by residents (four per month) 
but an increase in the median number of discarded 
needles and syringes seen by business respondents 
during the trial (six to 10 per month). 
The number of inappropriately disposed needles and syringes 
collected in the area surrounding the MSIR grew over the trial 
period. While some of this growth coincided with an escalation 
in cleaning activities in the last eight months of the trial, there 
was also an increase in the number collected in first 10 months 
of the trial.  
Stakeholders were strongly divided on the extent to which 
there had been a change at the end of the first year of 
operation of the MSIR.  
Part 55A(e): Improve the 
amenity of the 
neighbourhood for 
residents and businesses in 
the vicinity  
To assess this object, the Panel considered: 
• the MSIR Review Survey of local residents and 
businesses immediately before the trial and after one 
year of operations (within the transitional facility) 
• the results of a cohort study of people who inject drugs  
• surveys of local Victoria Police members 
• the Yarra City Council community survey 
• consultations with professional stakeholders, staff and 
service users 
• group consultations with local residents and businesses  
• their own direct observations. 
This finding of this review is that amenity has not improved 
during the review assessment period.  
• Most of the MSIR clients are not from Richmond but 
were already coming to the area before the MSIR trial 
began.  
• Prior research in North Richmond found the largest 
impact on the perception of amenity is from seeing 
discarded needles and syringes and other drug-related 
paraphernalia, and this appears to be largely 
unchanged. 
There are conflicting results in relation to perceptions of safety:  
• A Yarra City Council survey for the North Richmond 
area shows no change in residents’ perceptions of 
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Object Extent to which the trial has advanced that object 
safely walking alone during the day or at night before 
or during the trial. 
• Victoria Police members reported seeing significantly 
more:  
o people buying or selling drugs 
o people who appear to be under the influence of 
drugs 
o antisocial behaviour that appears to be drug-
related.  
• The MSIR Review Survey conducted for this review 
found that after the first year of operations:  
o significantly fewer residents and business 
respondents reported feeling safe walking alone 
during the day and after dark due to concerns 
about violence and crime, public visibility of drug 
use and drug deals, safety concerns for their own 
children and schoolchildren, concerns about 
aggressiveness and unpredictability, and 
discarded syringes in public places 
o more people reported considering moving house 
(32 per cent to 37.1 per cent) or their employment 
(27.6 to 32.5 per cent) because of drug-related 
activity. 
The Panel notes that agreement with having an injecting room 
in North Richmond reduced during the trial period for residents 
(from 61 to 44 per cent) and businesses (48 to 41 per cent).  
There are increasing and substantial efforts across a range of 
organisations to ameliorate concerns, and if the trial is 
extended both these and community sentiment should be 
monitored. 
Part 55A(f): Assist in 
reducing the spread of 
blood-borne diseases in 
respect of clients of the 
licensed medically 
supervised injecting 
centre, including, but not 
limited to, HIV and 
hepatitis C 
The Panel notes the implementation of significant screening, 
assessment, testing and treatment initiation undertaken by the 
MSIR to address this objective. It is likely that the work of the 
MSIR is contributing to a reduction in the spread of these 
viruses. 
To assess this object, the Panel considered:  
• MSIR data on health needs and services provided  
• the reports and views of the St Vincent’s Hospital 
Melbourne Health Independence Program  
• results of a cohort study of people who inject 
drugs linked with Victorian health datasets from the first 
year of operation. 
It does appear that this trial has contributed to advancing this 
object, particularly for more frequent users of the service, and 
for those requiring treatment for blood-borne diseases: 
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Object Extent to which the trial has advanced that object 
• The MSIR offers screening and treatment for blood-
borne viruses, both directly and through a St Vincent’s 
Hospital care coordinator (Health Independence 
Program infectious diseases). 
• Screening showed that most people were already 
reporting not sharing needles and syringes (an 
important measure to reduce the spread of blood-
borne viruses), with no significant difference between 
MSIR clients and other people who inject drugs. In the 
first 18 months, more than a third of people screened 
tested positive and a quarter had begun treatment for 
hepatitis C.  
After the first year of the trial, analysis of linked Medicare and 
Pharmaceuticals Benefits Scheme data did not yet show any 
significant difference in relevant tests or prescriptions, noting 
that efforts to provide these services have increased and the 
uptake and impact should continue to be monitored. Since 
previous levels of engagement in treatment of hepatitis C of 
this high health and support needs group are not known, it is 
possible that this equivalence is a measure of success of the 
MSIR in engaging people who might not otherwise be 
receiving treatment.  
If the trial is extended it may become possible to assess the 
extent to which the spread of blood-borne viruses associated 
with the MSIR has been advanced, noting that this would 
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Introduction 
In October 2017 the Victorian Government announced the trial of a medically supervised injecting 
room (MSIR), permitted through amending existing Victorian legislation. The trial is for two years (30 
June 2018 to 29 June 2020) at a specific location, with provision for the Secretary to the 
Department of Health and Human Services (DHHS) to amend the licence for another 36 months if 
the Secretary is satisfied that extending the period of the licence would further the objectives of the 
trial. The independent Medically Supervised Injecting Room Review Panel (the Panel) was 
established to conduct a review of the trial. This report gives the findings and recommendations 
from that review. 
About the trial 
Part 55A of the Drugs, Poisons and Controlled Substances Act 1981 provides for the trial of a 
‘medically supervised injecting centre’ as part of a scheme that aims: 
(a) to reduce the number of avoidable deaths and the harm caused by overdoses of drugs of 
dependence; and (b) to deliver more effective health services for service users of the licensed 
medically supervised injecting centre by providing a gateway to health and social assistance 
which includes drug treatment, rehabilitation support, health care, mental health treatment 
and support and counselling; and 
(c) to reduce attendance by ambulance services, paramedic services and emergency 
services and attendances at hospitals due to overdoses of drugs of dependence; and  
(d) to reduce the number of discarded needles and syringes in public places and the 
incidence of injecting of drugs of dependence in public places in the vicinity of the licensed 
medically supervised injecting centre; and  
(e) to improve the amenity of the neighbourhood for residents and businesses in the vicinity of 
the licensed medically supervised injecting centre; and  
(f) to assist in reducing the spread of blood-borne diseases in respect of service users of the 
licensed medically supervised injecting centre including, but not limited to, HIV and hepatitis C. 
(Parliament of Victoria Legal and Social Issues Committee 2017, No. 66) 
The site for the trial was specified in the legislation as the land described in Vol. 09195 Fol. 045, 
which is located at 23 Lennox Street, Richmond, the site occupied by an existing community health 
centre, North Richmond Community Health (NRCH). Under the current legislation, only one licence 
can be issued, and the service must operate from that location, although there is provision for 
partnerships with other service providers.  
Part IIA of the Act states that the Minister for Mental Health must arrange for a review to be 
conducted of: 
(a) the operation and use of the licensed medically supervised injecting centre; and 
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(b) the extent to which the object of this Part has been advanced during the period of the 
medically supervised injecting centre licence; and 
(c) how this Part and any regulations made for the purposes of this Part have operated and 
whether they require amendment. 
The Act specifies that the review must have begun no later than 12 months after the day on which 
the medically supervised injecting centre licence commenced and may be completed before or 
after the licence ceases to have effect.2 
The Act also stipulates that the Minister must table the review before each house of the Victorian 
Parliament as soon as practicable after the review is completed.  
Role of the Panel 
The independent review panel comprised Professor Margaret Hamilton (chair), Associate Professor 
Alex Cockram, Mr John Ryan, Mr Ken Lay and Associate Professor Ruth Vine. Their role was to 
oversee the review according to the terms of reference for this review (Appendix A), with support 
from government evaluators and analysts.  
To understand how the MSIR was operated and used, the extent to which the trial was advancing 
each of the objects (as detailed above) and any potential amendments to the legislation or 
regulations, the Panel: 
▪ systematically translated legislative objects to research questions and methods 
▪ developed a framework for the review, largely focusing on the first 18 months of the two-year 
trial, to provide the Secretary with enough time to make a decision about continuing or 
closing the MSIR trial before the licence was due to expire 
▪ agreed that key stakeholders were people for whom the MSIR trial had a: 
− direct impact (people who inject drugs and people who care about them) 
− professional impact (people who work at the injecting room and related health and 
social services) 
− geographical impact (people who live, own businesses or work near the facility; people 
who visit or work at the community health centre; staff, students and parents at the 
adjacent primary school) 
− systemic impact (emergency services, broader government services) 
▪ developed an analytical approach for systematically reviewing available information (Susan 
et al. 2019) 
▪ sought and considered two separate peer reviews by evaluation experts at the Australian 
and New Zealand School of Government and KPMG 
▪ agreed to use a range of sources of information to answer these questions including: 
− existing published and grey literature, including submissions to the parliamentary 
inquiries that preceded the decision to conduct this trial and the Hansard record 
relating to this decision 
 
2 See the Drugs, Poisons and Controlled Substances Amendment (Medically Supervised Injecting Centre) Act 2017, No. 66 of 
2017 
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− existing data collected by the MSIR, NRCH, DHHS, Ambulance Victoria, Victoria Police, 
the Department of Education and Training and the Coroners Court of Victoria 
− a survey of local residents and businesses (referred to in this report as the ‘MSIR Review 
Survey’ – see Appendix G for details of the first-wave survey and Appendix H for details 
of the second-wave survey) 
− a survey of local Victoria Police members 
− analysis of an existing longitudinal cohort study of people who inject drugs 
− direct observation and regular site visits to the facility and surrounding streets, parks and 
laneways, including the nearby housing estate 
− hearing directly from stakeholder groups affected by the MSIR trial through a range of 
mechanisms including interviews with: 
• service users of the MSIR  
• service users of the needle and syringe program (NSP) 
• staff of the service 
• staff of other relevant services, including the community health centre, gateway 
service providers, Victoria Police, Ambulance Victoria members, the Department of 
Education and Training, the Yarra City Council and other local services  
• local community members. 
Information about the framework, detailed design and methodologies for each of the above 





North Richmond has been the main site for heroin use and related harms in Victoria for the 
past decade, with evidence from a cohort study showing an increase in visits to the area by 
people who inject drugs increasing before the trial began. 
The trial occurred in the context of increasing heroin use and increased visibility of people 
who inject drugs in North Richmond, and a high number of overdose deaths. 
This section provides a brief overview of injecting drug use and the harms associated with injecting 
drug use for individuals and the community and provides an overview of the recent history of the 
North Richmond drug market. This section also describes the local community and changes during 
the trial period. 
Harms associated with injecting drug use  
Approximately 11.8 million people inject drugs worldwide (UNAIDS 2017). In Australia, approximately 
six per thousand people aged 15–64 years inject drugs. Injecting drug use is more common among 
men than women and most common among those aged 35–44 years (Larney et al. 2017). 
Injecting drug use poses risks to both the individual who injects drugs and to the broader 
community. In addition to the harms caused by fatal overdoses, there are significant physical 
health harms associated with non-fatal overdoses including: 
▪ opioid-induced respiratory depression and hypoxia-related brain injuries from non-fatal opioid 
overdoses 
▪ kidney failure 
▪ nerve damage, transitional motor paralysis and build-up of fluids in the lungs 
▪ injection-related injuries (scarring, bruising, venous injury, ulcers, arterial injury) 
▪ injection-related infections (thrombophlebitis, cellulitis, abscess) 
▪ complications of injection-related infections (tetanus, septicaemia, endovascular 
complications, musculoskeletal injections) 
▪ infectious diseases (sexually transmitted infections (STIs), hepatitis B and C, respiratory tract 
infections, tuberculosis, HIV/AIDS). 
Multiple and repeated overdoses correlate with decreasing cognitive performance and increased 
depression symptoms and suicidal ideation (Zibbell et al. 2019). Other mental health risks associated 
with drug use or injecting drug use include psychiatric disorders, substance dependence and 
substance use-related disorders. There are also common general health problems including pain, 
poor dental condition and constipation (World Health Organization 2009). 
These health challenges can also have serious social and economic consequences, both to the 
individual and the broader community. Community concerns, which can be perceived or actual, 
include: fears of increased risk of violence and crime; the public health threat of disease 
transmission; diminished amenity; negative business impacts; and social and family disruptions 
(Australian Medical Association – Victoria 2017). 
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Australian government policy 
Current policy in Australia governing all drug-related laws and responses is harm minimisation. Harm 
minimisation considers the health, social and economic consequences of alcohol and other drug 
(AOD) use in relation to the individual and the community. Harm minimisation has been the primary 
policy of Australian state and Commonwealth governments for 35 years (Commonwealth 
Department of Health 2017). This includes:  
▪ harm reduction – strategies aimed at reducing the harm from drugs for both individuals and 
communities (but do not necessarily aim to stop drug use), with examples including needle 
and syringe services, methadone maintenance, peer education and brief intervention 
▪ supply reduction – strategies aimed at reducing the production and supply of illicit drugs, with 
examples including legislation and law enforcement 
▪ demand reduction – strategies aimed at preventing the uptake of harmful drug use, with 
examples including community development projects and, importantly, drug dependence 
treatment.  
Harm reduction policies and services  
Harm reduction comprises a range of services aimed at minimising injury to self, others and the 
community by people who inject drugs, from the most casual users to those with the most severe 
drug dependencies. Harm reduction programs include promotion and support for safer AOD use 
and practices as well as providing medical and social support to AOD users; this includes linking 
users to AOD and mental health treatment resources. The goal of harm reduction has also 
historically shaped the design of particular treatment interventions – for example, opiate 
substitution therapies such as methadone or buprenorphine that is now available with the potential 
enhanced uptake as a longer acting depot form. Harm reduction services are shaped by the goals 
of reducing AOD-related transmission of blood-borne viruses such as HIV/AIDS and viral hepatitis, as 
well as reducing drug overdose deaths. 
Victorian harm reduction policy and services 
The state government is the primary funder of a range of prevention and treatment services for 
people who inject drugs in Victoria. This includes harm reduction services such as providing sterile 
injecting equipment, for which there is a strong evidence base. A number of these are directed at 
reducing harm from overdose, including direct health services funded to provide primary care, 
outreach local drug initiatives, mobile NSPs and providing the opioid reversal agent naloxone as 
part of overdose response training.  
A potential harm reduction element in a system of care  
There are more than 100 medically supervised injecting services operating across more than 60 
cities globally, and it has been more than 30 years since the first such service was established in 
Switzerland. To date there has been one service in Australia, the medically supervised injecting 
centre (MSIC) in Kings Cross, Sydney. Aside from providing people who consume drugs with safe 
and medically supervised locations to inject drugs, they can provide critical services such as case 
management and medical, social and mental health care. To meet the needs of the populations 
affected by opioid use, injection centres link to services that can help service users manage the 
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‘social determinants’ of health such as housing, income and community stability (Nursing@USC Staff 
2019). Service users are provided information about welfare, counselling and legal services in the 
area. Often, it is the most vulnerable populations that are disproportionately affected by opioid 
use. 
Integrated supervised injecting facilities are the most common model and are part of a broader 
and interlinked network of services. They are also regarded as best practice because clients can 
access a range of services in one location. In Germany, the Bonn integrated facility is located 
directly behind the city’s main train station and provides different services on different floors of the 
building. Specialist drug injecting centres are usually established close to other drug treatment 
services and near open drug scenes. The injecting facility in Frankfurt is an example of a specialised 
model with a focus on referral to other services such as counselling, substitution treatment and 
housing. There are also four mobile injecting facilities in Europe – in Barcelona, Berlin, Copenhagen 
and Lisbon. In Barcelona and Berlin, the mobile facilities comprise specially fitted vans that have 
three injecting booths (Dietze et al. (2012).  
All the supervised injecting facilities opened near locations of prominent drug markets. Some of 
these services (for example, Villa De Vallecas in Spain) were located in suburban areas. Evaluations 
have reported an overall positive impact on the communities where these facilities are located. For 
example, in Barcelona a four-fold reduction was found in the number of unsafely disposed syringes 
collected in the vicinity from a monthly average of more than 13,000 in 2004 to around 3,000 in 
2012 (Vecino et al. 2013). A review of 584 drug-related emergencies in 18 of the 24 existing injecting 
facilities in Germany in 2013 found that these severe incidents could have had a fatal outcome if 
the client had been alone at home or out in the community (Drug consumption rooms in Europe, 
2014).   
Service users can access a range of primary care services at a supervised injection site, including 
wound care and HIV/AIDS testing. Some facilities provide withdrawal management services. When 
users are ready to withdraw, they have access to clinician-monitored facilities and are paired with 
counsellors and coordinators to facilitate the transition. Cities with large drug markets and drug-
using populations (for example, Amsterdam, Hamburg, Frankfurt, Rotterdam and Zurich) have more 
than one service location and often provide a different suite of services or supplementary service 
arrangements, in an effort to meet demand.  
In general, the objectives of the European facilities are to:  
▪ reach as much of the target population as possible 
▪ achieve health objectives including enabling service users to access a range of primary care 
services including immunisations, wound care and HIV/AIDS and hepatitis B and C testing and 
treatment  
▪ provide a safe environment that enables lower risk, more hygienic drug consumption (short-
term objective) 
▪ reduce the mortality and morbidity of the target population (medium-term objective) 
▪ stabilise and promote the health of users (long-term objective) 
▪ realise public order and safety/crime objectives: 
− reduce public drug use and associated nuisance 
− avoid increases in crime in and around the facilities.  
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According to the European Monitoring Centre for Drugs and Drug Addiction (2004), there is no 
evidence that medically supervised injecting facilities contribute to increased morbidity or mortality 
risks among people who use drugs. Time series analysis of drug-related deaths in four German cities 
suggests the facilities can contribute to a reduction in drug-related deaths at the community level 
(Hedrich 2004).  
The European experience shows that the extent to which medically supervised injecting facilities 
are used is highly dependent on their location (although there are other factors such as capacity, 
the nature of the drug scene, opening hours and access criteria). Essentially, the facilities need to 
take the following into account: 
▪ proximity to illicit drug markets 
▪ closeness to places of drug purchase 
▪ locations where they can be embedded in a wider network of services 
▪ compatibility with the needs of people who use drugs 
▪ compatibility with the needs and expectations of local residents. 
The European facilities have had a greater impact where there is a political consensus that they 
are part of a comprehensive local strategy to respond to drug-related problems (European 
Monitoring Centre for Drugs and Drug Addiction 2004).  
A recent analysis of published reviews of supervised injecting programs (Belackova et al. 2019) has 
similarly identified key features to consider in designing future drug supervision facilities:  
▪ the location and co-location of the program  
▪ whether people who use drugs will trust the program and therefore access the service when 
the drug is criminalised 
▪ what operational hours will best capture the times and/or periods of increased overdose risk 
▪ what specific harm reduction practices should be prioritised or what level of assistance in 
referring people to other services is most appropriate. 
As an example of how a government has operationalised these considerations, in Canada, the 
Ontario Ministry of Health and Long-Term Care specified key conditions that must be satisfied 
before approving the operation of what they call a supervised consumption and treatment service 
(CTS) (Ministry of Health and Long-Term Care 2018) covering:  
▪ Location conditions – the service is to be located in communities in need based on Ministry-
defined criteria (mortality, morbidity, proxy measures for drug use). They will be established in 
community health centres, Aboriginal health access centres or similar incorporated health 
care or community-based organisations that offer integrated, wraparound services.  
▪ Service capacity – mandatory services must include supervised consumption and overdose 
prevention services, on-site or defined pathways to addiction treatment services and 
wraparound services (including primary care, mental health, housing and/or other social 
support) and harm reduction services. 
▪ Proximity – the service is to be located at least 600 m from other local CTS or similar services. 
CTS will not be concentrated in one area or neighbourhood, and where childcare centres, 
parks and/or schools (including post-secondary institutions) are within 100–200 m, community 




▪ Community support – all applicants require evidence of support from local stakeholders, 
including residents. At a minimum, health and social service stakeholders, local businesses, 
local citizens, local municipality, police and other emergency services, public health and 
persons with lived experience should be consulted. 
▪ Accessibility – CTS must comply with the Accessibility for Ontarians with Disabilities Act, be 
strategically located (walking distance from where open drug use is known to occur) and 
easily accessible by public transit. CTS should offer services that are culturally, 
demographically and gender appropriate.  
The Canadian experience with the recent opioid crisis, and the resulting increase in the need for 
such facilities, has placed these processes under such pressure that there are now both formal CTS 
that meet the above requirements as well as local sites. Findings from a recent review into the 
Canadian experience has been that, ‘When regulations are barriers, unsanctioned actions, such as 
overdose prevention sites, may be enacted by individuals to respond to urgent public health 
needs’ (Buxton et al. 2019).  
In Australia, at a coronial inquest in 2016 into the deaths of six opioid users in New South Wales, the 
deputy state coroner, Harriet Grahame, noted the need for more than a single injecting centre 
(Friezer 2018). International experience suggests that consideration should be given to opening 
more than one MSIR in a city the size of Melbourne where significant numbers of people use drugs. 
For example, as of April 2018, there were 31 official drug consumption facilities in 25 cities in the 
Netherlands, 24 in 15 cities in Germany, five in four cities in Denmark and 13 in seven cities in Spain 
(European Monitoring Centre for Drugs and Drug Addiction 2018). Within Germany, Hamburg 
operates five and Frankfurt four. There are two consumption rooms in Berlin (International Network 
of Drug Consumption Rooms 2015).  
Context of the North Richmond drug market 
During the 1990s the supply of heroin in Melbourne increased and the drug became readily 
available at levels of high purity in an emergent street-based drug-using setting (Dietze & Fitzgerald 
2002). The changes in street-based drug activity was associated with an increase in heroin 
consumption. Later, between 2003 and 2005, the Yarra local government area (LGA) had the most 
non-fatal heroin overdose ambulance attendances in metropolitan Melbourne: 21.1 per cent in 
2003, 18.8 per cent in 2004 and 22.2 per cent in 2005. 
In the early 2000s overall heroin-related harms started to decline, largely attributed to ongoing 
variable heroin supply including experience of reduced availability compared with the peak 
period in the 1990s (Yarra Drug and Health Forum 2017). As neighbouring markets reduced or were 
disrupted through saturation policing, gentrification and other mechanisms, it has been argued 
that North Richmond became a key heroin market. From 2000–01 to 2001–02 the number of 
overdoses (non-fatal) in the City of Yarra declined from 199 to 118, but as a proportion of overdoses 
in Greater Melbourne it rose from 12 per cent to 23 per cent (DHHS 2004).  
More recently the topic of injecting drug use in North Richmond was the subject of a research 
paper that concluded:  
… over several years, there has been significant public discussion and media exposure on the 
impact of public injecting in the City of Yarra. The area of particular interest has been the area 
known as North Richmond comprising the high-rise public housing estates and surrounding 
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streets and laneways. An active street-based heroin market has existed in the location for 
decades, with people who inject drugs coming to the neighbourhood from all over Melbourne 
to purchase and use heroin. Despite ongoing, regular intensive policing of the illicit drug market, 
commercial exchange of heroin and public injecting continues. Much of the attention on the 
North Richmond heroin market has highlighted public health concerns, including overdose, the 
discarding of drug injecting paraphernalia, witnessing of overdose and public injecting. It was 
noted that there are also problems associated with public nuisance perceived to be from 
the illicit drug market (Dwyer et al. 2016, p. 164) 
The Panel heard directly from community members that these were current concerns as well and 
they did not feel there was enough ongoing, visible community policing.  
The Coroners Court of Victoria has also been monitoring heroin-related overdose deaths in the City 
of Yarra since 2012. In a 2016 analysis of heroin overdose deaths in the City of Yarra, Coroner3 
Jacqui Hawkins noted that the deaths occurred in streets, parks, alleyways and other non-
residential locations, and involved people who had travelled from other parts of Melbourne and 
Victoria to purchase and use heroin there (Coroners Court of Victoria 2016, p. 2). The coroner held 
an inquest and recommended that a supervised injecting trial be established in North Richmond. 
The coroner’s data from the period 2012–2017 on heroin-associated harms in the City of Yarra and 
across Victoria more generally triggered a parliamentary inquiry, which culminated in establishing 
the Drugs, Poisons and Controlled Substances Amendment (Medically Supervised Injecting Centre) 
Act 2017.  
From 2009 to 2017, the City of Yarra had the highest frequency and average annual rate of heroin-
related overdose deaths in Victoria (Coroners Court of Victoria 2019). Unlike other Victorian 
jurisdictions, most people using and overdosing on drugs in the City of Yarra were not residents of 
the City of Yarra. Of the 91 people who died from heroin-involved overdoses in Yarra from January 
2014 to December 2018, about a third (29 per cent) lived in Yarra. Most (64 per cent) lived in other 
LGAs in Victoria (Coroners Court of Victoria 2019). 
DHHS analysis of ambulance attendances where naloxone was administered shows high levels of 
activity in the area surrounding the location of the MSIR in the 18 months before the MSIR opened 
(see Figure 1). There were 382 ambulance attendances where naloxone was administered within 1 
km of the MSIR for the 18 month-period before the MSIR opened on 30 June 2018. 
 
3 The Coroners Court independently investigates deaths and fires, reduces preventable deaths and promotes public health 
and safety and the administration of justice. 
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Figure 1: Ambulance attendances where naloxone was administered in public settings within 1 km 
of the MSIR (all hours) in the 18-month period before the MSIR opened on 30 June 2018 (n = 382)  
 
Source: Victorian Ambulance Clinical Information System.  
Note: The current location of the MSIR is shown with the red tag. 
Establishing the MSIR trial in North Richmond 
Stakeholders within DHHS reported to this review that some community groups in the local area 
have been advocating for an MSIR since the late 1990s. The decision to conduct a trial of an MSIR 
was based on support from coroners, a wide range of medical experts, first-responder agencies 
and the findings of a bipartisan parliamentary inquiry.  
Key timelines for recent events leading to establishing the MSIR in North Richmond are: 
▪ 2015 – increasing heroin-related deaths in Victoria, with 172 heroin overdose deaths, the 
highest since the 1990s (Coroners Court of Victoria 2017) 
▪ November 2015 – announcement of a parliamentary inquiry into the effectiveness of laws and 
procedures relating to illicit drugs (the Parliamentary Inquiry into Drug Law Reform) 
▪ Coroner Jacqui Hawkins, in the Finding into Death with Inquest of Ms A, delivered on 20 
February 2017, recommended that the government ‘take the necessary steps to establish a 
safe injecting facility trial in North Richmond’ (p. 24) 
▪ February 2017 – the Legislative Council referred the Drugs, Poisons and Controlled Substances 
Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 to the Legal and Social 
Issues Committee for review 
▪ September 2017 – the Report of Inquiry into Drugs, Poisons and Controlled Substances 
Amendment (Pilot Medically Supervised Injecting Room) Bill 2017 tabled in parliament 
▪ October 2017 – the Victorian Government announced the MSIR for a two-year trial. 
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Following a decade of monitoring deaths by heroin overdose, in 2017 the Coroners Court scoped 
an inquest to ‘explore the nexus between heroin-related harms and deaths and the City of Yarra, 
with particular focus on potential prevention opportunities in the Richmond area’ (Coroners Court 
Victoria 2017, p. 8). In another finding on the death of David Leslie Chapman in 2017, Coroner 
Audrey Jamieson stated that:  
... if a safe injecting facility can shift drug injecting from public locations to a clinically 
supervised environment, this would be hoped to lessen the impact of injecting drug use and 
overdose death on local residents who are exposed to these activities in their everyday life. 
(Coroners Court of Victoria 2017, p. 6) 
The recommendation by Corona Jacqui Hawkins to take necessary steps to establish a  supervised 
injecting facility in North Richmond was informed by the success of an equivalent service, the MSIC 
operating in Sydney’s Kings Cross, the only similar facility in the Australian context. The coroner cited 
a 2010 evaluation by KPMG of the Sydney service that found it had (among other benefits):  
▪ successfully managed more than 4,400 drug overdoses without a fatality 
▪ reduced the average number of overdoses in public locations around the area where it was 
located 
▪ reduced ambulance callouts to the Kings Cross area by 80 per cent. 
This inquest was delivered on 20 February 2017.  
Following the coroner’s inquiry, the Inquiry into the Drugs, Poisons and Controlled Substances 
Amendment (Pilot Medically Supervised Injecting Centre) Bill 2017 (Parliament of Victoria, 
Legislative Council, Legal and Social Issues Committee 2017) was convened and heard evidence 
from a number of sources, including the coroner. The Yarra Drug and Health Forum provided a 
submission that suggested the necessary requirements for locating a supervised injecting facility. 
These included:  
▪ prominence of public injecting  
▪ near drug markets 
▪ high numbers of fatal and non-fatal overdoses occurring in public places 
▪ community concern around publicly discarded injecting equipment. 
They reported that ‘such conditions currently exist in Melbourne, particularly in North Richmond’ 
(Yarra Drug and Health Forum 2009, p. 4). 
The Bill was introduced to parliament on 22 February 2017 in response to the escalating use of illicit 
drugs and overdose deaths in the North Richmond area. The Bill proposed a trial of a medically 
supervised injecting centre at an unspecified location in North Richmond.  
Parliament received submissions from local government, relevant stakeholders and community 
members. The overwhelming majority of submissions were in favour of a medically supervised 
injecting centre, including those from the City of Yarra, the Royal Australian College of General 
Practitioners, the Royal Australasian College of Physicians, the Royal Australian and New Zealand 
College of Psychiatrists and the Australian Medical Association (Victoria).  
The committee spoke with a number of local residents as part of the inquiry and heard that they 
were frequently exposed to confronting scenes of drug use, drug dealing, antisocial behaviour and 
discarded injecting equipment. The committee also considered written submissions made to 
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another Victorian parliamentary inquiry into drug law reform. The committee noted that all 15 
submissions received from Abbotsford and North Richmond residents supported a trial.  
In Victoria Police’s (2017) submission to the inquiry, Chief Commissioner Graham Ashton noted the 
strong evidence that the supervised injecting facility in Sydney has reduced the number of deaths 
from drug overdoses and improved access to drug treatment, health and welfare services 
(Parliament of Victoria, Legislative Council, Legal and Social Issues Committee 2017).  
The Parliament of Victoria Legal and Social Issues Committee (2017) reported in September 2017 
and found:  
▪ Drug use in North Richmond had reached crisis levels and was a major concern for residents, 
business owners and emergency services. 
▪ Medically supervised injecting centres improve the health of people who inject drugs and 
reduce signs of drug use in surrounding streets. 
▪ Sydney’s MSIC has provided public amenity benefits for the local community and reduced 
demand for ambulance services.  
Key themes from the recommendations included: 
▪ the need for integration across government 
▪ diversion from criminal responses in appropriate cases including therapeutic and social 
responses for complex drug-related offending 
▪ improved access to harm reduction and treatment services  
▪ a focus on connecting healthcare and drug services  
▪ increased community education and awareness on drug issues. 
In October 2017 Victorian Premier Daniel Andrews announced that the Victorian Government 
would establish a medically supervised injecting centre. 
In August 2018 the Victorian Government Response to the Parliamentary Inquiry into Drug Law 
Reform was tabled in parliament. The government focused its response to the report on three 
themes: 
▪ better, earlier treatment 
▪ saving lives and preventing harm  
▪ safer communities.  
Investment in concurrent programs to save lives and prevent drug-related harm included: 
▪ eliminating new transmissions of HIV  
▪ eliminating hepatitis B and C as public health concerns by 2030 
▪ strengthening the Victorian NSP program.  
Related commitments included:  
▪ additional support to treatment service users who may be at high risk of overdose  
▪ establishing new ‘hubs’ associated with emergency departments in six Melbourne hospitals to 
better support and respond to people experiencing a crisis related to their mental health or 
substance use.  
If the MSIR trial is extended, it would be prudent to consider these commitments insofar as they 
relate to the MSIR in any future evaluation. 
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Response to trialling a supervised injecting room 
Overall, there was strong support for conducting the trial, with most organisations and individuals 
who provided submissions to both parliamentary inquiries supporting it. Those submissions that 
advocated for a supervised injecting centre in North Richmond recognised that it had the potential 
to save lives and improve local safety and amenity.  
Organisations that called for an MSIR or supported the concept overall included the Yarra City 
Council, NRCH, the Australian Medical Association (Victoria), the Royal Australasian College of 
Physicians, Yarra Drug and Health Forum, Family Drug Support, the Pharmacy Guild of Australia, 
Turning Point, Alfred Health and Beyond Blue.  
A trial, according to the Australian Medical Association (Victoria), had significant potential to lessen 
the public impact of street-based injecting, improve service users’ access to primary and medical 
care and drug treatment, reduce the incidence of heroin-associated overdose, and assist in 
reducing blood-borne viral transmission. Victoria Police suggested the trial should be longer than 18 
months to allow health, social and justice indicators to be analysed over a significant time period.  
There were also submissions against establishing a medically supervised injecting centre. Opposition 
came from two key organisations: Drug Free Australia and the Australian Christian Lobby. In their 
submissions to the Inquiry into the Drugs, Poisons and Controlled Substances Amendment (Pilot 
Medically Supervised Injecting Centre Bill 2017, they argued that establishing an MSIR would 
appear to condone illicit drug use. Additionally, they highlighted what they perceived as technical 
limitations with the evaluations of Sydney’s MSIC.  
There were also concerns expressed in the media about the facility, particularly in relation to the 
potential impact on the local community including the adjacent primary school. This followed 
extensive media coverage in the lead-up to the MSIR trial being announced (see Henriques-Gomes 
2018) discussing the challenges associated with the local injecting room and community sentiment 
supporting the trial.  
Changes in drug market trends 
The pattern of drug injecting is associated with local and international changes of drug production 
and supply. Drug use and potential harm is determined by the availability of the substance, the 
characteristics of the person who wishes to use it and the circumstances or context of its use. As 
with most products, the market largely determines price, and this is influenced by availability 
(Australian Criminal Intelligence Commission 2018). With illicit products, this can fluctuate 
significantly.  
There are indications that heroin use in Victoria has increased in the recent past and continues to 
do so. The Penington Institute records and analyses overdose deaths and reports that the number 
of overall drug-induced deaths in Australia from all drugs increased from 981 in 2001 to 1,612 in 
2017, an increase of 64 per cent (Figure 2) (Penington Institute 2019). The number of unintentional 
deaths nationally relating to heroin rose from 195 deaths in 2013 to 358 in 2017 (an 84 per cent 
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increase). Victoria recorded the highest increase, with an increase of 225 per cent between 2012 
and 20174 (Penington Institute 2019). 
Figure 2: Number of drug-induced deaths in Australia compared with road traffic deaths, 2001–2017 
 
Source: Penington Institute 2019 
Self-report studies such as the National Illicit Drug Reporting System interviews also provide some 
insights. While noting that they generally recruit only participants who self-identify as people who 
inject drugs (Peacock et al. 2019), within this national cohort, heroin use remained stable in 2019, 
and 88 per cent of participants reported that heroin was ‘easy’ to ‘very easy’ to obtain, consistent 
with 2018 (Peacock et al. 2019). 
The system also noted noticeable differences in the proportion of people at each of its five 
recruitment sites who reported having injected heroin in the past six months in 2019 – 90 per cent of 
their sample recruited in Richmond reported this compared with 81 per cent in Footscray, 75 per 
cent in Frankston, 78 per cent in Dandenong, 92 per cent in Collingwood and 76 per cent in St Kilda 
(see Figure 3), supporting the impression that Richmond has been and continues to be primarily the 
site of heroin use (data provided directly to the Panel by the Burnet Institute).  
 
4 An increase in drug-related deaths does not necessarily relate to overall increased consumption but may also relate to the 
purity (strength) and quality (contamination) of drugs available, and to changing patterns of poly-drug use. 
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Figure 3: Percentage of people who use drugs reporting the use of heroin injection in the previous 
six months, 2016–2019 
 
Source: National Illicit Drug Reporting System data (2016–2019) provided directly to the Panel 
Changes in the national and Victorian heroin market over time are difficult to quantify definitively. 
Wastewater analysis undertaken nationally provides estimates of drug consumption at more than 
50 specific sites, including two sites in Melbourne and up to 10 in rural Victoria (Australian Criminal 
Intelligence Commission 2019). This analysis concludes that while heroin use has been stable or in 
decline in most jurisdictions nationally over the two-plus years of collection from March 2017 to 
August 2019, there have been increases in the capital city sites in both Victoria and New South 
Wales, with the greatest increases in Victoria.  
Local context  
This section describes the characteristics of North Richmond and key changes in the local 
environment during the trial period.  
About the local community 
The North Richmond MSIR is bounded by a largely residential street, a primary school and a public 
housing estate. It is in a densely populated, socio-demographic and culturally diverse area. There 
are also a significant number of people who sleep rough or who are homeless in the area.5  
 
5 In relation to people requiring specialist homelessness services, there has been an increase in people who were accessing 
these services while living in Richmond overall, and in proportion to clients living in the rest of the City of Yarra. This increase 
occurred during the trial period and peaked in January–March 2019, with 140 people who were homeless in Richmond 
accessing these services in that period compared with 97 people in the three months before the trial began (March–June 




DHHS’ rationale for the location of the MSIR was: 
The City of Yarra is the Victorian local government area with the highest frequency of heroin-
related deaths over nine years (2009–2018). In 2015, 35 people died from overdoses related to 
heroin purchased or used in the City of Yarra. 
The MSIR trial is located at the NRCH site on Lennox Street. The site was chosen because it is 
close to where people buy and sell drugs, and the centre already provides many vital health 
services to reduce the spread of blood borne viruses and other harms associated with drug use.  
(DHHS 2019c) 
Based on the above factors, this was a logical location to trial the service. As described earlier, 
other jurisdictions have taken into account broader factors, which may have been useful in 
considering the location.  
About the licensee 
The legislation allows for a trial at the existing site (23 Lennox Street, Richmond) and at no other 
location. This is the site of the licensee NRCH. This relatively small community health service was 
established in 1974, largely to serve the needs of the adjoining public housing estate (NRCH 2020). 
The community health centre offers a wide range of health and social services including: 
▪ general practitioner (GP) services 
▪ dental services 
▪ occupational therapy 
▪ child health and development 
▪ community nurses 
▪ counselling and casework 
▪ AOD treatment 
▪ the Centre for Culture, Ethnicity and Health 
▪ diabetes education 
▪ health and ageing services 
▪ Inner Melbourne Post-Acute Care 
▪ nutrition and dietetics 
▪ the healthy ageing hub. 
NRCH operates a range of AOD-related services including an NSP, health promotion, outreach in 
the local community and overdose response.6 From 2016 to late May 2019 it also provided a 24-
hour needle and syringe secure dispensing unit.  
Physical changes in the local precinct over the review period 
There have been several changes in the local area immediately prior to and during the trial period 
that may contribute to changes in the data being considered, and the experiences of the local 
 
homelessness services as compared with those living in the rest of the City of Yarra who had previously accessed AOD 
rehabilitation or who been referred by AOD services (24 people in the quarter before the trial began (March–June 2018)) 
and 31 people in the most recent quarter analysed (July–September 2019). 
6 Advice provided to the Panel from the DHHS Drug Policy and Reform Unit on 14/08/2019. 
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community. These include significant capital works undertaken by different organisations including 
the Yarra City Council and Yarra Trams, as well as roadworks in Lennox Street, including road re-
sheeting and upgrades to drainage. Shortly before the MSIR opened, a seating area at the corner 
of Lennox and Victoria streets (previously a space for congregation by people who buy and sell 
drugs) was enclosed for refurbishment for several months, with the result that Panel members heard 
from local community members and also directly observed that more people were dispersed on 
Victoria Street and also congregating on the adjacent Office of Housing estate.  
There have been other changes to the surrounding precinct and the immediate vicinity of the MSIR 
directed at improving amenity over the past six months. The Panel has not been able to assess the 




Operation and use 
Establishing an MSIR is a complex, highly visible and challenging endeavour, particularly with 
the requirement for accelerated implementation. DHHS has had significant input including 
initial licensing, central policy and performance oversight. It has also had considerable input 
in approving information about the MSIR for media and communications purposes. 
Although DHHS has been coordinating the trial, it has had significant contributions and 
goodwill from a number of stakeholders including Victoria Police, Ambulance Victoria, the 
Yarra City Council, the Department of Education and Training, many local service providers, 
residents and people who inject drugs. 
The initial focus was on getting the MSIR established and opened to begin providing service 
to people at risk of overdose, ensuring a safe and appropriate response to their activity and, 
as far as possible, their further health and social support needs. 
People began attending on opening day (Saturday 30 June 2018) and have continued to 
use the service (an average of 321 visits per day as of 31 December 2019. Note that an 
individual may make more than one visit a day, so visits are not the same as the number of 
people. In the first 18 months of the trial, 3,936 people registered to use the MSIR trial, with 
119,223 visits in this period.  
The MSIR trial has supervised 116,802 injections and responded to 2,657 overdoses. There 
have been no fatalities.  
Most injections (96.6 per cent) have been of heroin, with a few (2.5 per cent) injecting 
methamphetamine.  
The MSIR trial is attracting a group of people who inject drugs with particularly high support 
needs, even compared with other people who inject drugs in Richmond. 
Operation 
Once announced, the trial had a rapid establishment period, reflecting escalating public 
health and safety concerns about public injecting in North Richmond. 
The MSIR’s operating protocols were heavily influenced by the experience of and 
documentation from the Sydney MSIC. The North Richmond MSIR meets all necessary 
legislative, national accreditation and Victorian departmental licence requirements. 
Operational incidents have been reported to DHHS as required. 
The trial was phased, with an initial focus on supervising injecting drug use in a transitional 
facility. The MSIR then moved into a purpose-built facility next to NRCH, which provided 
additional capacity to provide clinical and other services in new consulting rooms.  
The new facility has attracted more people, and there has been an increase in the number 
of injections overseen. It has also enabled more people to access complementary services 
at NRCH including GP services, drug dependence treatment, oral health services, infectious 
disease diagnosis/treatment, wound management support and mental health services. 
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Although many are now being delivered, the potential benefits of these services have not 
yet been fully realised because this added aspect of care is still being implemented.  
The Panel considers that the core focus in the service’s initial establishment was on 
operational matters, especially those related to the injecting room and the response to 
overdose experiences. At the time of opening, services such as blood-borne virus testing 
were mainly available through the pre-existing services at NRCH and through external 
services, with MSIR staff focusing on referring people to NRCH or off-site services when 
needed. However, over time it became clear that it was more effective to offer services in 
the consulting room of the injecting room itself. It has taken some time to develop 
appropriate protocols, pathways, partnership agreements, memorandums of 
understanding, record keeping/sharing arrangements and timetabling to facilitate the 
range of services now present in the injecting room. The larger facility, which opened in July 
2019, took the concept of integrated service delivery in an injecting room further with the 
addition of a consulting area with three more consulting rooms.  
As the trial has progressed, it has become apparent that NRCH’s responsibility for 
governance and aspects of coordination and role clarification have needed significant 
improvement, along with implementing initiatives more directly related to amenity.  
Renewed focus on amenity is apparent in recent months, and additional resources have 
been added to try to minimise real and perceived unwanted impacts on the local 
community discussed elsewhere. This is involving the cooperation of several agencies and 
organisations and agreement on complex issues and is ongoing. 
The Sydney MSIC, which opened some 20 years ago,7 has informed some aspects of the 
MSIR trial, in particular overdose treatment guidelines, data collection and reporting 
structure. There are some important distinctions, however. 
This section outlines the operation and use of the service, describing first the key activities involved 
in establishing and implementing the service and supporting activities, and then describing the use 
of the service.  
The review considered implementation and use of the MSIR trial through reviewing the following 
sources of information: 
▪ results of independent accreditation against the National Safety and Quality Health Service 
Standards and the Quality Improvement Council’s Accreditation program, which occurred 
before the opening of both the transitional and larger facility 
▪ review of key documentation, including relevant contractual agreements, performance 
management frameworks, service agreements and internal management protocols  
▪ consultation with staff and service users 
▪ consultation with other local services and community members 
▪ expert observation 
▪ case studies. 
The key activities of the trial included:  
 
7 Licence issued in October 2000. It opened in the following year.  
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▪ initial planning and scoping (October 2017 – February 2018)  
▪ establishing governance and advisory mechanisms (October 2017 – current) 
▪ obtaining relevant approvals (October 2017 – 30 June 2018) 
▪ implementing the service in the transitional facility (30 June 2018 – July 2019) 
▪ additional measures introduced by government to support the trial (April 2019 – current) 
▪ implementing the service in the larger facility (July 2019 – current) 
▪ developing the broader precinct (February 2019 – current) 
▪ independent review of NRCH’s AOD program (October–December 2019) 
▪ reviewing the trial (April 2018 – December 2019). 
Overview of key stages of implementation 
Initial planning and scoping  
In October 2017 the Victorian Parliament passed the Drugs, Poisons and Controlled Substances 
Amendment (Medically Supervised Injecting Centre) Bill and in February 2018 it was proclaimed as 
an Act. The location of the trial was specified in the legislation, and the prospective licensee was 
identified when legislation was introduced. 
 NRCH was identified as a suitable option for several reasons: 
▪ NRCH’s NSP was the highest volume program of its kind in Victoria in 2017, evidence that 
people who inject drugs knew about NRCH, were willing to access it and staff had familiarity 
with many client issues and needs. 
▪ NRCH was located in the area described as ‘North Richmond’, recommended by the 
Coroners Court as the site of a supervised injecting service trial. 
▪ NRCH already operated a naloxone education program, blood-borne virus education, health 
promotion, outreach in the local community and an overdose response service. 
▪ NRCH was the only integrated community health centre offering AOD harm reduction and 
treatment in the North Richmond area. 
▪ Most submissions to both relevant parliamentary inquiries supported conducting a trial in North 
Richmond. 
▪ The service had existing links with the broader service sector as well as the local community. 
▪ NRCH had provided a submission to parliament stating that it supported a trial of a supervised 
injecting service and would be open to providing this service.  
Governance arrangements 
Seven governance and advisory mechanisms have been established since October 2017 to 
support the trial: 
▪ An internal departmental Project Control Group (October 2017 – June 2018) chaired by a 
senior DHHS executive was responsible for the initial planning stages of the project.  
▪ An Expert Advisory Group (December 2017 – March 2018) chaired by the original medical 
director of the Sydney MSIC considered critical policy and operational matters in developing 
regulations and issuing a licence for the room.  
▪ A Capital Project Control Group (January 2018 – December 2019) led by the Victorian Health 
and Human Services Building Authority oversaw the refurbishment of an existing community 
room to create the transitional facility and the design and construction of the larger facility. 
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▪ A Gateway Services Reference Group (May 2018 – ongoing) was established to develop 
networks and linkages between service providers that might facilitate referral pathways for 
clients and encourage client engagement with local services.  
▪ A Local Reference Group (May 2018 – ongoing) provides a forum for working collaboratively 
with relevant parties including first responders (such as Ambulance Victoria), residents, schools 
and businesses to address elements of the trial that concern the local community. 
▪ A Consumer Advisory Group (March 2019 – ongoing) composed of MSIR users advises on 
direct service provision and concerns.  
▪ The Medically Supervised Injecting Room Review Panel (April 2018 – June 2020) was 
established to conduct this review.  
The Panel noted that, as one would expect in this type of contractual arrangement, NRCH had 
limited involvement in the initial governance discussions until they were the confirmed service 
provider. The government and DHHS were seen as the primary source of information and 
comment. This is understandable in the context of the challenges associated with an initiative of 
this kind but may have resulted in less-than-ideal communication with the local community and the 
intended service provider. The Panel also noted the findings of a later review into NRCH’s AOD 
program, which commented on the importance of clear lines of accountability and responsibility 
between the department that funds a service and the entity that provides the service.  
The Panel noted that specific advice was also provided from other organisations throughout the 
trial period to support capital works and service model design. This included Victoria Police in 
relation to crime prevention, specialist consultants on matters such as security, safety and traffic, 
the Department of Education and Training, Richmond West Primary School and Yarra City Council. 
Commissioning and funding arrangements 
In June 2018 NRCH was licensed as the operator for the trial. DHHS amended an existing contract 
between the two organisations to include providing a medically supervised injecting service. A 
performance management framework and quarterly reporting requirements were agreed 
between the department and NRCH. 
Funding was provided to NRCH based on the Sydney MSIC’s historical operational funding 
provided by NSW Health. This figure was subsequently revised to more closely reflect actual 
operating costs associated with the MSIR.  
Service model development  
There were several aspects of the service model specified in the legislation, including the 
requirement for registered medical practitioners to fill two of the roles (a medical director to 
oversee the centre’s operations generally and a medical supervisor to oversee the centre’s clinical 
operations).  
Within these parameters, the Expert Advisory Group considered critical policy and operational 
matters relevant to a high-level service model, drawing on the collective experience of the group, 
experience of the Sydney MSIC and international evidence. The Sydney experience helped inform 
the development of treatment guidelines, data collection and reporting structure.  
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This advice was provided to government for decision making on regulations and licence conditions 
and subsequently informed NRCH’s internal management protocols (NRCH 2018) that formed the 
basis of the licence. These protocols specified important aspects of the model including:  
▪ staffing and the service responsibilities of the workforce profile 
▪ the service model, including nominating the activities that could be undertaken in each of 
the zones at the facility 
▪ eligibility for registration, including that: 
− service users are 18 years of age or older 
− service users have injected drugs previously 
▪ assessing existing registered service users where, at a particular visit, a client may be denied 
access to the Injecting Zone for the following reasons: 
− the client possesses a quantity of drugs above the permitted quantity (at a traffickable 
amount) 
− the client is not willing to adhere to the accepted behaviours outlined in the Client rights 
and responsibilities document  
− the client’s access to the MSIR has been limited due to past behaviour  
− the client is accompanied by children  
− the client is intoxicated and deemed to pose an unacceptable level of clinical risk  
− the client is severely unwell, to a level such that their access to the Injecting Zone would 
pose an unacceptable level of clinical risk  
− the client is identified as being pregnant (NRCH 2018). 
These criteria can result in people not being able to access the service. 
On reflection it is evident that the core focus in the initial establishment of the service was on the 
operation of the actual MSIR, especially the Injecting Zone and the response to overdose 
experiences. At the time of opening, some of the other services such as blood-borne virus testing 
were also available. However, it has taken some time to develop comprehensive protocols, 
pathways, partnership agreements and memorandums of understanding, record keeping/sharing 
arrangements and timetabling to facilitate other responses consistent with the expectations of an 
integrated service model. 
Opening the transitional facility 
Following it being identified as the prospective licensee, NRCH worked with DHHS to develop the 
specifics of the service model and aspects associated with implementation, including relevant 
policies, protocols and infrastructure such as IT systems. There was significant input from DHHS and 
existing injecting facilities/drug consumption room service providers including sharing of policies 
and protocols and efforts to build on lessons learnt from other experiences. This included site visits to 
Canadian and European services by personnel who were to staff the MSIR once it opened. All 
parties describe this collaboration as essential to enabling the trial. 
Over a period of 12 weeks, 57 staff were recruited and trained. This included recruiting the medical 
director. An addiction medicine specialist began full-time in mid-May 2018, before moving to three 
days per week with responsibility for overseeing the MSIR. In 2019 this role expanded to overseeing 
NRCH’s existing AOD treatment team. The Sydney MSIC provided some experienced staff to work 
at the MSIR trial for the initial weeks to support its opening. Some remain employed by the MSIR. 
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The service was initially located in a refurbished community engagement room accessible from the 
street-facing side of the community health centre. DHHS advised that refurbishing an internal area 
of the existing NRCH building had been the quickest way to provide the service.  
As shown in Figure 4, the transitional service provided an entry area, 11 injecting positions, a 
medical monitoring space, two consulting rooms and an aftercare zone.  
Figure 4: Floor plan of the transitional facility (site of the service 30 June 2018 – 6 July 2019) 
 
Source: Image provided by DHHS 
As shown in the photographs at Figure 5, the transitional facility had a separate entrance to the 
existing community health centre entrance and a standard clinical fit-out. This included booth 
positions for injecting and observation chairs. 
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Figure 5: Photographs of the transitional facility  
 
Source: Images provided by DHHS 
Developing the larger facility 
In parallel with the licensing, and before opening the transitional facility, plans were being agreed 
to build a larger facility to allow time for approvals and construction. As the location is included in 
the legislation, the larger facility was also constructed at 23 Lennox Street, Richmond. Within that 
land, the larger facility was constructed on the former turning circle outside NRCH.  
Advice from DHHS is that the design of the larger facility was primarily developed between DHHS, 
NRCH and the Victorian Health and Human Services Building Authority working with the contracted 
architects and project managers. The Panel was informed that key members of the NRCH MSIR 
team provided significant input into the design and function of the new building, including 
consulting directly with existing clients of the AOD program.  
As shown in Figure 6, the larger facility includes the Entry Zone (including space for the NSP to be 
co-located with the reception desk for the facility), 20 injecting booth positions, additional 
consulting rooms, a larger Aftercare Zone and space for a large meeting room that can be used 
for group activities.  
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Figure 6: Floor plan of the larger facility (site of the service 7 July 2019 – current)8 
 
Source: Image provided by DHHS 
As shown in the photographs in Figure 7, the larger facility is a separate building with its own 
entrance adjacent to the community health centre. The larger facility is closer to Lennox Street and 
has more space than the transitional facility and maintains a standard clinical fit-out.  
 
8 Image provided by DHHS, available at the Victorian Health and Human Services Building Authority’s website 
<https://www.vhhsba.vic.gov.au/health-infrastructure/medically-supervised-injecting-room>. Please note this is an early 
artist’s impression. Some internal infrastructure design changes were completed before the service opened on 7 July 2019. 





Figure 7: Photographs and location of the larger facility 
  
Source: Images provided by DHHS 
To support the move into the larger facility, there was a staggered increase in the number of 
injecting booth positions available. From its opening on 7 July 2019, hours of operation were also 
extended to 7.00 am – 9.00 pm weekdays and 8.00 am – 7.00 pm weekends and public holidays. 
(This provided an additional three hours per day on top of the transitional facility hours from 8.00 am 
– 7.00 pm weekdays and 9.00 am – 5.00 pm weekends and public holidays.) From the opening of 
the larger facility, there were 12 injecting booth positions operating by September 2019. The NRCH 
NSP program was transitioned to operate from the larger facility from July 2019, with the two teams 
sharing a large space in the entry zone. 
Relevant policies, procedures and protocols were revised to reflect the new environment. The 
increased capacity and extended hours necessitated a significant workforce increase, with the 
internal management protocols requiring at least two staff in each functional zone and additional 
staff members moving between areas to provide support when necessary, in addition to security 
staff (NRCH 2019).  
Noting the relatively rapid uptake of increased capacity in the service, the Panel has reflected on 
the extent to which one facility with one Injecting Zone can manage the emerging demand and 
the risks associated with any further increase in capacity within the same service, were this 
physically possible. Clients have indicated that one of the reasons they leave before injecting is 
when there is a waiting period. To manage potential staff shortages during times of peak demand 
or when acuity requires more focused resources, staff can and do close off new incoming service 
users at reception/Zone 1. The Panel considered that having more than one service location of this 
kind would lessen the focus and demand on the current service site.  
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Quality and safety of the service  
NRCH is an independent registered community health organisation and a company limited by 
guarantee governed by a board of directors. As required by the Australian Government’s 
Corporations Act 2001, NRCH is required to have robust governance and operational 
management processes in place. In the recent review into the NRCH AOD program,9 no evidence 
was found that NRCH has breached these requirements, nor did the DHHS 2017–18 and 2018–19 
performance reports for NRCH. Operational incidents have been reported to DHHS as required. 
Both the transitional facility and larger facility and their operating models were accredited under 
Quality Innovation Performance Limited against the Australian Commission on Safety and Quality in 
Health Care Standards. The MSIR is an accredited health service with a licence to store 
medications and provide medical care.  
Stakeholders with experience in acute health settings, particularly emergency departments and 
inpatient psychiatric settings, including senior and experienced medical staff, a major public 
hospital emergency department and mental health services noted the high level of acuity of 
medical and behavioural challenges presented by these service users. The impression formed by 
these experienced clinicians is of a dynamic and challenging environment. Some clinicians 
expressed reservations about having 20 injecting booth positions in one location, noting that in 
other acute settings there is generally a preference for having more but smaller units, making it 
easier to manage both medical and behavioural problems. Members of the Panel visited the new 
facility on several occasions. Panel members noted the additional challenges of having a larger 
number of people who use drugs on site and how busy and dynamic the environment had 
become.  
The increase in staff numbers to support the larger facility was significant, not only from a 
recruitment and training perspective but also for people and change management. Some staff 
noted that, in moving into the new facility, they needed to become familiar with a new space and 
also new colleagues. In the second round of recruitment the facility added people with 
appropriate clinical skills to respond to overdoses and, in drawing on a broader pool of staff, 
included others who had not necessarily experienced working with people who inject drugs in a 
harm reduction framework.  
Some external stakeholders voiced concerns to the Panel about NRCH’s capacity to provide 
appropriate clinical governance to the MSIR workforce. Their concerns related to whether the 
current structure had the capacity to provide sufficient clinical leadership, maintain a focus on 
scope of practice and provide appropriate clinical supervision (noting the additional complexity of 
staff coming from a range of clinical backgrounds, which they felt can take additional effort to 
manage). Feedback from the service is that there are clinical supervision challenges with a shift 
working cohort; however, these are being addressed with external clinical supervisors. 
Management noted that having increased access to experienced staff to mentor and support 
other staff could improve the safety and quality of the service.  
Despite the challenging context, the service has provided a generally safe environment for both 
staff and service users. There was one reportable incident per 1,000 visits during the trial period – 
 
9 The review into the NRCH AOD program was instigated in response to an incident involving staff from NRCH in relation to 
alleged drug offences. The staff were not from the MSIR. The report highlighted the importance of clear governance 
arrangements and clarity between DHHS and NRCH in relation to key performance areas.  
 
28 
most commonly involving occupational health and safety concerns (28 per cent of all incidents), 
verbal abuse/assault/aggression not involving staff (21 per cent) and other health concerns (18 per 
cent) (Table 2).  
Table 2: Reportable incidents at the MSIR by type of incident, total numbers reported from Quarter 1, 
2018–19 to Quarter 2, 2019–20 
Reportable incidents Number Percentage 
Occupational health and safety  38 28 
Verbal abuse/assault/aggression not involving staff  29 21 
Other health concerns(a) 24 18 
Verbal abuse/assault/aggression towards staff 18 13 
Other behaviour requiring removal from premises(b) 6 4 
Other client injury 11 8 
Other(c)  10 7 
Total number of incidents 136 100 
Source: MSIR database 
(a) Includes seizures, allergic reactions and arterial injection. 
(b) Includes property damage and dealing. 
(c) Includes client record system errors, pay errors and a medical error. 
As shown in Figure 8, during the period in the larger facility, despite an increase, the incident rate 
remained low, with around two incidents per 1,000 visits (0.2 per cent). 
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Figure 8: Reportable incident rate at the facility from Quarter 1, 2018–19 to Quarter 2, 2019–20  
 
There was an increase in the number of incidents reported in the transition to the larger facility 
(Figure 9). The increase in the number of reportable incidents appears to reflect, in part, the larger 
space and extended opening hours in the larger facility, with more potential for interactions 
between service users. This was also a period in which there was increased attention and training 
on reportable incidents, which may reflect better reporting.  
Figure 9: Reportable incidents at the facility from Quarter 1, 2018–19 to Quarter 2, 2019–20  
 
Source: MSIR database 
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In October 2019 there was an incident involving two AOD program staff members, which led to the 
employees involved and the then CEO being stood down, and a separate independent review 
into the NRCH AOD program. One of the key findings of that review was: 
… the recent allegations of inappropriate behaviour by NRCH employees have highlighted 
gaps and shortcomings in governance, leadership, culture and workforce management that 
will need to be addressed. 
(Aspex Consulting 2019, p. 3) 
The review into the NRCH AOD program made 12 recommendations to address the gaps. The 
incident that led to the review and the review itself were not primarily related to the MSIR. NRCH 
has implemented changes to meet each of the 12 recommendations.  
Broader activities to engage the community and improve the 
amenity 
There have been efforts to engage the community and improve local amenity over the course of 
the trial. The Panel was informed of a number of events and initiatives to further this goal, 
particularly in the second half of 2019. Much of the visible activity emerging from an April 2019 
announcement by the Minister for Mental Health that committed to more frequent sweeps to 
remove needles, more AOD outreach teams to help on the street, and an increased security 
presence and improved lighting on the Richmond housing estate, was not apparent at the time of 
the repeated MSIR Review Survey in the middle of 2019. Other changes have occurred including 
Yarra City Council increasing street cleaning in the Victoria Street precinct and Victoria Police’s 
regular proactive patrols seen by Panel members during walks through the immediate vicinity of 
the MSIR.  
Yarra City Council had initiated several locality focused renewal projects just before the MSIR 
opened. This included the Victoria Street master plan and demolition of an abandoned building 
with associated rubbish removal at Lennox Street, a reported previous informal injecting site, 
together with a project to promote graffiti removal and grants for shop roller-door decoration.  
DHHS has advised of local briefings and information sessions before and during the trial and 
establishing a local reference group for the MSIR, though many residents who spoke with the Panel 
reported a lack of consultation.  
The Panel has been informed of a cross-government roundtable, led by DHHS with collaboration 
from Yarra City Council and other Victorian Government departments and agencies including 
Victoria Police to oversee broader precinct development in North Richmond to respond to 
longstanding issues and improve community health, wellbeing and safety. DHHS has reported that 
the roundtable has met monthly since April 2019 to consider a long-term cross-agency approach 
to:  
▪ increase community participation and social cohesion in the area 
▪ improve access to health and social support services 
▪ enhance public amenity and infrastructure 
▪ improve experiences and perceptions of safety, security and crime. 
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The Panel observed that the role of NRCH and MSIR in managing the relationship with the local 
community surrounding the MSIR trial was at times confusing and apparently compromised. The key 
service requirements included in the performance monitoring framework for the MSIR contained a 
clause expecting NRCH to ‘engage with the local community to improve understanding of the 
MSIR’, but in parallel the MSIR CEO and the medical director of the MSIR reported to the Panel that 
they were required to have all their communications cleared through DHHS, making timely and 
direct responses to locals and the media difficult. Going forward, the Panel suggests that any 
licensee must be proactive in engaging with and communicating with the local community and 
key stakeholders. 
In July 2019 (shortly after the service moved into the larger facility), there was a joint information 
session held by DHHS, the Yarra City Council, Victoria Police and NRCH attended by more than 300 
people. 
More recently, the Panel understands that government has made further improvements on the 
Richmond housing estate. Victoria Police identified important safety and security issues through a 
Crime Prevention Through Environmental Design review. In response, DHHS made capital upgrades 
throughout the estate, including in the multi-deck carpark next to NRCH. Cleaning, needle 
collection and syringe disposal unit availability has also been increased. As the trial has progressed, 
the Panel has been informed about more crime prevention activities in the area in the vicinity of 
the MSIR and on the estate.  
In the interests of analysing the data the Panel had already collected, it has not been possible to 
further assess or review the impact of these changes since the Panel ended formal data collection 
at the end of 2019 when many of these initiatives might have been starting to take effect.  
It is unfortunate that these measures to engage the local community, consult and coordinate the 
many activities in the area to address public amenity were not initiated much earlier, before the 
opening of the MSIR trial.  
Comparison between the North Richmond and Sydney 
facilities 
The North Richmond MSIR is the second licensed supervised injecting service in Australia. Although it 
has many similarities with the first centre, the MSIC in Sydney, there are several key differences 
between the services (see also Table 3): 
▪ Legislated aims – the MSIR has legislated aims that go beyond direct service provision, 
including reducing overdoses requiring ambulance attendance or emergency services and 
improving local amenity. 
▪ Responsible authority – the responsible authority for licensing the MSIR is the DHHS Secretary, 
while both the Director-General of the Department of Health and Commissioner of Police are 
responsible authorities for the MSIC.  
▪ Funding – the MSIR is funded through the State Budget while the MSIC is funded through 
proceeds of crime. 
▪ Licensee – The MSIR is licensed to a small community health centre, the MSIC to a national 
health and human services provider. 
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▪ Location – the MSIR is co-located with a community health service that was designed to meet 
the primary health and social support needs of local communities, while the MSIC operates 
from a single shopfront near a railway station and within a commercial precinct. 
▪ Volume of services in the first 18 months – there were a similar number of people registered at 
both services, but the MSIR had more than double the number of visits. 
Table 3: Comparison of the MSIR with the Sydney MSIC 
Dimension MSIR (North Richmond) MSIC (Sydney) 
Operating 
period 
Commenced 30 June 2018 Commenced 6 May 2001 
Legislated 
aims 
Drugs, Poisons and Controlled 
Substances Act 1981. Objects to: 
• reduce the number of avoidable 
deaths and harm caused by drugs of 
dependence 
• deliver and provide a gateway to 
treatment and counselling for service 
users  
• reduce attendance by ambulance 
services, paramedics and 
emergency services and 
attendances at hospitals due to 
overdoes of drugs of dependence 
• reduce the number of discarded 
needles and syringes in public places 
and the incidence of injecting of 
drugs of dependence in public 
places 
• improve the amenity of the 
neighbourhood for residents and 
businesses in the vicinity 
• assist in reducing the spread of 
blood-borne diseases in respect of 
service users of the licensed injecting 
facility, including but not limited to, 
HIV and hepatitis C. 
Drug Misuse and Trafficking Act 1985 s. 36 
B: Objects to: 
• reduce the number of deaths from 
drug overdoses 
• provide a gateway to treatment and 
counselling for service users 
• reduce the number of discarded 
needles and syringes and the 
incidence of drug injecting in public 
places 
• assist in reducing the spread of blood-




Secretary, DHHS The Commissioner of Police and the 
Director-General of the Department of 
Health (now called Secretary) 
Funding Through usual budget processes to 
Department of Treasury and Finance 
Confiscated proceeds of crime account, 
managed by the NSW Treasury 
Location  23 Lennox Street, Richmond 
The service is co-located with a broad 
community health service that was 
designed to meet the primary health 
66 Darlinghurst Road, Potts Point 
The service is a shopfront, standalone 
service targeting people who inject drugs 
in the local area. It operates from a single 
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Dimension MSIR (North Richmond) MSIC (Sydney) 
and social support needs of the local 
residents 
shopfront immediately opposite a railway 
station and within a shopping precinct  
Licensee NRCH, an incorporated small, not-for-
profit community health centre with a 
board of directors 
Uniting, which is the services and 
advocacy arm of the Uniting Church in 
NSW and ACT, a faith-based health and 
human services provider 
Workforce Medical director and medical 
supervisors, operation manager, nurse 
unit manager, registered nurses, harm 
reduction staff, security staff and 
additional co-located services such as 
mental health support from St Vincent’s 
Hospital Melbourne 
Medical director, operations manager, 
nurse unit manager, mental health staff, 
health education staff, registered nurses, 
security staff and a commonwealth 
funded co-located mental health nurse. 
Visits in first 
18 months 
3,936 people registered 
Service users made 119,223 visits 
3,810 people registered  




• Crisis counselling, and support for a 
range of medical/physical/social/ 
emotional presentations associated 
with a vulnerable population of 
people who have high rates of 
homelessness, mental ill health, 
childhood trauma and general poor 
health 
• Care to reduce morbidity and 
mortality associated with drug 
injection and overdose 
• A range of practical harm reduction 
advice and referrals to support 
service users to engage with drug 
treatment services and other health 
care and social services (such as 
accommodation) 
• Regular open public tours of the 
service  
The MSIC’s core services align with those 
provided by the MSIR. 
The MSIR also offers on-site services provided by NRCH staff and collaborations with St Vincent’s 
Hospital Melbourne and the Burnet Institute. Other services include GP services, vaccinations, 
blood-borne virus testing, STI testing, hepatitis treatment, fibroscan, methadone and buprenorphine 
maintenance prescribing, long-acting buprenorphine administration, suboxone dispensing for the 
purpose of long-acting buprenorphine initiation, oral health care including silver fluoride varnish 
and basic oral x-rays, a mental health nurse and a wound care nurse. Additional on-site services 
are provided by external agencies including Launch Housing, ReGen alcohol and drug workers 
and Fitzroy Legal Service. 
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Use of the MSIR  
There were significant efforts to ‘pre-register’ people for the service by engaging existing NRCH 
service users, encouraging them to complete the intake questionnaire in the period immediately 
before the MSIR trial opened and answering important questions about the service to reduce 
barriers to engagement.  
As shown in Figure 10, in the first 18 months of the trial, 3,936 people registered for the MSIR. The first 
three months (including people pre-registered before the service opened) had the most 
registrations, and there was another increase when the larger facility opened.  
Figure 10: Number of newly registered MSIR service users from Quarter 1, 2018–19 to Quarter 2, 
2019–20 
 
Source: MSIR database 
The number of supervised injections remained steady between Quarter 2 and Quarter 4, 2018–19, 
and then began to increase steadily from Quarter 1, 2019–20 (coinciding with the opening of the 
larger facility) (Figure 11).  
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Figure 11: Number of visits that included a supervised injection from Quarter 1, 2018–19 to Quarter 2, 
2019–20 
 
Source: MSIR database 
The average number of daily visits to the facility gradually increased over the first five months of 
operation and then remained relatively stable (at around capacity) through the first half of 2019. 
The opening of the new facility in July coincided with a marked increase in daily visits, consistent 
with the increased capacity through additional booths and longer opening hours (Figure 12).  
Figure 12: Average number of daily visits to the MSIR by month, July 2018 to December 2019 
 
Source: MSIR database 
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Substances injected at the MSIR 
All injectable substances are permitted at the MSIR and there is no testing of the substances that 
service users bring to inject. Service users must inform the staff about what substance they plan to 
inject each time (with research indicating that most people who inject drugs are able to 
accurately identify the main substance in their drugs). As shown in Table 4, the primary drug 
injected has been heroin (96.6 per cent), whether alone or in combination with diphenhydramine. 
Table 4: Substances injected at the MSIR, June 2018 to December 2019 
Drug Percentage of all injections  
Heroin 80.8 
Heroin plus diphenhydramine 15.8 
Methamphetamine 2.5 
Mixed sedative and stimulant combination 0.5 
Other sedative combination 0.3 
Prescription opioid < 0.1 
Other drug < 0.1 
Other stimulant combination < 0.1 
All other drugs/combinations of drugs 0.01 
Source: MSIR database 
Refusals  
There are a number of reasons why some people are not able to access all MSIR services and, in 
particular, the injecting booths. Some of these are noted in the legislation used to set up the MSIR 
trial, some in the regulations, and some relate to government or service policy. These various 
reasons for refusal include: 
▪ people on bail/parole conditions – noting that people leaving custodial settings can be at 
increased risk of overdose due to decreased tolerance to substances 
▪ pregnant women and people with accompanying children – noting that pregnant women 
who inject drugs and their children, including unborn children, can benefit when supported 
by healthcare and other service providers 
▪ young people – noting many people who use the MSIR first injected at a relatively young age 
▪ people who cannot inject themselves – noting this can be a barrier to access for people who 
do not inject themselves in other settings 
▪ people who typically purchase drugs together – noting that people are unable to share drugs 
in the service 
▪ people who typically use drugs together – people are unable to attend in groups, and there 
are no more than two seats in any one booth 
▪ people who use drugs of dependence through routes of administration other than injecting.  
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From 30 June 2018 to 31 December 2019, 30 people were refused entry to the MSIR (Figure 13). Half 
involved people who have never injected. Pregnancy was the second most cited ground for 
refusal. These figures do not capture self-exclusion, either by people leaving before registering, or 
opting not to attend knowing that they would be refused (several stakeholders and service users 
reported that the exclusion criteria quickly became known and deterred these people from 
attempting to use the service).  
Figure 13: Number of occasions of refused entry to the MSIR by reason, 30 June 2018 to 31 
December 2019 
 
Source: MSIR database  
Referrals for people ineligible to attend  
MSIR staff offer support to those who are ineligible to access to the MSIR, with a view to assessing 
their needs and appropriately attempting to refer them to an alternative health or social support 
service. The facility refers pregnant people to the Women’s Alcohol and Drug Service. Referrals are 
offered to any presenting young person under the age of 18 years to youth services including the 
Youth Support and Advocacy Service. When people who have never injected present to the MSIR, 
staff engage them in a discussion about the risks of transitioning from other ways of using drugs and 
refer them to appropriate treatment. Occasionally, a client may present to the MSIR accompanied 
by a minor. In such cases, staff would undertake a risk assessment and, where necessary, provide a 
report to Child Protection.  
Other barriers to access 
The Panel also became aware of situations where individuals elected not to use the MSIR. These 
included: 
▪ having a preferred location to inject elsewhere, either in a less clinical private setting or with a 
preference for injecting outside 
 
38 
▪ being deterred by a real or perceived waiting time at the MSIR 
▪ being or accompanying someone who had been sanctioned 
▪ wishing to avoid other service users or staff  
▪ concerns about surveillance and police presence. 
People who inject at the MSIR 
Data provided by the MSIR indicates that, on average, facility service users during the trial were 41 
years of age. Three-quarters of the service users were male. A third (34.7 per cent) of service users 
were homeless or in insecure accommodation.10 Approximately a quarter (23.3 per cent) of the 
service users were released from prison or juvenile detention in the preceding three months. 
Thirteen per cent of service users identified as Aboriginal (see Table C1 at Appendix C).  
Most service users had been injecting for a significant period (92 per cent had been injecting for 
more than five years, and 61 per cent reported injecting for at least 20 years). Advice from the MSIR 
is that the most common age of initiation of injecting drug use was 16 years old. 
People who inject drugs and do not inject at the facility  
To understand the client profile, it is also useful to understand who does not use the facility. The 
data from the Burnet Institute’s SuperMIX study show that, of those surveyed (n = 598), those who 
visited the MSIR were more socially marginalised than those who did not visit the MSIR. That is, they 
were more likely to: 
▪ be unemployed 
▪ live in unstable accommodation 
▪ be homeless 
▪ live by themselves 
▪ have been incarcerated in the previous 12 months. 
SuperMIX data show that people who had visited the MSIR were statistically significantly more likely 
to have been arrested (for any reason) since their previous interview compared with those who 
had not visited the facility (65 per cent versus 41 per cent, respectively). Those who visited the MSIR 
were also more likely to identify as Aboriginal, more likely to state heroin as their main drug of 
choice and to have injected heroin in the last month (Burnet Institute 2019, p. 7). See Table C2 at 
Appendix C. 
This SuperMIX data indicates that many MSIR users have multiple and complex needs.  
 
10 Homeless and insecure accommodation is defined here as people experiencing primary homelessness (for example, 
sleeping rough or in improvised dwellings); secondary homelessness (for example, refuges, couch surfing, squat); or tertiary 
homelessness (for example, boarding house/hostel). This definition of homelessness 
<https://www.homelessnessaustralia.org.au/about/what-homelessness> is widely used in the homelessness sector. 
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Advancement of the objects of the 
legislation 
Each of the objects of the Drugs, Poisons and Controlled Substances Amendment (Medically 
Supervised Injecting Centre) Act are addressed in this section.  
Part 55A(a): Reduce the number of avoidable deaths and the 
harm caused by overdoses 
To assess this object, the Panel considered: 
▪ Coroner’s Court of Victoria data on fatalities involving heroin  
▪ MSIR data on the volume and nature of overdose interventions provided  
▪ staff and service user consultation 
▪ consultations with emergency department doctors and administrators. 
The finding of this review is that the trial has advanced this object. MSIR staff have reduced 
avoidable deaths and harms associated with overdose of drugs of dependence among 
people injecting within the service. 
▪ Establishing the MSIR has prevented overdoses and further harm and has saved lives.  
▪ Of those who do attend the service, the nature of the overdoses is significant, and 
without intervention it is likely that many would have died or been permanently injured.  
▪ While it is not possible to say with certainty how many people would have died without 
the MSIR, international approaches to modelling, based on conservative estimates, 
indicates that 21–27 deaths were avoided in the first 18 months of the trial. This does not 
include the prevention of permanent disability such as acquired brain injury.  
The MSIR attracts people who are at high risk of overdose, with many reporting previous 
experiences of overdose. This is recognised as one of the strongest predictors of a 
subsequent fatal opioid overdose. 
▪ Just over 2 per cent of the visits to the MSIR involved an overdose requiring intervention.  
▪ The MSIR has supervised 116,802 injections. 
▪ Of the 2,657 overdoses, the MSIR responded to 271 extremely serious overdoses with 
naloxone. 
▪ Of the 2,657 overdoses, the MSIR responded to 2,615 overdoses with oxygen and other 
measures to keep the airways open, potentially saving additional lives and avoiding 
harms associated with lack of oxygen to the brain.  
▪ There have been no fatalities from overdoses in the facility. 
▪ All staff and service users interviewed provided examples where they believed the 
facility had saved lives. 
 
40 
▪ The early focus of the MSIR was appropriately on the facility’s readiness and capacity 
to oversee the service within the injecting room itself. Protocols, guidelines and staff 
selection focused on overseeing injecting and preventing overdose and harm.  
A detailed analysis of the first 12 months’ instances of overdose within the injecting room 
showed that the overdoses ranged from less severe (reduced respiratory rate and reduced 
conscious state), which require oxygen and physical manoeuvres to keep the airway open, 
to severe overdoses with profound unconsciousness (21.1 per cent), with no breathing at all 
over five minutes (13.5 per cent), that are life threatening and could result in death and 
required either assisted ventilation with a bag valve mask (13.8 per cent) and/or naloxone 
(14.2 per cent). An experienced doctor who worked as a volunteer in the facility 
commented that some of the overdoses were ‘at least as acute an emergency as those we 
receive in an [emergency department]’.  
The facility has the appropriate equipment to respond to the medical emergencies that 
arise as a result of drug use, including administration of necessary responses to administer a 
response to avoid death or further harm. The MSIR staff are well trained and clearly 
demonstrate capacity to respond, manage and administer the required intervention. 
Almost all of the overdose incidents (99 per cent) are managed by the MSIR’s harm 
reduction and nursing staff, and the level of staffing is sufficient to provide timely responses. 
The facility was designed to provide medical supervision to service users while they self-administer 
injectable substances intravenously. Service users are monitored while in the injecting area and 
elsewhere in the facility for signs of overdose. The legislation states that the facility aims ‘to reduce 
the number of avoidable deaths and the harm caused by overdoses of drugs of dependence’ 
(Part 55A(a) of the Act). The review initially considered evidence that: 
▪ people who inject drugs are attending and injecting at the facility 
▪ those using the facility are injecting under medical supervision 
▪ overdoses are being identified and responded to according to protocols  
▪ staff are engaging service users regarding their needs  
▪ critical incidents are being responded to according to protocols. 
As the trial progressed, the review analysed evidence to understand the extent to which: 
▪ people who inject drugs are using the facility in preference to injecting in higher risk settings 
▪ staff can safely and effectively deliver the required services. 
Overdoses cause significant harm, even if they are not fatal 
A person’s overdose risk increases with every overdose they experience (Olfson et al. 2018). 
Previous experience of overdose is one of the strongest predictors of subsequent fatal opioid 
overdose (Stoove et al. 2009). Non-fatal opioid overdose victims who experience multiple/recurring 
opioid overdose are at greater risk for long-term physical and cognitive consequences (Zibbell et 
al. 2019). 
Non-fatal opioid overdoses are associated with a wide range of acute and chronic medical 
complications (Zibbell et al. 2019). These include aspiration pneumonia, pulmonary oedema, 
bronchopneumonia, muscle tissue breakdown, hypoxic brain injury, peripheral neuropathy, renal 
failure, cognitive impairment and traumatic injuries sustained during overdose. One study found 
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that more than three-quarters of overdose victims report at least one post-overdose morbidity 




The facility is attracting people at risk of overdose 
On registration, MSIR service users report significant experience of overdose: 
▪ 56 per cent of service users report having experienced an overdose, either on heroin or other 
opioids 
▪ 49 per cent have witnessed someone else overdose.  
The Burnet Institute’s (2019) SuperMIX study also found that people who previously injected in high-
risk settings are about twice as likely to visit the MSIR than those who did not previously inject in 
high-risk settings (Table C3, Appendix C). Of the study participants who reported visiting the centre, 
a third performed at least half of their previous month’s injections in the facility (Table C4, Appendix 
C). 
People are injecting at the facility and under medical supervision 
People who inject drugs are using the facility and injecting drugs on site under medical supervision. 
Under the MSIR Internal management protocols (DHHS 2019b), service users receive appropriate 
interventions according to the clinical management protocols including:  
▪ observation, including monitoring of blood oxygen saturation with pulse oximeters 
▪ prompting to breathe 
▪ oxygen 
▪ manoeuvres to open the airway 
▪ assisted ventilation with a bag, valve and mask 
▪ naloxone where required 
▪ advice from the medical supervisor as required 
▪ ambulance as required. 
Naloxone can be administered according to best practice  
Naloxone is a medication that can be used to reverse the experience of an overdose. Naloxone is 
an extremely safe medication but can precipitate opioid withdrawal symptoms, including agitation 
or irritability, anxiety, body aches, nausea/vomiting, diarrhoea and sweating, particularly if too high 
a dose is administered. More severe reactions are rare but may include acute respiratory distress 
syndrome, hypertensive emergency, ventricular tachycardia, fibrillation and, in extremely rare 
circumstances, sudden death (European Monitoring Centre for Drugs and Drug Addiction 2015).  
The facility’s approach is to attempt to rouse a person first by talking or lightly touching them, then 
provide oxygen, and only if they are not responding, then provide naloxone. This allows the dose to 
be sufficient to achieve respiratory function without precipitating withdrawal symptoms. This is 
consistent with international standards (European Monitoring Centre for Drugs and Drug Addiction 
2015).  
The MSIR’s ability to use non-pharmaceutical responses initially and then low doses is due to the 
capacity of the service and the skills of the staff to monitor service users, similar to a hospital setting 
(Lynn & Galinkin 2018).  
All staff are trained to identify and respond to overdose incidents. Any staff member can provide 
oxygen, although in practice it is typically provided by a registered nurse. In the event naloxone is 
required, a registered nurse administers it. If there are complications, the on-call medical supervisor 
43 
is contacted for advice or, if clinically appropriate, MSIR staff will call for an ambulance. It is, in 
essence, a nurse-led model of care.  
Under current protocols, providing naloxone is not within the scope of practice of harm reduction 
practitioners while working inside the MSIR, although they, as any other community member, are 
able to administer it when not at work. Some staff would prefer that harm reduction practitioners, 
as well as the nursing and medical staff, had the authorisation to provide naloxone.  
People who have overdosed elsewhere or who are heavily sedated can also be safely observed at 
the MSIR, providing an opportunity for staff to intervene at an important time and potentially 
reducing the risk of a subsequent unsupervised overdose.  
Ambulance Victoria has sought the support of the facility to manage people who are found to be 
overdosed or heavily sedated in the community who would benefit from ongoing monitoring (as an 
alternative to being taken to an emergency department or in the absence of being able to go to 
family or friends). In addition, staff report that several people have asked to be brought to the 
facility, where they can be looked after in the consulting space. This is seen as a positive option 
since the facility is perceived by service users as more supportive and less stigmatising than their 
experience of emergency departments. It also addresses any risk of a person going into acute 
withdrawal, which can occur if a higher dose of naloxone is used in community settings. This can 
lead to the person subsequently using again to achieve the desired state, with a risk of further 
overdose. This also allows an opportunity to engage with these people, even if they are not existing 
MSIR service users, noting that anecdotally the period immediately after an overdose can be a 
valuable chance to discuss harm reduction practices and treatment options.  
People are becoming more aware of signs and responses to overdose 
and increasingly educated in how to respond 
Through witnessing or experiencing an overdose in the facility, some service users reported that this 
had improved their recognition of signs of overdose. The Burnet Institute (2019) study found that 
MSIR service users were statistically significantly more likely to report a non-fatal overdose since the 
facility opened than other people who inject drugs (Table C5, Appendix C). The Panel recognises 
that there could be other interpretations of these data.  
Facility data also show that the MSIR trained 193 service users during the trial period (78 in the last 
quarter) in how to identify and respond to overdoses in the community using naloxone and invited 
the AOD team to train many additional clients. Depending on the availability of medical staff, 
clients were either provided with naloxone on the spot or given a voucher to pick it up from a local 
pharmacy.  
Case study 1: Overdose prevention and response training after prison 
A client received overdose first response training with naloxone when their partner, another client 
of the MSIR, was released from prison. Their insight regarding their partner’s high risk of overdose 
after release was terrific to see. ‘I know they could drop … it’s best to be safe,’ they said. They 
planned to keep the naloxone kit with them because, as a couple, they were likely to use while 
out and about. The couple were encouraged to continue accessing the MSIR, and the partner 
was provided with harm reduction education on using smaller amounts of heroin while tolerance 
was low. 
Case study provided by the MSIR 
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Naloxone training has been more broadly promoted through other DHHS programs including by the 
NRCH AOD program. On registration at the MSIR, 220 people reported that they had previously 
received this training through another program. More than a third of all MSIR service users (34.4 per 
cent) would like training for overdose response. Given the effectiveness of naloxone in reversing 
opioid overdoses (European Monitoring Centre for Drugs and Drug Addiction 2015), this could 
usefully be expanded. 
People who work at and use the service believe it has saved lives 
All staff members and people who inject drugs interviewed by the Panel reported that they think 
the service saves lives. Service users frequently provided examples where they feel it had directly 
saved their own life or that of someone they witnessed overdosing. 
Case study 2: Experience of being revived from overdose 
One client interviewed for the review described their experience of having an overdose at the 
MSIR, stating: ‘Why use somewhere where you could die when you can use somewhere and know 
that you’re going to be safe? They’re absolutely excellent. They do not muck around over there. 
As soon as you show signs of an OD, bang they’re on you. They’re on you and make sure you’re 
healthy and happy and safe. They put a mask on you. I might have spent 10 minutes in there 
before with a mask on me because they said that I might be affected by drugs. I thought, that’s 
beautiful, you know, in the harsh morning here they are still looking after people.’  
Service user interview, June 2019 
Impact on drug-related deaths  
To understand the impact of the facility in its geography, coronial data were analysed to examine 
any changes in the number of deaths in the area immediately surrounding the site. Over a four-
year period, the numbers of heroin-related deaths in the Yarra LGA and the rest of Victoria have 
been relatively stable (Figure 14). The Panel notes that numbers of heroin-related deaths in the City 
of Yarra in these Coroners Court figures are comparatively small and they are presented here for 
accurate reporting but do not provide sufficient data for more detailed analysis or commentary at 
this time.11 
 
11 Please note that data from the Coroners Court of Victoria has been verified at the time of finalising this report. The 
contents of coronial databases are continually revised and updated as coroners’ investigations progress and new 
information becomes available regarding deaths. In this process, recoding and reclassification of deaths may occur. 
Consequently, data extracts done at different times may report different results.  
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Figure 14: Number of heroin-related deaths in Yarra LGA and the rest of Victoria, Quarter 3, 2014–15 
to Quarter 1, 2019–20  
 
Source: Coroners Court of Victoria 
Variations in the number of heroin-related deaths in the Yarra LGA across financial year quarters 
are shown in Figure 15. To robustly establish whether there was a difference in the overdose death 
trend before and after the intervention, the Panel considered using statistical tests. However, the 
low frequency of heroin-related overdose deaths in Yarra LGA and the short time period under 
examination (3.5 years before the intervention, 1.25 years following the intervention) significantly 
limit the applicability of statistical techniques. 
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Figure 15: Number of heroin-related deaths in Yarra LGA, Quarter 3, 2014–15 to Quarter 1, 2019–20, 
quarterly and financial year  
 
Source: Coroners Court of Victoria 
It should be noted that Figure 15 only relates to deaths within the Yarra LGA and does not include 
those deaths that occurred beyond the Yarra LGA that were linked to heroin purchased within the 
Yarra LGA. In the Inquest into the death of Ms A (Coroners Court of Victoria 2017), the Coroners 
Prevention Unit reported that, in 2015, in addition to 20 overdoses that occurred in Yarra, in a further 
15 overdose deaths that occurred in other LGAs, there was evidence that the heroin was sourced 
in the Yarra LGA (a total of 35). This is likely to be conservative as in many overdose cases there is 
no clear evidence of where the drugs were purchased.  
For comparison, Figure 16 shows variations in the number of heroin-related deaths in the rest of 
Victoria across financial year quarters. 
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Figure 16: Number of heroin-related deaths in rest of Victoria, Quarter 3, 2014–15 to Quarter 1, 2019–
20 – quarterly and financial year  
 
Source: Coroners Court of Victoria12 
More than half (57 per cent) of heroin-related deaths in Yarra occurred within 1 km of the MSIR. Of 
the deaths that occurred within 1 km of the MSIR, three-quarters (75 per cent) happened in a non-
residential location.  
The number of heroin-related deaths within 1 km of the MSIR declined six months after the MSIR 
opened (Quarter 3, 2018–19) and then increased again in the next quarter (Quarter 4, 2018–19; see 
Figure 17). This pattern was also evident for heroin-related deaths that occurred in non-residential 
locations within 1 km of the MSIR (Figure 18). 
 
12 The contents of Coronial databases are continually revised and updated as coroners' investigations progress and new 
information becomes available regarding deaths. In this process, recoding and reclassification of deaths may occur. 




Figure 17: Number of heroin-related deaths within 1 km of the MSIR, Quarter 3, 2014–15 to Quarter 1, 
2019–20  
 
Source: Coroners Court of Victoria 
Figure 18: Number of heroin-related deaths in non-residential locations within 1 km of the MSIR, 
Quarter 3, 2014–15 to Quarter 1, 2019–20  
 
Source: Coroners Court of Victoria 
Among the top 20 LGAs for heroin-related deaths, the proportion of deaths occurring in non-
residential locations varies (Table 5). Between January 2015 and September 2019, Yarra recorded 
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the highest proportion of heroin-related deaths in non-residential locations (55 per cent), and 
Melbourne recorded the second highest (49 per cent). For the other LGAs, two to 30 per cent of 
heroin-related deaths occurred in non-residential locations.  
Table 5: Percentage of deaths occurring in non-residential locations – top 20 LGAs for heroin-
related deaths between January 2015 and September 2019 
 
Source: Coroners Court of Victoria 
While the top five LGAs for heroin-related deaths all recorded decreases in the number of heroin-













related deaths  
Yarra 51 55 93 
Melbourne 25 49 51 
Brimbank 17 30 57 
Port Phillip 10 19 52 
Greater Geelong 8 20 40 
Frankston 6 20 30 
Wyndham 6 26 23 
Greater Dandenong 6 11 53 
Maribyrnong 5 16 32 
Whitehorse 4 16 25 
Maroondah 4 21 19 
Stonnington 3 17 18 
Hume 3 17 18 
Yarra Ranges 2 9 22 
Moonee Valley 2 11 18 
Monash 1 5 22 
Greater Bendigo 1 6 18 
Boroondara 1 6 18 
Moreland 1 3 30 
Knox 1 3 29 
Darebin 1 2 41 
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recording fluctuations in the number of deaths. The numbers of deaths recorded since the MSIR 
opened were largely similar to those recorded before the MSIR opened (Figure 19). 
Figure 19: Number of heroin-related deaths in selected LGAs, Quarter 3, 2014–15 to Quarter 1,  
2019–20 
 
Source: Coroners Court of Victoria 
Of the top four suburbs MSIR service users reported as their location of residences at registration, 
three – Melbourne, Richmond and St Kilda – recorded decreases in the number of heroin-related 
deaths three to six months after the MSIR opened (Figure 20). Overall, there were no obvious trends 
observed, with the numbers of deaths recorded since the MSIR opened largely similar to those 
recorded before the MSIR opened.  
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Figure 20: Number of heroin-related deaths in selected suburbs, Quarter 3, 2014–15 to Quarter 1, 
2019–20 – top suburbs MSIR users report at registration 
 
Source: Coroners Court of Victoria 
Part 55A(b): Deliver more effective health services by 
providing a gateway to health and social assistance 
To assess this object, the Panel considered: 
▪ MSIR data on health needs and services provided 
▪ emergency department and hospital data 
▪ results of a cohort study of people who use drugs linked with Victorian and national 
health datasets 
▪ consultations with professional stakeholders, staff and service users. 
The finding of this review is that the trial has advanced the object of providing a gateway to 
health and social assistance but in the first year of operation has not demonstrated higher 
levels of service take-up for MSIR users as compared with other people who use drugs.  
Having noted that the MSIR is attracting people with particularly high health and support 
needs, it is a potential site for proactive engagement and providing supplementary services. 
▪ The MSIR provided 10,540 services beyond the supervision of injecting during the trial 
period. Most commonly this was health promotion, dressing wounds, providing 
medication and first aid but also included providing specialist services such as hepatitis 
treatment, oral health services and opioid substitution treatment. 
▪ MSIR users are considerably less likely than other people who use drugs to be on opioid 
substitution treatment at registration, and many request access to this.  
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▪ NRCH and staff of the MSIR have made significant progress in delivering additional 
services and developing referral pathways to other service providers. 
▪ With the move to the larger facility the range and number of services is expanding.  
▪ An ongoing trial would provide the opportunity to develop and assess ongoing 
integration of services and possible different ways of achieving this. 
The legislation provides for integrated services, expecting that this would be a more 
effective way of attending to the perceived needs of people who inject drugs. Many 
community services struggle to engage people who inject drugs, and the MSIR offers an 
opportunity to trial doing this differently.  
Not all people who inject drugs seek or want other services, and not all take up services 
when they are offered. Some are clear that they attend the MSIR only to use their drugs in a 
safer place and then leave. Some prefer to access more extensive services elsewhere. 
NRCH and MSIR staff have made significant progress in delivering additional services and 
developing referral pathways to other service providers, with expanding service offerings. 
The potential benefits of these services have not yet been fully realised. Take-up is still 
growing, and the full complement of services was still being implemented when data 
collection for the review ended. It is too early to assess the pros and cons of alternative 
models of providing integrated care, including whether there are advantages of co-
location within the MSIR. The work of the Gateway Services Group is promising.  
Findings indicate that progress is being made on connecting people who attend the MSIR 
with additional services.  
 
The model of care could be further considered to examine options regarding matters such 
as staffing, optimum opening hours and the ways of providing additional services, 
recognising that many of the service users require navigation support to connect to systems 
of care. 
The MSIR was designed to provide health and other services through internal and external referrals. 
Specifically, the legislation states that the facility is to contribute to advancing the objective to 
‘deliver more effective health services for service users of the licensed medically supervised 
injecting centre by providing a gateway to health and social assistance which includes drug 
treatment, rehabilitation support, healthcare, mental health treatment and support and 
counselling’ (Part 55A(b) of the Act).  
The review examined evidence to consider whether: 
▪ staff were able to engage with service users regarding their health and social assistance 
needs  
▪ referrals were being made to internal and external services. 
As the trial progressed, the review analysed evidence to understand the extent to which: 
▪ service users increasingly respond to staff efforts to engage and accept offers of referral 
▪ improvements to the referral procedures and service pathways, as well as service user 
engagement, intended to lead to increased use of support services as a platform to more 
effective health service delivery.  
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This chapter also provides findings from the Burnet Institute’s SuperMIX cohort study on the impact 
the facility has had on health service utilisation for the people who participated in that study.  
Service users have very high support needs 
People who use drugs, especially those who inject their drugs, are at higher risk of dying from both 
acute and chronic diseases than people who do not use drugs (Mathers et al. 2013). They are also 
at risk of a range of mental health disorders and mental illnesses including anxiety disorders, mood 
disorders and personality disorders. Many people who inject drugs have a history of trauma and 
abuse, often in the context of family or other domestic relationships. As shown in Table 6, at 
registration, more than half of MSIR service users reported they were currently taking prescribed 
medication and nearly a third had been hospitalised in the six months before registration. People 
who use a supervised injecting service are also more likely to have experienced adverse life events 
and have a greater risk of mental illness and mental disorder (European Monitoring Centre for Drugs 
and Drug Addiction 2015. 
Table 6: Prior health service utilisation by MSIR service users at initial registration, data collection 
period 30 June 2018 to 31 December 2019 
Reported healthcare utilisation(a) Percentage(b) 
History of medication for mental health  57.9 
Currently taking prescribed medication 55.3 
Currently receiving treatment for a drug-use disorder 41.5 
Hospitalised in last six months 31.2 
Ambulance transport in last 12 months 28.1 
Ever hospitalised for mental health 27.7 
Source: MSIR database 
(a) Service users self-reported health service utilisation at registration as provided in the NRCH MSIR October to 
December 2019 report. At registration, new MSIR service users are asked questions about their health service 
utilisation, prescribed medication use and current drug treatment status (such as pharmacotherapy, 
withdrawal, residential rehabilitation, counselling and self-help groups). Completion of the survey is voluntary. 
(b) As a percentage of total registered service users who completed the survey during the period from 
October to 31 December 2019. 
Service needs and priorities of service users are commonly directly related to 
injecting drug use  
There are several mechanisms in place to identify the health and social assistance needs of service 
users including data collected at their first visit. During the trial period, 77 per cent of service users 
indicated at least one specific healthcare need, most commonly related to drug dependence, 
anxiety/depression, hepatitis C or lung problems including asthma. As shown in Table 7, areas of 
treatment interest captured at registration commonly related to hepatitis, drug treatment and 
mental health.  
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Table 7: Areas of treatment interest at registration, 30 June 2018 to 31 December 2019 
Areas of treatment interest(a) Percentage(b) 
Hepatitis testing and/or treatment at MSIR 31.6 
Drug treatment 21.8 
Referral to a mental health service/professional  11.3 
Source: MSIR database 
(a) Service users self-reported treatment demand at registration (total from 1 June to end December 2019) as 
provided in the NRCH MSIR quarterly reports. At registration, new MSIR service users are asked questions about 
their health service utilisation, prescribed medication use and current drug treatment status (such as 
pharmacotherapy, withdrawal, residential rehabilitation, counselling and self-help groups). Completion of the 
survey is voluntary. 
(b) As a percentage of registered service users who completed the survey during the period from 30 June 2018 
to 31 December 2019. 
The combined workforce of registered nursing staff and harm reduction practitioners appears to 
provide a sound basis for effectively engaging with service users. Staff report being able to engage 
with service users regarding their health and social assistance needs, noting the need to build trust 
over time in the light of service users’ previous negative experiences with authority, including health 
providers. This means the proportion of people who take up offered support on each visit is 
relatively low, but because the number of people who use the service is high, the services offered 
have high rates of utilisation. This aspect of the MSIR is still evolving and its full potential in providing 
access to treatment and support for a range of physical and mental health needs is still not 
realised.  
Staff reported that, as a team, they had the skills to engage and directly provide services to service 
users and had clear roles and protocols to undertake their work in engaging with service users. They 
were able to identify which of their colleagues had particular skills and networks to meet various 
needs and to identify whether and when it was more appropriate for the conversation to be with a 
harm reduction practitioner or nurse. The move into the larger facility has provided more physical 
space for staff to engage with service users. Posters and a range of health promotion materials 
about local services targeted at this group of service users are displayed throughout the MSIR.  
Based on experience over the trial period and findings from other settings, is that it is likely that, for 
many of the people who use the MSIR, providing on-the-spot treatment is the most effective way of 
providing supplementary services including vaccinations, naloxone training and provision, 
infectious disease screening, assessment and treatment and initiation of drug dependence 
treatment. However, not all these services are available at all times the MSIR is open. In addition, 
given the priority is to keep people safe when injecting, responding to overdose can mean there is 
not always capacity for staff to engage sufficiently with all service users to facilitate referral to 
additional services.  
The below case study provides an example of service user experiences accessing drug treatment 
and mainstream health services. 
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Case study 3: Access to drug treatment services  
A client overdosed at the MSIR after having recently left a private rehabilitation facility 
before the end of their planned treatment. After this event, the client sought support 
from the MSIR to access drug treatment. Over the next few months the client and their 
family were supported by the MSIR and ReGen staff in relation to both drug treatment 
and mental health services. The client ultimately accessed public drug treatment 
services. 
Case study provided by the MSIR 
This example demonstrates the value of immediate and assertive referral to engage service users, 
especially when it requires access to services that are located elsewhere, have waiting lists or need 
further assessment of needs and wishes. Noting that people who inject drugs have traditionally 
been hard to engage and provide services to, whether it is a service that is not readily available at 
the time or in the MSIR, providing service navigators or care coordinators who can follow through 
with referrals is a valuable approach.  
In addition to health needs, MSIR service users have indicated a need for legal advice. Some of 
these might be directly or indirectly related to crime associated with drug use, but it also includes a 
need for assistance with rental disputes and other civil matters.  
People who are on relevant bail, parole or other orders are excluded from the MSIR because, unlike 
other clients, they are not exempt from criminal liability under s. 55K of the Act. This can be a 
significant impediment to responding to people who continue to inject drugs. Some community 
members and other service providers have noted that at least some of the people who continue to 
inject in public places in the vicinity of the MSIR do so because of this exclusion. (See also the 
‘Regulations’ section of this report.)  
Those who had visited and could access the MSIR were more likely to report committing a property 
crime in the preceding month (27 per cent) than those who had not visited the MSIR (18 per cent) 
(Burnet Institute 2019, p. 48), although there was no difference found between people who visited 
and did not visit the MSIR for reported drug dealing or being arrested for dealing in the last month, 
either before or after the MSIR opened (Burnet Institute 2019) (see Table C11, Appendix C). 
An analysis of follow-up interviews after the MSIR opened showed that those who visited the MSIR 
were more likely to report being arrested since their previous interview (65 per cent) than those who 
had not visited the MSIR (41 per cent) (see Table C12, Appendix C). 
This is further evidence of the high-needs nature of the people who use the MSIR and the potential 
value of the Fitzroy Legal Service visiting the MSIR.  
The model of service integration is evolving  
There are various models that can be used to provide services to this client group, which range 
from a standalone facility providing a single service, to co-location, to full integration with a range 
of services.  
Analyses of the facility data show there are many ways that additional services (beyond injecting 
oversight) are provided:  
▪ health promotion, nursing and medical care by MSIR staff 
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▪ outreach/AOD care, oral health and medical care by NRCH staff in the MSIR (AOD team and 
GPs, oral hygienists) 
▪ referrals from the MSIR to oral health and GP services at NRCH 
▪ shared care between the AOD and MSIR teams 
▪ shared care between St Vincent's Hospital Melbourne and the MSIR (Health Impact 
Programme, blood-borne virus screening, mental health assessments including wound care 
nurses and the St Vincent’s hepatitis nurse) 
▪ specialist services by external providers inside the facility (MSIR clinics) 
▪ referrals to external services. 
There has been an increase over time in services provided within the MSIR (directly and through 
clinics). While MSIR data reflected a reduction in referrals to NRCH and external services from the 
third operating quarter (Figure 21), the MSIR medical director suggests this is mainly due to changes 
in the way referrals were counted, with access to other NRCH and external services on site 
considered service provision rather than referral. 
Figure 21: Number of services and referrals provided to service users at the MSIR and number of 
supervised injections over time, Quarter 1, 2018–19 to Quarter 2, 2019–20 
 
 
Source: MSIR database 
Notes: 
▪ MSIR services is a count of the total number of services provided in the facility. MSIR services includes 
medical services provided in the facility, except in the Quarter 1, 2018–19, where medical services are 
not included in the count because the data were not available. 
▪ MSIR clinics is a count of the total number of service users seen. 
▪ Referrals to external providers is a count of the total number of referrals. 
▪ Referrals to NRCH is a count of the total number of referrals. 
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The MSIR directly provides services to service users  
Since opening on 30 June 2018 (and up until 31 December 2019), the MSIR provided 10,540 services 
in addition to injecting supervision (largely health promotion in relation to injecting and wound 
dressing) (Table 8). Staff at the service indicated that on-site integrated care was preferable to 
referrals.  
Table 8: Number and percentage of types of services provided in the MSIR, 30 June 2018 to 31 
December 2019 
Service type Number Percentage of 
total services 
Health promotion(a)  6,206 58.9 
Wound dressing / medication provision / other first aid  1,122 10.6 
Social welfare(b)  791 7.5 
BBV/STI testing and treatment  445 4.3 
Drug treatment advice and information  445 4.2 
Counselling and crisis intervention  439 4.2 
Mental health  319 3.0 
Material aid  207 2.0 
Overdose first response with naloxone training (CPR)  133 1.3 
Family violence support 38 0.4 
Other  385 3.7 
Total  10,540 100 
Source: MSIR database 
(a) Health promotion refers to services such as safer injecting advice and support and vein care. 
(b) Social welfare includes legal, financial, housing and homelessness advice. 
This suggests that with the increased capacity for services within the consulting space, more activity 
is happening within the facility itself, rather than through referrals. The relative benefits of full 
integration with a co-located community health service compared with providing separate in-
house services to those who present to the MSIR are still evolving. It is apparent that a number of 
those with significant health issues do not or are not able to follow through with further health 
appointments when they come to self-inject. It is also apparent that many of those who present 
have their own GP and other health providers closer to where they live. As such, the Panel supports 
having access to a range of supports and facilitated access to other health services but remains 
undecided on whether this should be provided by the auspicing agency or by dedicated staff 
within the MSIR. 
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Referrals are offered, but the rate of non-attendance has been high for 
some services 
This section contains data about services offered and provides a more nuanced description of the 
complexity regarding the provision of services beyond supervision of injecting. It represents an 
account of the experience of the MSIR in making referrals for additional services.  
Between 30 June 2018 and 31December 2019, the MSIR provided 702 referrals to NRCH, largely for 
health care and AOD harm reduction. MSIR staff reported that it is straightforward to refer service 
users to NRCH, but they do not always have capacity to walk the service users to the service. This 
means, at times, MSIR staff recruited other NRCH staff (care coordinators or members of the AOD 
team) to support the client to facilitate the referral. Some staff working in both the MSIR and NRCH 
reported that they found it easier to refer between the services while in the transitional facility rather 
than moving between the buildings.  
MSIR staff reported to the Panel that their initial experience of referring service users within NRCH 
was that there was a low uptake of referrals from the facility to the community health centre. For 
example, the MSIR staff observed that after referring 30 people for hepatitis testing in NRCH, that 
only one in 10 of those clients completed the testing process (a combination of seeing a GP and 
having blood collected from the pathology service). This contributed to the MSIR establishing drop-
in clinics using GPs from NRCH and revising its model of hepatitis diagnosis and treatment in 
partnership with St Vincent’s Hospital. This is reported to have resulted in most people who wanted 
blood-borne virus testing subsequently completing testing and initiating treatment. 
As noted above, while people may have several health and social needs, they do not necessarily 
wish to follow these up at the time or place of self-injecting. The Panel supports providing readily 
accessible and available primary health care while noting that the preferences of clients to visit 
their own practitioner need to be respected. The Panel also notes the importance of a trusting 
relationship that may take some time to form and expect that this aspect of the MSIR will increase 
over coming months. The Panel also notes the input of St Vincent’s Health staff in relation to mental 
health, wound management and infectious diseases. These are all areas where St Vincent’s has 
expertise in engaging with those who are often socially isolated and disenfranchised (see below). 
Having staff linked to the local area mental health service means that direct referral is more likely, 
with better information sharing and communication.  
The most frequent mental illnesses or disorders present in those who attend the MSIR are likely to be 
related to past trauma and to be evidenced by poor affect regulation, poor self-image and 
impulsivity. Some will have major mental illness such as schizophrenia or other psychoses. For many 
the most important aspect of care is a consistent level of engagement with a trusted mental health 
clinician. It is not clear what proportion would be assisted by referral and ongoing treatment 
through state-funded mental health services or by participating in a mental health plan under 
Better Access. The Panel noted that in both the MSIR and NRCH, AOD program staff had been able 
to support service users to comply with prescribed treatment for mental and other illnesses by 
giving reminders or even storing medication at the centre. The Panel also noted that the mental 
health support service was still in its early days and such support was not available over extended 
opening hours. Tables 9 breaks down referrals to NRCH and gateway services. 
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Table 9: Referrals to NRCH and gateway services, 30 June 2018 to 31 December 2019 




Healthcare(b) 356 50.7 66 6.0 
AOD harm 
reduction(c) 
142 20.2 63 5.7 
Drug treatment 93 13.2 241 21.8 
Mental health(d)  23 3.3 143 12.9 
BBV/STI testing 
and treatment(e) 
20 2.8 196 17.7 
Counselling and 
casework 
19 2.7 – – 
Housing and 
homelessness 
8 1.1 130 11.7 
Social welfare 6 0.9 10 0.9 
Legal – – 81 7.3 
Material aid(f)  – – 66 6.0 
Family violence – – 11 1.0 
Other 35 5.0 101 9.1 
Total 702 100.0 1,108 100.0 
Source: MSIR database 
(a) As a percentage of all referrals 
(b) Healthcare referrals to hospitals, GPs, dental services and allied health services 
(c) AOD harm reduction referrals include naloxone training, NSP and health promotion 
(d) Mental health includes counselling and casework 
(e) BBV refers to blood-borne viruses (for example, hepatitis B, C and D viruses and HIV) 
(f) Material aid refers to support accessing showers, food and transportation 
Referrals made to external services 
Within the first 18 months, the facility provided 1,108 referrals to external services, representing 61.2 
per cent of all referrals. More than half were for drug treatment such as pharmacotherapy, 
withdrawal, counselling/support, blood-borne virus and STI testing and treatment and/or mental 
health.  




Table 10: Number of clinical interactions with MSIR clients seen in MSIR consulting rooms 
Service provider Service type Q2 Oct–Dec 
2019 
Total to date (Jul 
2018 – Dec 2019) 
MSIR staff Health promotion, e.g. safer 
injecting advice and support, 
vein care 
1,887 6,206 
Wound dressing/ medication 
provision/other first aid  
272 1,122 
Counselling, crisis 
management, mental health 
support, etc.  
582 2,624 
Blood-borne virus 62 455 
NRCH staff Oral health clinic 48 361 
Medical (GP and MSIR medical 
staff)  
160 455 
Shared care BBV clinic (Burnet Institute, St 
Vincent’s Hospital)  
99 219 
St Vincent’s Hospital HIP BBV 195 403 





ReGen drug treatment clinic 38 161 
Fitzroy Legal Service 11 55 
Launch Housing 21 47 
Total  3,601 12,426 
Additional services are increasingly being provided by other organisations from within the MSIR. In 
addition to these services, there are others provided at the facility including: 
▪ a specialist clinic run by an anaesthetist to support service users with poor vein health, 
including to support pathology tests for service users who are unable to have blood taken at 
mainstream pathology services due to damaged veins 
▪ non-appointment services in the Aftercare Zone and Consulting Zone to enable opportunistic 
engagement with key health and psychosocial services that service users may otherwise not 
access 
▪ oral health care with an oral hygienist, using silver diamine fluoride for on-the-spot treatment 
of dental caries, an inexpensive way of reducing pain and infection in the mouth. 
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To provide further insights into these services, descriptions of work being conducted within the 
facility by St Vincent’s Hospital Melbourne and Fitzroy Legal Service are provided below. 
St Vincent’s Hospital Melbourne 
St Vincent’s Hospital Melbourne directly provides three clinicians at the MSIR. These are funded 
through its Inclusive Health Program fund, aimed at improving health outcomes for particularly 
vulnerable people. The roles are: 
▪ an infectious diseases clinical nurse consultant (since April 2019) 
▪ a mental health clinician (since August 2019) 
▪ a wound nurse consultant (since mid-December 2019). 
The reported focus of their work with service users has been direct service provision (most 
commonly brief interventions, engagement and care coordination). They report that the remainder 
of their efforts has been on clinical leadership including streamlining existing processes, building 
relationships and pathways, and capacity building and professional development.  
Drug outreach lawyer provided by Fitzroy Legal Service 
The Fitzroy Legal Service provides legal advice and representation in several ways, including via a 
drug outreach lawyer, family violence outreach and its Neighbourhood Justice Centre. The drug 
outreach lawyer assists individuals with legal problems concerning drug use and works in close 
collaboration with community and health agencies to promote rehabilitation and harm 
minimisation. A drug outreach lawyer is provided fortnightly at NRCH and other locations (Inner 
Space, Youth Support and Advocacy Service, Odyssey House Victoria and Living Room). Case 
studies provided by this team provide insights into the complexity and benefits of challenges facing 
service users with appropriate services.  
Case study 4: Providing a pathway to legal support and psychosocial care 
An MSIR client approached the drug outreach lawyer and told them they had been the 
victim of a crime. The lawyer referred them to lawyers who specialised in that specific 
area of law, as well as a social worker at NRCH, who was able to meet them that day to 
provide support, and to a GP at NRCH to explore a mental health plan for more intensive 
psychological counselling. 
 MSIR report: April to June 2019 quarterly report 
 
Case study 5: Access to drug outreach lawyers 
A drug outreach lawyer introduced themselves to an MSIR client while on site. The client 
mentioned they had an outstanding matter and no lawyer. On obtaining the legal 
documents it became apparent that the client was facing a lengthy term of 
imprisonment for offences relating to homelessness and drug use.  
The lawyer coordinated a treatment plan with the client’s existing service providers 
(external to the MSIR) and made the necessary referrals to ensure appropriate 
treatment. Because of the presence of wraparound services and the lawyer’s 
advocacy, the magistrate released the client with a reduced sentence. 
MSIR report: April to June 2019 quarterly report 
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Staff commented on how the facility is uniquely positioned to provide service users with a gateway 
to health and social services. Overall, staff seem to have a positive relationship with service users, 
which helps when making referrals. Staff observed that service users were often interested in 
accessing health services, including drug treatment services, but found it challenging for a range of 
reasons.  
It was noted that many service users do not always have access to a phone, and therefore it is 
helpful that the MSIR has the capacity to link them with services via telephone (such as calling 
housing services). Overall, staff feel they are doing a good job at using an opportunistic approach 
to referring service users to other services, particularly dental and GP services, but expressed some 
frustration with not being able to follow up on client referrals, or to case manage service users to 
the extent they wanted. The MSIR’s ‘drop-in’ model was cited as a reason for this. 
Nurses and harm reduction practitioners report having established strong partnerships with an array 
of external service providers to increase the service’s capacity to respond to client needs. The MSIR 
believes that the additional four consulting rooms in the larger facility has provided much-needed 
space from which to provide these services and referrals.  
Staff noted that not all staff members have the knowledge of how to help service users access 
different types of health and social services, including housing services and Centrelink. In the case 
where a staff member does not feel confident, there is generally another staff member who can 
assist. When interviewed, many of the nursing staff felt they were ill-equipped to identify and 
process referrals, particularly to social services. This was partly due to the complexity of those 
service systems. The range and complexity of issues that arise reflect the importance of having 
multidisciplinary staff with sound training and supervision and access to a range of expertise either 
within the MSIR or within NRCH. 
Staff reported that it can be difficult to get service users into broader social services due to lack of 
availability. They also reported that stigma associated with drugs use can act as a barrier to 
accessing other services for some service users, particularly relating to hospital admissions. Not 
having stable housing makes access to and delivery of these services difficult. 
Impact the facility has had on health service use  
At the end of the first year of operation in the transitional facility (using available data, Burnet 
Institute 2019), there was not yet evidence of an impact on health service use at the population 
level, although case studies provided illustrate the nature and impact of referrals at the individual 
level.  
Alcohol and other drug services, including opioid substitution therapy 
Using linked data from the Alcohol and Drug Information Service and the Burnet Institute SuperMIX 
study did not find evidence of a difference between the average number of initiated AOD 
treatments for the participants who reported visiting the MSIR compared with those who did not, 
either before or after the MSIR opened. This finding applies to withdrawal treatment, drug 
counselling and all other treatments recorded in the Alcohol and Drug Information System dataset 
(including residential rehabilitation) (Burnet Institute 2019, p. 13). 
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People who reported visiting the MSIR were less likely to report being on opioid substitution therapy 
compared with those who did not visit the MSIR (34 per cent versus 49 per cent, respectively) 
(Burnet Institute 2019, p. 14). 
Case study 6: Supporting access to pharmacotherapy treatment 
A person started using the MSIR after leaving prison and subsequently overdosing in the 
community. The overdose was serious, requiring hospitalisation. The person expressed 
interest in ceasing their drug use to MSIR staff, who connected them to the ReGen 
worker at the MSIR. The ReGen worker supported them to start pharmacotherapy 
treatment, complete an intake and assessment for further AOD treatment and begin 
AOD counselling. The person was then referred to a residential AOD rehabilitation 
program. 
MSIR report: October to December 2018 quarterly report 
Use of health services 
Based on linked data from the Medicare Benefits Schedule, there was no difference between the 
average number of GP visits for conditions unrelated to drug use between the group of participants 
who reported visiting the MSIR and those who did not, either before or after the MSIR opened 
(Burnet Institute 2019, p. 20). 
More frequent MSIR users (who had more than half of their injections at the facility) were 
significantly less likely than people who didn’t use the facility to access after-hours GPs (Burnet 
Institute 2019, p. 21). 
Using linked data from the Pharmaceuticals Benefit Scheme, they did not find evidence of a 
difference between the average number of prescriptions dispensed between the group of 
participants who reported visiting the MSIR compared with those who didn’t, either before or after 
the MSIR. This finding applies across all the different pharmaceutical drug groups considered, 
including mental health medication, sleeping pills and pain management medication (Burnet 
Institute 2019, p. 26). 
Case study 7: Access to general practitioners 
A client has been opioid dependent for several years. They regularly attend the MSIR 
and presented to the GP clinic after a staff referral. For some time, the client had been 
contemplating reducing and stopping their heroin use, so requested to see a doctor. 
They met with a GP who discussed strategies for reducing use and prescribed 
pharmacotherapy. Staff of the MSIR supported the client to find a convenient pharmacy 
to dispense his methadone. After several follow-up visits, the client asked the NRCH GP to 
change the methadone prescriber and dispensing pharmacy so that both were closer 
to home. The client reported no longer needing to visit North Richmond because they 
had no intention of using. At the time, the client also advised the NRCH GP that they 
were employed and recently promoted. This person has not attended the MSIR as a 
client since January 2019. 






In a cross-sectional analysis of all interviews undertaken after the MSIR opened, there was no 
significant difference in the frequency of self-reported visits to a mental health professional for those 
who visited the MSIR compared with those who did not (Burnet Institute 2019, p. 35). Staff have 
noted that it takes considerable time to engage service users and to establish trust that will then 
allow more assertive support and intervention. 
Case study 8: Access to mental health services  
A client met with the mental health care coordinator with concerns about the effect 
that homelessness was having on them. The mental health care coordinator engaged 
the client using a trauma-informed approach and obtained the client’s consent for care 
coordination. The care coordinator enabled access to crisis accommodation. The client 
also indicated to the care coordinator that they wished to recommence 
pharmacotherapy and was linked with one of the co-located NRCH GPs in the MSIR. As 
a result, the client is having fewer general health and accommodation problems. The 
client has a significant history of trauma and related trust issues, so engaging with them is 
a slow and continuing process.  
MSIR report: July to September 2019 quarterly report  
 
65 Appendix A: Terms of reference for the review 
Part 55A(c): Reduce attendance by emergency services and 
attendances at hospitals due to overdoses 
To assess this object, the Panel considered: 
▪ Ambulance Victoria data for attendances involving naloxone 
▪ results of a cohort study of people who use drugs linked with Victorian health datasets  
▪ analyses of emergency department presentations and hospital admissions data  
▪ consultations with professional stakeholders, staff and service users. 
This finding of this review is that the trial has advanced this object for frequent users of the 
MSIR in relation to ambulance attendance, noting there is not yet evidence of an impact on 
broader health service use or outcomes. 
▪ The MSIR attracts people who appear to be at greater risk of serious harm or death 
than the overall population of people who inject drugs because more required 
naloxone.  
▪ Frequent users of the facility have had fewer ambulance attendances involving 
naloxone since the facility opened but a small increase in the number of drug-related 
emergency department presentations during the trial. 
▪ There has been a reduction in ambulance attendances in the vicinity of the facility 
during opening hours. 
▪ There have been no observable changes in emergency department presentations 
that can be attributed to the MSIR. 
The MSIR is designed to respond to people who are experiencing an overdose of any severity (see 
Part 55A(a) in this report). It is reasonable to assume that Ambulance Victoria or a local hospital 
would have otherwise managed a portion of these overdoses.  
The review examined evidence to consider that relevant emergency services are continuing their 
usual service to this location and also engaging with the MSIR to track relevant data. To note, all 
instances where the Metropolitan Fire Brigade had been despatched through the triple zero (000) 
process and attended with Ambulance Victoria are included in this data. The Metropolitan Fire 
Brigade is only despatched if conditions represent an immediate threat to life, which is not all 
overdoses.  
As the trial progressed, the review analysed evidence to understand the extent to which there 
were: 
▪ fewer emergency services attendances for overdoses in this vicinity  
▪ fewer hospital attendances for overdoses. 
In the first instance, simply by responding to these overdoses internally, it is reasonable to infer that 
the MSIR is contributing to the legislated object ‘to reduce attendance by ambulance services, 
paramedic services and emergency services and attendance at hospitals due to overdoses of 
drugs of dependence’ (Part 55A(c) of the Act). 
In addition to managing overdoses that have occurred within the MSIR, the facility also monitored 
and managed people who had overdosed in the community. Management reported that some 
were transported to the service by Ambulance Victoria for monitoring, having been assessed as not 
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requiring further intervention or medical care. Others were brought in by other people, including 
the NRCH AOD program team as part of its outreach service. It is reasonable to assume that some 
of these individuals would have otherwise used additional paramedic and emergency services. 
Staff reported a limited number of overdose incidents that required emergency and health services 
involvement, including from Ambulance Victoria. Some staff reported referring service users to 
hospital emergency departments for wounds and other injuries. 
Emergency services attendances for overdoses 
There are two sources of information about emergency services attendance involving the provision 
of naloxone: 
▪ Ambo-AODstats is a website managed by Turning Point, a national addiction treatment and 
research centre funded by DHHS that codes the Victorian Ambulance Clinical Information 
System (VACIS) clinical records to identify ambulance attendances involving over or 
inappropriate use of alcohol and/or other substances.  
▪ VACIS is Ambulance Victoria’s electronic patient care record system, which includes 
mandatory and supplementary data collected by paramedics. Data from VACIS is 
synchronised to the Ambulance Victoria Data Warehouse at the end of each shift.  
The raw data in VACIS differs from the Ambo-AODstats Victoria data because Turning Point reviews 
all VACIS case notes, including free-text sections, to identify any attendances involving overdoses. 
Due to this, Ambo-AODstats reports a higher number of cases involving overdoses compared with 
VACIS data. The VACIS and Ambo-AODstats systems are therefore not comparable and care 
needs to be taken when interpreting findings. 
Turning Point Ambo-AODstats findings  
As described above, the case notes accompanying the data used in the VACIS analysis are further 
coded by an external research agency, Turning Point, which means that additional cases can be 
identified qualitatively. Analysis of those data show an increase in the number of attendances for 
heroin overdoses (measured as where the person was provided and responded to naloxone) in 
Victoria from 1,241 in 2017–18 (the year before the trial) to 1,423 in 2018–19. In the City of Yarra, 
there were four more ambulance attendances in that period (245 to 249). However, Figure 22 
shows that the rate of ambulance attendances for heroin overdoses (responded to naloxone) per 
100,000 population in Yarra decreased from 262.4 to 252.7 the year after the MSIR opened (2017–18 
compared with 2018–19). Further analyses of these data are recommended once available.  
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Figure 22: Heroin overdose (where the person was provided and responded to naloxone) 
ambulance attendance rate for the City of Yarra and Victoria, 2011–12 to 2018–19 
 
Source: Turning Point Ambo-AODstats Victoria 
Victorian Ambulance Clinical Information System findings 
Ambulance Victoria provided data to this review. Ambulance attendances involving naloxone 
administration was used as the review’s key measure for identifying overdose cases where death 
may potentially have occurred without intervention. (The analysis below is based on all ambulance 
attendances where paramedics administered naloxone and may therefore include overdoses of 
other opioid drugs as well as heroin overdoses.)  
Figure 23 shows the number of ambulance attendances where naloxone was administered over 
time within 1 km of the MSIR and for the rest of Victoria. Nine months after the MSIR opened the 
number of ambulance attendances within 1 km of the MSIR decreased, while the number of 
attendances for the rest of Victoria did not change substantially.  
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Figure 23: Number of ambulance attendances where naloxone was administered by paramedics 
within 1 km of the MSIR and for the rest of Victoria, Quarter 3, 2014–15 to Quarter 2, 2019–20  
 
Source: Victorian Ambulance Clinical Information System 
Notes: 
▪ ‘Rest of Victoria’ is a count of all cases in Victoria minus cases identified within 1 km of the MSIR. 
▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here only includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related. The VACIS data presented here differs from 
the Turning Point Ambo-AODstats data because Turning Point reviews all VACIS case notes to identify 
any cases involving heroin overdoses where naloxone was administered. The VACIS and Ambo-
AODstats systems are therefore not directly comparable and care needs to be taken when 
interpreting findings.  
▪ This analysis includes data for ambulance attendances at any time of day, including when the MSIR 
was closed. The impact of the MSIR can be better understood by analysing the change in ambulance 
attendances during MSIR opening hours.  
The opening of the MSIR was expected to primarily have an impact on ambulance attendance 
during MSIR opening hours, not outside opening hours. During MSIR opening hours the number of 
ambulance attendances where naloxone was administered within 1 km of the MSIR also declined 
nine months after the MSIR opened. For the rest of Victoria, the number of ambulance attendances 
were largely similar to those observed before the MSIR opened (Figure 24).  
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Figure 24: Number of ambulance attendances where naloxone was administered by paramedics 
within 1 km of the MSIR and the rest of Victoria during MSIR opening hours, Quarter 3, 2014–15 to 
Quarter 2, 2019–20  
 
Source: Victorian Ambulance Clinical Information System 
Notes:  
▪ ‘Rest of Victoria’ is a count of all cases in Victoria minus cases identified within 1 km of the MSIR. 
▪ MSIR opening hours before 7 July 2019 are defined as between 8.00 am and 7.00 pm on a weekday 
and 9.00 am and 5.00 pm on a weekend. From 7 July 2019 MSIR opening hours are defined as 
between 7.00 am and 9.00 pm on a weekday and 8.00 am and 7.00 pm on a weekend. Note: the 
MSIR opening hours changed over the trial period; as such, the opening hours measure presented in 
this review is used as an approximate measure. 
▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related. Due to this, care needs to be taken when 
interpreting the data because the primary drug injected at the MSIR is heroin (95 per cent), whether 
alone or in combination with diphenhydramine. The MSIR cannot be expected to influence changes 
in ambulance attendances for pharmaceutical opioid overdoses. 
▪ The VACIS data presented here differs from the Turning Point Ambo-AODstats data because Turning 
Point reviews all VACIS case notes to identify any cases involving heroin overdoses where naloxone 
was administered. The VACIS and Ambo-AODstats systems are therefore not directly comparable and 
care needs to be taken when interpreting findings.  
Comparing trends13 before and after the MSIR opened shows that before the MSIR opened the 
number of ambulance attendances within 1 km of the MSIR during MSIR opening hours appeared 
to be on an upward trend, although there was a sharp decline just before the MSIR opened14 
(between January 2015 and June 2018). (In Figure 25, the trendlines are presented to show the 
general trend of the data and are not to be taken as a formal statistical analysis.) After the MSIR 
 
13 The trendlines presented are indicative only and not to be taken as formal statistical analysis; they are not intended for 
statistical inference or prediction purposes. 
14 The sharp decline may be due to changes in the drug market or anticipation of the MSIR opening. 
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opened the number of ambulance attendances started to trend down (between July 2018 and 
December 2019). The trend for the rest of Victoria was different, with the number of ambulance 
attendances before and after the MSIR both showing upward trends (Figure 26 Figure 25). 
An interrupted time series method was applied to the monthly aggregate count data to test for 
any statistically significant change in the number of ambulance attendances within a 1 km radius 
of the MSIR during opening hours, after the MSIR opened. Results of the analysis showed a trend 
towards a reduction in ambulance attendances after the MSIR opened that just failed to reach 
statistical significance (p < 0.10).15  
Figure 25: Ambulance attendances where naloxone was administered by paramedics within 1 km 
of the MSIR during MSIR opening hours, number and trendline before and after the MSIR opened, 
January 2015 to December 2019 
 
Notes:  
▪ MSIR opening hours before 7 July 2019 are defined as between 8.00 am and 7.00 pm on a weekday 
and 9.00 am and 5.00 pm on a weekend. From 7 July 2019 MSIR opening hours are defined as 
between 7.00 am and 9.00 pm on a weekday and 8.00 am and 7.00 pm on a weekend. Note: the 
MSIR opening hours changed over the trial period; as such, the opening hours measure presented in 
this review is used as an approximate measure. 
 
15 An interrupted time series approach was applied to the monthly aggregate count data to determine if there was a 
statistically significant change in ambulance attendances after the MSIR opened. The approach was based on the method 
described in Lopez et al. 2017. The results of this analysis should be used with caution. There are several important 
assumptions made in this analysis. If these assumptions are violated, the results could be invalid. First, the model assumes 
there is no other time-varying confounders could lead to the reduction of ambulance attendances. For example, in the 
study period, if there are other time-varying confounders, such as police operations, changes in drug availability or trading in 
private markets, the results could become invalid. Second, the model assumes the characteristics of the population remain 
unchanged throughout the study period and study area.  
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▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here only includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related. Due to this, care needs to be taken when 
interpreting the data because the primary drug injected at the MSIR is heroin (95 per cent), whether 
alone or in combination with diphenhydramine. The MSIR cannot be expected to influence changes 
in ambulance attendances for pharmaceutical opioid overdoses. 
▪ These trendlines are indicative only and not to be taken as formal statistical analysis; they are not 
intended for statistical inference or prediction purposes. The trendlines are presented to show the 
general pattern or overall direction of the data. 
 
Figure 26: Ambulance attendances where naloxone was administered by paramedics during MSIR 
opening hours, number and trendline before and after the MSIR opened, January 2015 to 
December 2019 
 
Source: Victorian Ambulance Clinical Information System 
Notes:  
▪ MSIR opening hours before 7 July 2019 are defined as between 8.00 am and 7.00 pm on a weekday 
and 9.00 am and 5.00 pm on a weekend. From 7 July 2019 MSIR opening hours are defined as 
between 7.00 am and 9.00 pm on a weekday and 8.00 am and 7.00 pm on a weekend. Note: the 
MSIR opening hours changed over the trial period; as such, the opening hours measure presented in 
this review is used as an approximate measure. 
▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here only includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related.  
▪ These trendlines are indicative only and not to be taken as formal statistical analysis; they are not 
intended for statistical inference or prediction purposes. The trendlines are presented to show the 
general pattern or overall direction of the data. 
In order to explore this trend further, direct comparison was made between the number of 
attendances during and outside MSIR opening hours. In the 18-month period after the MSIR 
opened, the number of ambulance attendances where naloxone was administered within 1 km of 
the MSIR declined by 25 per cent (382 attendances for the 18-month period before the MSIR 
opened compared with 288 for the 18-month period after the MSIR opened) (Figure 27). As 
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indicated, the opening of the MSIR was expected to primarily have an impact on ambulance 
attendances during MSIR opening hours, not outside opening hours. In line with this expectation the 
overall decrease was largely driven by a decline in the number of ambulance attendances during 
MSIR opening hours. A visual comparison of ambulance attendances within 1 km of the MSIR in the 
18-month period before and 18-month period after the MSIR opened (see Figure 28) shows that the 
total number of attendances during MSIR opening hours decreased by 36 per cent after the MSIR 
opened (288 attendances compared with 184 attendances). In comparison, the number of 
attendances occurring within 1 km of the MSIR outside MSIR opening hours increased by 11 per 
cent in the 18-month period after the MSIR opened (104 attendances) compared with the 18-
month period before the MSIR opened (94 attendances) (Figure 29). This difference in distributions 
was statistically significant (Χ2(2) = 10.34, p < 0.01). This result includes the distribution of attendances 
outside MSIR opening hours, which largely followed the pattern for the remainder of Victoria. The 
time series analysis above does not include consideration of this trend. While these results are 
encouraging, further time is needed to fully understand the pattern of results in relation to 
ambulance attendances.  
Figure 27: Ambulance attendances where naloxone was administered by paramedics within 1 km 
of the MSIR for all hours, 18 months before the MSIR opened and 18 months after the MSIR opened 
 
Source: Victorian Ambulance Clinical Information System 
Notes:  
▪ Time periods are 18 months before the MSIR opened and 18 months after the MSIR opened; the MSIR 
opened 18 June 2018. 
▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here only includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related. Due to this, care needs to be taken when 
interpreting the data because the primary drug injected at the MSIR is heroin (95 per cent), whether 
alone or in combination with diphenhydramine. The MSIR cannot be expected to influence changes 
in ambulance attendances for pharmaceutical opioid overdoses. 
18 months post-MSIR (n = 288) 18 months pre-MSIR (n = 382) 
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Figure 28: Ambulance attendances where naloxone was administered by paramedics within 1 km 
of the MSIR during MSIR opening hours, 18 months before the MSIR opened and 18 months after the 
MSIR opened 
 
Source: Victorian Ambulance Clinical Information System 
Notes:  
▪ Time periods are 18 months before the MSIR opened and 18 months after the MSIR opened; the MSIR 
opened 18 June 2018. 
▪ MSIR opening hours before 7 July 2019 are defined as between 8.00 am and 7.00 pm on a weekday 
and 9.00 am and 5.00 pm on a weekend. From 7 July 2019 MSIR opening hours are defined as 
between 7.00 am and 9.00 pm on a weekday and 8.00 am and 7.00 pm on a weekend. Note: the 
MSIR opening hours changed over the trial period; as such, the opening hours measure presented in 
this review is used as an approximate measure. 
▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here only includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related. Due to this, care needs to be taken when 
interpreting the data because the primary drug injected at the MSIR is heroin (95 per cent), whether 
alone or in combination with diphenhydramine. The MSIR cannot be expected to influence changes 
in ambulance attendances for pharmaceutical opioid overdoses. 
  
18 months post-MSIR (n = 184) 18 months pre-MSIR (n = 288) 
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Figure 29: Ambulance attendances where naloxone was administered by paramedics within 1 km 
of the MSIR outside MSIR opening hours, 18 months before the MSIR opened and 18 months after the 
MSIR opened 
 
Source: Victorian Ambulance Clinical Information System 
Notes:  
▪ Time periods are 18 months before the MSIR opened and 18 months after the MSIR opened; the MSIR 
opened 18 June 2018. 
▪ MSIR opening hours before 7 July 2019 are defined as between 8.00 am and 7.00 pm on a weekday 
and 9.00 am and 5.00 pm on a weekend. From 7 July 2019 MSIR opening hours are defined as 
between 7.00 am and 9.00 pm on a weekday and 8.00 am and 7.00 pm on a weekend. Note: the 
MSIR opening hours changed over the trial period; as such, the opening hours measure presented in 
this review is used as an approximate measure. 
▪ Outside MSIR opening hours is defined as the hours not within the MSIR opening hours detailed above. 
▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here only includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related. Due to this, care needs to be taken when 
interpreting the data because the primary drug injected at the MSIR is heroin (95 per cent), whether 
alone or in combination with diphenhydramine. The MSIR cannot be expected to influence changes 
in ambulance attendances for pharmaceutical opioid overdoses. 
 
18 months post-MSIR (n = 104) 18 months pre-MSIR (n = 94) 
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Figure 30: Number of ambulance attendances where naloxone was administered by paramedics 
within 1 km of the MSIR, during and outside MSIR opening hours, 18-month total before and after the 
MSIR opened  
 
Source: Victorian Ambulance Clinical Information System 
Notes:  
▪ Time periods are 18 months before the MSIR opened and 18 months after the MSIR opened; the MSIR 
opened 18 June 2018. 
▪ MSIR opening hours before 7 July 2019 are defined as between 8.00 am and 7.00 pm on a weekday 
and 9.00 am and 5.00 pm on a weekend. From 7 July 2019 MSIR opening hours are defined as 
between 7.00 am and 9.00 pm on a weekday and 8.00 am and 7.00 pm on a weekend. Note: the 
MSIR opening hours changed over the trial period; as such, the opening hours measure presented in 
this review is used as an approximate measure. 
▪ Outside MSIR opening hours is defined as the hours not within the MSIR opening hours detailed above. 
▪ Naloxone is a medication that rapidly reverses an opioid overdose. Naloxone only works on overdoses 
caused by opioid drugs such as heroin and pharmaceutical opioids such as oxycodone. The VACIS 
data presented here only includes ambulance attendances where naloxone was reported and may 
therefore include overdoses that are not heroin-related. Due to this, care needs to be taken when 
interpreting the data because the primary drug injected at the MSIR is heroin (95 per cent), whether 
alone or in combination with diphenhydramine. The MSIR cannot be expected to influence changes 
in ambulance attendances for pharmaceutical opioid overdoses. 
Burnet Institute study 
Results from the Burnet Institute’s SuperMIX study linked with VACIS data found no evidence at this 
stage of a difference between the average number of ambulance attendances with naloxone 
administration between those who visited the MSIR and those who did not. 
Using linked data from VACIS, the Burnet Institute findings shows a projected decrease in 
ambulance attendance with naloxone administration for participants who visited the MSIR (Burnet 
Institute 2019, p. 38). Despite the overall drop for participants who visited the MSIR, there was no 
evidence of a difference in the average number of ambulance attendances with naloxone 
administration between the two groups (Burnet Institute 2019, p. 38). 
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However, people who used the MSIR had a significant reduction in ambulance attendances with 
naloxone administration compared with those who had not visited the MSIR (particularly for those 
who injected more than half of their injections at the MSIR) (Figure 31). 
Figure 31: Average number of ambulance attendances with naloxone administration per year by 
MSIR frequency of use, 2006–07 to 2018–19 
 
Source: Burnet Institute 2019, p. 38 
Emergency department attendances  
Using linked data from the Victorian Emergency Minimum Dataset, the Burnet Institute SuperMIX 
study did not find evidence of a difference between the average number of emergency 
department presentations for drug-related reasons (including overdoses) between the group of 
participants who reported visiting the MSIR compared with those who did not, either before or after 
the MSIR opened (Burnet Institute 2019, p. 39). 
However, as with the findings for ambulance attendances, for more frequent users of the MSIR 
(who had more than half of their injections at the facility) there was weak evidence of an increase 
in the average number of emergency department presentations for drug-related reasons 
(including overdose) between the group of participants who reported having had 50 per cent or 
more of their injections in the MSIR and those who had not visited the facility (Burnet Institute 2019, 
p. 40).  
Using the same approach, the study did not find evidence of a difference between the average 
number of emergency department presentations for conditions unrelated to drug use between 
participants who visited the MSIR and those who did not, either before or after the MSIR opened 
(Burnet Institute 2019, p. 16). 
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An analysis of heroin overdose presentations within MSIR opening hours16 at St Vincent’s Hospital 
Melbourne (the nearest hospital to the MSIR) from before and after the MSIR opened found that 
the number of heroin overdose cases did not change significantly after the facility opened. While 
Figure 32 suggests that the number of cases increased around the time the MSIR opened, this 
increase was not statistically significant.17  
Figure 32: Heroin overdose emergency department presentations during MSIR opening hours at 
St Vincent’s Hospital Melbourne, Quarter 1, 2012–13 to Quarter 2, 2019–20 
 
Source: Victorian Emergency Minimum Dataset  
Notes: 
▪ Heroin overdose emergency department presentations refer to presentations with a primary diagnosis 
of ‘heroin overdose’. The primary diagnosis represents the primary reason for presentation to the 
emergency department and is recorded when the patient is discharged. 
▪ MSIR opening hours before 7 July 2019 are defined as between 8.00 am and 7.00 pm on a weekday 
and 9.00 am and 5.00 pm on a weekend. From 7 July 2019 MSIR opening hours are defined as 
between 7.00 am and 9.00 pm on a weekday and 8.00 am and 7.00 pm on a weekend. 
Using linked data from the Victorian Admitted Episode Dataset, the Burnet Institute’s SuperMIX study 
did not find evidence of a difference between the average number of admissions for conditions 
related to drug use (including overdose) between participants who reported visiting the MSIR 
compared with those who did not, either before or after the MSIR opened (Burnet Institute 2019, p. 
40). Using the same approach, the study did not find evidence of a difference between the 
average number of hospital admissions for conditions unrelated to drugs between participants who 
visited the MSIR and those who did not, either before or after the MSIR opened (Burnet Institute 
 
16 MSIR opening hours defined as: before 7 July 2019: weekdays 8.00 am to 7.00 pm; weekends 9.00 am to 5.00 pm; and after 
7 July 2019: weekdays 7.00 am to 9.00 pm; weekends 9.00 am to 7.00 pm. 
17 The review analysed heroin overdose emergency department presentations (within opening hours of the MSIR) at St 
Vincent’s Hospital between July 2012 and December 2019. Structural break detection and interrupted time-series analyses 
were conducted on the monthly aggregated count and daily rate with statistical significance tested (p < 0.05). The 
interrupted time-series analysis applied was based on the method described in Lopez et al. 2017.  
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2019, p. 18). It should be noted that presentations at emergency departments for all causes are 
rising at this time (Australian Institute of Health and Welfare 2018).  
 
 79 
Part 55A(d): Reduce the number of discarded needles and 
syringes in public places and the incidence of injecting of 
drugs in public places in the vicinity 
To assess this object, the Panel considered:  
▪ needle and syringe collection data  
▪ surveys of local residents and businesses before and during the trial (MSIR Review 
Survey).  
The findings of this review are mixed regarding the extent to which the trial has advanced 
this object. There has been a reduction in reports of public injecting. Local people report no 
difference in seeing discarded injecting equipment. There has been an increase in 
collected injecting equipment (noting also an increase in collection activity later in the trial).  
There had been no change for local community members reporting seeing discarded 
needles and syringes but a decrease in the proportion who reported witnessing public 
injecting at the time of the MSIR Review Survey in July 2019. The number of inappropriately 
disposed needles and syringes collected in the area surrounding the MSIR grew over the trial 
period. While some of this growth coincided with an escalation in cleaning activities in the 
last eight months of the trial, there was also an increase in the number of syringes collected 
in first 10 months of the trial.  
Stakeholders were strongly divided on the extent to which there had been a change.  
▪ There has been very little change in the proportion of people seeing discarded 
needles and syringes (16 per cent in the year before and 17 per cent during the trial). 
▪ There has been no change in the median number of discarded needles and syringes 
seen by residents (four per month).  
▪ There was an increase in the median number of discarded syringes seen by business 
respondents during the trial (six to 10 per month). 
▪ There has been a decrease in the proportion of residents and business respondents 
who saw public injecting (24 per cent to 20 per cent of residents, and 27 per cent to 22 
per cent of business respondents). 
▪ There has been no change in the number of injections seen by residents (three per 
month) and an increase for business respondents (from four to five). 
▪ Stakeholders were strongly divided on the extent to which there had been a change, 
some stating that the area had never been better and others stating that it had never 
been worse.  
The MSIR is designed to provide an alternative to injecting in public. Part 55A(d) of the Act states 
that the facility aims ‘to reduce the number of discarded needles and syringes in public places and 
the incidence of injecting drugs of dependence in public places in the vicinity of the licensed 
medically supervised injecting centre’. 
The review examined evidence to consider whether injections that would have otherwise occurred 
in public places were occurring in the facility.  




▪ reductions in discarded injecting equipment in the vicinity of the MSIR 
▪ reductions in public injecting in the vicinity of the MSIR. 
About the needle and syringe program 
The Victorian NSP is a public health initiative that aims to minimise the spread of blood-borne viruses 
such as HIV, hepatitis B and hepatitis C among people who inject drugs and into the wider 
community. The program began in 1987 and operates through a range of different service 
providers including:  
▪ funded NSP locations whose primary function is to provide a full suite of NSP services including 
harm reduction information, advice and referrals 
▪ community health services 
▪ hospital emergency departments 
▪ municipal councils 
▪ drug treatment agencies 
▪ youth organisations 
▪ participating pharmacies. 
NSPs provide a range of services including access to sterile injecting equipment and help with 
disposing of used injecting equipment. There are more than 500 NSP locations in Victoria, including 
two NSPs in Richmond (located at NRCH and a pharmacy located in the Richmond Plaza 
Shopping Centre) and a mobile NSP that can also service the area. 
Until 7 July 2019 the NRCH NSP operated from the main health centre building, sharing office space 
with NRCH AOD services. The NSP could be accessed by the public through a dedicated window. 
From 7 July 2019 the NRCH NSP has been co-located with the MSIR. The NSP desk is situated 
alongside the MSIR intake desk, although integration arrangements are currently being reviewed.  
As previously described, the NRCH NSP also provided a secure dispensing unit (also known as a 
needle vending machine) to facilitate access to sterile injecting equipment outside of the NSP fixed 
site’s operating hours. This unit operated for two years and closed on 23 May 2019, before the 
larger facility opened.  
People are appropriately disposing of their injecting equipment at the 
facility 
Consideration of counts of both appropriate and inappropriate disposal and collection of injecting 
equipment before the trial and at the end of 2019 (when data consideration had to end) is 
complicated by changes in the collection services responsible for data on this measure.  
The SuperMIX study found that many people injecting at the facility had previously injected in 
public or semi-public settings, presumably with some of those injections involving inappropriate 
disposal of injecting equipment. 
The facility also asked a sample of its service users where they would have injected if the MSIR 
wasn’t available and, as shown in Table 11, by far the most common response was in the carpark 
(a multi-level carpark adjacent to NRCH and a common site of overdoses before the trial began). 
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Table 11: Alternative injecting locations reported by people who injected at the MSIR, snapshot as 
at September 2019 
Alternative location Number of service users 
Carpark 121 
Public area 22 
Public toilet 20 
Alleyway 18 
Anywhere 19 
BBQ area 7 
Underneath commission flats 3 
Carpark or river 2 
Friend’s house 2 
Source: MSIR database 
Reportable incident data are consistent with this, with the number of overdoses attended at the 
multi-storey carpark adjacent to the community health centre declining from 14 overdoses in the 
six-month period before the facility opened to eight overdoses over the same period a year later 
(January to June 2019). Overall, in 2018 there were 27 incident reports concerning overdoses in the 
carpark, whereas in 2019 there were only 14, almost a 50 per cent decrease in overdoses attended 
to at the NRCH carpark (Figure 33).  
Figure 33: Overdoses attended to at the NRCH carpark from January 2018 to December 2019 
  
Source: MSIR database 
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Collection of discarded injecting equipment in the vicinity  
Consideration of counts of both appropriate and inappropriate disposal and collection of injecting 
equipment before the trial and at the end of 2019 (when data consideration had to end) is 
complicated by changes in the collection services responsible for data on this measure.  
The Yarra City Council has primary responsibility for collecting needles and syringes found in public 
places, including those disposed of appropriately (for example, in sharps bins) and inappropriately 
(for example, on the street). In mid-2019 the council doubled the level of cleaning services in the 
local area. The increase in cleaning services included street sweeping and a two-person cleaning 
crew conducting daily foot patrols in North Richmond and southern Abbotsford, up to three times 
per day. Figure 34 details the streets and laneways patrolled. 
Figure 34: Yarra City Council foot patrols, 2019  
 
Source: Yarra City Council 
There are some other caveats to these data, including that the Yarra City Council is not the only 
agency collecting disposed syringes within the municipality; pharmacies, community health 
organisations and others (including the Office of Housing on the Richmond housing estate) also 
manage safe disposal of syringes. Discarded syringes and associated litter found by the general 
public (traders, visitors and householders) may not necessitate a service request to the council 
because people may choose to dispose of these themselves. Regarding syringe disposals, there is 
no manual counting of syringes and instead the capacity of the unit is used as an indicator of 
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volume, and this is the figure that is captured. Of those disposed syringes collected, either 
appropriately or inappropriately, some may not have necessarily been used. Syringe management 
incident data has historically been recorded by the council’s contractor, cohealth, via a manual 
process, with pen-and-paper recording in the field and data later entered into electronic 
spreadsheets. In mid-2019 this moved to a ‘real-time’ system to allow geocoded syringe 
management for both the council and cohealth. Historic datasets have been retrospectively 
geocoded to facilitate analysis.  
Given the caveats on use of these data, caution should be exercised in drawing definitive 
conclusions on the number of syringes discarded in the area. In the area surrounding the MSIR,18 the 
number of syringes disposed of appropriately and inappropriately have increased over time (Figure 
35). For each month between July 2017 and December 2019, more syringes were disposed of 
appropriately than inappropriately (53–89 per cent of syringes collected were disposed 
appropriately each month). 
Figure 35: Number of appropriately and inappropriately disposed syringes collected in the local 
area surrounding the MSIR, July 2017 to December 2019  
 
Source: Yarra City Council 
As described in the caveats above, during the trial period the Yarra City Council doubled its 
cleaning activities in the area surrounding the facility. This escalation of cleaning activities 
coincided with the number of inappropriately disposed syringes collected in the area almost 
doubling over an eight-month period (Figure 36).  
The number of syringes collected as a direct result of internal and external customer service 
requests to the Yarra City Council also fell from June 2019, two months after cleaning activities 
 
18 The area surrounding the MSIR was defined by the City of Yarra – a polygon bounded clockwise by Hoddle St, Gipps St, 




escalated. New, larger sharps bins were also recently installed near the NRCH carpark, which some 
staff at MSIR and NRCH suggest have contributed to a decrease in discarded injecting equipment. 
Figure 36: Number of inappropriately disposed syringes collected in the local area surrounding the 
MSIR, July 2017 to December 2019  
 
Source: Yarra City Council 
Note: The area surrounding the MSIR was defined by the Yarra City Council – a polygon bounded clockwise by 
Hoddle St, Gipps St, the Yarra River, Duke St, Johnson St, Coppin St and Bridge Rd (see Appendix C, Figure C1 
for a map showing the defined boundary). 
It should be noted that the escalation in cleaning activities only relates to the last eight months of 
the trial. Prior to this, in the first 10 months of the trial, the number of inappropriately disposed 
syringes collected in the surrounding area increased by 27 per cent (compared with the 10 months 
before the MSIR opened; see Figure 37). This suggests that even before cleaning efforts escalated, 
the number of inappropriately disposed syringes were already increasing. It is not possible to tell 
from this data if the increase in the number of syringes collected was due to more people injecting 
drugs in the area or to other factors.  
The Panel heard that after the MSIR opened, local residents were regularly provided with 
information on the Yarra City Council syringe disposal service through a public awareness 
campaign that included door knocking and distribution of letters, letterbox drops, posters and 
fridge magnets. The increasing marketing may have improved awareness and use of the service 
and increased the number of syringes the council collected. 
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Figure 37: Number of inappropriately disposed syringes collected in the local area surrounding the 
MSIR, before and after the MSIR opened, July 2017 to December 2019  
 
Source: Yarra City Council 
Note: The area surrounding the MSIR was defined by the Yarra City Council – a polygon bounded clockwise by 
Hoddle St, Gipps St, the Yarra River, Duke St, Johnson St, Coppin St and Bridge Rd (see Appendix C, Figure 7.1.1 
for a map showing the defined boundary). 
Community perceptions of discarded needles and syringes  
Conducted before the opening of the MSIR and approximately one year later (around the time 
MSIR operations moved to the larger facility), the MSIR Review Survey assessed whether there had 
been any change in the experience of local residents and businesspeople regarding seeing 
discarded injecting equipment. 
Most respondents (about 80 per cent) reported seeing discarded needles and syringes. There was 
little change in the proportion of residents who had seen discarded needles and syringes in the 
previous year (16.1 per cent to 16.9 per cent) but an increase for business respondents (20 per cent 
to 24.6 per cent) (see Table C6, Appendix C).  
In relation to the number of needles and syringes seen, the average or mean number seen in the 
month preceding the MSIR Review Survey reduced significantly for both residents and 
businesspeople (13.3 to 8.7 for residents; 21.9 to 17.5 for businesses) (see Table C6, Appendix C).  
Residents noted many concerns regarding discarded injecting equipment. Most related to the 
frequency and volume of the drug paraphernalia, the health hazard and the safety of children. For 
example, one survey respondent said: ‘I worry about children and don’t want kids to be exposed to 
it on the street and mistakenly pick up a syringe’.  
The Panel directly heard a wide range of views on this, from ‘the streets have never been cleaner’ 
to the ‘streets have never been worse’. Panel members frequently walked in the area during this 
review. While improvements were apparent on many of these occasions during 2019, there was 
often still visible evidence of discarded injecting equipment.  
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Public injecting in the vicinity of the facility 
Findings from the Burnet Institute study about public injecting is that there was no significant 
difference in reports of using the last purchase of heroin in public between those who had visited 
the MSIR and those who had not (Burnet Institute 2019, p. 42; Table C7, Appendix C). 
The results of the MSIR Review Survey regarding public injecting require careful analysis. As with the 
results relating to needles and syringes, most respondents reported seeing public injecting in the 
past (see Table C8, Appendix C).  
For residents, there was no statistically significant change in the proportion reporting they had seen 
public injecting in the previous week or month. Residents and businesses reported a statistically 
significant decline in having seen public injecting in the year preceding the survey (23.5 per cent to 
19.7 per cent for residents; 26.8 per cent to 22.2 per cent for businesses). 
When asked for estimates of the number of public injections observed in the month before the 
survey, there was no change for residents (median of three at both time points) and an increase 
from four to five for businesses (not a statistically significant change).  
There is evidence from research that people who inject drugs in public places will almost always 
inject close to where they obtained the drug. Studies about the nature and reasons for using 
particular public spaces suggest that, as well as proximity to the place of purchase, there are also 
factors such as proximity to transport connections, privacy, avoiding police attention, lighting and 
a sense of personal safety. This can include choosing to use laneways, alcoves and public toilets to 
avoid other people who might want their drugs but also a place that is sufficiently public to allow 
someone to see if they have overdosed and seek help.  
To understand why some people who acquire their drugs in the vicinity of the MSIR but apparently 
do not go there to inject, in mid-2019 a Collingwood local primary health centre for people who 
inject drugs (many of whom do use the MSIR) asked some clients about their experience of the 
transitional service: ‘If you have not used the MSIR, what is preventing you from using it?’. Responses 
included: 
▪ Personal preference.  
▪ Would feel ‘nannied’.  
▪ Comfortable using by myself or my friends. 
▪ Too busy, you wait to get in, even too busy for the chill out area and too many idiots. 
▪ Other users don’t go in, too scared – cameras. Believe blood testing being done from used 
syringes, DNA. 
▪ I have a home to safely use at. 
In response to the question: ‘Have you injected on the streets while the injecting room has been 
open? If yes, what was the reason you didn’t go to the injecting room?’, responses included: 
▪ Yes, in a rush. 
▪ Yes, I couldn’t find it, people talk about not going there because it’s so packed. 
▪ Yes, didn’t want to walk there. Comfortable on the streets. 
▪ Yes, most people do because they get fed up waiting. Quicker to go to NSP and then on 
street. 
▪ Yes, it was closed, hours need increasing. 
▪ Yes, people I was with don’t like it due to cameras, etc. 
▪ Yes, last night, injecting room would not let me in. 
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Research exploring the reasons that people who inject drugs do not use injecting facilities offers 
some explanations. These include a perception that the facility is too far away, if police were 
stationed nearby or if the rules and regulations made their preferred practices difficult (Wood et al. 
2003). For example, one study identified that potential service users would not use a facility if they 
could not share drugs (reason given by 34 per cent of those who were not willing to use a service) 
or if they were prohibited from assisting others to inject (18 per cent of those not willing to use) (Fry & 
Miller 2001).  
Part 55A(e): Improve the amenity of the neighbourhood for 
residents and businesses 
To assess this object, the Panel considered: 
▪ surveys of local residents and businesses before and during the trial (MSIR Review 
Survey) 
▪ results of a cohort study of people who use drugs 
▪ surveys of local Victoria Police members 
▪ a Yarra City Council community survey 
▪ consultations with professional stakeholders, staff and service users 
▪ group consultations with local residents and businesses  
▪ the impact on the school and community health centre 
▪ direct observations of the area. 
This finding of this review is that amenity has not improved during the review assessment 
period.  
▪ Prior research in North Richmond found the largest impact on the perception of 
amenity is from seeing discarded needles and syringes and other drug-related 
paraphernalia, and this appears to be largely unchanged. 
There are conflicting results in relation to perceptions of safety:  
▪ A Yarra City Council survey for the North Richmond area shows no change in residents’ 
perception of safely walking alone during the day or at night before or during the trial. 
▪ Victoria Police members reported seeing significantly more:  
o people buying or selling drugs 
o people who appear to be under the influence of drugs 
o antisocial behaviour that appears to be drug-related.  
▪ The MSIR Review Survey conducted for this review found that after the first year of 
operations:  
o significantly fewer residents and business respondents reported feeling safe walking 
alone during the day and after dark due to concerns about violence and crime, 
public visibility of drug use and drug deals, safety concerns for their own children 
and schoolchildren, concerns about aggressiveness and unpredictability, and 
discarded syringes in public places 
o more people reported considering moving house (32 per cent to 37.1 per cent) or 
their employment (27.6 to 32.5 per cent) because of drug-related activity. 
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▪ Most of the MSIR service users are not from Richmond but were already coming to the 
area before the facility opened.  
▪ Victoria Police reported seeing significantly more:  
o people buying or selling drugs 
o people who appear to be under the influence of drugs 
o antisocial behaviour that appears to be drug-related.  
▪ During the first year of the trial period more people reported considering moving house 
(32 per cent to 37.1 per cent) or their employment (27.6 to 32.5 per cent) because of 
drug-related activity. 
▪ It is difficult to assess the impact on the school, with the Panel hearing very different 
perspectives about parent experiences. However, advice from the school is that 
enrolments have increased, critical incidents involving discarded needles/syringes or 
overdoses have decreased and results of both parent and staff satisfaction surveys 
with the school have remained stable.  
▪ Advice from NRCH is that the congregation of clients at the front door of the 
community health service, who were often assumed to be clients of the MSIR, has 
influenced other clients. Maternal and child health, general practice patients and 
some other services have seen some reduction in attendance. Work to address this has 
recently been undertaken to improve the appearance and amenity of the MSIR 
entrance. The 2018 Victorian Healthcare Experience Survey reported that 56 per cent 
of NRCH clients felt safe coming to the community health centre. This compares with 
other similar services that average in the mid-90 per cent range.  
▪ The trial has been extensively covered in print and social media, with coverage most 
commonly assessed as being ‘negative’ in sentiment, which can affect people’s 
perceptions. 
▪ Overall, agreement with having an injecting room in North Richmond reduced for 
residents (from 61 to 44 per cent) and businesses (48 to 41 per cent) over the first year 
of the trial.  
▪ There continues to be substantial efforts across a range of organisations to ameliorate 
concerns, and if the trial is extended both these and community sentiment should be 
monitored. 
In addition to providing a space for using injectable drugs and the secure disposal of associated 
equipment, the Victorian legislation states that the facility aims to ‘improve the amenity of the 
neighbourhood for residents and businesses in the vicinity of the licensed medically supervised 
injecting centre’ (Part 55A(e) of the Act). While other supervised injecting facilities have been 
found to contribute to improved amenity, this is not typically one of their stated aims. As described 
in earlier sections, there is a separate aim of reducing discarded needles and syringes and public 
injecting. Use of the facility was also anticipated to benefit the amenity of the neighbourhood in 
other ways; however, these benefits are not defined by the legislation.  
The period from mid-1995 to 2001 saw the emergence of street-based markets in Melbourne. Dietze 
and Fitzgerald (2002, p. 297) note that, ‘access to the market is high, drug dealing is highly visible, 
the market is mobile and redeploys rapidly in response to police activity, there is a high level of 
associated crime and public disorder and drug use occurs in public locations’. Previous research 
has found that public injecting has had a substantial negative impact on public amenity in the 
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North Richmond/Abbotsford area (Dwyer et al. 2013). In particular, discarded needles and syringes 
and other injecting-related paraphernalia is a key factor in perceptions of amenity. 
In relation to broader amenity issues, the Panel initially examined evidence to consider if 
community engagement was occurring, including tracking amenity issues.  
As the trial progressed, the Panel analysed evidence to understand the extent to which there has 
been: 
▪ improved liveability of the neighbourhood  
▪ improved perceptions of safety 
▪ a reduction in public injecting and discarded injecting equipment  
▪ improvements in amenity of the neighbourhood leading to increased support for establishing 
the facility over time. 
The above indicators relate to potential changes in amenity arising from the operation of the MSIR 
more broadly. In relation to specific activities undertaken to address amenity, there are several 
entities with areas of responsibility that may contribute to experiences of amenity, including the 
MSIR and NRCH, Victoria Police, Yarra City Council and the Office of Housing. 
The Panel considers that a person’s experience of living or working in the area could reasonably be 
influenced by the MSIR. This includes the above activities as well as other contributors such as 
media coverage.  
Before the MSIR opened, there had been significant public discussion and media exposure on the 
impact of public injecting in the City of Yarra, with a particular focus on the North Richmond heroin 
market. This attention highlighted existing concerns about the discarding of drug injecting 
paraphernalia, witnessing of overdose, public injecting and the public nuisance perceived to stem 
from the illicit drug market.  
Media coverage  
External analysis found the MSIR trial was highly visible in the print media, with articles reaching a 
potential audience of around 20 million (Media Measures 2020). There was a strong focus during 
the first 18 months of the trial by the two Melbourne daily newspapers, with 54 stories appearing in 
the Herald Sun and 32 stories in The Age.  
Print media coverage of the MSIR trial was largely negative (45.9 per cent), with the remainder 
relatively evenly split between positive and neutral coverage. The bulk of the print media’s positive 
coverage dealt with stories on the state government’s release of data on the MSIR that indicated a 
large number of client visits to the facility and the large number of overdoses successfully 
managed. The two main negative issues in the print media were public concerns (including from 
local residents) and the incident involving staff of NRCH incorrectly reported as two MSIR workers 
being accused of drug trafficking. In some instances, negative reporting was made more intense 
by the inclusion of emotive photos depicting drug injecting and antisocial activities in the North 
Richmond precinct. 
Analysis across print media, broadcast media and internet media found sentiment was 47 per cent 
negative and only 9 per cent positive about the MSIR trial. Analysis of social media using a product 
called ‘TalkWalker’ found that Twitter was the key forum for discussion of the trial (84.1 per cent of 
all media results), followed by online news (7.2 per cent). The impact of negative media coverage 
may have contributed to people’s views about the trial.   
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Crime in the local area  
The number and type of offences recorded within a 1 km radius of the MSIR largely remained stable 
between October 2014 and September 2019 (Figures 38 and 39), except for offences relating to 
drug use and possession (Figure 39). Offences for drug use and possession declined after the 
opening of the MSIR and then increased again three months later (Figure 40). Almost all offences 
under this offence category were drug possession offences (98 per cent). 
These trends may reflect that in the earlier months of the MSIR trial Victoria Police identified that, 
after delivering training on the matter, some of its members had developed a misunderstanding 
about the extent to which they could enforce drug-related crimes in the area, based on an ill-
informed reference to an ‘exclusion zone’ around the MSIR discussed in the media at the time 
(Sakkal 2019). This led to some members being confused about who and when they could 
approach, with the result that their drug enforcement activity was lower than usual in the initial 
period of the trial.  
Once this misunderstanding became apparent, Victoria Police provided additional training to 
members about their remit, with the expectation that the law is enforced in all locations while 
advising police officers not to ‘over-police’ the entrance – that is, not to target people as they 
enter or exit the facility. In addition, more resources were provided to the location, including bike 
patrols covering the estate and laneways from mid-2019 (data beyond then was not available at 
the time of reporting). With increased resourcing comes the opportunity to detect more crime, so 
these figures may increase in the future.  
Figure 38: Number of offences recorded within a 1 km radius of the MSIR from Quarter 2, 2014–15 to 
Quarter 1, 2019–20 – offence subdivisions relating to crimes against the person and property and 
deception offences 
 
Source: Victorian Crime Statistics Agency 
 
 91 
Figure 39: Number of offences recorded within a 1 km radius of the MSIR from Quarter 2, 2014–15 to 
Quarter 1, 2019–20 – offence subdivisions relating to drug offences and public order and security 
offences 
 
Source: Victorian Crime Statistics Agency 
Figure 40: Number of drug use and possession offences recorded within a 1 km radius of the MSIR 
from Quarter 2, 2014–15 to Quarter 1, 2019–20 
 
Source: Victorian Crime Statistics Agency 
In general, the rate of drug possession offences per 100,000 population in the City of Yarra was 
higher than the Victorian rate. The rate of drug possession offences increased in Quarter 1, 2019–20 
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for both the City of Yarra (from 150.2 per 100,000 population to 228.7) and Victoria (from 97.7 per 
100,000 population to 108.8), although the increase was larger for the City of Yarra than Victoria 
(Figure 41). The large increase in the City of Yarra may reflect the increase in policing training and 
resources to the area from mid-2019, as mentioned above and further considered below. 
Figure 41: Rate of drug possession offences for City of Yarra and Victoria from Quarter 2, 2014–15 to 
Quarter 1, 2019–20 – per 100,000 population 
 
Source: Victorian Crime Statistics Agency 
Note: These statistics relate to offence group C32: drug possession. 
These data relate to detection of offences only, and they do not necessarily match drug use trends 
in the area because other possible indicators changed in another direction. For example, the 
number of needles and syringes dispensed from NRCH increased between 2012 and 2017, possibly 
suggesting a large increase in drug use in the area before the trial commenced; however, the 
police statistics on use/possession show a decrease in the same period. These data seem to clearly 
reflect changes in policing effort, particularly since April 2019 when Victoria police committed to 
regular, concerted efforts and increased patrols in the area.  
Changes in police numbers, training, operational protocols and possible special operations from 
other police areas can all influence drug crime data, so these are very hard to use as an accurate 
measure of criminal activity. Additional local policing resources were allocated to the Richmond 
local police station in the police service area of Yarra at about the time that the MSIR was opened, 
with local changes in policy direction also likely to have contributed to an increase in arrests. 
Police attendance in the local area 
During the trial several organisations, including Victoria Police, the Yarra City Council, DHHS and 
some in the community, were actively encouraging people to contact the police if they had drug-
related concerns. Several community stakeholders reported to the Panel or others within DHHS that 
this had led to them calling triple zero (000) in circumstances where they previously might not 
otherwise have done so. At the same time, Victoria Police were encouraging people to report 
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drug-related concerns through triple zero (000) rather than the station number. This makes directly 
comparing figures of emergency calls and police attendance before and during/after 
comparisons difficult since it is likely to have increased detection and reporting rates rather than 
necessarily indicating a change in drug-related activity requiring police intervention.  
Figures 42 and 43 show total police callouts in the Richmond area compared with drug-related 
callouts from the end of 2014 to March 2015.  
Figure 42: Total Victoria Police computer-aided dispatch events per 1,000 people, Richmond, 
January 2015 to March 2019 
 
Source: Victoria Police Computer Aided Dispatch data 
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Figure 43: Drug-related computer-aided dispatch events per 1,000 people, Richmond, 
January 2015 to March 2019 
 
Source: Victoria Police Computer Aided Dispatch data 
Note: The Panel notes that changes in police numbers, training, operational protocols and possible special 
operations from other police areas can all influence drug crime data, and so these are very hard to use as an 
accurate measure of criminal activity. 
Victoria Police observations 
Victoria Police noted their awareness of significant attention from community members who 
reported concerns about an increase in people using drugs publicly or who appeared to be drug-
affected in the community.  
This was also the experience of many of the respondents to a survey conducted with local Victoria 
Police members for this review in November 2019. To note, this survey occurred shortly after the 
incident involving NRCH staff and may have affected police views at that time. An invitation was 
sent via email to all members working in the North West Division (which incorporates the area 
surrounding the MSIR) with at least one year’s policing experience including policing the North 
Richmond area. Of the 41 members who responded, most reported observing significantly more 
people who appeared to be buying or selling drugs, or who appeared to be under the influence of 
drugs or undertaking drug-related antisocial behaviour (Table 12). 
Table 12: Police observations on drug-related activity, November 2019 
Issue Degree Percentage  
Observed people who appear to be 
buying or selling drugs 
Significantly more 77.5 
About the same 12.5 
Slightly more 10.0 
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Issue Degree Percentage  
Observed people who appear to be under 
the influence of drugs 
Significantly more 67.5 
Slightly more 17.5 
About the same 10.0 
Slightly less 5.0 
Observed antisocial and/or disorderly 
behaviour that appears to be drug-related 
Significantly more 57.5 
About the same 22.5 
Slightly more 17.5 
Slightly less 2.5 
Source: MSIR review of local police 
Victoria Police reported to the Panel that, over the period of the MSIR trial, crime in the area 
surrounding the facility was largely attributable to local crime trends not connected to the trial. For 
example: 
▪ There was an increase in robberies during the period of the trial, but this did not appear to be 
associated with drug use.  
▪ There was an increase in reported assaults, but these are typically alcohol-related and from a 
different cohort of people from those who inject drugs. 
▪ Thefts from motor vehicles were being conducted by individuals already known to Victoria 
Police and were not associated with injecting drug activities. 
▪ Thefts of motor vehicles in the local area were attributed to an increase in food delivery 
service personnel coming into the area and leaving their motorbikes unattended with keys in 
the ignition, leading to opportunistic crime, which also did not appear to be connected to 
people who inject drugs. 
▪ There was an increase in congregation on the housing estate, particularly in the afternoons 
and by a group of local people consuming alcohol, although again, Victoria Police believes 
this was a different group of people from those using the MSIR. 
▪ One possible barrier to effectively policing the stairwells and laundries at the local housing 
estate, both popular places to inject drugs, was the understanding of some police that they 
required a warrant to enter these spaces after the introduction of additional ‘concierge’ 
services, although this has now been clarified and is not true. 
Impact on the nearby primary school 
The Panel heard very different perspectives from parents about their experiences of the facility 
being located close to the school. It has not been possible to draw a conclusion from this 
feedback. Incidents involving discarded injecting equipment or overdoses have decreased, and 
results of both parent and staff satisfaction with the school in general have remained stable. Figure 




Figure 44: Number of students enrolled at the local school, 2016 to 2020 
 
Source: Victorian Department of Education 
Community surveys 
There were two sources of community sentiment expressed in surveys available to the Panel. These 
were the MSIR Review Survey of local residents and businesses conducted for the Panel by Colmer 
Brunton immediately before the trial commenced in mid-2018 (see Appendix G) and repeated after 
one year of operations within the transitional facility in mid-2019 (see Appendix H) and separate 
surveys of householders conducted by Metropolis Research for the Yarra City Council (see 
Appendix B). The findings differ somewhat, and responses to questions about perceptions of safety 
are reported here.  
MSIR Review Community Survey results 
Results regarding responses to perception of public injecting, disposal of injecting equipment and 
other indicators of experience of amenity have already been reported above.  
The proportion of local people randomly surveyed who reported feeling safe when walking alone 
during the day had fallen significantly in the first year of operations of the MSIR: businesses from 61.8 
per cent to 45.8 per cent, and residents from 69.5 per cent to 54.7 per cent. The trend is similar 
regarding walking alone after dark.  
Significantly more residents and businesses reported being approached and offered heroin within 
the year of the MSIR opening compared with the year before (21 to 30 per cent of residents and 19 
to 22 per cent of businesses).  
The percentage of residents who have considered moving out of the area because of drug-related 
activity increased significantly from 32.0 per cent before the MSIR to 37.1 per cent in mid-2019. 
Similarly, for business employees and owners, the percentage who have considered finding a new 
job or moving their business out of the area rose significantly from 27.6 per cent to 32.5 per cent. 
For residents, the most frequently reported reasons for feeling unsafe were: 
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▪ violence and crime (30 per cent) 
▪ public visibility of drug use and drug deals (29.2 per cent) 
▪ safety concerns for their children and schoolchildren (21 per cent) 
▪ aggressiveness and unpredictability of people who use drugs (19.4 per cent)  
▪ discarded syringes in public places (16.1 per cent).  
For businesses, the most common reasons were:  
▪ public visibility of drug use and drug deals (29.7 per cent) 
▪ violence and crime (18.8 per cent) 
▪ aggressiveness and unpredictability of people who use drugs (17.7 per cent) 
▪ safety concerns for their children and schoolchildren (11.8 per cent) 
▪ discarded syringes in public places (9.8 per cent). 
Yarra City Council Annual Customer Satisfaction Survey  
Respondents to the Yarra City Council Annual Customer Satisfaction Survey are asked to identify 
any improvements noticed in their local area in the preceding two years. In the 2019 annual survey 
results, Richmond North19 and Abbotsford respondents were more likely than average to report 
improvements to drug-related issues (Yarra City Council 2019). Drug-related issues were the second 
most noticed improvement in both Richmond North and Abbotsford after parks, gardens and open 
spaces (Table 13). Respondents for the 2019 survey were interviewed in February–March 2019; this 
means respondents were asked this question eight to nine months after the MSIR opened. The 2018 
survey findings differ from the 2019 findings, with respondents not reporting drug-related issues as a 
top improvement noticed in Abbotsford or Richmond North (respondents were surveyed in 
February–March 2018, before the MSIR opened). These findings suggest that after the MSIR opened 
there have been improvements in drug-related issues in Richmond North and Abbotsford, at least 
for some people living in the area. 
Table 13: Top improvements noticed in the local area in the last two years by precinct, 2018 and 
2019 
Survey year Abbotsford Richmond North 
2018 1. Parks, gardens, open spaces: 11.9% 1. Parks, gardens, open spaces: 16.9% 
2. Road maintenance and repairs: 6.0%  2. Cleanliness of areas including streets: 
13.3%  
2019 1. Parks, gardens, open spaces: 15.7% 1. Parks, gardens, open spaces: 13.3% 
2. Drug-related issues: 9.6%  2. Drug-related issues: 12.0%  
Source: Yarra City Council: Annual Customer Satisfaction Surveys, 2018, 2019 
Note: 2018 survey conducted February to March 2018; 2019 survey conducted February to March 2019. 
Respondents to the Yarra City Council Annual Customer Satisfaction Survey are also asked to 
identify preferred improvements to the local area in the next two years. In the 2018 annual survey, 
 
19 The area that the MSIR is located in is referred to by various stakeholders as North Richmond and Richmond North. In the 
Yarra City Council referred to above, it is referred to as Richmond North, and is presented as such in this section.  
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Richmond North and Abbotsford participants reported drug, alcohol and cigarette issues as the 
most preferred improvement to the local area in the next two years (Table 14). This differs from the 
2019 findings in which Richmond North participants reported parking as their top preferred 
improvement, with drug-related issues listed second. For Abbotsford participants, both ‘parking’ 
and ‘safety, crime and policing’ were the top preferred improvements. These findings suggest that 
drug, alcohol and cigarette issues were identified as a top issue and area of improvement before 
the MSIR opened; however, after the MSIR opened it moved below parking as the issue where 
improvements would be preferred.  
Overall, findings from the survey indicate that for some people in North Richmond and Abbotsford 
drug-related issues have improved; however, for other people drug-related issues are an ongoing 
problem. 
Table 14: Top preferred improvements to the local area in the next two years by precinct, 2018 and 
2019 
Survey year Abbotsford Richmond North 
2018 1. Drug, alcohol & cigarette issues: 19.0% 1. Drug, alcohol & cigarette issues: 21.7% 
 2. Bike tracks & facilities/infrastructure: 
13.1%  
2. Parking: 13.3%  
2019 1. Parking: 12.0% 1. Parking: 20.5% 
 2. Safety, crime & policing: 12.0%  2. Drug-related issues: 15.7%  
Source: Yarra City Council: Annual Customer Satisfaction Surveys, 2018, 2019 
Note: 2018 survey conducted February to March 2018; 2019 survey conducted February to March 2019. 
The annual Yarra City Council survey asks local residents: ‘On a scale of 0 (very unsafe) to 10 (very 
safe), how safe do you feel in public areas in the City of Yarra?’ In 2018 and 2019 this was 
conducted in the first half of the year. There was a small decrease in the mean rating score for 
North Richmond residents, although less than in the neighbouring area of Abbotsford (Table 15). 
Figure 45 provides the trend for this score between 2010 and 2019. 
Table 15: Perceptions of safety during the day and night, Abbotsford and North Richmond, mean 
rating scores, 2018 and 2019 
Time of day/night Abbotsford residents North Richmond residents 
Safety during the day – 2018 8.7 8.0 
Safety during the day – 2019 7.7 7.7 
Safety during the night – 2018 7.0 6.1 
Safety during the night – 2019 6.4 6.2 
Source: Yarra City Council: Annual Customer Satisfaction Surveys, 2018, 2019 
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Figure 45: Perceptions of safety during the day and night in Richmond North, mean rating scores, 
2010 to 2019 
 
Source: Yarra City Council: Annual Customer Satisfaction Surveys, 2018, 2019 
Observation and consultation with community members  
In forums that Panel members directly observed and in consultations conducted by the Panel with 
local residents, businesses and interested groups, the Panel heard a range of experiences, with 
some suggesting improvements in amenity and others speaking strongly about deterioration. These 
involved real and perceived risks to their safety through what they saw as an increased number of 
people behaving in unpredictable and at times confronting ways. For example, a resident of the 
nearby housing estate noted times when ‘we cannot leave the flat’, having encountered 
individuals or groups injecting in the stairwell. In that week they made five calls to security and one 
to police. 
Although the Panel heard from a small number of people who did not support the trial at all, the 
more common view was one of support for the trial but also concerns about the impact of it on the 
local community. Different people and groups called for different responses: some wanted the trial 
to continue in the current location; others were supportive of the trial of such a service but wanted 
the location to move, possibly to a more industrial or commercial area of North Richmond. A 
number of people suggested opening additional sites to ‘spread the load’.  
Has the MSIR attracted people who sell or use drugs to the area?  
One of the most common concerns historically for supervised injecting facilities and other drug 
consumption rooms is that they will bring people who inject drugs into an area who otherwise 
would not have come, a so-called ‘honeypot’ effect.  
This review explicitly sought to test this. It does not appear there has been a direct ‘honeypot’ 
effect driven by the MSIR. From data collected at registration, Melbourne is the most commonly 
cited area of residence, and from the evidence available, most people who have used the MSIR 
trial do not identify as residents of North Richmond. This could be because it is used as a default by 
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people who do not want to be more specific. Richmond is the second most often recorded place 
of residence. Most people using the MSIR (86 per cent) were already coming to North Richmond 
before the MSIR trial was established to purchase and use heroin. Separately, the Burnet Institute’s 
SuperMIX study (2019) found a shift towards purchasing heroin in Richmond by cohort members in 
the year before the facility opened, which continued after it opened (Figure 46). There could be 
many explanations for this. 
Figure 46: Location of latest heroin purchase for participants recruited before 2017 and interviewed 
after MSIR opening, 2008–09 to 2018–19  
 
Source: Burnet Institute 2019 
The Burnet Institute study found that MSIR service users were more likely to report purchasing heroin 
in public spaces (62 per cent) than those who had not visited the MSIR (42 per cent), who usually 
purchase their drugs in other locations. Frequent users of the MSIR were more likely to have 
purchased heroin in public than less frequent users of the MSIR – 58 per cent versus 69 per cent 
respectively (Burnet Institute 2019, p. 44). 
Of the Burnet Institute study participants who were interviewed outside Richmond, those who visited 
the MSIR were more likely to report their last purchase of heroin in public than those who didn’t visit 
the MSIR (see Table C10, Appendix C). 
Local community support for the MSIR  
Support for an injecting room fell among residents over the first year of the MSIR’s operations. 
Among businesses, there was no marked change in support level. Regarding the location of North 
Richmond, support decreased in both groups, as much as 17 per cent among residents and 7 per 




Where is implementation up to? 
Implementation of a necessary suite of responses to local amenity is still in its early stages. 
The main focus of the first year of the trial has been to establish the service and to oversee injecting 
by people attending the MSIR. The new facility has only recently become fully operational with 
regular clinics in Zone 4.  
The Panel is aware of a series of more recent additional measures that have been initiated to help 
address the objective of improved community amenity. These have included a precinct and social 
landlord initiative in the immediate area and actions to respond to a Crime Prevention Through 
Environmental Design assessment led by Victoria Police. These initiatives demonstrate a 
commitment to better link various government programs with the Yarra City Council as well as 
community groups and other services.  
The Panel notes that the legislation that enacted the Sydney MSIC did not include improved 
amenity of the local area as an objective, and a review of the literature suggests that this objective 
is very hard to achieve or to demonstrate in association with establishing a supervised drug 
injecting service. The Yarra City Council and the Victorian Government have been more focused 
on addressing amenity during the most recent phase of the MSIR trial’s implementation, especially 
since late 2019. 
Most recently the Panel has been provided with the following by DHHS: 
In April 2019, the Minister for Mental Health announced that there will be more frequent sweeps 
to remove needles, more AOD outreach team providing help on the street, and on the 
Richmond housing estate, an increased security presence and improved lighting. The 
announcement was followed by Yarra City Council’s decision to increase the amount of street 
cleaning in the Victoria street precinct and Victoria Police’s commitment to regular proactive 
patrols and ongoing enforcement activity in the area, focused on holding drug traffickers and 
dealers to account. 
The Government recently made further improvements on the Richmond housing estate and 
Victoria Police identified important safety and security issues through a Crime Prevention 
Through Environmental Design review. In response, DHHS made capital upgrades throughout 
the estate, including in the multi-deck carpark next to NRCH. Cleaning needle collection and 
syringe disposal unit availability has also been increased on the estate. As the trial has 
progressed, there have also been more crime prevention activities in the area in the vicinity of 
the MSIR and on the estate. 
Given this timing, it is not possible for the review to examine evidence of impact or to comment on 




Part 55A(f): Assist in reducing the spread of blood-borne 
diseases among MSIR users 
To assess this object, the Panel considered: 
▪ MSIR data on health needs and services provided  
▪ St Vincent’s Hospital’s Independence Program data  
▪ results of a cohort study of people who use drugs linked with Victorian health datasets.  
The trial has advanced this object, particularly for more frequent users of the service, and for 
those requiring treatment for blood-borne diseases.  
▪ Most people were already reporting not sharing needles and syringes (an important 
measure to reduce the spread of blood-borne viruses), with no significant difference in 
needle sharing rates between MSIR service users and other people who inject drugs. 
▪ The MSIR has provided screening, assessment and treatment initiation and monitoring 
of blood-borne infections.  
▪ In the first 18 months, approximately 300 people were tested for blood-borne viruses, 
with more than one-third of people screened testing positive for hepatitis C and a 
quarter had begun treatment for hepatitis C. 
▪ After the first year of the trial, an analysis of linked Medicare and Pharmaceuticals 
Benefits Scheme data showed no significant difference in relevant tests or prescriptions 
between people who use the MSIR and other people who inject drugs, noting that 
efforts to provide these services have increased and the uptake and impact should 
continue to be monitored. 
One of the aims of the MSIR is to ‘assist in reducing the spread of blood-borne diseases in respect of 
service users of the licensed medically supervised injecting centre, including, but not limited to, HIV 
and hepatitis C’ (Part 55A(f) of the Act). For the purpose of this report, blood-borne diseases are 
defined as blood-borne viruses that are commonly transmitted through risky injecting practices 
such as sharing injecting equipment.  
As outlined in the program logic, the review initially examined evidence to consider whether: 
▪ injecting at the facility is taking place with sterile equipment and according to protocols 
▪ mechanisms are in place for identifying service users with blood-borne viruses. 
As the trial progressed, the review analysed evidence to understand the extent to which there are 
accessible, suitable and effective health promotion and harm reduction messages at the facility, 
including techniques to minimise the risk of blood-borne viruses. 
All injections at the MSIR are conducted with appropriate injecting equipment and access to harm 
reduction advice and education. Staff indicated that they had the skills and capacity to support 
practices that aim to reduce the spread of blood-borne viruses, including following sanitation 
protocols and wearing protective equipment. Staff reported that service users adhere to the 
operating policy of zero sharing of injecting equipment.  
In relation to injections outside of the MSIR, MSIR service users reported a much higher number of 
injections per week (14 per week compared with three for other people who inject drugs), which 
may increase their risk of acquiring a blood-borne infection if they are using used equipment. There 
is not a significant difference between MSIR service users and other people who inject drugs in 
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reporting that they had injected with someone’s used needle/syringe in the previous month (9 per 
cent of MSIR service users and 11 per cent of other people who inject drugs) (Burnet Institute 2019, 
p. 51) (see Table C19, Appendix C). Some staff and service users raised concerns that the closure of 
the secure dispensing unit at NRCH could contribute to an increased risk of acquiring a blood-
borne infection.  
There is high demand at the service for blood-borne infection testing. At registration, hepatitis C is 
the fourth most frequently identified health need among service users. Between 30 June 2018 and 
31 December 2019, the MSIR screened more than 284 service users for HIV and viral hepatitis 
(hepatitis A, B and C). Of this number, 35.6 per cent (101) tested positive (via a hepatitis C 
polymerase chain reaction (PCR) test) and 25.7 per cent (73) initiated hepatitis C treatment.  
The co-location of a St Vincent’s Hospital care coordinator (Health Independence Program, 
Infectious Diseases) provides pre- and post-test HIV and viral hepatitis counselling, venepuncture 
and treatment. The care coordinator provided 195 occasions of service to service users in the 
October–December 2019 quarter (Table 16). Additionally, 116 occasions of service were provided 
to MSIR service users in the community.  
Table 16: St Vincent’s Hospital Melbourne Health Independence Program infectious diseases 
occasions of service  
Service type Oct–Dec 2019 30 Jun 2018 to 31 Dec 2019 
Brief intervention 57 97 
Care coordination 46 76 
Blood-borne virus education 24 36 
Nurse assessment 23 27 
Blood-borne virus screening 22 40 
Engagement 13 45 
Secondary consultation 7 31 
Other 3 45 
Source: St Vincent’s Hospital 
The following case study illustrates the work undertaken by the St Vincent’s Health Independence 
Program infectious diseases clinical nurse consultant in the October–December 2019 quarter. 
Case study 9: Screening for blood-borne viruses 
This client has a long history of intermittent heroin and methamphetamine use and travel to 
NRCH to access pharmacotherapy due to concerns about privacy and stigma. The client spoke 
to the infectious diseases care coordinator with concerns about sexually transmitted and blood-
borne diseases they were afraid to discuss with their local doctor. The care coordinator referred 
them to a trusted local GP for future needs, and supported them to undertake a full screen, 
which gave a positive result on a communicable disease. The care coordinator supported 
contact with both the new GP and DHHS for partner notification support. 
Case study provided by St Vincent’s Hospital Melbourne 
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In relation to the impact of the trial on testing and treatment, there was not yet any evidence 
through analysis of linked data with the Medicare Benefits Schedule of any significant difference 
between the average number of hepatitis C PCR tests in preparation for treatment and tests to 
confirm treatment success for participants who visited the MSIR compared with those who did not 
in the years surrounding the opening of the MSIR (Burnet Institute 2019, p. 52). There was also not yet 
any evidence of any significant difference between the average number of hepatitis C 
prescriptions for participants who visited the MSIR compared with those who did not in the years 
surrounding the opening of the MSIR (Burnet Institute 2019, p. 53). Since then, there have been 
substantial efforts to increase the number of people screened and treated at the service, and if the 
trial is extended, it would be helpful to continue to monitor access, use and clearance rates of 
diseases such as hepatitis C. Population rates for blood-borne viruses in Victoria have gradually 
declined over time (between 2016 and 2019), whereas rates in the City of Yarra have fluctuated. 
While the number of hepatitis C cases involving reported injecting drug use in Victoria shows a 
decline between 2018 and 2019 (from 579 to 392, respectively), it is not possible to directly attribute 




Legislation and regulations 
This section of the report describes how the legislation and regulations made for the purposes 
of trialling a medically supervised injecting centre in Victoria have operated and whether they 
need amending. 
Legislation 
The Drugs, Poisons and Controlled Substances Amendment (Medically Supervised Injecting Centre) 
Act: Part IIA – Trial of medically supervised injecting centre, confers certain powers on the Secretary 
to DHHS. Under the Act, the Secretary may issue a licence for an MSIR at the permitted site. The 
Secretary may refuse to issue the MSIR licence to an entity for any reason the Secretary thinks fit. 
Only one MSIR licence may be issued.  
The Secretary must also consider whether to approve the draft internal management protocols 
proposed by that entity. In doing so, the Secretary must have regard to whether, if the MSIR licence 
were issued, the draft protocols would require that: (a) the centre must have a director; (b) the 
centre must be under the supervision of a supervisor at all times; and (c) the centre must be 
operated so as to facilitate access or referrals to services such as primary healthcare services, drug 
and alcohol treatment services, services for testing for blood-borne diseases and STIs and services 
involving a needle and syringe exchange program. With the written approval of the Secretary, the 
MSIR internal management protocols may be amended or replaced from time to time.  
If satisfied that extending the period of the MSIR licence would further the legislative objectives, the 
Secretary may do so by amending the licence to change the day specified under subsection 
(1)(b) to a day that is not later than 36 months after the day previously specified under that 
provision. The period may be extended only once. On extending the period of the MSIR licence 
under s. 55F (3), the Secretary must publish in the Government Gazette a notice that states that the 
period of the licence has been extended. The MSIR licence is subject to the several conditions 
including: (a) no child is to be admitted to any part of the facility for the purpose of the 
administration of any injecting centre drug; and (b) the internal management protocols must be 
observed at all times. 
The Panel notes that the legislation allows for a single non-transferrable licence during the trial 
period and is specific about the location at which the trial can occur. The specificity of the 
legislation could be restrictive in the event that government wished to make any changes during 
the trial period, or if there were external circumstances that meant the site was inaccessible (for 
example, a fire) that would mean the service would not be able to operate in another site. 
The legislative requirement for the medical director to have oversight of the centre, and in addition 
a medical supervisor to be available at all times, embeds workforce requirements in a way that 
does not allow DHHS or the licensee to revise them during the trial period. 
The specificity of the legislation makes any adaption or innovation of the trial elements difficult.  
The legislation is prescriptive in defining many elements of the development and operation of the 
trial. This makes it difficult to adapt to any change that might occur in the context of the service or 
among the service users or in other service developments. It prevents innovation and certain 
adaptions that might make for a more responsive or efficient service. Further, it creates complexity 
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in the governance arrangements for the MSIR. For example, embedded in the legislation and the 
internal management protocols that flow from the regulations are the tightly defined requirements 
of the licensee including specific management directives that may constrain or compromise the 
usual role of a board and executive management of a contracted service.  
Regulations  
The Drugs, Poisons and Controlled Substances Amendment (Medically Supervised Injecting Centre) 
Regulations prescribe that any drug of dependence is able to be used at the MSIR and that 
individuals are permitted to have with them less than a trafficable amount of those drugs. 
The regulations also prescribe the content required to be included in the internal management 
protocols of the licensed medically supervised injecting centre including: 
(a) responding to clients who are at risk of causing harm to themselves or others 
(b) ensuring minimum staffing levels are maintained at the licensed medically supervised 
injecting centre 
(c) ensuring minimum security levels are maintained at the licensed medically supervised 
injecting centre 
(d) excluding the employment of potential and existing staff members deemed unsuitable for 
employment at the licensed medically supervised injecting centre on the basis of their 
criminal history 
(e) setting eligibility criteria for accessing any part of the licensed medically supervised injecting 
centre that is used for the purpose of administration of any injecting centre drug 
(f) preventing access to the licensed medically supervised injecting centre by clients known to 
be on parole, on bail or subject to any other order of a court or tribunal that prohibits the 
use of injecting drugs 
(g) preventing and responding to any potential or suspected trafficking in a drug of 
dependence in the licensed medically supervised injecting centre.20 
Impact from legislation and regulations 
There are aspects of the legislation and regulations that may require further consideration, such as 
barriers to access for some individuals who might benefit from attending the MSIR who are unable 
to do so. This includes: 
▪ people on bail/parole conditions – noting that people leaving custodial settings can be at 
increased risk of overdose due to decreased tolerance to substances 
▪ young people – noting that many people who use the MSIR first injected at a relatively young 
age. 
A number of groups have expressed concerns about barriers to access, regardless of the 
mechanism that excludes them. The Panel believes these concerns warrant further exploration if 
 





the trial was extended. Government may wish to monitor the impact of barriers to or exclusions 





The implementation of this service and associated responses remains a work in progress.  
It has clearly been possible to establish a medically supervised injecting service that has attracted 
people who are at high risk of overdoses associated with injecting drugs. NRCH has managed a 
complex challenge that has included a significant increase in its budget, staffing levels and 
external attention. The MSIR has been responsive and able to oversee many people injecting drugs 
within the facility. There have been no overdose deaths in the MSIR, and a number of people have 
been assisted to access health and support services.  
The trial has shown that the concept of a medically supervised injecting service in Victoria can be 
implemented successfully.  
The expectations detailed as objects in the Act are ambitious and completed assessment of their 
achievement is premature. Considerable detail has been provided in this report. Most of the 
objects of the Act have been advanced during the first 18 months of the trial.  
This review has used many sources of data. Findings relating to illicit drug availability, use and 
associated harm must always consider diverse and often incomplete data in order to draw any 
conclusions that, at the end of the day, must sometimes rely on inference through the weight of a 
mix of evidence. There are benefits to using the unique mix of data Victoria has available, and the 
continued collection of these is warranted. This includes data that provide some insight and 
opportunity to monitor the drug market for heroin and other injectable drugs, the movement of 
people who use these drugs as well as their service seeking, and changes to patterns of use and 
harm as well as uptake of additional services. 
The location of the MSIR in a health service should provide benefits of ensuring access to broader 
health and other support services. Many NRCH staff were already trusted by people who have 
been injecting drugs in Richmond, evidenced by the very rapid take-up of the MSIR upon opening. 
However, ongoing efforts to assess changing dynamics in the area, including possible shifts in the 
location of trafficking and consumption, will be important as well as monitoring the success of the 
various ways that the MSIR approaches provision of integrated responses, particularly if additional 
services are opened. 
With only six months of operation in the purpose-built, larger facility, there has not been sufficient 
data or experience to allow a considered comparison of the two different locations of the MSIR, 
albeit they have been on the same designated land and physically close. It is too early in 
implementation to determine if the MSIR should be terminated or made permanent. More time and 
the possibility of further supervised injecting services in an additional three-year trial period could 
provide greater experience and an opportunity to explore other means of responding to demand. 
It would also allow for the measures directed at amenity and precinct renewal that are only now 
emerging to be actioned in the vicinity of the MSIR.  





▪ North Richmond has been the main site for heroin use and related harms in Victoria for the 
past decade.  
▪ The trial occurred in the context of increasing heroin use and increased visibility of people 
who inject drugs in North Richmond and a high number of overdose deaths.  
▪ The MSIR provides a responsive and safe service to people who inject drugs.  
▪ The service has been well utilised by the intended client group.  
▪ The service is attracting a group of people who inject drugs with high health and support 
needs, many with recent experiences of overdose. 
▪ The model of care could be further considered to examine options regarding matters such as 
staffing, optimum opening hours and the ways of providing additional services, recognising 
that many of the service users require navigation to connect to systems of care.  
▪ The establishment of the MSIR has prevented overdoses and further harm and has saved lives.  
▪ Of those who do attend the service, the nature of the overdoses is significant, and without 
intervention it is likely that many would have died or been permanently injured.  
▪ Modelling allows an estimate of the number of lives that the MSIR may have saved and, while 
there are different ways to model this, using conservative estimates, these data suggest that 
between 21 and 27 deaths were avoided over the 18 months of this review. This does not 
include the prevention of permanent disability including acquired brain injury.  
▪ NRCH and MSIR staff have made significant progress in delivering additional services and 
developing referral pathways to other service providers. 
▪ With the move to the larger facility the range and number of services is expanding. 
▪ An ongoing trial would provide the opportunity to develop and assess ongoing integration of 
services and alternative ways of achieving this. 
▪ There has been a reduction in ambulance attendances involving naloxone in the vicinity of 
the facility during opening hours. 
▪ There have been no observable changes in emergency department presentations that can 
be attributed to the MSIR.  
▪ There has been a reduction in reports of public injecting. Local people report no difference in 
seeing discarded injecting equipment. There has been an increase in collected injecting 
equipment (noting also an increase in collection activity later in the trial).  
▪ Amenity has not improved during the review assessment period. 
▪ Implementation of a necessary suite of responses to local amenity is still in its early stages.  
▪ The MSIR has provided screening, assessment and treatment initiation and monitoring of 
blood-borne infections.  
▪ The specificity of the legislation makes any adaption or innovation of the trial elements 
difficult.  
▪ The operating exclusion criteria limit access for vulnerable people who are likely to 





Based on these findings, the Panel recommends that:  
1. The medically supervised injecting room (MSIR) trial at North Richmond Community Health 
(NRCH) continues in order to allow it to operate for the possible full duration of the licence (three 
further years).  
2. The MSIR operates with no more than 20 injecting booth positions to ensure ongoing effective 
management in this high-acuity health setting for the duration of the trial.  
3. Based on demand and international experience, the Victorian Government expands the current 
trial to include another supervised injecting service in an appropriate location within the City of 
Melbourne.21 Trialling further services in this period could help manage demand, potentially save a 
greater number of lives and would allow an opportunity to test effectiveness in different locations 
as well as trial another model of supervised injecting facility in Victoria. 
4. The Department of Health and Human Services continues to lead the MSIR trial as a health 
response with coordination support from the Department of Justice and Community Safety to 
ensure that both health and community needs are considered as the trial evolves to improve real 
and perceived levels of community safety.  
5. The Victorian Government works with local government and the community to continue to 
develop local safety and amenity, including formalising the role of the existing roundtable to be 
responsible for community engagement, community safety and coordination of relevant services. 
This should include representatives from at least the Department of Health and Human Services, 
Victoria Police, Yarra City Council, local service providers (including the MSIR) and the local 
community.  
6. The licensee of any supervised injecting service be proactive in engaging and communicating 
with the local community and key stakeholders on issues that may potentially affect the 
community.  
7. There be more emphasis on place management, including in the vicinity of the MSIR, with a clear 
understanding among staff, service users and community members that disturbing and antisocial 
behaviour will not be tolerated. Visible community policing is required in areas of active drug 
trafficking to increase the experience and perception of community safety.  
8. The model of care be further considered, including:  
▪ the requirement for medical supervision since clinical (nursing) oversight could achieve the 
same level of safety more efficiently    
▪ the current hours of operation to best match demand for the service    
▪ enhancing the access to and availability of care coordination in areas such as mental health, 
housing and drug dependence treatment.  
 
21 This recommendation is based on the international research and experience described in this report, patterns of overdose-
related deaths in non-residential locations, ambulance attendance involving the provision of naloxone, publicly available 
crime data and the Panel’s own knowledge and insights into street-based injecting activity in Victoria. Consideration of a 
local government area for another service was not originally part of the terms of reference for this review; however, in 




9. The Victorian Government continues to monitor the implementation of the recommendations of 
the NRHC Alcohol and Other Drug Review, recognising that further refinement in policy or practice 
may be required.  
10. Further reviews associated with establishing any MSIRs be conducted, with a report to be 
submitted at least six months before the potential expiry of any licence. This should draw on 
performance monitoring data from within the service and focus particularly on local amenity 
planning and implementation, and the experience and perception of local community members.  
11. Funding is provided to enable ongoing provision of services that meet the needs of injecting 
room users.  
12. Statewide drug-related patterns of use and harms continue to be monitored through analyses 
of data such as ambulance attendance, the provision of naloxone and deaths involving heroin 
and other injectable drugs. This could usefully include qualitative research methodologies in 
locations where evidence indicates high levels of activity related to injecting drugs. 
13. Harm reduction initiatives continue to be provided to those areas and people experiencing 
most harm, such as by expanding overdose response training and the direct provision of naloxone 
including through needle and syringe programs and in prisons, detoxification and rehabilitation 
settings and other relevant services.  
14. The Victorian Government monitors the impact of current exclusion criteria on access for 







Addendum: Additional advice 
regarding the most appropriate LGA 
for a possible second service  
This addendum provides further detail in relation to the development of Recommendation 3, in 
particular the rationale for naming the City of Melbourne as the second LGA for an injecting 
service.  
Consideration of an LGA for another service was not originally part of the terms of reference for this 
review; however, in recommending another supervised injecting service, the Panel agreed to 
provide additional advice regarding the most appropriate LGA.  
The Panel considered the following information to form this recommendation:  
▪ international research and experience described in this report 
▪ patterns of overdose-related deaths in non-residential locations 
▪ ambulance attendances involving the provision of naloxone 
▪ drug-related crime data 
▪ the Panel’s own knowledge and insights into street-based injecting activity in Victoria.  
International research and experience  
As described previously, the European experience shows that the extent to which medically 
supervised injecting facilities are used is highly dependent on their location. Essentially, the service 
needs to be: 
▪ near to illicit drug markets 
▪ close to places of drug purchase 
▪ located where they can be embedded in a wider network of services 
▪ compatible with the needs of people who use drugs 
▪ compatible with the needs and expectations of local residents. 
A recent analysis of published reviews of supervised injecting programs (Belackova et al. 2019) has 
identified key features to consider in designing future drug supervision facilities:  
▪ the location and co-location of the program  
▪ whether people who use drugs will trust the program and therefore access the service when 
possession and use of that drug is criminalised 
▪ what operational hours will best capture the times and/or periods of increased overdose risk 
▪ what specific harm reduction practices should be prioritised or what level of assistance in 
referring people to other services is most appropriate. 
These features need to be fully considered during the period when the service is being designed 
and decisions made about specific location(s).  
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Patterns of overdose deaths in non-residential locations 
The Panel considered deaths in non-residential locations and identified that the LGA of Melbourne 
had the second highest number and percentage of these deaths after the City of Yarra (Table 17).  
Table 17: Percentage of deaths occurring in non-residential locations – top 20 LGAs for heroin-













related deaths  
Yarra 51 55 93 
Melbourne 25 49 51 
Brimbank 17 30 57 
Port Phillip 10 19 52 
Greater Geelong 8 20 40 
Frankston 6 20 30 
Wyndham 6 26 23 
Greater Dandenong 6 11 53 
Maribyrnong 5 16 32 
Whitehorse 4 16 25 
Maroondah 4 21 19 
Stonnington 3 17 18 
Hume 3 17 18 
Yarra Ranges 2 9 22 
Moonee Valley 2 11 18 
Monash 1 5 22 
Greater Bendigo 1 6 18 
Boroondara 1 6 18 
Moreland 1 3 30 
Knox 1 3 29 
Darebin 1 2 41 




Ambulance attendance involving the provision of naloxone 
The Panel considered ambulance attendance involving the provision of naloxone as a proxy for 
understanding patterns of overdose and identified Melbourne as the LGA with the highest number 
of attendances during the trial period (Figure 47). 
Figure 47: Ambulance attendances where naloxone was administered by paramedics – Greater 
Melbourne region, July 2018 to December 2019 
 
Drug-related crime data 
The Panel also considered drug-related crime data – in particular, drug use and possession – and 
identified the Melbourne LGA as having the highest rate of these crimes recorded (Figure 48). 
Figure 48: Drug use and possession data from Melbourne LGAs and Victoria overall, 2015 to 2019  
 
Based on the above, and the Panel’s own knowledge and insights into street-based injecting 
activity in Victoria, the LGA of Melbourne was identified as the most appropriate LGA for a possible 
second service. 
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Appendix A: Terms of reference for 
the review22 
Overview 
The Victorian Government is trialling a medically supervised injecting room at the North Richmond 
Community Health site in North Richmond, Melbourne. 
The trial will take place for an initial two-year period, with the option to extend the trial for a further 
three years. It is proposed that the trial will commence in mid-2018. 
Role of the Panel 
The Medically Supervised Injecting Room Review Panel (the Panel) will oversee the conduct of a 
review as outlined in s. 55P of the Drugs, Poisons and Controlled Substances Act 1981 (the Act), 
including:  
▪ the operation and use of the licensed medically supervised injecting room 
▪ the extent to which the objects outlined in Part IIA of the Act have been advanced during the 
period of the medically supervised injecting room licence 
▪ how Part IIA and any regulations made for the purposes of this Part of the Act have operated 
and whether they require amendment. 
Specifically, the responsibilities of the Panel are to:  
▪ develop, with the Department of Health and Human Services (the department), the review 
scope, structure (including any preliminary or interim reports) and data and evidence 
collection requirements 
▪ review data and evidence to closely monitor the objects of the Act 
▪ provide the Secretary to the department with a draft copy of the review, to inform a decision 
on whether the trial should be extended 
▪ provide an endorsed review to the Minister for Mental Health (the Minister) prior to the 
completion of the two-year trial, meeting the requirements outlined above. 
The review must commence no later than 12 months after the day on which the medically 
supervised injecting centre licence commences. It may be completed before or after the licence 
ceases to have effect. 
Membership  
Composition 
1. The membership of the Panel will consist of the following members, appointed by the Minister: 
▪ chairperson 
 
22 Department of Health and Human Services (DHHS) 2019, Medically Supervised Injecting Room: frequently asked questions, 
‘Why is the Victorian Government trialling a MSIR in North Richmond?’ Online. Accessed February 2020 
<https://www2.health.vic.gov.au/alcohol-and-drugs/aod-treatment-services/injecting-room> 
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▪ up to two other members, as determined by the Minister. 
2. The Minister shall appoint the chairperson and members in accordance with the Victorian 
Government’s Appointment and remuneration guidelines (the guidelines). 
Appointment 
3. A person is not a member of the Panel until appointed by an instrument signed by the Minister.  
Probity checks  
4. Prospective members are subject to probity checks including:  
▪ a declaration of private interests 
▪ a national police record check 
▪ an Australian Securities and Investment Commission (ASIC) check 
▪ an Australian Financial Security Authority (AFSA) check. 
5. Members will be required to make a declaration of private interests annually during their term of 
appointment.  
Term of appointment 
6. Members will be appointed from the date listed in the Instrument of Appointment until 29 June 2020.  
7. At this time, the terms of reference and membership of the Panel will be reviewed. The Minister will 
direct whether the Panel should continue and whether any necessary changes to terms of 
reference or membership are required, or whether the Panel should be dissolved. 
8. Where a replacement member is appointed, the term of office for that member shall be the 
balance of the term of office of the replaced member. 
Vacancies  
9. A member of the Panel may resign in writing, addressed to the Minister. 
10. The Minister may remove a member from the Panel at any time by providing that member with 
notice in writing, which shall have immediate effect. 
11. The office becomes vacant if:  
▪ a member dies 
▪ for any other reason determined by the Minister. 
12. Upon a vacancy occurring, the vacancy may be filled in accordance with these terms of 
reference. 
Remuneration and expenses 
13. Members of the Panel are entitled to receive remuneration as fixed by the Minister in accordance 
with the guidelines for a Group D2 classified body.  
14. Members are eligible to be reimbursed for reasonable out-of-pocket expenses in accordance with 
7.27 of the guidelines and the policies of the department. 
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Confidentiality  
15. Members shall maintain confidentiality of the following information in order to provide a basis for 
independent advice and debate:  
▪ deliberations of the Panel 
▪ correspondence between the Minister or the department and the Panel 
▪ departmental papers supplying information in relation to business matters before the Panel 
▪ any other documents provided to members marked confidential unless otherwise stated by 
the Minister. 
16. Members shall only use and copy information for the purposes set out in the terms of reference and 
the duties of the Panel.  
17. Members may explain and provide general feedback on the work of the Panel and consult closely 
with their representatives, stakeholders and networks on a needs to know basis for the purpose of 
carrying out the terms of reference and subject to confidentiality requirements.  
18. A member who resigns, retires or is removed from the Panel shall not, without the express approval 
of the Minister, disclose any information accruing from the membership.  
19. Invited attendees at panel meetings may be requested to sign a confidentiality deed.  
Conflicts of interest  
20. At the start of each panel meeting, a member, non-member or observer shall declare if he or she 
has an interest in respect to any item on the agenda.  
21. In declaring an interest, the individual will state the nature of the interest and the conflict that results 
or may result. An interest must be declared even if it is already recorded in the member’s 
Declaration of Private Interest. 
22. A member or observer who becomes aware during the meeting that he or she has an undeclared 
interest will declare it immediately. 
23. When a chairperson, member or observer makes a declaration of conflict of interest, the 
chairperson, or in the case of a declaration by the chairperson, the members as a collective may: 
▪ refuse the member the right to speak to the business 
▪ refuse the member the right to vote on that business 
▪ require the member to withdraw from a meeting for the period of discussion and resolution of 
that business. 
24. Where a member or observer declares a conflict of interest, this will be recorded in the minutes of 
the meeting. 
Business operations  
Frequency of meetings 
25. The Panel shall meet no less than quarterly, or as determined by the chairperson, in consultation 
with the responsible project manager.  
Invitations 
26. Invitations to panel meetings are non-delegable. 
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27. Other persons may be invited to attend panel meetings as required for specific purposes.  
Quorum 
28. All panel members are required for the meeting to be recognised as an authorised meeting, and for 
the recommendations or resolutions to be valid. If all members cannot participate in a scheduled 
meeting, the meeting must be rescheduled.  
Chairing 
29. The chairperson is not permitted to delegate chairing responsibilities.  
 Meeting agenda and papers 
30. Items can be submitted by members for inclusion on the Panel agenda, in consultation with the 
responsible project manager. 
31. The Panel agenda, with attached meeting papers, will be distributed at least five working days prior 
to the next scheduled meeting. 
32. The chairperson has the right to refuse to list an item on the formal agenda, but members may raise 
an item under ‘Other business’ if necessary and as time permits. 
33. Any urgent item that cannot wait until the next meeting, or is for information only, can be circulated 
out of session. All members will be asked to respond to the out-of-session item, endorsing, noting or 
otherwise indicating their position on the paper. 
Meeting records 
34. The minutes of each panel meeting will be prepared by the responsible project manager. These 
minutes should accurately reflect decisions or recommendations made by the Panel, specify each 
item of business discussed and briefly summarise essential items of discussion.  
35. Minutes and all meeting papers shall be provided to all panel members no later than five working 
days following each meeting. 
36. Minutes may be circulated to relevant officers within the department, unless the chairperson 
determines a particular item to be confidential in which case the minutes will be circulated 
excluding confidential items. 
37. By agreement of the Panel, out-of-session decisions will be deemed acceptable. Where agreed, all 
out-of-session decisions shall be recorded in the minutes of the next scheduled panel meeting. 
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Appendix B: Framework for the 
Review of the Medically Supervised 
Injecting Room 
The Drugs, Poisons and Controlled Substances Act 1981 (the Act) provides the scope of the 
medically supervised injecting room (MSIR) including the key aims for the facility. This was used to 
develop the analytic frame for this review (Figure B1). 
Figure B1: Legislated objectives for the review of the medically supervised injecting room 
 
Key stakeholders for the trial 
The Panel considered several groups of individual, community and organisational stakeholders for 
this trial. This framework considers stakeholders in terms of direct impact, professional impact, 
geographical impact and systemic impact, as outlined in Figure B2.  
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Figure B2: Layers of impact for the medically supervised injecting room 
 
About the review 
As outlined in s. 55P of the Act, the Panel reviewed: the operation and use of the facility; the extent 
to which the aims outlined in Part IIA of the Act has been advanced; and how Part IIA and any 
regulations made for the purposes of the Act have operated and whether they require 
amendment. As the period for this review was two years from establishing the facility, the review 
primarily focuses on: 
▪ the implementation of the trial 
▪ early indicators that the trial is on track to deliver longer term outcomes 
▪ the extent to which the facility has contributed to progression of each of the aims identified in 
the legislation  
▪ identifying potential longer-term indicators of success for consideration beyond the review 
period 
▪ consideration of any potential amendments.  
To enable sufficient time for analyses and to provide the government with findings ahead of 
decision making, the Panel focused on information from the first 18 months of the trial. 
Cost of the review 
The review was provided $500,000 to procure specialist advice and analyses, and to fund specific 
review activities. This included contracting Colmar Brunton and Q&A Market Research to conduct 
two rounds of resident and business surveys, and the Burnet Institute to conduct analyses from a 
longitudinal cohort study of people who inject drugs. The Panel was provided technical and 
secretariat support from evaluators located in the DHHS Centre for Evaluation and Research. 
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Design and methods 
There are many scientific, practical and ethical challenges that need to be considered when 
reviewing complex health interventions such as supervised injecting facilities (NCHECR 2007). An 
early activity of this review was to develop a pragmatic approach that would provide the best 
evidence possible given these challenges. 
Design 
In developing the approach for this review, a literature review and other activities were conducted 
to inform the design and methods of the review. The review included the following approaches: 
▪ a desktop review of key documents and published evidence including: 
 relevant legislation, internal management protocols, performance management 
requirements and accreditation requirements  
 analytical approaches to international and local evaluations/reviews on medically 
supervised injecting facilities 
▪ development of a theory of change and program logic to connect the goals and activities 
described in the legislation to measurable outcomes  
▪ consideration of relevant parliamentary debates, enquiries and submissions to identify further 
potential lines of enquiry 
▪ site visits to North Richmond Community Health Centre, the MSIR and the Sydney Medically 
Supervised Injecting Centre 
▪ consideration of observations, reports and opinions expressed during the time of the review  
▪ consultation on the review approach and potential data sources with key stakeholders23 
including: 
 individuals and organisations who had previously made submissions to relevant 
parliamentary inquiries, members of the expert advisory group, local reference groups 
and Gateway Services Group to identify particular and/or further potential lines of 
enquiry24 
 interested groups from the locality through a series of planned, semi-structured 
consultation meetings. 
Review principles 
The review is guided by the objects of the legislation, as well as the following principles: 
▪ build on existing information sources where possible to alleviate data collection burden 
 
23 The Panel thanks the following for their early input to inform this process: the MSIR, North Richmond Community Health, 
Victoria Police, Ambulance Victoria, Metropolitan Fire Brigade, the Coroner’s Court of Victoria, the City of Yarra, the 
Department of Premier and Cabinet’s special advisor on self-determination of Aboriginal and Torres Strait Islanders, the Chair 
of the Expert Advisory Group (also the founding medical director of the Sydney Medically Supervised Injecting Centre), the 
chair of the Local Reference Group, the chair of the Gateway Services Group, and the broader Gateway Services Group, 
the Youth Support and Advocacy Service (YSAS) and the DHHS Drugs Policy and Reform Unit.  
24 The Panel thanks the following for their responses: Alcohol & Drug Foundation, Ambulance Victoria, Australasian College of 
Emergency Medicine, Australian Medical Association, cohealth, Fred Hollows Foundation, Harm Reduction Victoria, Hepatitis 
Victoria, Kirby Institute, Metropolitan Fire & Emergency Services Board, RMIT University, Royal Australasian and New Zealand 
College of Psychiatrists, Victoria Police, Victorian Drug and Alcohol Association, Windana Drug & Alcohol Recovery Inc and 
individuals who had previously provided submissions to the relevant inquiries. 
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▪ ensure that structured data collection approaches are independently assessed as ethical or 
are approved by independent research ethics bodies  
▪ use appropriate data collection techniques that will include analysis of quantitative and 
qualitative data and, where possible, case studies from the community as illustrations 
▪ use methodologically and statistically rigorous approaches to enable, as far as possible, 
detection of changes in indicators  
▪ use appropriate quantitative and qualitative analytical techniques  
▪ use appropriate benchmarking to enable fair comparisons across time, locations and 
populations 
▪ consider using an appropriate modelling approach25 to estimate possible deaths prevented, 
with due regard to the complexity of such modelling and the availability of data, suggesting 
use of conservative interpretations in conducting development of this estimate26.  
▪ spend some unstructured time in the vicinity of the MSIR to better understand the local 
context 
▪ consider the findings within the broader context, including the dynamic nature of drug use 
and drug markets. 
Methods 
The review applies a pragmatic mixed-methods approach and draws on multiple information 
sources to provide a comprehensive understanding of advancement towards the aims of the 
facility as stated in the legislation (Figure B3). 
 
25 A number of international studies regarding modelling of overdose deaths were consulted to inform the review approach 
including Irvine et al. 2019 and Babu et al. 2019.  
26 Consideration was given to the recent international review on assessing the evidence on supervised injecting 
services/drug consumption sites including especially Chapter 4: mathematical and simulation studies (Pardo et al. 2018) and 
further discussed in Caulkins et al. 2019 together with other subsequent academic discussion of these publications. Caution is 
needed in the estimation of lives saved. 
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Figure B3: Methodological tools utilised by the review 
 
A note on defining ‘vicinity’ for this review  
Although the legislation refers to ‘vicinity’, it does not define the geographic area that is in the 
vicinity of the facility. A specific definition was required so that only those communities directly 
surrounding the facility were included in the review datasets. The review therefore established a 
working definition of ‘vicinity’. The geographic boundary in the ‘vicinity’ of the facility was defined 
through consideration of the following: 
▪ the boundary used for the resident survey in the evaluation of the Sydney Medically 
Supervised Injecting Centre  
▪ the time, distance and mode of travel that people who inject drugs is likely to take between 
purchasing and injecting drugs  
▪ data on location and rates of discarded needles and syringes in the City of Yarra  
▪ the available census data on geographic location of residents that could be mapped to 
geographic data collected as part of the survey to ensure sample representativeness without 
undue risks to the privacy of respondents.  
Ethical assessment  
The review used the following approaches to ensure ethical conduct of the review: 
▪ only undertaking review activities that are associated with a clear purpose and benefit 
▪ approval of research activities by a National Health and Medical Research accredited 
Human Research Ethics Committee, as well as relevant departmental and agency approvals 
▪ obtaining informed consent for the collection and/or use of identifiable or re-identifiable 
data, including any linkage of individual data records 
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▪ working with data custodians on the appropriateness and quality of relevant datasets 
▪ minimisation of distress associated with participating in review activities through careful design 
of survey and interview protocols. 
Qualitative methods 
Semi-structured and small group interviews 
To understand the experiences and perspectives of individuals who inject drugs, service users and 
key staff and management at relevant organisations were interviewed, allowing them an 
opportunity to comment on experience of intended and unintended consequences. Information 
from these interviews have been subject to content and thematic analyses. These help to inform 
the focus of data collection and, where appropriate, these form the basis for case studies into 
specific areas of enquiry and facilitate interpretation of other data. 
Almost 100 semi-structured interviews were conducted, led by the Panel. In most cases, interviews 
were conducted by two interviewers, with a small number conducted by one or three people. 
Interviews lasted 15 minutes to slightly over an hour in length and followed a semi-structured 
interview guide to obtain information on predetermined topics aligned with the overarching review 
framework for the project. Interviewers used prompts throughout the interviews to access 
information about a variety of additional topics. Interviews were audio-recorded and transcribed. 
Once transcribed, the interview scripts were analysed thematically using NVivo 12 software. 
Interview questions 
MSIR staff 
38. How long have you worked in the MSIR? 
39. Can you please describe your experience of working in the MSIR for the past 
couple of months? 
40. (Have you worked in other injecting facilities? How does the Richmond facility 
compare to others you have worked in?) 
41. Is there anything about the MSIF you believe should be changed? 
42. What are the key challenges for you, working in the facility?  
43. Have you experienced any obstacles in providing assistance or support to clients? 
44. What sort of feedback (if any) are you hearing from clients about the facility? 
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NRCH staff 
1. How long have you worked in the NRCH? What is your role here? 
2. Can you please describe your experience of working at NRCH since the opening 
of the MSIR? 
3. Have you noticed any changed in the vicinity of NRCH since the opening of MSIR? 
4. Is there anything about the MSIR you believe should be changed? 
5. What are the key benefits and challenges for you, working so close to the Facility?  
6. Have you experienced any obstacles in providing assistance or support to your 
clients? 
7. What have been your experiences working with MSIR clients in a referral capacity, 
if any? 
8. What sort of feedback (if any) are you hearing from clients about the Facility?  
 
People who use the MSIR 
1. How many times have you used the facility? 
2. When you don’t use it, why don’t you? 
3. Do you feel comfortable here? Why/why not? 
4. Do you usually come alone, or with someone? 
5. Do you recommend the facility to other people, who are still injecting outside/in a 
public place? Why? 
6. How do you find the staff? What have they done for you? Have they helped look 
after you in any way? 
7. Have you learnt anything new about taking care of yourself, at the MSIR? 
8. Do you do anything differently, as a result of something you may have learnt at the 
MSIR? This could be in relation to how you inject drugs or how you look after 
yourself afterwards.  
9. Do you have any suggestions for how the facility could be improved so that more 
people would feel comfortable coming here? 
10. What is it like for you getting to and leaving the facility? 
11. What differences does the MSIR make on your day-to-day life (if any)? 
12. Have you noticed any changes in the North Richmond area? 
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People who access the North Richmond Needle and Syringe Program 
1. Have you heard of the Medically Supervised Injecting Facility?  
2. (If yes) What have you heard about it? 
3. Have you used the Facility to inject drugs before?  
4. (If no) Why not?  
5. (If yes) Why aren’t you using it today? 
6. What would make you more likely to use it (or use it more often)? 
 
Community consultations 
1. How long have you been in this area? 
2. Are you noticing any changes in drug-related activity in the Richmond area? 
3. What has been your experience since the establishment of the trial? 
4. What are your perspectives on the trial? Why? 
5. What are your suggestions for the trial?  
Content and thematic analysis of written materials 
To understand policies and procedures, health promotion materials and existing literature and 
research describing injecting drug use, these documents have been subject to content and 
thematic analyses. To understand any changes in the community discussion about the facility, 
parliamentary debate and media coverage was considered throughout the trial.  
Analysis of print media was conducted by an external provider, Media Measures, on print media 
articles and using the analytical tool ‘Talkwalker’ on social media.  
The Media Measures report is at Appendix D and the Talkwalker report is at Appendix E.  
Services and referral mapping 
A service mapping exercise was undertaken by the local Primary Care Partnership, together with 
members of the Gateway Services Group, to: (a) identify the capacity of Gateway Services 
Reference Group members to support MSIR staff and the means through which they can do this; 
(b) improve the understanding of local referral options and pathways; (c) determine the barriers to, 
and enablers of, access to health and social support services in the City of Yarra and surrounds for 
people who inject drugs. 
Quantitative analyses 
Descriptive statistics have been used to provide an aggregate-level understanding of available 
data from the facility, departmental and public agency datasets. Where suitable, inferential 
statistics were used to understand changes over time and/or geography using analytical 
techniques. The department conducted the following analyses of available data: 
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MSIR database 
The MSIR database is an administrative dataset that includes information on MSIR service users, 
services accessed, referrals and events at the facility.  
The review conducted a descriptive statistical analysis of MSIR data from 30 June 2018 to 31 
December 2019, including demographic characteristics of service users, supervised injections, 
substances injected, service utilisation, referrals to other services, overdoses and reportable 
incidents. 
Coroners Court of Victoria  
The Coroners Court of Victoria maintains a database of deaths reported to the coroner. This 
database includes information around the cause of death, geographic locations and other 
statistical information. 
The review analysed heroin-related deaths data from January 2015 to June 2019, including by local 
government area, distance from the MSIR and the type of location (residential vs non-residential 
locations). 
Victorian Admitted Episode Dataset (VAED)  
The VAED is a comprehensive dataset of the causes, effects and nature of illness and the use of 
health services in Victoria. All Victorian public and private hospitals, including rehabilitation centres, 
extended care facilities and day procedure centres, report a minimum set of data for each 
admitted patient episode. 
The Burnet Institute analysed VAED data linked to participants in the SuperMIX cohort sample. A 
total of 3,579 records were linked to 481 participants in the sample. For more information on the 
methodology, see the Burnet Institute report at Appendix F. 
Victorian Emergency Minimum Dataset (VEMD) 
The VEMD comprises de-identified demographic, administrative and clinical data detailing 
presentations at Victorian public hospitals with designated emergency departments. 
The Burnet Institute analysed VEMD data linked to participants in the SuperMIX cohort sample. A 
total of 11,649 records were linked to 515 participants in the sample. For more information on the 
methodology, see the Burnet Institute report at Appendix F. 
The review analysed heroin overdose related emergency department presentations (within 
opening hours of the MSIR) at St Vincent’s Hospital between July 2012 and December 2019. 
Structural break detection and interrupted time-series analyses were conducted on the monthly 
aggregated count and daily rate, with statistical significance tested (p < 0.05). The interrupted 
time-series analysis applied was based on the method described in Lopez et al. 2017.  
Victorian Ambulance Clinical Information System (VACIS) 
The VACIS is a patient care record computer application specifically designed for Australian 
ambulance services. VACIS contains all patient data, from ambulance call to discharge. 
The Burnet Institute analysed VACIS data linked to participants in the SuperMIX cohort sample. A 
total of 4,433 records were linked to 499 participants in the sample. For more information on the 
methodology, see the Burnet Institute report at Appendix F.  
The review analysed ambulance attendances where naloxone was administered between January 
2015 and December 2019, including by location (within 1 km of the MSIR and the rest of Victoria) 
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and time of day (during MISR opening hours and outside MSIR opening hours). An interrupted time 
series analysis was conducted on the monthly aggregated count of ambulance attendances 
within 1 km of the MSIR during MSIR opening hours with statistical significance tested (p < 0.05). The 
interrupted time series analysis applied was based on the method described in Lopez et al. 2017. A 
chi-square test was conducted on the number of ambulance attendances in the 18-month period 
before and 18 month-period after the MSIR opened, during and outside MSIR opening hours. 
Ambo-AODstats Victoria 
Ambo-AODstats Victoria is the Victorian alcohol and drug interactive statistics and mapping 
webpage. Ambo-AODstats provides information on alcohol and drug-related ambulance 
attendances in Victoria. 
The review analysed descriptive statistics from 2011–12 to 2018–19 for the City of Yarra and Victoria. 
Data presented is the heroin-related overdose ambulance attendance rate per 100,000 
population. 
Victorian Crime Statistics Agency (CSA) 
CSA is responsible for processing, analysing and publishing Victorian crime statistics, independent of 
Victoria Police. Data presented in this report are offences data within a 1 km radius of the MSIR 
location at 23 Lennox St, Richmond. Offences are recorded in the Police Law Enforcement 
Assistance Program (LEAP) database, where Victoria Police have recorded a crime prohibited by 
criminal law. These include crimes that have been reported to police as well as those identified by 
police. 
The review analysed the number and rate of offences recorded within a 1 km radius of the MSIR 
from October 2014 to September 2019. Rates per 100,000 population were calculated by CSA. The 
quarterly rates were calculated using the annual population figures, and fluctuations in populations 
between quarters has not been taken into account. The CSA advises caution when comparing 
quarter-on-quarter trends. 
Victoria Police Computer Aided Dispatch (CAD) 
CAD data captures all triple zero (000) calls. The review received data from January 2015 to March 
2019 for total triple zero (000) calls (CAD callouts) and for drug-related CAD calls in Richmond. 
‘Drug-related’ callouts include the following four types of events: 
▪ drug deal/use in public 
▪ suspected lab/plantation 
▪ drug overdose 
▪ drug overdose with violence. 
The review analysed the rate of callouts per 1,000 people in Richmond over time. Rates were 
calculated using Australian Bureau of Statistics population data.  
Public Health Event Surveillance System (PHESS) 
Under the Public Health and Wellbeing Act 2008, the department is authorised by law to collect 
information from doctors and laboratories about diagnoses of certain health-related conditions in 
Victoria. The law exists to monitor and control the occurrence of infectious diseases and other 
specified conditions and helps to prevent further illness. The aim is to protect the health and safety 
of the community. 
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The review analysed hepatitis B, hepatitis C and HIV notifications in the City of Yarra and Victoria 
from 2016 to 2019. The data presented are from the public local government areas surveillance 
report <https://www2.health.vic.gov.au/public-health/infectious-diseases/infectious-diseases-
surveillance/interactive-infectious-disease-reports/local-government-areas-surveillance-report>. 
Local community surveys 
City of Yarra annual resident survey 
Yarra City Council commissions Metropolis Research to conduct an annual survey of householders 
to gauge their satisfaction with the range of council services and to establish emerging issues and 
priorities. To ensure results can be generalised, a randomised sample of households is selected, 
which is stratified by neighbourhood. The results are weighted by precinct (neighbourhood) to 
ensure each precinct within Yarra contributes proportionally to the municipal result. Metropolis 
Research interviewers are multilingual to ensure good representation from culturally diverse 
community members.  
The City of Yarra analysed the survey results and provided findings to the review team for inclusion 
in the report. 
The MSIR Community Survey 
To understand the impact on residents and businesses in the vicinity of the facility, results from 
statistically representative surveys at baseline (June 2018, wave 1) and after approximately 12 
months (July 2019, wave 2) capture changes in community members’ observations, attitudes and 
support towards the facility. Colmar Brunton conducted the community survey. The Colmar Brunton 
technical report for wave 1 is at Appendix G and the wave 2 report is at Appendix H. 
Prospective cohort study of street-based people who inject drugs  
To understand the impact on people who inject drugs, results from an established cohort study 
being led by the Burnet Institute (SuperMIX) have provided between and within subject measures 
for people injecting in North Richmond (both inside and outside of the facility), and in comparison 
with people who inject drugs in other key drug markets in greater Melbourne. The full report is 
provided at Appendix F. 
Synthesis and interpretation 
Central to the approach are structured synthesis mechanisms to test the findings of individual data 
sources with other qualitative and quantitative sources, including with key stakeholders. Information 
collected through these means was considered in conjunction with direct observations made by 
the Panel and team through visits to the facility and surrounding areas.  
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Appendix C: Additional data from 
various sources 
This appendix provides additional detail to expand on key information outlined in the main body of 
the report. 
Table C1: Key demographics of facility clients between 30 June 2018 and 31 December 2019 
Measure Key demographic Percentage 
Gender Male 74.8 
Female 24.8 
Not specified 0.4 
Country of birth Australia 88.9 
United Kingdom 1.8 
New Zealand 1.7 
Vietnam 1.2 
Other 6.2 
Aboriginal and/or Torres 
Strait Islander peoples 
Aboriginal and/or Torres Strait Islander 13.4 
Accommodation Rental house/flat 45.8 
Sleeping rough 15.1 
Family 10.4 
Boarding house/hostel 9.5 
Home owner 7.5 
Friends/couch surfing 6.3 
Shelter/refuge 2.5 
Squat 1.3 
Not specified 1.6 
Education Some high school 50.5 
High school certificate or equivalent 13.5 
Completed tertiary 11.8 
Some tertiary 11.2 
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Measure Key demographic Percentage 
Not specified 3.7 
Source: MSIR database 
Table C2: Demographics – Burnet Institute SuperMIX study (2019) 






Total   181 417 598   
Age at interview ≤ 30 12% 8% 9% 0.007* 
31–40 55% 44% 47%   
41–50 23% 36% 32%   
≥ 50 10% 12% 12%   
Missing 0 0 0   
Gender identity Male 70% 66% 68% 0.614† 
Female 30% 33% 32%   
Non-binary/gender fluid 0% 0% 0%   
Missing 0 0 0   
Employment status Unemployed 95% 84% 87% < 0.001* 
Employed 5% 16% 13%   
Missing 0 0 0   
Housing status Unstable 39% 28% 31% 0.007* 
Stable 61% 72% 69%   
Missing 3 3 6   
Housing type Owner-occupied, rental, 
community, boarding or 
other rent-free 
68% 85% 80% < 0.001* 
Homeless, squat or 
supported accommodation 
32% 15% 20%   
Missing 1 0 1   
Living conditions With relatives, friends or 
housemates 
51% 67% 62% < 0.001* 
Alone 49% 33% 38%   
Missing 11 9 20   
≤ Year 9 31% 28% 29% 0.432 
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Education level Year 10–12 44% 46% 45%   
Tertiary/diploma/trade 22% 20% 20%   
Other 4% 7% 6%   
Missing 0 0 0   
Aboriginal and Torres Strait 
Islander 
No 73% 88% 83% < 0.001* 
Yes 27% 12% 17%   
Missing 2 1 3   
Is a parent No 35% 36% 36% 0.714 
Yes 65% 64% 64%   
Missing 5 17 22   
Main drug of choice Heroin 87% 64% 71% < 0.001* 
MA 7% 20% 16%   
Cannabis 3% 12% 9%   
Other 3% 4% 3%   
Missing 5 19 24   
Drug injected most in last 
month 
Heroin 89% 59% 68% < 0.001* 
MA/other 11% 41% 32%   
Missing 0 0 0   
Previous incarceration No 18% 23% 21% 0.192 
Yes 82% 77% 79%   
Missing 2 11 13   
Incarceration in the 12 
months prior to interview 
No 62% 75% 71% 0.003* 
Yes 38% 25% 29%   
Missing 9 7 16   
Area of residence Richmond 9% 3% 5% N/A 
Western suburbs 16% 27% 24%   
Mornington Peninsula 6% 25% 20%   
Inner city 20% 9% 12%   
St Kilda area 18% 12% 14%   
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Dandenong area 1% 2% 2%   
Other south/east 14% 7% 9%   
Other north 12% 9% 10%   
Country Victoria 4% 5% 5%   
Missing 21 29 50   
By location Richmond 77% 18% 36% N/A 
Footscray 10% 28% 23%   
Frankston 4% 26% 19%   
Collingwood 3% 8% 6%   
St Kilda 2% 6% 5%   
CBD 0% 4% 3%   
Dandenong 1% 1% 1%   
Outreach 0% 2% 2%   
Phone 2% 6% 5%   
Burnet/Alfred 1% 0% 1%   
Missing 0 10 10   
By type Baseline 48% 54% 52% 0.168 
Follow-up 52% 46% 48%   
Missing 0 0 0   
Source: Burnet Institute 2019 
* statistically significant, p < 0.05 
† Fisher exact test instead of chi-square test, due to low numbers in some categories 
Table C3: Use of MSIR among those who previously used heroin in high-risk settings 
Measure Most recently 
used in private 
Most recently  
used in public 
Total p-value 
Total 92 89 181   
Has visited MSIR 15% 28% 22% 0.035* 
Hasn't visited MSIR 85% 72% 78%   
Source: Burnet Institute 2019 
* Represents statistically significant difference; Pearson’s chi-squared test 
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Table C4: Percentage of injections in the MSIR in the month prior to the interview 
Measure Visited MSIR(a) Visited MSIR and recruited in 
Richmond 
Total 181 109 
All injections 4% 7% 
Most injections (> 70%) 17% 17% 
Half of injections 11% 12% 
Some injections (25–50%) 4% 6% 
A few injections (10–25%) 10% 11% 
Hardly any injections (< 10%) 36% 37% 
No injections (13%) 13% 6% 
Ceased to inject in previous 
month 
3% 5% 
Source: Burnet Institute 2019 
Percentages may not add up to 100 per cent due to rounding errors 
(a) Total does not add up to 100 per cent due to missing responses for two participants. 
Table C5: Self-reported non-fatal overdose(a) (only follow-up) 






Total 94 191 285   
No 73% 84% 81% 0.027* 
Yes 27% 16% 19%   
Source: Burnet Institute 2019 
* Represents statistically significant difference; Pearson’s chi-squared test 
a) Overdose for all drug types (heroin, other opioid, methamphetamines); findings predominately relate to 
heroin overdose. 
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Figure C1: Area surrounding the MSIR as defined by City of Yarra (focus area) 
 
Table C6: Perceptions of discarded needles and syringes in the MSIR Review Community Survey  
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Issue Residents(a) Businesses 
Pre-MSIR Post-  
MSIR 
p-value Pre-MSIR Post-MSIR p-value 
Percentage (%) of 
respondents reporting 
having seen discarded 
needles and syringes in 
the past week 
29.4 30.9 > 0.05 34.0 26.3 < 0.05* 
Percentage (%) of 
respondents reporting 
having seen discarded 
needles and syringes in 
the past year 
16.1 16.9 > 0.05 20.0 24.6 < 0.05* 
Median estimated 
number of discarded 
needles and syringes 
reported in the past 
month 
4 4 No change 6 10 < 0.05* 
Mean estimated 
number of discarded 
needles and syringes 
reported in the past 
month 
13.25 8.73 < 0.05* 21.9 17.5 < 0.05* 
Note: (a) Weighted. * Significant 
Table C7: Where last purchase of heroin was used 






Total 181 417 598   
Where last purchase of heroin was used         
Private and MSIR(a) 51% 57% 54% 0.248 
Public(b) 49% 43% 46%   
Missing 29 184 213   
Source: Burnet Institute 2019 
* Represents statistically significant difference; Pearson’s chi-squared test 
In this analysis private locations refers to private spaces, such as private homes (including dealer’s homes) 
Public locations refer to public spaces, such as streets, public toilets, parks and cars 
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Table C8: Perceptions of public injecting in the MSIR Review Community Survey 
Issue Residents(a) Businesses 
Pre-MSIR Post-  
MSIR 
p-value Pre-MSIR Post-MSIR p-value 
Percentage (%) of 
respondents reporting 
having ever seen 
public injection 
69.9 71.8 > 0.05 61.1 65.8 < 0.05* 
Percentage (%) of 
respondents reporting 
having seen public 
injection in the past 
week 
27.7 29.5 > 0.05 21.8 34.8 < 0.01** 
Percentage (%) of 
respondents reporting 
having seen public 
injection in the past 
month 
28.6 28.2 > 0.05 26.3 17.7 < 0.01** 
Percentage (%) of 
respondents reporting 
having seen public 
injection in the past 
year 
23.5 19.7 < 0.05* 26.8 22.2 < 0.05* 
Median estimated 
number of public 
injecting reported in 
the past month 
3.0 3.0 No change 4 5 > 0.05 
Mean estimated 
number of public 
injecting reported in 
the past month 
7.68 7.94 > 0.05 45.96 13.94 < 0.01** 
Note: (a) Weighted. * Significant. ** Highly significant 
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Table C9: Perceptions of feeling safe when walking in their local area alone in the MSIR Review 
Community Survey 
Issue Residents(a) Businesses 
Pre-MSIR Post- 
MSIR 
p-value Pre-MSIR Post-MSIR p-value 
Percentage (%) of 
respondents reporting 
feeling safe when 
walking alone during 
the day 
69.5 54.7 < 0.01** 61.8 45.8 < 0.01** 
Percentage (%) of 
respondents reporting 
feeling safe when 
walking alone after 
dark 
61.8 28.2 < 0.01** 26.0 20.3 < 0.05* 
Percentage (%) of 
respondents reporting 
being approached to 
buy drugs within the 
last 24 hours 
9.0 10.1 > 0.05 23.4 8.5 < 0.01** 
Percentage (%) of 
respondents reporting 
being approached to 
buy drugs within the 
last week 
27.8 21.7 < 0.05* 23.4 32.2 < 0.05* 
Percentage (%) of 
respondents reporting 
being approached to 
buy drugs within the 
last month 
26.3 26.4 > 0.05 27.7 25.4 > 0.05 
Percentage (%) of 
respondents reporting 
being approached to 
buy drugs within the 
last year 
19.5 31.8 < 0.01** 19.1 22.0 < 0.05* 
Percentage 9%) of 
respondents reporting 
being approached 
and offered heroin 
within the last year 
63.8 44.8 < 0.01** 60.0 48.7 < 0.01** 
Percentage (%) of 
respondents (residents) 
reporting having 
considered moving out 
of the area because of 
drug related activity 
32.0 37.1 < 0.05*       
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Issue Residents(a) Businesses 
Pre-MSIR Post- 
MSIR 
p-value Pre-MSIR Post-MSIR p-value 




finding a new job or 
moving their business 
out of the area 
because of drug 
related activity  
      27.6 32.5 < 0.05* 
Note: (a) Weighted. * Significant. ** Highly significant 
Table C10: Last location of purchase of heroin in a public versus private space, in percentages 
(note: Burnet Institute analysis of SuperMIX cohort) 
  Visited MSIR (n = 152) Hasn’t visited MSIR (n = 232)  
 Private Public Private Public Different 
Whole sample (n = 384) 38 62 58 42 Yes (p < 
0.001) 
Interviewed in Richmond 
(n = 150) 
36 64 53 47 No (p = 
0.051) 
Interviewed outside 
Richmond (n = 234) 
42 58 60 40 Yes (p = 
0.019) Table C11: Use of MSIR among those who engaged in property crime and drug dealing 







Total   181 417 598   
Engaged in property crime 
in the last month 
No 73% 82% 79% 0.019* 
Yes 27% 18% 21%   
Missing 6 6 12   
Engaged in dealing in the 
last month 
No 72% 76% 75% 0.298 
Yes 28% 24% 25%   
Missing 5 5 10   
Arrested for dealing in the 
last month 
No 86% 87% 87% 0.713 
Yes 14% 13% 13%   
Missing 0 0 0   
Source: Burnet Institute 2019 
 
Appendix C: Additional data from various sources 141 
* Represents statistically significant difference; Pearson’s chi-squared test 
Table C12: Use of MSIR among those have been arrested since previous interview (only follow-up)  






Total   94 191 285   
Arrested since previous 
interview 
No 35% 59% 51% < 0.001* 
Yes 65% 41% 49%   
Missing 1 0 1   
 
Source: Burnet Institute 2019 
* Represents statistically significant difference; Pearson’s chi-squared test 
Table C13: Agreement with the idea of injecting rooms in the MSIR Review Community Survey  
Issue Residents(a) Businesses 
Pre-MSIR Post-  
MSIR 
p-value Pre-MSIR Post-MSIR p-value 
Percentage (%) of 
respondents agreeing 
with the idea of 
injecting rooms 
generally 
67.3 60.0 < 0.05* 59.7 58.5 > 0.05 
Percentage (%) of 
respondents agreeing 
with having an 
injecting room in North 
Richmond 
59.7 42.2 < 0.01** 48.1 41.2 < 0.05* 
Note: (a) Weighted. * Significant. ** Highly significant 
Departmental Public Health Event Surveillance System notification data 
Tables C14–C18 show relevant notification data from the DHHS Public Health Event 
Surveillance System. 
Blood-borne virus notification data and methodology 
Among those who identified as having injected drugs in the previous two years, hepatitis C 
notifications were more common than hepatitis B and HIV notifications. Local government 
area of residence is calculated using the postcode of the patient’s residence provided at the 
time of diagnosis. This does not necessarily indicate where the infection was acquired. This 
excludes where postcode of residence was not reported. 
Notes on the data 
▪ Where there were fewer than five cases per cell, data are suppressed as < 5. 
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▪ Local government area of residence is calculated using the postcode of residence of the 
patient provided at the time of diagnosis. This does not necessarily indicate where the 
infection was acquired. This excludes where postcode of residence was not reported. 
▪ Notification follow-up varies for different disease conditions, and availability of data on 
diseases varies on the type and level of follow-up undertaken. 
▪ All HIV notifications are followed up and risk factor information for HIV are available. Whereas 
all hepatitis B and C notifications are not routinely followed up as a result, risk factor 
information such as injecting drug use status is not available. DHHS implemented an 
enhanced surveillance system in July 2016 with an aim of collecting additional information. 
This has improved demographic information and risk factor information including injecting 
drug use status for hepatitis B and C. 
▪ Data are subjected to change due to the ongoing data quality. 
Table C14: Number and rate of hepatitis B notifications for the City of Yarra and Victoria, by year, 
2016–2019 
Year City of Yarra: 
Number of cases 
detected 




of cases detected 
Victoria: Rate per 
100,000 
population 
2016 37 39.6 1,825 29.5 
2017 20 21.4 1,785 28.9 
2018 30 32.1 1,770 28.6 
2019 27 28.9 1,669 27.0 
Source: Public Health Event Surveillance System, DHHS 
Table C15: Number and rate of hepatitis C notifications for the City of Yarra and Victoria, by year, 
2016–2019 
Year City of Yarra: 
Number of cases 
detected 




of cases detected 
Victoria: Rate per 
100,000 
population 
2016 40 42.8 2,420 39.2 
2017 37 39.6 1,973 31.9 
2018 26 27.8 1,921 31.1 
2019 40 42.8 1,702 27.5 
 
Source: Public Health Event Surveillance System, DHHS 
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Table C16: Number and rate of HIV notifications for the City of Yarra and Victoria, by year, 2016– 
2019 
Year City of Yarra: 
Number of cases 
detected 




of cases detected 
Victoria: Rate per 
100,000 
population 
2016 10 10.7 325 5.2 
2017 7 7.5 301 4.9 
2018 < 5 3.2 259 4.2 
2019 9 9.6 273 4.4 
Source: Public Health Event Surveillance System, DHHS 
Table C17: Number and proportion of notified cases of hepatitis B, C and HIV reported injecting 
drug use as the risk factor for Victoria, by year, 2016–2019 
Infectious disease 2016 2017 2018 2019 
Hepatitis B 33 (2%) 43 (2%) 36 (2%) 38 (2%) 
Hepatitis C 509 (21%) 676 (34%) 579 (30%) 392 (23%) 
HIV 3 (0.9%) 13 (4.3%) 15 (5.8%) 5 (1.8%) 
Source: Public Health Event Surveillance System, DHHS 
Table C18: Notified cases of hepatitis C, reported injecting drug use as the risk factor for the City of 
Yarra, by year, 2015–2019  





Source: Public Health Event Surveillance System, DHHS 
Table C19: Injected with someone’s used needle/syringe in last month and median injecting 
frequency in past week 






Total   181 417 598   
Injected with someone’s No 91% 89% 90% 0.462 
used needle/syringe in the 
last month 
Yes (once or more) 9% 11% 10%   
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  Missing 5 31 36   
Injecting frequency in Median number 14 (IQR = 4– 3 (IQR = 1–   < 0.001* 
past week   28) 13)     
Source: Burnet Institute 2019 
* Represents statistically significant difference; Pearson’s chi-squared test 
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Appendix D: Analysis of selected print 
and radio media  
  
MEDIA MEASURES PTY LTD
DHHS VICTORIA
MEDICALLY SUPERVISED INJECTING ROOM: 
ANALYSIS OF SELECTED MEDIA FOR THE 
PERIOD JULY 2018 – DECEMBER 2019
OBSERVATIONS ON MEDIA REPORTING
The following report presents analysis of media coverage on the North Richmond Medically 
Supervised Injecting Room (MSIR) Trial. Research was based on 98 clippings, provided to Media 
Measures by DHHS, covering the first 18 months of the trial (July 2018 to December 2019).
• Of the 98 clippings, 87.8% came from Melbourne daily newspapers. There were 54 stories 
from the Herald Sun and 32 from The Age.
• The total reach of the 98 stories was 20,715,796, most of which (16,482,370 or 79.6%) came 
from the Herald Sun.
• Of the 98 stories 25.5% were favourable, 45.9% unfavourable, and 28.6% were neutral.
• The Herald Sun provided slightly more favourable coverage (27.7% vs 25.0%) and considerably 
higher levels of unfavourable (50.0% vs 40.6%) coverage than The Age. The Age provided more 
neutral coverage (34.4% vs 22.2%) than the Herald Sun.
• The Australian did not feature any favourable coverage at all while the Geelong Advertiser featured one 
favourable and two unfavourable stories.
• Monique Hore of the Herald Sun authored four positive pieces (50.0%) and four negative pieces 
(50.0%), while Genevieve Alison, also of the Herald Sun, authored one positive (16.7%) and five 
negative stories (83.3%). 
• Jewel Topsfield from The Age wrote two positive (25.0%), three neutral (37.5%) and three 
negative (37.5%) stories. 
• Minister for Mental Health Martin Foley was quoted in 21 stories, 21.4% of the total. There 
were 17 instances in which local residents were quoted (17.3%) and 11 instances in which  
Cr Stephen Jolly was quoted (11.2%). 
• In some instances negative reporting was made more intense by the inclusion of emotive photos 
depicting drug injecting and anti-social activities in the North Richmond precinct. A Herald Sun 
report on July 6, 2018 for example, featured graphic images of drug users in Richmond streets.  
As the theme developed, reporting became more graphic, both in written descriptions and 
accompanying photos, as evidenced in a story in the Herald Sun (21 May 2019) featuring photo 
images of drug injecting in a car park and a laneway near the injecting centre. 
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Expansion of MSIR/extended facility and longer operating hours


















































Expansion of MSIR/extended facility and longer operating hours
Two MSIR workers accused of drug trafficking
MEDIA MEASURES PTY LTD  DHHS VICTORIA MEDICALLY SUPERVISED INJECTING ROOM JULY 2018 – DECEMBER 2019 3
GRAPH 3 > VOLUME
Melbourne Daily Newspapers (86) 87.8%
National Daily Newspapers (6) 6.1%
Victorian Regional Newspapers (5) 5.1%
Domestic Online (1) 1.0%
GRAPH 4 > AUDIENCE REACH
Melbourne Daily Newspapers (19,412,256) 93.7%
National Daily Newspapers (765,208) 3.7%
Domestic Online (476,580) 2.3%
Victorian Regional Newspapers (61,752) 0.3%
TABLE 1 > MEDIA COVERAGE OVERVIEW
 Total Stories Audience Reach
Melbourne Daily Newspapers 86 19,412,256
National Daily Newspapers 6 765,208
Victorian Regional Newspapers 5 61,752
Domestic Online 1 476,580
Total 98 20,715,796
TABLE 2 > MAJOR MEDIA OUTLETS
 Total Stories Audience Reach
Herald Sun 54 16,482,370
The Age 32 2,929,886
The Australian 5 721,828
Geelong Advertiser 3 50,061
Other 4 531,651
Total 98 20,715,796
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TONE OF COVERAGE




TABLE 3 > FAVOURABILIT Y – MAJOR MEDIA OUTLETS
 Total Stories Favourable Neutral Unfavourable
Herald Sun 54 15 (27.8%) 12 (22.2%) 27 (50.0%)
The Age 32 8 (25.0%) 11 (34.4%) 13 (40.6%)
The Australian 5 0 (0.0%) 3 (60.0%) 2 (40.0%)
Geelong Advertiser 3 1 (33.3%) 0 (0.0%) 2 (66.7%)
Other 4 1 (25.0%) 2 (50.0%) 1 (25.0%)
Total 98 25 (25.5%) 28 (28.6%) 45 (45.9%)
GRAPH 6 > FAVOURABILITY – MAJOR MEDIA OUTLETS












Media coverage was mainly negative (45.9%), with positive and neutral coverage relatively evenly  
split. The bulk of the positive coverage dealt with stories on state government’s release of data on the 
MSIR which indicated a large number of client visits to the facility and the large number of overdoses 
successfully managed. The two main negative issues were the concerns of local residents and two MSIR 
workers accused of drug trafficking.


















































Data on positive contribution by MSIR after 12 months
Richmond residents' concerns Richmond residents' concerns


















































Alcohol sponsorship of AFL
MSIR workers accused of drug trafficking
Richmond residents' concerns
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TABLE 4 > FAVOURABILIT Y – MAJOR JOURNALISTS
 Total Stories Favourable Neutral Unfavourable
Monique Hore (Herald Sun) 8 4 (50.0%) 0 (0.0%) 4 (50.0%)
Jewel Topsfield (The Age) 8 2 (25.0%) 3 (37.5%) 3 (37.5%)
Genevieve Alison (Herald Sun) 6 1 (16.7%) 0 (0.0%) 5 (83.3%)
Ian Royall (Herald Sun) 6 2 (33.3%) 1 (16.7%) 3 (50.0%)
Tom Minear (Herald Sun) 5 2 (40.0%) 2 (40.0%) 1 (20.0%)
Michael Fowler (The Age) 4 0 (0.0%) 1 (25.0%) 3 (75.0%)
GRAPH 9 > FAVOURABILITY – MAJOR JOURNALISTS
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MAJOR THEMES
TABLE 5 > MAJOR THEMES – VOLUME AND REACH
 Total Stories Audience Reach
MSIR is saving lives 25 5,729,123
Residents' concerns re unsuitable location of MSIR 20 3,962,991
Residents' concerns that shooting up is common in Richmond  
streets and laneways
13 2,777,866
Police action against drug trafficking in Richmond 10 2,654,388
Residents' concerns re public safety eg aggressive behaviour,  
violence, syringes, etc
10 2,150,347
Residents' concerns re drug trafficking in full view and drug  
related crime
8 1,874,668
Drug overdoses still taking place in Richmond/City of Yarra  
despite MSIR
6 1,404,887
0 20 40 60 80 100
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Residents' concerns that shooting up
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Police action against drug trafficking
in Richmond
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Drug overdoses still taking place in
Richmond/City of Yarra despite MSIR
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TABLE 6 > FAVOURABILITY – MAJOR THEMES
 Total Stories Favourable Neutral Unfavourable
MSIR is saving lives 25 14 (56.0%) 4 (16.0%) 7 (28.0%)
Residents' concerns re unsuitable 
location of MSIR
20 3 (15.0%) 2 (10.0%) 15 (75.0%)
Residents' concerns that shooting 
up is common in Richmond streets 
and laneways
13 1 (7.7%) 0 (0.0%) 12 (92.3%)
Police action against drug 
trafficking in Richmond
10 0 (0.0%) 0 (0.0%) 10 (100.0%)
Residents' concerns re public 
safety eg aggressive behaviour, 
violence, crime, syringes, etc
10 0 (0.0%) 1 (10.0%) 9 (90.0%)
Residents' concerns re drug 
trafficking in full view
8 1 (12.5%) 1 (12.5%) 6 (75.0%)
Drug overdoses still taking place 
in Richmond/City of Yarra despite 
MSIR
6 2 (33.3%) 4 (66.7%) 0 (0.0%)
COMMON THEMES AND HOW THESE EVOLVED
Councillor Stephen Jolley’s Community Consultation Meeting at All Nations  
Hotel Richmond
The facilitation of a community consultation meeting by City of Yarra Councillor Stephen 
Jolley, in April 2019, was an important peg in the media sequence. It harnessed negative debate 
and brought attention to the concerns of residents. Adverse commentary on community 
impacts of the MSIR grew from this point while commentary on broader issues surrounding  
the conduct of the trial became less evident.
The location of the injecting facility was a central theme for negative media coverage.  
Local community concerns were perpetrated by a residents’ action group formed at the time  
of Cr Jolley’s community consultation meeting. 
Media reporting featured quotes from individuals identifying as representatives of the 
community action group. These quotes centred on the unsuitability of the location, the demise 
of community wellbeing, reduced property values and dangers to primary aged school children, 
who were regularly exposed to drug use, drug dealing and general anti-social behaviours. 
The proximity of Richmond West Primary School was a major discussion point, augmented by 
concerns that student vulnerability was a measure of the degree to which the facility had 
negatively impacted community safety and wellbeing. 
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Release of Data
The release of performance data in June and September 2019, appeased concerns over a lack of 
transparency on the facility’s operations and contributed to stronger evidence-based reporting. 
Statistical information released by the state government presented a counter-argument to the 
largely negative stories on concerns expressed by Richmond residents. 
The use of data provided a positive balance to otherwise negative reporting on the MSIR. The 
data reported on the number of overdoses managed without loss of life, as well as numbers of 
referrals to auxiliary health, social support and drug dependency services. 
Data references were frequently accompanied by quotes from the minister that lives were being 
saved and that thousands of people were engaging with health providers for the first time in years. 
Increased Services
The announcement of increased MSIR operating hours and expanded facilities in July 2019 
brought attention to the increased demand for services, but also gave rise to further action by 
opposing groups.
Local residents used the announcement to amplify their concerns about the increasing presence 
of anti-social behaviour, violence and drug taking in the surrounding precinct.
Some coverage raised concerns that the trial expansion would extend to other drug hot-spots  
in the state. A report in the Geelong Advertiser for instance (11 July 2019), presented unfounded 
suggestions that a MSIR could be established in Geelong. 
Arrest of MSIR Workers
The arrest of two MSIR workers on drug trafficking charges in October 2019 was a “last straw” 
moment. Those opposed to injecting rooms seized on the event and called for the trial to  
be discontinued forthwith. Headlines also supported local community arguments that the  
MSIR was diminishing safety and wellbeing across the precinct. 
In response to calls for outright closure, Cr Stephen Jolley clarified his position, noting  
that residents were concerned about the location of the trial in North Richmond, but not  
the provision of medically supervised injecting room services. 
In a perhaps unexpected twist, the arrests also triggered positive content, hedged in the  
defence of the achievements of MSIR in the face of criticism. Letters, editorials and opinion 
pieces gave rise to balanced discussion which acknowledged the arrests and called for debate  
on the Medically Supervised Injecting Room to not lose sight of the lives saved. Many articles 
referred to the highly successful management of overdoses and the auxiliary support benefits  
for drug users. 
Reports on the Premier’s commitment to maintain the trial, and the Minister’s actions to 
dismiss the facility’s CEO and announce an independent review of management practices, acted 
as a circuit breaker. These announcements, and the declaration of zero tolerance for illegal 
conduct, started a new cycle dedicated to improved practices and governance frameworks at 
North Richmond Community Health. Later reports reflected the benefits of the review, namely, 
the removal of a needle exchange program in the precinct and improved governance and the 
introduction of workplace culture strategies.
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GRAPH 11 > KEY SPOKESPEOPLE
Martin Foley – Minister for Mental Health (21) 21%
Local residents – (17) 17%
Cr Stephen Jolly – City of Yarra Councillor (11) 11%
Dr Nicolas Clark – MSIR Director (8) 8%
Luke Donellan – Acting Mental Health Minister (5) 5%
Georgie Crozier – Opposition Mental Health Spokesperson (3) 3%
Judy Ryan – Victoria Street Drug Solutions Action Group (3) 3%
SPOKESPEOPLE AND COMMENT ORIGIN
In total there were 124 spokespeople quoted in the media coverage sample. Many quotes came 
from Members of Parliament with relevant portfolio responsibilities, and from representatives 
of MSIR, and the City of Yarra and associated organisations. 
Minister for Mental Health Martin Foley was quoted 21 times, Acting Minister, Luke 
Donnellan, five times, and Opposition Spokesperson Georgie Crozier, three times. Others 
included Police Minister Lisa Neville, and a number of Opposition MPs. MSIR Director  
Dr Nicholas Clark was quoted eight times and City of Yarra councillor Stephen Jolly was  
quoted 11 times. 
There were 17 quotes from “local residents,” who were either referred to as “local resident(s)” 
without any further identification (10 instances), or referred to as “Richmond resident,” along 
with the person’s name (7 instances). No indication was given as to whether they were involved 
with residents’ action groups or other organisations.
The most prominent organisation quoted was Victoria Police, with 10 quotes in total, including 
by Assistant Commissioner Luke Cornelius and Victorian Police Association President Wayne 
Gatt. 
Two residents’ action groups were quoted, the MSIR Residents Action Committee (4 quotes) 
and the Victoria Street Drug Solutions Action Group (3). Spokespeople were not always clearly 
identified with their specific groups. David Horseman from MSIR Residents Action Committee 
was referred to by The Age (25 October 2019) as “the spokesman for a residents committee calling 
for the injecting room to be relocated.” Judy Ryan, from the Victoria Street Drug Solutions 
Action Group, was referred to in The Weekend Australian (25 May 2019) as someone “who 
campaigned for the injecting facility but feels more needs to be done to deal with the large 
numbers of sick people in the areas.”
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Introduction 
For the analyses below we have used interviewer-administered questionnaire data from the 
Melbourne injecting drug user cohort study (SuperMIX). SuperMIX commenced in 2008 and 
has involved recruitment of over 1300 people who inject drugs (PWID) into the study from a 
range of locations across Melbourne, including North Richmond. It involves collection of a 
range of indicators (outcome measures) related to the objectives of the Medically 
Supervised Injecting Room (MSIR) in North Richmond outlined in the legislation. For more 
information on SuperMIX please refer to Appendix 1: Methods. 
 
Our analysis dataset includes self-report interview data for the period 26/4/2008 through to 
1/7/2019, in addition to linked data from Medicare Benefits Schedule (MBS), 
Pharmaceutical Benefits Scheme (PBS), Alcohol and Other Drugs Information System (ADIS), 
Victorian Admitted Episodes Dataset (VAED), Victorian Emergency Minimum Dataset 
(VEMD), and Victorian Ambulance Clinical Information System (VACIS). We have also used 
data from participants in the Illicit Drug Reporting System (IDRS) as a complement to the 
SuperMIX participants for demographic, drug use and psychosocial indicators. See Appendix 
1: Methods for more information on the data sets used, as well as the different samples that 
have been used for the SuperMIX self-reported data and the samples for the several linked 
data set. 
Samples used for this report 
For the analyses in this report we have used all participants that have responded to the 
question whether they have visited the MSIR (“MSIR visit”; n=598) or responded to the 
question about intensity of use in the previous month (“MSIR intensity”; n=596) , for all 
recruitment locations. 
At request we can provide the data on those participants who have responded to the MSIR 
visit question and have been recruited in Richmond (n=174), and those who have responded 
to the MSIR intensity question and have been recruited in Richmond (n=172). 
Demographics 
Among the whole analysis sample (n=598), those who visited the MSIR were relatively 
younger, with a median age at the time of interview of 36 years, compared to 40 years for 
those who did not visit the MSIR. They typically reported being more socially marginalised. 
To this end, they were more likely to be unemployed, more likely to live in unstable 
accommodation, more likely to be homeless, more likely to live by themselves and more 
likely to be incarcerated in the previous 12 months than those who did not visit the MSIR. 
Those who visited the MSIR were also more likely to identify as Aboriginal or Torres Strait 
Islander, more likely to state heroin as their main drug of choice and to have injected heroin 
in the last month. See Appendix 2: Demographics for all of these findings and for a 
comparison with the Illicit Drug Reporting System (IDRS) sample which generally showed 
similar findings. 
MSIR visits 
Of the total 598 participants, 181 (30%) reported that they visited the facility compared to 
417 (70%) who did not. Of the total of 598, 285 participants had at least one interview 
before the MSIR opened. Of these participants, 94 reported that they visited the MSIR and 
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191 reported that they did not. Of the 313 new participants recruited into the study after 
the MSIR opened, 87 reported visiting the MSIR, and 226 reported that they did not. 
Statistical methods for the self-reported data 
To test for changes within the same individuals over time we performed fixed-effects logistic 
regression models in which we measured associations between changes in “MSIR visit” 
(yes/no) and changes in the outcome variables. We report on the odds ratio (OR) with “not 
having visited the MSIR” as the reference category. 
Statistical methods for the linked data 
To test for changes over time we performed fixed-effects Poisson regression models. A 
continuous variable “month” was included as a fixed-effect term in the model. We 
compared MSIR visit groups (yes versus no) and MSIR intensity groups (no 
visits/<50%/≥50%) for the different outcome measures in the six different linked datasets 
(i.e. PBS, MBS, ADIS, VAED, VEMD, VACIS). We report on the incidence rate ratio (IRR) with 
“not having visited the MSIR” as the reference category for both the MSIR visit and MSIR 
intensity analyses. In these analyses we only considered all records from one year prior to 
the MSIR opening. 
The remainder of this report details the main findings of our analyses of the SuperMIX data 
related to the stated aims of the MSIR listed in Legislation and the set of indicators required 
for consideration by the Centre for Evaluation and Research.  
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2. Aim a: Reduce the number of avoidable deaths and the harm 
caused by overdoses of drugs of dependence 
People who would have previously injected in high-risk settings are now using the 
facility at least some of the time 
We defined previously injected in “high-risk settings” as previously using and scoring heroin 
in “public spaces”, or having an overdose in a public space. Of the 285 participants who 
were recruited into the study before the opening of the MSIR, 92 most recently used their 
heroin in private prior to the MSIR opening, 89 most recently used it in public spaces, and 
we are missing this information for 104 participants. This is because this question was 
accidentally left out of the survey in the year prior to the MSIR opening, as well as some 
participants not answering this question. 
Participants who reported most recently using their heroin in public prior to the MSIR 
opening are about twice as likely to have visited the MSIR (28%) than those who reported 
most recently using their heroin in private (15%) (Table 2.1). 
Table 2.1 Use of MSIR among those who previously used heroin in high-risk settings 
 
Most recently 
used in private 
Most recently 
used in public Total p-value 
Total 92 89 181 
 
Use of the MSIR 
Visited MSIR 14 (15%) 25 (28%) 39 (22%) 0.035* 
Hasn’t visited MSIR 78 (85%) 64 (72%) 142 (78%) 
 
* Pearson’s chi-squared test     
 
Of the 285 participants who were recruited into the study before the opening of the MSIR, 
126 most recently purchased their heroin in private, 122 most recently purchased it in 
public spaces, and we are missing this information for 37 participants. Participants who 
report most recently purchasing their heroin in public are about twice as likely to have 
visited the MSIR (47%) than those who report most recently purchasing their heroin in 
private (24%) (Table 2.2). 
Table 2.2 Use of MSIR among those who previously scored heroin in high-risk settings 
 
Most recently 
purchased in private 
Most recently 
purchased in public Total p-value 
Total 126 122 248 
 
Use of the MSIR 
Visited MSIR 30 (24%) 57 (47%) 87 (35%) <0.001* 
Hasn’t visited MSIR 96 (76%) 65 (53%) 161 (65%) 
 
 




purchased in private 
Most recently 
purchased in public Total p-value 
* Pearson’s chi-squared test     
 
Of the 285 participants who were recruited into the study before the opening of the MSIR, 
54 reported most recently overdosing in private prior to the opening of the MSIR, 102 most 
recently overdosed in public spaces, and we are missing this information for 129 
participants (some of these participants did not report having an overdose). Participants 
who report most recently overdosing in public are almost twice as likely to have visited the 
MSIR (34%) than those who report most recently overdosing in private (19%) (Table 2.3). 
 
Table 2.3 Use of MSIR among those who previously overdosed in high-risk settings 
 
Most recently 
overdosed in private 
Most recently 
overdosed in public Total p-value 
Total 54 102 156 
 
Use of the MSIR 
Visited MSIR 10 (19%) 35 (34%) 45 (29%) 0.038* 
Hasn’t visited MSIR 44 (81%) 67 (66%) 111 (71%) 
 
* Pearson’s chi-squared test     
Proportion of injections taking place in the facility 
Of the 598 participants interviewed after the MSIR opened, 417 (70%) had not visited the 
MSIR, and 181 (30%) visited the MSIR at least once. Of those who visited the MSIR at least 
once, 121 (66%) performed less than half of their previous month’s injections in the facility 
or did not inject in the month prior to their interview, 58 (33%) performed at least half of 
their previous month’s injections in the facility, and 2 were missing the answer to this 
question. In the IDRS sample similar findings were evident: 59% reported performing less 
than half of their previous month’s injections in the facility and 41% reported performing at 
least half of their previous month’s injections in the facility. 
Death of cohort member by overdose of drugs using linked data from National Death 
Index 
No cohort members who were interviewed since the MSIR opened have died. 
Self-reported non-fatal overdose 
In a cross-sectional analysis of all follow-up interviews done after the MSIR opened, those 
who visited the MSIR were more likely to have experienced an overdose since their previous 
interview (27%) compared to those who did not visit the MSIR (16%) (Table 2.4). 
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MSIR Total p-value 
Total 94 191 285 
 
Any overdose since previous interview (only follow-up) 
No 68 (73%) 160 (84%) 228 (81%) 0.027* 
Yes 25 (27%) 30 (16%) 55 (19%) 
 
* Pearson’s chi-squared test     
If we only consider participants who were asked this question in both their latest interview 
before the facility opened (i.e. had a follow-up interview before) and after the MSIR opened 
(N=190), we found no significant difference between the proportion of participants who 
reported having an overdose since their previous interview at the interview before the MSIR 
opened, but we found a statistically significant difference for the interview after the facility 
opened (Table 2.5). The fixed effects logistic regression analyses show weak, but 
inconclusive, evidence of a difference between the two groups (OR=2.9, p=0.122). 
 






MSIR Total p-value 
Total 38 152 190 
 
Any overdose since previous interview at interview before MSIR opened 
No 28 (82%) 117 (85%) 145 (84%) 0.727 
Yes 6 (18%) 21 (15%) 27 (16%) 
 
Missing n<5 14 18 
 
Any overdose since previous interview at interview after MSIR opened 
No 26 (68%) 129 (85%) 155 (82%) 0.019* 
Yes 12 (32%) 23 (15%) 35 (18%) 
 
* Pearson’s chi-squared test     
We do not know, however, what the relative timing of these events are in order to further 
interpret these findings. One possibility is that after experiencing an overdose, participants 
decide to start injecting in the MSIR so that future overdoses can be more easily attended 
to, in which case the self-reported overdose may have occurred before the visit to the MSIR. 
Another possibility is that MSIR staff have a stricter definition of overdose and therefore 
participants who have experienced an overdose inside the MSIR are more aware and thus 
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more likely to report such an event as being an overdose, in contrast to those who have 
experienced an overdose outside of the MSIR. 
Figure 2.1 shows the changes over time between the two interviews. 
 
Figure 2.1 Changes over time in self-reported non-fatal overdose (only follow up) before and after MSIR opened 
 
Self-reported intentional overdose 
Very few intentional overdoses were reported in the analytic sample (Table 2.6). We did not 
find evidence of a difference in the rates of intentional overdoses between those who 
reported visiting the MSIR and those who did not (OR=2; p=0.571). No further analyses are 
reported due to small numbers. 






MSIR Total p-value 
Total 94 191 285 
 
Intentional overdose since previous interview (only follow-up) 
No 88 (95%) 186 (97%) 274 (96%) 0.304† 
Yes 5 (5%) 5 (3%) 10 (4%) 
 
† Fisher exact test, due to low numbers in some categories 
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3. Aim b: Deliver more effective health services for clients of the 
licensed medically supervised injecting centre by providing a 
gateway to health and social assistance which includes drug 
treatment, rehabilitation support, health care, mental health 
treatment and support and counselling 
Use of alcohol and other drug services 
Using linked data from ADIS, we did not find evidence of a difference between the average 
number of initiated treatments for the participants who reported visiting the MSIR 
compared to those who did not; either before or after the MSIR opened (IRR=0.90; p=0.68). 
This applies to withdrawal treatment (IRR=0.69; p=0.31), drug counselling (IRR=0.85; 
p=0.98), and all other treatments recorded on the ADIS dataset (including residential 
rehabilitation; IRR=2.63; p=0.88) (Figure 3.1). 
Figure 3.1 Average number of initiated treatments per year by MSIR use 
 
For intensity of MSIR use, we did not find evidence of a difference between the average 
number of initiated treatments for the participants who reported visiting the MSIR 
compared to those who did not; either before or after the MSIR opened. This applies to 
withdrawal treatment, drug counselling, and all other treatments (including residential 
rehabilitation) (Figure 3.2 and Table 3.1). 
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Table 3.1 Initiated treatments by MSIR frequency of use: results from the fixed-effects Poisson regression analysis (ADIS) 
  IRR 95%CI P 
All treatments No visit 1   
 <50% 0.97 0.51-1.86 0.93 
 ≥50% 0.82 0.35-1.95 0.66 
Analyses regarding withdrawal treatment, drug counselling, and all other treatments are not reported due to small 
numbers. 
 
Figure 3.2 Average number of initiated treatments per year for three treatment types by MSIR frequency of use (ADIS) 
 
Use of opioid substitution therapy 
Because data on opioid substitution therapy (OST) are not collected through the PBS, we 
rely on self-report data for assessment of OST use. In a cross-sectional analysis of all 
interviews done after the MSIR opened, those who reported visiting the MSIR were less 
likely to be on OST (34%) compared to those who did not (49%) (Table 3.2), and 36% of 
those who reported having less than 50% of their injections in the facility reported being on 
OST compared to 25% of those who reported having more than 50% of injections in the 
facility. These effects reflect pre-MSIR differences between groups, as outlined below. 
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MSIR Total p-value 
Total 181 417 598 
 
On OST at the time of interview 
No 119 (66%) 213 (51%) 332 (56%) 0.001* 
Yes 62 (34%) 204 (49%) 266 (44%) 
 
* Pearson’s chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened, 
we see that there was a pre-existing difference in OST utilisation between those who 
reported subsequently using the MSIR and those who didn’t, and their percentages changed 
little between interviews (OR=0.90; p=0.77, see Table 3.3 and 
Figure 3.3). 





MSIR Total p-value 
Total 94 184 278 
 
On OST at the time of interview before MSIR opened 
No 70 (74%) 97 (53%) 167 (60%) <0.001* 
Yes 24 (26%) 87 (47%) 111 (40%) 
 
On OST at the time of interview after MSIR opened 
No 71 (76%) 85 (46%) 156 (56%) <0.001* 
Yes 23 (24%) 99 (54%) 122 (44%) 
 
* Pearson’s chi-squared test     
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Figure 3.3 Changes over time in self-reported OST at time of interview before and after MSIR opened 
 
Emergency department presentations for conditions unrelated to drugs 
Using linked data from the Victorian Emergency Minimum Dataset (VEMD), we did not find 
evidence of a difference between the average number of emergency department 
presentations for conditions unrelated to drug use between the group of participants who 
reported visiting the MSIR compared to those who didn’t; either before or after the MSIR 
opened (IRR=0.90; p=0.47). Many VEMD records do not contain a diagnosis and so we have 
included those in Figure 3.4 as “Diagnosis missing”. 
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Figure 3.4 Average number of emergency department presentation per year for not-drug-related presentations and 
presentations with no diagnosis (VEMD) 
 
For intensity of MSIR use, we did not find evidence of a difference between the average 
number of emergency department presentations for conditions unrelated to drug use 
between the group of participants who reported visiting the MSIR compared to those who 
didn’t (see Table 3.4 and Figure 3.6). 
Table 3.4 Initiated treatments by MSIR frequency of use: results from the fixed-effects Poisson regression analysis (VEMD) 
  IRR 95%CI p 
Not-drug related ED 
presentations 
No visit 1   
<50% 0.89 0.66-1.20 0.45 
≥50% 1.01 0.63-1.61 0.96 
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Figure 3.5 Average number of emergency department presentation per year for three types of presentations by MSIR 
frequency of use (VEMD) 
 
Hospitalisations for not drug-related issues 
Using linked data from the Victorian Admitted Episodes Dataset (VAED), we did not find 
evidence of a difference between the average number of hospital admissions for conditions 
unrelated to drug use between the group of participants who reported visiting the MSIR 
compared to those who didn’t; either before or after the MSIR opened (IRR=1.09; p=0.66, 
Figure 3.6). 
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Figure 3.6 Average number of not-drug-related hospital admissions per year (VAED) 
 
For intensity of MSIR use, we did not find evidence of a difference between the average 
number of hospital admissions for conditions unrelated to drug use between the group of 
participants who reported visiting the MSIR compared to those who didn’t; (see Figure 3.7 
and Table 3.5).  
Table 3.5 Not-drug related hospital admissions by MSIR frequency of use: results from the fixed-effects Poisson regression 
analysis 
  IRR 95%CI p 
Not-drug related hospital 
admissions 
No visit 1   
<50% 0.97 0.66-1.43 0.88 
≥50% 1.78 0.77-4.14 0.18 
 
Review of the MSIR using the SuperMIX cohort and linked data sets, 25 February 2020 20 
 
Figure 3.7 Average number of hospital admissions per year for two types of admissions by MSIR frequency of use (VAED) 
 
Use of GP health services – linked data 
Using linked data from the Medicare Benefits Schedule (MBS), we did not find any 
significant difference between the average number of GP visits for conditions unrelated to 
drug use between the group of participants who reported visiting the MSIR compared to 
those who didn’t; either before or after the MSIR opened, IRR=1.09; p=0.25 (Figure 3.8). 
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Figure 3.8 Average number of GP visits per year (MBS) 
 
For intensity of MSIR use we did not find evidence of a difference between the average 
number of GP visits for conditions unrelated to drug use between the group of participants 
who reported visiting the MSIR compared to those who didn’t (Table 3.6 and Figure 3.9). 
However, the average number of GP after hour visits for conditions unrelated to drug use 
among those who reported having had 50% or more of their injections in the MSIR was 
fewer compared to those who had not visited the facility (IRR=0.44, p=0.03). 
Table 3.6 GP visits by MSIR frequency of use: results from the fixed-effects Poisson regression analysis (MBS) 
  IRR 95%CI p 
GP visits No visit 1   
 <50% 1.10 0.92-1.32 0.28 
 ≥50% 1.06 0.85-1.34 0.60 
GP mental health No visit 1   
 <50% 0.93 0.54-1.61 0.79 
 ≥50% 1.11 0.76-1.63 0.59 
GP after hours No visit 1   
 <50% 1.05 0.74-1.52 0.76 
 ≥50% 0.44 0.21-0.93 0.03 
GP pathology No visit 1   
 <50% 1.53 0.94-2.51 0.09 
 ≥50% 0.83 0.42-1.63 0.59 
GP HCV testing No visit 1   
 <50% 0.94 0.52-1.71 0.85 
 ≥50% 0.93 0.45-1.93 0.85 
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Figure 3.9 Average number of GP visits by MSIR frequency of use (MBS) 
 
For other professional attendances claimed through Medicare, there is insufficient evidence 
of an impact of the MSIR opening (see Figure 3.10, Figure 3.11 and Table 3.6). 
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Figure 3.11 Average number of other doctor visits by MSIR frequency of use (MBS) 
 
Use of GPs for non-OST services – self-report 
MBS records do not differentiate OST visits from other visits and so we relied on self-report 
data to explore participants’ use of GPs for non-OST related reasons. In a cross-sectional 
analysis of all interviews done after the MSIR opened, there was no evidence of a difference 
in the frequency of GP visits for non-OST related reasons for those who visited the MSIR 
compared to those who did not (Table 3.7). 
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MSIR Total p-value 
Total 181 417 598 
 
Seen GP for reasons other than OST 
No 78 (43%) 146 (35%) 224 (38%) 0.07 
Yes 103 (57%) 268 (65%) 371 (62%) 
 
* Pearson’s chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened, 
again we find no evidence of a difference (see Table 3.8 and Figure 3.12). There was no 
significant difference in the rates of seeing a GP between the two groups (OR=0.75; 
p=0.384). 





MSIR Total p-value 
Total 94 184 278 
 
Seen GP for reasons other than OST at interview before MSIR opened 
No 38 (43%) 67 (40%) 105 (41%) 0.584 
Yes 50 (57%) 102 (60%) 152 (59%) 
 
Missing 6 15 21 
 
Seen GP for reasons other than OST at interview after MSIR opened 
No 46 (49%) 80 (44%) 126 (46%) 0.455 
Yes 48 (51%) 101 (56%) 149 (54%) 
 
* Pearson’s chi-squared test     
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Figure 3.12 Changes over time in seening a GP for reasons other than OST, before and after MSIR opened 
 
Prescriptions for medications other than OST 
Using linked data from the Pharmaceutical Benefits Scheme (PBS), we did not find evidence 
of a difference between the average number of prescriptions dispensed between the group 
of participants who reported visiting the MSIR compared to those who didn’t; either before 
or after the MSIR opened (IRR=1.02; p=0.85) (Figure 3.13). This finding applies across all of 
the different pharmaceutical drug groups considered in Figure 3.14. 
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Figure 3.13 Average number of mental health prescriptions per year (PBS) 
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Figure 3.14 Average number of prescriptions per year (PBS) 
 
For intensity of MSIR use we did not find evidence of a difference between the average 
prescriptions dispensed between the group of participants who reported visiting the MSIR 
compared to those who didn’t ( 
Table 3.9 and  
Figure 3.15). 
 
Review of the MSIR using the SuperMIX cohort and linked data sets, 25 February 2020 29 
 
Table 3.9 Average number of prescriptions dispensed by MSIR frequency of use: results from the fixed-effects Poisson 
regression analysis (PBS) 
  IRR 95%CI p 
Mental health medication No visit 1   
 <50% 0.99 0.81-1.23 0.98 
 ≥50% 1.04 0.59-1.84 0.89 
Sleeping pills (benzos) No visit 1   
 <50% 0.99 0.75-1.33 0.99 
 ≥50% 0.93 0.57-1.50 0.77 
Pain management No visit 1   
 <50% 0.93 0.57-1.52 0.78 
 ≥50% 0.78 0.68-2.85 0.36 
 
Figure 3.15 Average number of prescriptions dispensed per year for five medication types by MSIR frequency of use (PBS) 
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IDU-specific primary care services 
MBS records do not differentiate IDU primary care visits from other visits and so we relied 
on self-report data to explore participants’ use of IDU primary care services. In a cross-
sectional analysis of all interviews done after the MSIR opened, we found no evidence of a 
difference in the frequency of IDU primary care centre visits for those who visited the MSIR 
compared to those who did not (Table 3.10). 
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MSIR Total p-value 
Total 181 417 598 
 
Visited primary care centre 
No 116 (64%) 299 (72%) 415 (70%) 0.077 
Yes 64 (36%) 118 (28%) 182 (30%) 
 
* Pearson’s chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened, 
again we found no evidence of a difference in the rates of primary care centre visits 
between the two groups (OR=1.1; p=0.863, see also Table 3.11 and Figure 3.16).  






MSIR Total p-value 
Total 94 184 278 
 
Visited primary care centre at interview before MSIR opened 
No 62 (72%) 135 (79%) 197 (77%) 0.22 
Yes 24 (28%) 36 (21%) 60 (23%) 
 
Missing 8 13 21 
 
Visited primary care centre at interview after MSIR opened 
No 67 (71%) 146 (79%) 213 (77%) 0.133 
Yes 27 (29%) 38 (21%) 65 (23%) 
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Figure 3.16 Changes in visited primary care centre before and after MSIR opened 
 
Ambulance for non-overdose 
Linked data from the Victorian Ambulance Clinical Information System (VACIS) shows a 
projected decrease in ambulance attendances for participants who visited the MSIR (Figure 
3.17). We only have two months of data for the year offset July2019-June2020 (up to 30 
August 2019), so we multiplied that number by 6 to get a projected average number per 
group per year. Despite an overall drop for the participants who have visited the MSIR, we 
found no evidence of a difference in the average number of ambulance attendances 
between those who did visit the facility and those who didn’t (IRR=0.95; p=0.77). 
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Figure 3.17 Average number of ambulance attendances per year 
 
For intensity of MSIR use we did not find evidence of a difference between the average 
number of ambulance attendances between the group of participants who reported visiting 
the MSIR compared to those who didn’t (Table 3.12 and Figure 3.18). 
Table 3.12 Total number of ambulance attendances by MSIR frequency of use: results from the fixed-effects Poisson 
regression analysis (VACIS) 
  IRR 95%CI p 
Ambulance attendances No visit 1   
<50% 1.03 0.68-1.57 0.88 
≥50% 0.85 0.53-1.34 0.48 
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Figure 3.18 Total number of ambulance attendances per year by MSIR frequency of use (VACIS) 
 
Use of dental services 
In a cross-sectional analysis of all interviews done after the MSIR opened, there was no 
evidence of a difference in the frequency of reports of dentist visits for those who visited 
the MSIR compared to those who did not (Table 3.13). 





MSIR Total p-value 
Total 181 417 598 
 
Seen a dentist 
No 130 (72%) 325 (78%) 455 (76%) 0.108 
Yes 50 (28%) 90 (22%) 140 (24%) 
 
* Pearson's chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened, 
there was weak, but inconclusive, evidence of a difference between the two groups (OR=2, 
p=0.08, see also Table 3.14 and Figure 3.19). 
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MSIR Total p-value 
Total 94 184 278 
 
Seen a dentist at interview before MSIR opened 
No 70 (80%) 126 (75%) 196 (77%) 0.291 
Yes 17 (20%) 43 (25%) 60 (23%) 
 
Missing 7 15 22 
 
Seen a dentist at interview after MSIR opened 
No 71 (76%) 143 (78%) 214 (77%) 0.624 
Yes 23 (24%) 40 (22%) 63 (23%) 
 
* Pearson's chi-squared test     
Figure 3.19 Changes in seening a dentist before and after MSIR opened 
 
Use of mental health services 
In a cross-sectional analysis of all interviews done after the MSIR opened, there no 
significant differences in the frequency of reports of visiting a mental health professional for 
those who visited the MSIR compared to those who did not (Table 3.15). 
 
 
Review of the MSIR using the SuperMIX cohort and linked data sets, 25 February 2020 36 
 





MSIR Total p-value 
Total 181 417 598 
 
Visited a mental health professional in 12 months prior to interview 
No 112 (62%) 257 (62%) 369 (62%) 0.918 
Yes 68 (38%) 159 (38%) 227 (38%) 
 
* Pearson's chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened, 
there was weak, but inconclusive, evidence of a difference (OR=0.51, p=0.071, see Table 
3.16 and Figure 3.20). 





MSIR Total p-value 
Total 94 184 278 
 
Visited a mental health professional in 12 months prior to interview before MSIR opened 
No 63 (67%) 128 (70%) 191 (69%) 0.618 
Yes 31 (33%) 55 (30%) 86 (31%) 
 
Visited a mental health professional in 12 months prior to interview after MSIR opened 
No 64 (68%) 141 (77%) 205 (74%) 0.126 
Yes 30 (32%) 43 (23%) 73 (26%) 
 
* Pearson's chi-squared test     
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4. Aim c: Reduce attendance by ambulance services, paramedic 
services and emergency services and attendances at hospitals due 
to overdoses of drugs of dependence 
Attendance by ambulance at overdose over time 
Linked data from the Victorian Ambulance Clinical Information System (VACIS) shows a 
projected decrease in ambulance attendances with naloxone administration for participants 
who visited the MSIR (Figure 4.1). Despite an overall drop for the participants who have 
visited the MSIR, we did not find evidence of a difference between the average number of 
ambulance attendances with naloxone administration between those who did visit the 
facility and those who didn’t (IRR=0.72; p=0.41). 
Figure 4.1 Average number of ambulance attendances requiring naloxone administration (VACIS) 
 
However, for intensity of MSIR use we found the average number of ambulance 
attendances with naloxone administration between the group of participants who reported 
having had 50% or more of their injections in the MSIR compared to those who had not 
visited the facility was lower (IRR=0.39, p=0.03, Table 4.1and Figure 4.2). 
Table 4.1 Total number of ambulance attendances with naloxone administration by MSIR frequency of use: results from the 
fixed-effects Poisson regression analysis (VACIS) 




No visit 1   
<50% 1.03 0.38-2.99 0.91 
≥50% 0.39 0.17-0.93 0.03 
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Figure 4.2 Total number of ambulance attendances with naloxone administration per year by MSIR frequency of use 
(VACIS) 
 
Emergency Department presentations for drug related reasons (including overdose) 
Using linked data from the Victorian Emergency Minimum Dataset (VEMD), we did not find 
evidence of a difference between the average number of emergency department 
presentations for conditions related to drug use between the group of participants who 
reported visiting the MSIR compared to those who didn’t; either before or after the MSIR 
opened (IRR=1.71, p=0.16, Figure 4.3). 
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Figure 4.3 Average number of drug-related emergency department presentations (VEMD) 
 
However, for intensity of MSIR use there was weak evidence of an increase in the average 
number of emergency department presentations for conditions related to drug use between 
the group of participants who reported having had 50% or more of their injections in the 
MSIR and those who had not visited the facility (see Figure 3.5 and Table 4.2). 
Table 4.2 Drug-related emergency department presentations by MSIR frequency of use: results from the fixed-effects 
Poisson regression analysis (VEMD) 
  IRR 95%CI P 
Drug-related ED 
presentations 
No visit 1   
<50% 1.60 0.53-4.81 0.41 
≥50% 2.44 0.99-6.02 0.05 
Hospitalisations for drug related reasons (including overdose) 
Using linked data from the Victorian Admitted Episode Dataset (VAED), we did not find 
evidence of a difference between the average number of hospitalisations for conditions 
related to drug use (including overdose) between the group of participants who reported 
visiting the MSIR compared to those who didn’t; either before or after the MSIR opened 
(IRR=1.56, p=0.20, Figure 4.4). 
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Figure 4.4 Average number of drug-related hospital admissions (VAED) 
 
For intensity of MSIR use we did not find evidence of a difference between the average 
number of hospitalisations for conditions related to drug use (including overdose) between 
the group of participants who reported having had less than 50% of their prior month’s 
injections in the MSIR and those with 50% or more, compared to those who had not visited 
the facility (see Figure 3.7 and Table 4.3). 
Table 4.3 Drug-related hospital admissions by MSIR frequency of use: results from the fixed-effects Poisson regression 
analysis (VAED) 
  IRR 95%CI p 
Drug-related hospital 
admissions 
No visit 1   
<50%    
≥50%    
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5. Aim d: Reduce the number of discarded needles and syringes in 
public places and the incidence of injecting of drugs of dependence 
in public places in the vicinity 
No data on discarded needles are collected in the SuperMIX study and so only proxies of 
public drug use were examined in relation to this objective. 
Use of heroin purchase by location 
In these analyses we categorised public drug use as streets, public toilets, parks, and cars; 
and private spaces as private homes (including dealer’s homes). 
In a cross-sectional analysis of all interviews done after the MSIR opened, there was no 
evidence of a difference in the frequency of reports of purchasing heroin in a public location 
for those who visited the MSIR compared to those who did not (Table 5.1). 






MSIR Total p-value 
Total 181 417 598 
 
Where last purchase of heroin was used 
Private & MSIR 77 (51%) 132 (57%) 209 (54%) 0.248 
Public 75 (49%) 101 (43%) 176 (46%) 
 
Missing 29 184 213 
 
* Pearson’s chi-squared test     
A comparison of interviews before and after the facility opened was not possible as there 
were not sufficient data available for the interviews conducted prior to the facility opening. 
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6. Aim e: Improve the amenity of the neighbourhood for residents 
and businesses in the vicinity 
No direct data on public amenity are collected in the SuperMIX study and so only proxies of 
public drug use and public amenity were examined in relation to this objective. 
Location of most recent residence and interview location 
In a cross-sectional analysis of all interviews done after the MSIR opened, those who had 
visited the MSIR were more likely to reside in Richmond (9%) than those who did not visit 
the MSIR (3%) (Table 6.1). For those who reported visiting the facility, the percentages 
residing in Richmond were 7% and 12% for those who had less than 50% of their injections 
within the facility versus those who had 50% of their injections or more within the facility, 
respectively (p=0.023). 
 






MSIR Total p-value 
Total 181 417 598 
 
Location of most recent residence 
Not Richmond 146 (91%) 375 (97%) 521 (95%) 0.008* 
Richmond 14 (9%) 13 (3%) 27 (5%) 
 
Missing 21 29 50 
 
* Pearson’s chi-squared test     
In a cross-sectional analysis of all interviews done after the MSIR opened, those who had 
visited the MSIR were more likely to be interviewed in Richmond (77%) than those who did 
not visit the MSIR (18%) (Table 6.2).  






MSIR Total p-value 
Total 181 417 598 
 
Interview location 
Not Richmond 42 (23%) 333 (82%) 375 (64%) <0.001* 
Richmond 139 (77%) 74 (18%) 213 (36%) 
 
Missing 0 10 10 
 
* Pearson’s chi-squared test     
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Location of drug purchase 
We categorised heroin purchases into private (dealer’s home, friend or home delivery) and 
public (street, mobile dealer or street drop off) locations. In a cross-sectional analysis of all 
interviews done after the MSIR opened, those who reported visiting the MSIR and had 
purchased heroin in the last week were more likely to report purchasing in public spaces 
(62%) than those who did not visit the MSIR (42%). For those who have visited the facility, 
the percentages reporting purchasing in public were 58% and 69% for those who had less 
than 50% of their injections within the facility versus those who had 50% of their injections 
or more within the facility, respectively (p<0.001). 





visited MSIR Total p-value 
Total 181 417 598 
 
Where last purchase of heroin was scored from 
Private (dealer’s home, friend, or home delivery) 58 (38%) 135 (58%) 193 (50%) <0.001* 
Public (street or mobile dealer, street drop off) 94 (62%) 97 (42%) 191 (50%) 
 
Missing 29 185 214 
 
* Pearson’s chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened, 
we see that those who reported subsequently using the MSIR were more likely to purchase 
their heroin in a public space compared to those who didn’t use the MSIR both before and 
after the MSIR opened, and this distribution changed little (Table 6.4). 
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visited MSIR Total p-value 
Total 94 184 278 
 
Where last purchase of heroin was scored from before MSIR opened 
Private (dealer’s home, friend, or home delivery) 27 (33%) 63 (57%) 90 (47%) 0.001* 
Public (street or mobile dealer, street drop off) 54 (67%) 47 (43%) 101 (53%) 
 
Missing 13 74 87 
 
Where last purchase of heroin was scored from after MSIR opened 
Private (dealer’s home, friend, or home delivery) 27 (37%) 54 (54%) 81 (47%) 0.027* 
Public (street or mobile dealer, street drop off) 46 (63%) 46 (46%) 92 (53%) 
 
Missing 21 84 105 
 
* Pearson’s chi-squared test     
The changes in place of latest heroin purchase between the two timepoints for participants 
who have and have not visited the MSIR have been depicted in Figure 6.1. 
Figure 6.1 Changes over time in where last purchase of heroin was scored from, before and after MSIR opened 
 
 
We also looked at the flow of self-reported purchasing locations for heroin over the years 
for all questionnaires for which participants had reported about this behaviour. Figure 6.2 
 
Review of the MSIR using the SuperMIX cohort and linked data sets, 25 February 2020 46 
 
shows a barplot of the reported heroin purchase location between July in each year and 
June in the next. We have chosen this time interval so that the latest year coincides with the 
first year of operation of the MSIR (1 July 2018). The bands joining the bars represent the 
same participant’s response in subsequent interviews. For this plot we have only used 
participants recruited before 2017 (N=223). It should be noted that the data in the plot are 
not corrected for the location of interview. 
Figure 6.2 shows a shift towards heroin purchase in Richmond by cohort members in recent 
years. This shift occurs in the year prior to the facility opening and continues after the 
facility opened. 
Figure 6.2 Location of latest heroin purchase for participants recruited before 2017 and interviewed after MSIR opening 
 
Main reason for coming to Richmond 
The total number of participants who were interviewed in Richmond was 213. Of those, 
seven did not answer about their main reason for being in Richmond. See figure below for 
the main reason for being in North Richmond (Figure 6.3). 
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Figure 6.3 Main reason to be in Richmond 
 
Reasons for using MSIR 
Data on reasons given for using the MSIR were available from the SuperMIX and IDRS 
surveys. Study participants reported that being away from police (IDRS=53%, 
SuperMIX=35%), concerned about overdose risk (IDRS=32%, SuperMIX=25%) and being 
curious about the service (IDRS=28%, SuperMIX=34%) were the main reasons for their visit 
to the MSIR (Table 6.5). 
Table 6.5 Reasons for visiting the MSIR, for IDRS and SuperMIX data sets  
Why did you visit MSIR? 
IDRS 2019 SuperMIX 
Yes (%) Yes (%) 
Being away from police 53 35 
Concerned about overdose risk 32 25 
Curious 28 34 
Concerned about threat of 
violence/standover 22 
15 
Concerned about using alone 16 8 
Clean / Safe 14 18 
Away from the public 9 7 
Comfortable/convenient 7 10 
Others 7 5 
Need help and advice about injecting 4 6 
Reasons for not using MSIR 
In both IDRS and SuperMIX samples, the main reason for not visiting the MSIR service was 
distance, ‘too far from where I live’ (IDRS=50%, SuperMIX=39%) and ‘too far from where I 
score drugs’ (IDRS=34%, SuperMIX=27%). A residential map confirms these findings. 
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Figure 6.4 Number of participants residing in each LGA in the Melbourne metropolitan area, by intensity of MSIR use 
 
 
The top 5 reasons for not visiting are depicted in Table 6.6. 
Table 6.6 Top 5 reasons for not visiting the MSIR, for IDRS and SuperMIX data sets 
Top 5 reasons for not visiting MSIR 
IDRS 2019 SuperMIX 
Yes (%) Yes (%) 
Too far from where I live 50 39 
Too far from where I score drugs 34 27 
Prefer to inject at home 28 21 
Already have a safe place to inject 15 18 
Prefer to keep drug use private 8 8 
NB: These are the top five reasons that respondents mentioned. Other reasons that participants mentioned for not using 
the MSIR includes: Prefer to inject alone, don’t want to inject with strangers, long waiting time, for heroin users only, too 
many police near site/ has been in prison, need help to inject and doesn’t want to register. 
Engagement in property crime and drug dealing  
In a cross-sectional analysis of all interviews done after the MSIR opened, those who had 
visited the MSIR were more likely to have been engaged in property crime (27%) than those 
who did not visit the MSIR (18%) (Table 6.7). For those who have visited the facility, the 
percentage reporting engaging in property crime were 29% and 24% for those who had less 
than 50% of their injections within the facility versus those who had 50% or more of their 
injections within the facility, respectively (p=0.039). 
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MSIR Total p-value 
Total 181 417 598 
 
Engaged in property crime in the last month 
No 128 (73%) 336 (82%) 464 (79%) 0.019* 
Yes 47 (27%) 75 (18%) 122 (21%) 
 
Missing 6 6 12 
 
* Pearson’s chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened, 
we see an identical pattern to the table above but smaller numbers means that the effect 
was not significant (Table 6.8). 






MSIR Total p-value 
Total 94 184 278 
 
Engaged in property crime before MSIR opened 
No 69 (76%) 149 (82%) 218 (80%) 0.205 
Yes 22 (24%) 32 (18%) 54 (20%) 
 
Missing  n<5  n<5 6 
 
Engaged in property crime after MSIR opened 
No 66 (73%) 149 (81%) 215 (79%) 0.125 
Yes 24 (27%) 34 (19%) 58 (21%) 
 
Missing  n<5  n<5 5 
 
* Pearson’s chi-squared test     
Arrest (since previous interview only) 
In a cross-sectional analysis of all follow-up interviews done after the MSIR opened (N=285), 
those who had visited the MSIR were more likely to have been arrested (65%) than those 
who did not visit the MSIR (41%) (Table 6.9). For those who have visited the facility, the 
percentage reporting being arrested was 58% and 79% for those who had less than 50% of 
their injections within the facility versus those who had 50% or more of their injections 
within the facility, respectively (p<0.001). 
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MSIR Total p-value 
Total 94 191 285 
 
Having been arrested since previous interview (only follow-up) 
No 33 (35%) 112 (59%) 145 (51%) <0.001* 
Yes 60 (65%) 79 (41%) 139 (49%) 
 
Missing  n<5 0  n<5 
 
* Pearson’s chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened 
and had a follow-up interview (N=190), there was no statistically significant difference 
between the two groups before the facility opened ). 
Table 6.10). 






MSIR Total p-value 
Total 38 152 190 
 
Having been arrested before MSIR opened 
No 21 (57%) 88 (59%) 109 (58%) 0.833 
Yes 16 (43%) 62 (41%) 78 (42%) 
 
Missing  n<5  n<5  n<5 
 
Having been arrested after MSIR opened 
No 18 (47%) 94 (62%) 112 (59%) 0.105 
Yes 20 (53%) 58 (38%) 78 (41%) 
 
Missing 0 0 0  
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7. Aim f: Assist in reducing the spread of blood-borne diseases in 
respect of clients of the licensed medically supervised injecting 
centre, including, but not limited to, HIV and hepatitis C 
Injected with someone’s used needle/syringe 
In a cross-sectional analysis of all interviews done after the MSIR opened, there was no 
significant difference in reports of having injected with someone’s used needle/syringe in 
the last month between those who had (9%) and those who had not visited the MSIR (11%) 
(Table 7.1). There was no significant difference between those who had less than 50% of 
their injections within the facility versus those who had 50% or more of their injections 
within the facility, (p=0.774). 






MSIR Total p-value 
Total 181 417 598 
 
Injected with someone’s used needle/syringe in the last month  
No 160 (91%) 343 (89%) 503 (90%) 0.462 
Yes (once or more) 16 (9%) 43 (11%) 59 (10%) 
 
Missing 5 31 36 
 
* Pearson’s chi-squared test     
If we only consider participants who were recruited into the study before the MSIR opened 
(N=278), there was no significant pre-existing difference the two groups (Table 7.). 
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MSIR Total p-value 
Total 94 184 278 
 
Injected with someone’s used needle/syringe before MSIR opened 
No  80 (88%) 165 (92%) 245 (91%) 0.253 
Yes (once or more) 11 (12%) 14 (8%) 25 (9%) 
 
Missing  n<5 5 8 
 
Injected with someone’s used needle/syringe after MSIR opened 
No  83 (93%) 143 (88%) 226 (90%) 0.168 
Yes (once or more) 6 (7%) 20 (12%) 26 (10%) 
 
Missing 5 21 26 
 
* Pearson’s chi-squared test     
Using linked data from the Medicare Benefits Schedule (MBS), we did not find any 
significant difference between the average number of HCV RNA tests, viral load testing in 
preparation for treatment and testing to confirm treatment success for the group of 
participants who reported visiting the MSIR compared to those who didn’t in the years 
surrounding the opening of the MSIR (see Figure 7.1). 
 
Review of the MSIR using the SuperMIX cohort and linked data sets, 25 February 2020 53 
 
Figure 7.1 Average number of hepatitis C tests per year (MBS) 
 
Hepatitis C prescriptions 
Using linked data from the Pharmaceutical Benefits Scheme (PBS), we did not find any 
significant difference between the average number of Hepatitis C prescriptions for the 
group of participants who reported visiting the MSIR compared to those who didn’t in the 
years surrounding the opening of the MSIR (Figure 7.2). 
Figure 7.2 Average number of hepatitis C prescriptions per year (MBS) 
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8. Appendix 1: Methods 
Study population 
The Melbourne Injecting Drug User Cohort Study (SuperMIX) follows people who inject drugs (PWID) 
recruited from urban locations in Melbourne, Australia, between 2008 and 2019. Initial recruitment 
(2008-2010) resulted in a cohort of 688 that was subsequently expanded to 757 in 2011 and 
increased to around 1300 from 2017 onwards. Eligibility criteria included: residing in Melbourne, 
aged 18 years or over, injected either heroin or amphetamines at least once in the six months prior 
to entering the study, and having a valid Medicare number (needed for record linkage). Initial age 
criteria aimed to recruit younger PWID (<30 years) but these were relaxed over time. 
Interviews are conducted annually and participants are reimbursed AUD$30 for their time and 
expenses, with an extra $10 if the y provide a venous blood sample from 2011. Further study details 
including detailed baseline characteristics of the cohort are available elsewhere (Horyniak et al., 
2013; O’Keefe, Scott, Aitken, & Dietze, 2016). 
Linked data 
Linkage to records kept in administrative datasets collected by a range of data custodians was 
performed in different ways depending on the data sources in question. However, several steps 
were involved in establishing the linkage process. Firstly, a raw cohort file for SuperMIX participants 
with identifier data and source ID, as well as the questionnaire data files with the same Source ID 
were sent separately to the Australian Institute of Health and Welfare (AIHW). AIHW created a 
unique AIHW ID for each participant, and added it to both files. AIHW then linked the cohort file to 
Medicare Enrolment data to obtain the Person Identifier Number (PINS) on Medicare Benefits 
Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) records, as well as National Death Index 
(NDI). AIHW then extracted MBS and PBS data using these PINs, attached the AIHW ID to de-
identified MBS and PBS data, as well as NDI, and removed PINs. 
The raw cohort file with identifier data and AIHW ID was then sent to the Centre for Victorian Data 
Linkage (CVDL) for linkage to state datasets. CVDL linked the cohort file to identifier data of the 
Alcohol and Drug Information Services (ADIS), the Victorian Emergency Minimum Dataset (VEMD) 
and the Victorian Admitted Episodes Dataset (VAED). CVDL then extracted the relevant data from all 
the datasets, attached AIHW ID to the de-identified datasets, and removed the Victorian IDs and 
then sent the linked files to the AIHW. Ambulance Victoria applied a similar linkage protocol to 
VACIS data. 
AIHW then released all of the de-identified datasets, including the SuperMIX questionnaire, with 
AIHW ID to a secure environment at the Australian Institute of Family Studies (AIFS) for analysis. 
SuperMIX 
SuperMIX collects self-report information from PWID on their demographics, drug use, health 
service use, drug purchasing characteristics, and use of the Melbourne Supervised Injecting Room. 
From the self-report data in the SuperMIX dataset, we derived 712 interviews following the opening 
of the after the Melbourne Supervised Injecting Room (MSIR) on 30 June 2018, from 657 
participants. We only kept participants who had answered the question of whether they have had 
visited the MSIR in the period between its opening and their first interview (n=622) (See Figure 8.1). 
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Of those, we only included participants who had injected at least one drug 1 in the year prior to the 
interview (n=598). That leaves us with 598 unique participants who were injecting at their time of 
the interview and answered the MSIR questions. Of those, 285 were follow-up interviews, and 313 
were new baseline participants recruited into the study after the MSIR opened. Therefore, there are 
285 participants for which we have at least one interview before the MSIR opened, and one after. 
For our before and after MSIR analyses, we also excluded those participants who had ceased to 
inject in the year prior to their interview before MSIR opened. For questions that are present in both 
follow up and baseline interviews this leaves us with 278 participants who had an interview before 
and after MSIR opened. For follow-up-only questions this leaves us with 190 participants. 
Figure 8.1 Flow diagram. SuperMIX participants who have responded to the “MSIR visit” question, regardless of whether 
they were recruited in Richmond or not. Depicted in yellow are the different samples used in this report for the self-report 
data. 
 
For each AIHW ID, we extracted the answer to whether the participant had visited the MSIR or not 
and what percentage of their injections took place in the MSIR in the month prior to their SuperMIX 
interview, categorised into ‘none’, ≤50%, ≥50%. We then merged this subset of SuperMIX data into 
each of the linked datasets by AIHW ID. This merge left us with a total of 586 out of 598 participants. 
NDI 
The National Death Index (NDI) contains records of all deaths occurring in Australia since 1980, 
obtained from the Registrars of Births, Deaths and Marriages in each state and territory. Cause of 
death information is recorded as ICD10 codes derived by the Australian Bureau of Statistics from the 
death certificates. 
Linked NDI data included deaths occurred up to 2018, but no deaths occurred among the 586 
participants considered in this analysis. 
 
1 any drug injected of the following: heroin, methamphetamine, benzodiazepines, suboxone, buprenorphine, 
methadone, antidepressants, antipsychotics, cocaine, ecstasy, hallucinogens, morphine, oxycodone, (non-) 
prescribed, prescription stimulants, pharmaceutical stimulants, unisom, Pregabalin/lyrica, or speed powder. 
SuperMIX self-report 
data after opening MSIR 
(30/6/2018)
712 interviews from 
N=657 participants




N=35 participants without 
reported information on 
MSIR use
First interview after MSIR 




N=24 participants who did 










who did not inject in 
the year prior to their 
interview before MSIR 
opening
Before (follow-up & 
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MBS 
Medicare Benefits Schedule (MBS) records contain information on services that qualify for a benefit 
under the Health Insurance Act 1973 and for which a claim has been processed. The database 
comprises information about MBS claims, patients, and service providers. 
We received linked data comprising the period between 1 January 2008 until 31 March 2019 
(n=498,280 records) of which 244,310 records linked to 577 participants in our analysis sample. Nine 
participants were not present in the linked MBS data, we assumed that they had no claims within 
the time period for the purposes of this analysis.  
N=99,952 records were related to seeing a medical professional (defined as Category 1: professional 
attendances) and n=73,522 records were specifically related to seeing a GP (defined as Group A1: 
general practitioner attendances to which no other item applies). 
Hepatitis pathology tests 
The MBS has three charge categories for hepatitis C RNA testing, which can each be accessed 
independently. Service providers specify whether the RNA test is either: qualitative to confirm active 
hepatitis C infection (item number 69499 or 69500); quantitative in preparation for treatment (item 
number 69488 or 69489); or qualitative to confirm treatment success (item number 69445 or 
69451). 
N=1,185 records corresponded to hepatitis tests, with 396 participants in our sample having at least 
one. 
PBS 
Pharmaceutical Benefits Scheme (PBS) records contain information on prescription medicines that 
qualify for a benefit under the National Health Act 1953 and for which a claim has been processed. 
The database comprises information about PBS scripts and payments, patients, prescribers and 
dispensing pharmacies. 
We used the Anatomical Therapeutic Chemical (ATC) codes, controlled by the World Health 
Organization Collaborating Centre for Drug Statistics Methodology (WHOCC), to categorise all 
prescriptions. We considered two categories of mental health medications: Antidepressants (N06A) 
and Antipsychotics (N05A). We considered that the likely case-use scenario of anxiolytics (N05B), 
and hypnotics and sedatives (N05C) for this particular population was as a sleeping aid, rather than 
mental health concerns, therefore we categorised these as non-mental-health medications, and 
collectively labelled them “Benzodiazepines”. The other category of interest were pain management 
medications, grouping opioids (insert ATC code here) and pregabalin (insert ATC code here). All 
other prescriptions were grouped into the “Other” label.  
We received linked data between 1 January 2008 until 31 March 2019 (n=208,187 records) of which 
n=108,444 records linked to 563 participants in our sample. The other 23 participants were not 
present in the linked PBS data, we assumed that they had no claims within the time period for the 
purposes of this analysis. 
N=21,774 records corresponded to mental health prescriptions, n=664 records to hepatitis C 
treatment, and n=86,006 to other medications. 
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ADIS 
The Alcohol and Drug Information System (ADIS) collection is the primary source of data for a 
number of alcohol and other drug treatment service programs. We categorized “treatment type” 
into withdrawal, counselling, and other treatment (including residential rehabilitation). 
We received linked data between 6 July 2006 until 29 January 2019 (n=10,718 records) of which 
n=4,559 records linked to 447 participants in our sample. The other 139 participants were not 
present in the linked ADIS data, we assumed that they had not initiated any drug treatment within 
the time period for the purposes of this analysis. 
N=1,342 records corresponded to drug counselling, 908 to withdrawal, and 2,309 to ‘other’ 
treatments. 
VEMD 
The Victorian Emergency Minimum Dataset (VEMD) contains state-wide administrative and clinical 
data detailing emergency department (ED) presentations at all Victorian public hospitals with 
designated EDs.  
Principal diagnoses at the ED were described using the International Classification of Disease 10th 
revision Australian Modification (ICD-10-AM). We also considered secondary and tertiary diagnoses, 
although they were not available for the majority of presentations (95% and 99% for secondary and 
tertiary diagnoses, respectively). We categorised the presentations using an “any mention method” 
(Injury Surveillance Workgroup 7, 2012), which included any mention of the relevant codes at any 
diagnostic level. For any drug-related presentations we included all the codes that can be related to 
a diagnosis that is wholly (or partially) attributable to any illicit substances (TurningPoint, 2016). 
Consistent with DiRico et al 2018 (Di Rico, Nambiar, Stoove, & Dietze, 2018), we used F-codes F11.0 
to 11.9 for cases representing “mental and behavioural disorders due to opioid use” and T-codes 
40.0-40.4 and T40.6 for cases representing “poisoning by drugs, medicaments and biological 
substances”. 
We calculated the average number of total ED presentations, drug- and not-drug-related and 
poisoning by opioid-related ED presentations and the average number for mental disorder 
presentations due to opioid use, per year and by year offset. 
A total of 26,978 records were retrieved between 1 July 1999 until 14 March 2019. Of those, 
n=11,649 records linked to 515 participants in our sample. The other 71 participants were not 
present in the linked VEMD data, we assumed that they had not presented to any of the qualifying 
ED’s in this period for the purposes of this analysis. 
VAED 
The Victorian Admitted Episodes Dataset (VAED) provides a comprehensive dataset of the causes, 
effects and nature of illness, and the use of health services in Victoria. All Victorian public and 
private hospitals, including rehabilitation centres, extended care facilities and day procedure 
centres, report a minimum set of data for each admitted patient episode.  
For categorising ED presentations and calculating averages per year we used the same methods as 
for the VEMD data set, as described above. 
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A total of 9,052 records were retrieved between 5 April 2008 until 4 March 2019. Of those, n=3,579 
records linked to 481 participants in our sample. The other 105 participants were not present in the 
linked VAED data, we assumed that they had not been admitted to any hospitals within in this period 
for the purposes of this analysis. 
VACIS 
The Victorian Ambulance Clinical Information System (VACIS) is a patient care record computer 
application specifically designed for Australian ambulance services. Although originating in Victoria, 
it is used in every ambulance service in Australia’s eastern states, covering 80% the Australian 
population. VACIS contains all patient data, from ambulance call to discharge. 
Probabilistic linkage was conducted by Ambulance Victoria using First Name + Last Name + Date of 
Birth (DOB) for participants with an available DOB. For participants with missing DOB, the linkage 
consisted of three steps:  
1. Probabilistic match using First Name + Last Name 
2. The absolute difference between the ‘estimated age captured by paramedics’ and the 
SuperMIX participant’s age on the ambulance case date was calculated 
3. Records were considered to be a match if the age difference was ≤5 years.  
Linkage was performed ‘1 to many’ such that a unique SuperMIX participant (AIHW ID) could be 
linked to many Ambulance Victoria records. All patients with a match score of ~80-85% were 
manually reviewed for accuracy. Match scores ≥85% were assumed to be true, and match scores 
<80% were assumed to be untrue. 
Using the provided medication file from VACIS, we flagged each ambulance attendance for whether 
Naloxone was administered or not, and used that as a proxy for an ambulance attendance for opioid 
overdose. 
A total of 9,726 records were retrieved, covering the period between 3 January 2007 and 30 August 
2019. Of those, n=4,433 records linked to 499 participants in our sample. The other 87 participants 
were not present in the linked VACIS data, we assumed that they had not been attended by any 
ambulance within this period for the purposes of this analysis. Naloxone was administered in n=464 
ambulance attendances. 
Illicit Drug Reporting System (IDRS) 
The Illicit Drug Reporting System (IDRS) is an ongoing illicit drug monitoring system which has been 
conducted in all states of Australia since 2000. The IDRS interviews are conducted annually with a 
sentinel group of people who regularly inject drugs. Participants were recruited using multiple 
methods such as needle and syringe programs (NSP) and peer referral with eligibility criteria of a) be 
at least 18 years of age (due to ethical requirements); b) have injected at least monthly during the 
six months preceding interview; and c) have been a resident for at least 12 months in the capital city 
in which they were interviewed. In 2019, a total of 148 participants were recruited in Melbourne, 
Victoria as part of national IDRS study. It was then oversampled to 181 for the purpose of reviewing 
the MSIR, of whom four participants had missing data regarding MSIR visit. 
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Exposure variables 
From July 2018 onwards we have included items in the questionnaire that ask about the use of the 
injecting facility. The main exposure variable for the current study is “MSIR visit”: whether 
participants had or had not visited the MSIR since their last interview (follow up interviews) or ever 
(baseline interviews). Those who had responded that they had “never heard” of the MSIR were also 
categorised as “not visited”. We also constructed a variable around the percentage of injections that 
took place in the facility within the previous months, indicating “intensity of MSIR use”: not visited 
the facility versus those who did and had less than 50% of their injections within the facility (or no 
injections) versus those who had more than 50% of their injections within the facility. 
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9. Appendix 2: Demographics 
In this document we outline the demographics of the sample of SuperMIX participants with 
a first interview after MSIR opening (N=598) and for participants in the IDRS study. Please 
refer to Appendix 1 (Methods) for more information on the different samples and datasets 
used (Table 9.1). 
SuperMIX: All interviews after MSIR opening (n=598) 
 




MSIR Hasn’t visited MSIR Total p-value 
Total 181 417 598 
 
Age at interview 
<=30 12% 8% 9% 0.007* 
31-40 55% 44% 47% 
 
41-50 23% 36% 32% 
 
≥=50 10% 12% 12% 
 
Missing 0 0 0 
 
Gender identity 
Male 70% 66% 68% 0.614† 
Female 30% 33% 32% 
 
Non binary/gender fluid 0% 0% 0% 
 
Missing 0 0 0 
 
Employment status 
Unemployed 95% 84% 87% <0.001* 
Employed 5% 16% 13% 
 
Missing 0 0 0 
 
Housing status 
Unstable 39% 28% 31% 0.007* 
Stable 61% 72% 69% 
 
 




MSIR Hasn’t visited MSIR Total p-value 
Missing 3 3 6 
 
Housing type  
Owner-occupied, rental, community, 
boarding, or other rent-free 
68% 85% 80% <0.001* 
Homeless, squat, or supported 
accommodation 
32% 15% 20% 
 
Missing n<5 0  n<5 
 
Living conditions 
With relatives, friends, or housemates 51% 67% 62% <0.001* 
Alone 49% 33% 38% 
 
Missing 11 9 20 
 
Education level 
< = year 9 31% 28% 29% 0.432 
Year 10-12 44% 46% 45% 
 
Tertiary/diploma/trade 22% 20% 20% 
 
Other 4% 7% 6% 
 
Missing 0 0 0 
 
Aboriginal and Torres Strait Islander 
No 73% 88% 83% <0.001* 
Yes 27% 12% 17% 
 
Missing  n<5  n<5  n<5 
 
Is a parent 
No 35% 36% 36% 0.714 
Yes 65% 64% 64% 
 
Missing 5 17 22 
 
Main drug of choice 
Heroin 87% 64% 71% <0.001* 
 




MSIR Hasn’t visited MSIR Total p-value 
MA 7% 20% 16% 
 
Cannabis 3% 12% 9% 
 
Other 3% 4% 3% 
 
Missing 5 19 24 
 
Drug injected most in last month 
Heroin 89% 59% 68% <0.001* 
MA/Other 11% 41% 32% 
 
Missing 0 0 0 
 
Previous incarceration 
No 18% 23% 21% 0.192 
Yes 82% 77% 79% 
 
Missing  n<5 11 13 
 
Incarceration in the 12 months prior to interview 
No 62% 75% 71% 0.003* 
Yes 38% 25% 29% 
 
Missing 9 7 16 
 
Area of residence 
Richmond 9% 3% 5% NA 
Western suburbs 16% 27% 24% 
 
Mornington peninsula 6% 25% 20% 
 
Inner city 20% 9% 12% 
 
St Kilda area 18% 12% 14% 
 
Dandenong area 1% 2% 2% 
 
Other south/east 14% 7% 9% 
 
Other north 12% 9% 10% 
 
Country Victoria 4% 5% 5% 
 
 




MSIR Hasn’t visited MSIR Total p-value 
Missing 21 29 50 
 
By location 
Richmond 77% 18% 36% NA 
Footscray 10% 28% 23% 
 
Frankston 4% 26% 19% 
 
Collingwood 3% 8% 6% 
 
St Kilda 2% 6% 5% 
 
CBD 0% 4% 3% 
 
Dandenong 1% 1% 1% 
 
Outreach 0% 2% 2% 
 
Phone 2% 6% 5% 
 
Burnet/Alfred 1% 0% 1% 
 
Missing 0 10 10 
 
By type 
Baseline 48% 54% 52% 0.168 
FollowUp 52% 46% 48% 
 
Missing 0 0 0  
** statistically significant, p<0.05 
† Fisher exact test instead of chi-square test, due to low numbers in some categories  
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IDRS 2019 (n=177) 
In the IDRS 2019 study, a total of 177 participants were recruited. Of those, 168 have heard 
of the presence of medically supervised injecting room (MSIR) and 81 (46%) have ever 
visited the MSIR (Table 9.2). As in SuperMIX, the majority (68%) of those who have visited 
the MSIR were interviewed in Richmond. Furthermore, comparable to the SuperMIX 
sample, those who have visited the MSIR are more likely to be young, Aboriginal or Torres 
Strait Islander, live in unstable accommodation and their main drug of choice is more likely 
to be heroin than participants who have not visited the MSIR. Those who have visited the 
facility were also more likely to be currently on treatment, experiencing accidental overall 
drug overdose and accidental heroin overdose in the last 12 months. 
 
Table 9.2 Demographics IDRS 
 
Have you ever visited MSIR 
No (%) Yes (%) p-value 
N=96 N=81  
Gender 
Female 27 33  0.51 
Male 73 67  
Age  
≤30 n<5 10  0.012 
31-40 32 49  
40-50 44 28  
≥50 21 12  
Aboriginal/Torres Strait 
Islander 
No 90 54 <0.001 
Yes 10 46  
Currently employed 
Not employed 93 94  1.00 
Employed 7  6  
Accommodation status 
Unstable 24 40  0.034 
Stable 76 60  
Interview site 
North Richmond 9  68  
Footscray 22 n<5  
Frankston 25 0  
Dandenong 24 2   
Collingwood 9  19  
St Kilda 10  7  
Interview site - dichotomous 
Richmond 9  68 <0.001 
Non-Richmond 91 32  
Ever been in prison   
No 31 30  0.75 
Yes 69 70  
MAIN drug of choice 
Heroin 63 83 0.016 
Methamphetamine 25 7  
Cannabis 8 5  
Others n<5 5  
Currently on drug treatment 
No 45 63 0.035 
Yes 53 37  
Any OD in the last 12months 
No 88 72  0.013 
Yes 13 28  
No 91 72  0.001 
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Heroin OD in the last 
12months 
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1. Executive summary 
This technical report provides an overview of the research design, methodology and data preparation 
processes employed for The Review of the trial of the Medically Supervised Injecting Room (MSIR), 
Survey of Residents and Businesses (hereafter referred to as the MSIR Survey of Residents and 
Businesses). The study is an initiative of the Victorian Government Department of Health and Human 
Services (the department). 
In May 2018, the department contracted independent social research agency Colmar Brunton to 
conduct the Data Collection component of the MSIR Survey of Residents and Businesses. Colmar 
Brunton engaged Q&A Market Research as a sub-contractor to conduct the fieldwork for the project. 
The purpose of the MSIR Survey of Residents and Businesses was to collect representative data on 
the experiences and attitudes of the community within a defined geographical area surrounding the 
MSIR, prior to its operational commencement. The survey covered topics including: witnessing public 
injecting; discarded needles and syringes; being offered drugs for purchase; experiences of drug 
activity; and attitudes towards the MSIR. The survey was administered to community members who 
live in the local area (resident survey) and community members who work in the local area (business 
survey). The methodology was designed to ensure that the sample was representative of the local 
community. 
The aim was to survey a representative sample of 500 residents and 300 businesses within a 
predefined geographical area surrounding the MSIR in June 2018, prior to its operational 
commencement. A total of N = 944 community members completed the survey (n = 651 residents; 
and n = 293 businesses). 
 
2. Background 
The Victorian Government is committed to addressing drug problems within the state of Victoria. 
Forming part of this commitment, the Government’s Drug Rehabilitation Plan will invest $87 million to 
address drug harms, including 100 new rehabilitation beds, trialling a medically supervised injecting 
centre and boosting training in the alcohol and other drug workforce. 
The Drug Rehabilitation Plan includes a trial of a medically supervised injecting room at North 
Richmond Community Health. The Drugs, Poisons and Controlled Substances Amendment (Medically 
Supervised Injecting Centre) Act 2017 allows for the licence of a medically supervised injecting room 
trial for a two year period. The objects of the Act are:  
 






(b) to deliver more effective health services for clients of the licensed medically supervised 
injecting centre by providing a gateway to health and social assistance which includes drug 
treatment, rehabilitation support, healthcare, mental health treatment and support and 
counselling; and  
(c) to reduce attendance by ambulance services, paramedic services and emergency 
services and attendances at hospitals due to overdoses of drugs of dependence; and  
(d) to reduce the number of discarded needles and syringes in public places and the 
incidence of injecting of drugs of dependence in public places in the vicinity of the licensed 
medically supervised injecting centre; and  
(e) to improve the amenity of the neighbourhood for residents and businesses in the vicinity of 
the licensed medically supervised injecting centre; and  
(f) to assist in reducing the spread of blood borne diseases in respect of clients of the licensed 
medically supervised injecting centre including, but not limited to, HIV and hepatitis C.  
 
The department is conducting a review of the operation and use of the MSIR so as to inform potential 
extension of the trial period. One of the components of the review is the MSIR Survey of Residents 
and Businesses. 
On the 30th of May, the department contracted independent social research agency Colmar Brunton to 
conduct the Data Collection component of the MSIR Survey of Residents and Businesses. Colmar 
Brunton engaged Q&A Market Research as a sub-contractor to conduct the fieldwork for the project. 
The purpose of the MSIR Survey of Residents and Businesses was to collect baseline data on the 
experiences and attitudes of a representative sample of the community, prior to MSIR trial 
commencement. The survey covered topics including: witnessing public injecting; discarded needles 




The methodology for the MSIR Survey of Residents and Businesses was designed by the 







The initial scoping session was held on the 31st of May, 2018. Dr. Kirstin Couper and Naomi Downer 
represented Colmar Brunton at this meeting. Josephine Norman and Katherine Scarcebrook attended 
from the department. Paul Hoger attended from Q&A Market Research. 
The following topics were covered during the scoping meeting:   
• Confirmation of the objectives of the survey; 
• Roles of individuals in Colmar Brunton, Q&A Market Research and the department’s project 
teams; 
• Confirmation of the project schedule; 
• Confirmation of the participant communication material; 
• Confirmation of the methodology including the sampling, recruitment, face-to-face fieldwork 
and computer-assisted telephone interviewing (CATI) fieldwork; 
• Discussion of the ethics application process; 
• Discussion of the fieldwork briefing agenda; 
• The setup of an online portal to provide real-time updates of fieldwork progress; 
• Reporting requirements. 
3.1.2. Ethics approval 
An ethics application pertaining to the conduct of this study was submitted to The University of 
Queensland Human Research Ethics Committee (HREC). Initial approval was obtained on the 5th of 
July and approval of amendments was obtained on the 11th of July (approval number: 20180000982). 
The department managed this process and were responsible for providing updates to the committee 
when required.  
3.1.3. Sampling 
The study population parameters consisted of the boundaries of 26 Statistical Area Level 1’s (SA1’s), 
confined to the Melbourne suburbs of Richmond, Abbotsford and East Melbourne (refer to Table 1). 
These parameters approximated a 500m radius of the location of the MSIR (North Richmond 
Community Health, 23 Lennox Street, Richmond). A graphical representation of the sampling frame is 






Figure 1: MSIR Survey of Residents and Businesses sampling frame. 
Sampling for the resident survey 
Household selection 
All private dwellings located within the sampling frame were considered eligible for participation in the 
study. The total count and proportion of private dwellings in each SA1 are listed below in Table 1. This 
population data was sourced from the Australian Bureau of Statistics (ABS), 2016 Census. The total 
number of eligible households within the sampling frame was N = 6,208. 
Prior to the commencement of data collection, Q&A Market Research fieldwork officers conducted a 
residential address indexation exercise. This involved physically walking the streets of the sample 
frame and logging all discoverable and accessible households into an electronic database to be used 
during fieldwork. 
The sampling design was guided by three core objectives: (i) to ensure all community residents living 
within the sampling frame had an even chance of participating in the study, (ii) to ensure that the 
sample was demographically representative of the population (according to age, gender, 
SA1/location), and (iii) to maximise the total number of surveys to be completed within the narrow 
fieldwork timeline (two week period). The timeline was narrow and non-flexible as fieldwork had a 






In order to address these three objectives, the sampling was conducted in two stages. 
1. In the first stage, the aim was to maximise the level of response from community residents. 
As such, the approach was to attempt contact with as many residences as possible within the 
given timeframe. Using information obtained during the address indexation exercise, the 
fieldwork team developed logical run sheets that enabled efficiency during fieldwork. Separate 
run sheets were developed for each SA1 located within the sampling frame. The run sheets 
excluded premises determined to be non-eligible (i.e. commercial properties, vacant 
properties and inaccessible properties). All residences were attempted in the order of the run 
sheets. The first address on each run sheet (i.e. the first address to be approached in each 
SA1) was selected at random. The run sheets were then ordered such that each eligible 
address on that first street was approached, in a consecutive manner. Addresses on both 
sides of the street were approached to participate. Once all eligible addresses on the street 
had been approached, fieldworkers moved to the next street in closest proximity, and the 
process was repeated. First calls were initially prioritised over second calls (except in the 
case of call backs and appointments) to ensure as many residences as possible were given 
the initial opportunity to participate in the study. If residents were not home at the point of 
initial contact, a calling card was left to allow the residents to initiate contact. 
 
Fieldwork shifts were allocated to ensure good representation across each SA1. Fieldwork 
shifts were divided into 2-3 hour blocks by SA1, such that each fieldwork team was allocated 
a 2-3 hour block of fieldwork in a single SA1, then the team would progress to another SA1 
for another 2-3 hour block of fieldwork and so on until they finished their shift. The time and 
day (weekday/weekend) of the visits were staggered for subsequent allocation of the same 
SA1. Each SA1 was visited between 5 and 6 times during fieldwork. On return visits to SA1’s, 
fieldworkers would begin approaching addresses at different areas of the SA1 (i.e, not at the 
end point of the last visit to the SA1). The new start points were not chosen systematically, 
rather they were chosen at the discretion of the fieldworkers. 
 
2. In the second stage, the sampling strategy shifted focus to ensure a representative sample by 
SA1/location was achieved. Minimum target quotas were set by SA1. Minimum quotas were 
determined by actual population spread by SA1. Responses rates and sub-sample sizes by 
SA1 relative to household-level population data were monitored closely to ensure 
proportionate representation was achieved.  
 
This sampling approach allowed us to achieve a representative sample of the community; according 
to age, gender, country of birth and location/SA1. Due to time constraints and the move from stage 
one to stage two sampling approaches, some addresses in the sampling frame were not approached 
to participate. However, as the sample is proportionately representative by key demographic 










Table 1. Count and proportion of private dwellings and businesses in sample universe. 
 Private dwellingsa Businessesb 
SA1 Count Proportion of 
total 
Count Proportion of 
total 
2114402 199 3.2% 0 0.0% 
2114405 171 2.8% 0 0.0% 
2114406 196 3.2% 0 0.0% 
2114407 189 3.0% 0 0.0% 
2114454 285 4.6% 90 10.1% 
2114404 475 7.7% 28 3.1% 
2114403 356 5.7% 24 2.7% 
2114401 187 3.0% 89 10.0% 
2114459 158 2.5% 9 1.0% 
2114457 536 8.6% 15 1.7% 
2114458 184 3.0% 42 4.7% 
2114439 146 2.4% 78 8.8% 
2114441 339 5.5% 79 8.9% 
2111902 265 4.3% 22 2.5% 
2111903 214 3.4% 11 1.2% 
2111904 122 2.0% 31 3.5% 
2113910 223 3.6% 55 6.2% 
2113901 126 2.0% 63 7.1% 
2114422 130 2.1% 47 5.3% 
2114421 160 2.6% 26 2.9% 
2114420 189 3.0% 7 0.8% 
2113905 269 4.3% 98 11.0% 
2113903 368 5.9% 29 3.3% 
2114411 248 4.0% 24 2.7% 
2114419 250 4.0% 8 0.9% 
2114442 223 3.6% 15 1.7% 
Total 6,208  890  
a. Data source: 2016 Census, ABS. 
b. Data source: Discoverable businesses located within the sample frame.  Refer to Sampling for Business 






Resident respondent selection 
Respondents within an eligible household were selected using a conditional-replacement next-
birthday method. This means that at the point of initial approach, the householder with the next 
birthday was invited to participate. In order for the next-birthday householder to participate, the 
following inclusion criteria must have been satisfied: 
• They were contactable during the fieldwork period; 
• They were aged 18 years or over; 
• They had been living in the area for at least two months; 
• They had the ability to participate in English or one of the 5 priority languages: Mandarin, 
Cantonese, Hakka, Vietnamese, or Greek; and 
• They provided informed consent. 
In the event that the next-birthday household member could not complete for any of these reasons, 
the person with the subsequent birthday was invited to participate. If the next-birthday person refused, 
the household was excluded from the sample and the next household was sampled. 
Only a single person per household completed the survey. The target sample size for the resident 
sample was n = 500. 
Sampling for the business survey 
Business selection 
Q&A Market Research purchased a list of business telephone numbers confined to businesses 
located in Richmond (SA2: 206071144), Abbotsford (SA2: 206071139) and East Melbourne (SA2: 
(206041119) from Reach DM (Marketing Agency in Victoria). A total of 1,552 telephone numbers 
were included in this list. The sample universe was confined to businesses located within the study 
population parameters (i.e. the 26 SA1’s). Additional inclusion and exclusion criteria were then 
applied. Businesses located along Bridge Road and Wellington Parade were excluded, while 
businesses located on both sides of Victoria Street (between Powlett Street, SA1: 2111904; and 
Johnston Street, SA1: 2114422) were included. Upon applying these criteria, the list of discoverable 
business telephone numbers reduced to 669. A further 221 discoverable businesses were added to 
this list. These were discovered via a comprehensive check of all Google My Business listings and via 
the address indexation exercise conducted in preparation for the resident survey fieldwork. As a result 
of these inclusions, the total number of discoverable business numbers located within the sample 
frame was N = 890. The total count and proportion of discoverable business in each SA1 are listed 
above in Table 1. 
Business respondent selection 
Initially, a random sampling strategy was to be utilised for the business survey. However, throughout 
the field period, the sample was exhausted. As such, all discoverable businesses within the sampling 
frame were approached to participate in the survey (N = 890). Business respondents were 
approached to participate via telephone. In order for respondents to be selected, the following 





• They were contactable during the fieldwork period; 
• They were aged 18 years or over; 
• They had been working in the area for at least two months; 
• They were a senior staff member (e.g. business owner or manager). If the business owner or 
manager were not available, the most senior staff member available at the time of the call 
was invited to participate; 
• They had the ability to participate in English or one of the 5 priority languages: Mandarin, 
Cantonese, Hakka, Vietnamese, or Greek; and 
• They provided informed consent. 
Only a single person per business was invited to complete the survey. The target sample size for the 
business sample was n = 300. 
3.1.4. Participation of people from non-English speaking 
backgrounds 
The department identified five languages other than English that were most commonly spoken (based 
on lowest English proficiency) within the area that the survey was being conducted. They were 
Vietnamese, Cantonese, Mandarin, Greek and Hakka. In order to enable participation of people from 
non-English speaking backgrounds, the survey was translated into these five priority languages. Both 
the resident survey and the business survey were translated into the five priority languages. 
Translated surveys were facilitated by the following ways: 
On the occasion that a fieldworker approached a resident who had difficulty communicating in 
English, the fieldworker would directly ask whether they spoke English. If the resident’s response was 
not in English, the fieldworker would probe further as to the resident’s spoken language. If required, 
fieldworkers would also use translated cards in order to establish whether the resident spoke one of 
the five priority languages (these translated cards provided an introduction and a brief overview of the 
survey). If the resident did speak one of the priority languages, the fieldworker would show the 
respondent the translated survey preamble (via the tablet) and they would gain consent at this point.  
If consent was established, the interviewer would follow the normal interviewing procedure (survey 
was self-completed via the tablet). 
For translated surveys completed via CATI, fieldworkers were typically advised by the gatekeeper 
(person that first answered the phone call) that the eligible respondent spoke a language other than 
English. The fieldworker would then arrange a call back appointment with an interviewer who speaks 
the priority language. Alternatively, the interviewer would tell the gatekeeper that they would call back 
at a later date, and arrange for a foreign language interviewer to re-attempt the call, and subsequent 
recruitment process. 
3.1.5. Data collection procedures 
During the scoping stage, the methodology and data collection procedures were discussed with the 
department and the most suitable approach was agreed upon. The procedures for the resident survey 






Data collection procedure for the resident survey 
A total of 14 Q&A Market Research interviewers conducted the face-to-face fieldwork for the resident 
survey. Fieldwork was conducted via household door knocking between the hours of 10am to 7pm on 
weekdays and 10am to 6pm on weekends. Fieldwork shifts were allocated across the 26 SA1’s to 
ensure a relatively proportionate number of residents were able to complete the survey, relative to 
general population spread. 
Fieldworkers conducted data collection in pairs (they attended households individually). Fieldworkers 
used a live call sheet (hard copies were available as well) to track recruitment. On the call sheet they 
were able to record the recruitment status of every household in the sampling frame (e.g. refusal, not 
eligible, inaccessible, non-contact, completed survey, unknown eligibility, etc). 
Order of sampling per residence: 
• Fieldworkers knocked on the door or pressed the intercom button of each private dwelling that 
was approached. Fieldworkers remained on the doorstep throughout all interactions with 
residents. At no point did fieldworkers cross the threshold. 
• When a resident was available at the time of initial approach, the fieldworker would introduce 
themselves, and the study (refer to preamble to the survey in Appendix B). They would then 
screen for eligibility, as per the study inclusion criteria (described above in 3.1.3). If eligible, 
the resident would be invited to participate in the survey. All respondents were provided with 
the Participant Approach Letter and Participant Information Form (refer to Appendix C) prior 
to participating. Participant consent was implied in their completion of the survey. 
• If contact was made but the eligible resident was unable to complete the survey at the time of 
initial approach, the fieldworker would collect the residents’ contact name and number and 
arrange a re-appointment (either via call back to complete the survey via CATI or in person to 
complete the survey face-to-face at their door step). 
• If no contact was made at the address, a call back card was left in the letter box (refer to 
Appendix C). Residents had the option of calling the Victorian Government Contact Centre 
(VGCC) telephone number if they wished to participate in the survey. These calls were able to 
be patched directly through to the Q&A Market Research survey hotline. 







The survey was administered by one of three modes: 
• English, interviewer-administered, face-to-face, Computer-Assisted Personal-
Interviewing (CAPI). If the respondent was able to complete the survey at the time the 
fieldworker visited the household, and in English, then the survey was interviewer-
administered, face-to-face. The fieldworker would read the survey text from a tablet and 
record the responses on the tablet. 
• One of the priority languages, self-administered, Computer-Assisted Self-Interviewing 
(CASI). If the respondent was able to complete the survey at the time the fieldworker visited 
the household, was unable to complete the survey in English, but was able to complete the 
survey in one of the priority languages (Mandarin, Cantonese, Greek, Vietnamese or Hakka) - 
the survey was self-completed on the tablet. 
• English or one of the priority languages, Computer-Assisted Telephone Interviewing 
(CATI). If a respondent indicated they would be willing to participate but they were unable to 
complete at the time the fieldworker visited the household, the fieldworker arranged a CATI 
call back. Surveys completed via CATI could be completed in English or in one of the priority 
languages. 
Data collection procedure for the business survey 
A total of 9 Q&A Market Research interviewers conducted the telephone interviewing for the business 
survey. Fieldwork was conducted between the hours of 9am – 5pm on weekdays. All discoverable 
businesses within the sampling frame were approached to participate in the survey. 
Fieldworkers used a live call sheet to track recruitment. On the call sheet they were able to record the 
recruitment status of every business in the sampling frame (e.g. refusal, not eligible, non-contact, 
disconnected, completed survey, unknown eligibility, etc.) 
Order of sampling per business: 
• Interviewer called the business telephone number. 
• If the call was answered, the interviewer would introduce themselves, and the study (refer to 
preamble to the survey in Appendix B). They would then screen for eligibility, as per the study 
inclusion criteria (described above in 3.1.3. Sampling). If eligible, the owner/employee would 
be invited to participate in the survey. If respondents requested further information about the 
study, they were sent the Participant Approach Letter and Participant Information Form (refer 
to Appendix C) via email. Participant consent was implied in their completion of the survey. 
• If contact was made and the respondent was not able to complete the survey at the time of 







3.1.6. Survey programming and testing 
The department delivered a final survey instrument to Colmar Brunton on the 6th of June. 
Colmar Brunton reformatted and edited the survey instrument to include instructions for survey 
scripting. The department reviewed this document, provided feedback and final approval on content. 
The final survey is appended to this report (refer to Appendix B). 
The final version of the survey was then sent to Q&A Market Research analysts for the electronic 
survey build. All routing and validations were programmed into the electronic interface of the survey.  
The survey tool was translated into five priority languages (Mandarin, Cantonese, Hakka, Vietnamese 
and Greek).  
Once the survey had been programmed, a number of checks occurred prior to the commencement of 
fieldwork. The Q&A Market Research analyst who was responsible for the survey build conducted the 
first test and Colmar Brunton’s Account Manager conducted a second test. Dummy datafiles were 
also checked to ensure all routing and filters were functioning as intended. Once the internal checks 
had been finalised, the department conducted a check of the dummy datafile and provided approval 
on the content prior to the commencement of fieldwork. 
3.2. Data collection 
3.2.1. Training the field team 
Training the field team for the resident survey 
A total of 14 Q&A Market Research interviewers conducted the face-to-face fieldwork for the Resident 
Survey. All fieldworkers had substantial experience in the conduct of social research fieldwork and all 
were accredited with The Australian Market & Social Research Society (AMSRS). The fieldwork team 
attended a face-to-face briefing at Colmar Brunton South Melbourne office on the 13th of June, prior to 
the commencement of fieldwork. The briefing was facilitated by Dr. Kirstin Couper, Emily Bariola 
(Colmar Brunton) and Paul Hoger (Q&A Market Research), with assistance from Josephine Norman 
and Katherine Scarcebrook (from the department). A total of 12 interviewers attended the briefing 
session. Two interviewers did not attend the face to face briefing.  They were given a full briefing by 
phone before commencing their first shift.  They were also placed with an interviewer that had 
attended the briefing for their first shift. 
The briefing provided an overview of the rationale for the trial, contextual information about the MSIR, 
the sampling approach, recruitment strategy, participant introductory script, the survey tool, ethical 
requirements, timelines, escalation processes and interviewer safety. 
A detailed fieldwork protocol document was produced to ensure that members of the field team and 






Prior to the commencement of fieldwork, interviewers were provided with the following materials: 
• Q&A Market Research ID on lanyard, to be worn at all times; 
• A tablet (for survey administration) and portable battery charger; 
• A map of the fieldwork area; 
• Interview protocol; 
• Survey tool (refer to Appendix B); 
• Live contact sheet link and hard copies of the contact sheet (used to record 
contact/recruitment data); and 
• Printed copies of the Call Back Card, Participant Approach Letter and Participant Information 
Form (refer to Appendix C). 
Fieldworkers were encouraged to dress appropriately for cold weather and to carry a light if 
conducting fieldwork in the late afternoon/early evening. 
In the event respondents requested further information about the survey or the MSIR, or had a 
complaint about the survey or the MSIR, interviewers were instructed to direct respondents to the 
Victorian Government Contact Centre. 
The Richmond Housing Office was notified about the survey and approval to visit the Richmond 
Housing Estates provided pending notification of residents. The Office was also provided with the 
names and phone numbers of the fieldworkers who were conducting the fieldwork in the Richmond 
Housing Estates. Interviewers were provided with the Security Control Room contact number and 
were instructed to call security should they feel unsafe at any time.  
Colmar Brunton maintained regular contact with fieldwork supervisors throughout data collection in 
order to monitor progress of fieldwork and also provide support/advice to the field team, when 
required.  
 
Training the field team for the business survey 
A total of 10 Q&A Market Research interviewers conducted the CATI data collection for the business 
survey (and also the resident survey CATI survey completions). As was the case for the face-to-face 
interviewers, all CATI interviewers who worked on this project had substantial experience in the 
conduct of social research fieldwork and all were accredited with the AMSRS. The fieldwork team and 
fieldwork supervisors dialled into a teleconference briefing on 18th of June prior to the commencement 
of fieldwork for the business survey. The briefing was facilitated by Dr. Kirstin Couper and Emily 
Bariola (Colmar Brunton) and was also attended by Josephine Norman and Katherine Scarcebrook 
(from the department). Two interviewers initially attended the teleconference, 8 were subsequently 
briefed in the main briefing. 
This briefing provided an overview of the rationale for the trail, contextual information about the MSIR, 
sampling approach, recruitment strategy, participant introductory script, the survey tool, ethical 
requirements, timelines and escalation processes. 
A detailed fieldwork protocol document was produced to ensure that members of the field team and 







Prior to the commencement of fieldwork, fieldworkers were provided with the following materials: 
• Interview protocol; 
• Survey tool (refer to Appendix B); 
• Live contact sheet link and hard copies of the contact sheet (used to record 
contact/recruitment data); and 
• Electronic copies of the Participant Approach Letter and Participant Information Form (refer to 
Appendix C). 
In the event respondents requested further information or wished to lodge a complaint about the 




Recruitment for the resident survey 
Fieldwork for the resident survey commenced on the 15th of June and ended on the 29th of June. 
Fieldwork for the resident survey was finalised prior to the operational commencement of the MSIR on 
the 30th of June, 2018. 
A total of n = 651 residents completed the survey. n = 630 respondents completed the survey face-to-
face and n = 21 completed the survey via CATI (these respondents responded to the call back card 
that was left in their letter box). Average survey completion times were 13.8 minutes and 16.8 minutes 
for the surveys completed face-to-face and via CATI, respectively. Table 2 provides an overview of 






Table 2: Resident survey recruitment outcomes. 
Recruitment outcomes Count 
Proportion of 
population 
Completed total (C) 651 10.5% 
Completed face-to-face 630 10.1% 
Completed CATI 21 0.3% 
Non-contact (eligible, non-interview) total (NC) 11 0.2% 
Refusal (eligible, non-interview) total (R) 169 2.7% 
Other (eligible, non-interview) total (O) 203 3.3% 
Other - language barrier 70 1.1% 
Other - unable to complete due to illness or disability 8 0.1% 
Other - broken appointment 109 1.8% 
Other - other non-response 16 0.3% 
Unknown eligibility, non-interview total (UE) 5,159 83.1% 
Unknown eligibility - not attempted 3,176 51.2% 
Unknown eligibility - inaccessible 91 1.5% 
Unknown eligibility - received call back carda 1,892 30.5% 
Not eligible, non-interview total 15 0.2% 
Not eligible - out of sample (aged <18 years; lived in the area <2 
months) 
15 0.2% 
Total populationb 6,208  
Response Rate (RR) - Proportion of cases interviewed of all eligible cases    
C / (C) + (NC+R+O) + (UE) 
- 10.5% 
Co-operation Rate (COOP) - Proportion of cases interviewed of eligible 
cases contacted      C / (C)+(R+O) 
- 63.6% 
Refusal Rate (REF) - Proportion of eligible sample that refused 
R / ((C)+(NC+R+O) + (UE)) 
- 2.7% 
Contact Rate (CON) - Proportion of eligible sample where a household was 
reached      (C+R+O) / (C+R+O+NC+UE) 
- 16.5% 
a. Households that received a call back card in the letter box, but did not respond are included in this tally. 






The overall response rate (proportion of cases interviewed of all eligible cases) for the resident survey 
was 10.5%. The co-operation rate (proportion of cases interviewed of eligible cases contacted) was 
63.6%. 
Several reasons for non-completion due to language barrier were recorded. It was noted that 
fieldworkers encountered individuals that spoke languages not covered by the survey methodology 
(i.e. other than English, Greek, Vietnamese, Hakka, Mandarin, Cantonese). It was also noted that 
some individuals who were from non-English speaking backgrounds did not allow the interviewers the 
time to introduce the study, before they terminated the conversation (i.e. before they could express 
interest or disinterest in participating). 
Recruitment for the business survey 
Fieldwork for the business survey commenced on the 19th of June and ended on the 4th of July.  A 
total of n = 293 respondents completed the business survey (all via CATI). n = 271 respondents 
completed the survey prior to the commencement of the trial, and n = 22 completed the survey within 
four days after trial commencement (these cases are flagged with a binary variable: 
COMPLETION=2). The sample was exhausted, meaning all discoverable businesses were 
approached to participate. The average survey completion time was 19.08 minutes. 
Table 3 provides an overview of the recruitment outcomes for the business survey. The overall 
response rate (proportion of cases interviewed of all eligible cases) for the business survey was 
44.5%. The co-operation rate (proportion of cases interviewed of eligible cases contacted) was 
58.5%. 
In regards to reasons for refusal, it was noted that many instances of refusal occurred at the initial 
point of approach, by the gatekeeper (i.e. the person who first answered the call). There were many 
instances of a hard refusal at introduction. For example, individuals would say ‘we don’t do surveys 
here.’ 
Response rates for each sampling unit (SA1) 
Response rates for the resident survey and the business survey for each SA1 are presented in Table 
4. 
For the resident sample, response rates were relatively evenly spread across each of the SA1’s, 









Table 3. Business survey recruitment outcomes. 
Recruitment outcomes Count 
Proportion of 
population 
Completed totala (C) 293 32.9% 
Completed face-to-face 0 0.0% 
Completed CATI 293 32.9% 
Non-contact (eligible, non-interview) total (NC) 18 2.0% 
Refusal (eligible, non-interview) total (R) 175 19.7% 
Other (eligible, non-interview) total (O) 33 3.7% 
Other - language barrier 27 3.0% 
Other - unable to complete due to illness or disability 0 0.0% 
Other - broken appointment 0 0.0% 
Other - other non-response 6 0.7% 
Unknown eligibility, non-interview total (UE) 140 15.7% 
Unknown eligibility - not attempted 0 0.0% 
Unknown eligibility - non-contact (always ringing, always voicemail) 136 15.3% 
Unknown eligibility - business number, unknown if eligible person 4 0.4% 
Not eligible, non-interview total 231 26.0% 
Not eligible - out of sample (aged <18 years; worked in the area <2 months) 2 0.2% 
Not eligible - number out of service or disconnected 145 16.3% 
Not eligible - other ineligible 84 9.4% 
Total populationa 890  
Response Rate (RR) - Proportion of cases interviewed of all eligible cases                         
C / (C) + (NC+R+O) + (UE) 
- 44.5% 
Co-operation Rate (COOP) - Proportion of cases interviewed of eligible cases contacted      
C / (C)+(R+O) 
- 58.5% 
Refusal Rate (REF) - Proportion of eligible sample that refused                                          
R / ((C)+(NC+R+O) + (UE)) 
- 26.6% 
Contact Rate (CON) - Proportion of eligible sample where a business was reached      
(C+R+O) / (C+R+O+NC+UE) 
- 76.0% 





Table 4. Response ratesa for the resident and business surveys, by SA1. 
SA1 
Resident survey response 
rate 
Business survey response 
rate 
2114402 9.0% - 
2114405 9.4% - 
2114406 8.2% - 
2114407 7.9% - 
2114454 7.7% 56.9% 
2114404 8.0% 42.1% 
2114403 6.8% 57.1% 
2114401 8.6% 42.5% 
2114459 8.3% 16.7% 
2114457 8.2% 45.5% 
2114458 9.2% 35.7% 
2114439 17.8% 35.9% 
2114441 9.1% 42.2% 
2111902 8.3% 38.5% 
2111903 18.8% 14.3% 
2111904 13.9% 45.5% 
2113910 12.6% 39.5% 
2113901 15.9% 40.0% 
2114422 13.2% 47.2% 
2114421 8.1% 68.4% 
2114420 18.1% 50.0% 
2113905 11.5% 43.8% 
2113903 9.3% 56.5% 
2114411 15.8% 38.5% 
2114419 8.4% 85.7% 
2114442 17.6% 37.5% 
Total 10.5% 44.5% 







3.2.3. Survey outcomes 
The count and proportion of respondents who completed the resident and the business surveys by 
SA1 are presented below in Table 5. 
Table 5. Count and proportion of respondents by SA1. 
 Resident survey Business survey 
SA1 Count Proportion of total Count Proportion of total 
2114402 18 2.8% 0 0.0% 
2114405 16 2.5% 0 0.0% 
2114406 16 2.5% 0 0.0% 
2114407 15 2.3% 0 0.0% 
2114454 22 3.4% 37 12.6% 
2114404 38 5.8% 8 2.7% 
2114403 24 3.7% 8 2.7% 
2114401 16 2.5% 31 10.6% 
2114459 13 2.0% 1 0.3% 
2114457 44 6.8% 5 1.7% 
2114458 17 2.6% 10 3.4% 
2114439 26 4.0% 23 7.8% 
2114441 31 4.8% 27 9.2% 
2111902 22 3.4% 5 1.7% 
2111903 40 6.1% 1 0.3% 
2111904 17 2.6% 10 3.4% 
2113910 28 4.3% 15 5.1% 
2113901 20 3.1% 20 6.8% 
2114422 17 2.6% 17 5.8% 
2114421 13 2.0% 13 4.4% 
2114420 34 5.2% 3 1.0% 
2113905 31 4.8% 32 10.9% 
2113903 34 5.2% 13 4.4% 
2114411 39 6.0% 5 1.7% 
2114419 21 3.2% 6 2.0% 
2114442 39 6.0% 3 1.0% 






The count and proportion of surveys completed in each of the survey languages are presented below 
in Table 6. 
Table 6. Count and proportion of surveys completed in each of the survey languages. 
 Resident survey Business survey 






English 620 95.2% 286 97.6% 
Vietnamese 20 3.1% 6 2.0% 
Mandarin 8 1.2% 1 0.3% 
Cantonese 2 0.3% 0 0.0% 
Greek 1 0.2% 0 0.0% 
Hakka 0 0.0% 0 0.0% 
Total 651  293  
 
A relatively small proportion of respondents completed the translated versions of the survey (4.8% of 
the resident sample and 2.4% of the business sample). It was noted by the field team that the majority 
of the respondents who were from non-English speaking backgrounds were able to complete the 
survey in English, hence the low proportion of completions in the surveys translated into languages 
other than English. 
3.2.4. Sample representativeness for the resident survey 
An assessment of sample representativeness for the resident survey, relative to population data is 
presented below in Table 7. The representativeness of the business sample was not assessed as 











Table 7: Resident sample representativeness according to demographic characteristics, relative to 
individual-level population data. 
 Sample Populationa 
Demographic characteristic Count Proportion of 
total 
Count Proportion of 
totalb 
Gender     
Male 329 50.5% 5,975 48.6% 
Female 321 49.3% 6,314 51.4% 
Other 1 0.2% - - 
Age group     
0 – 17 year olds - - 1,473 - 
18 – 19 year olds 12 1.8% 197 1.8% 
20 – 24 year olds 44 6.8% 1,072 10.0% 
25 – 34 year olds 186 28.6% 3,779 35.2% 
35 – 44 year olds 124 19.0% 1,801 16.8% 
45 – 54 year olds 82 12.6% 1,394 13.0% 
55 – 64 year olds 99 15.2% 1,143 10.7% 
65 – 74 year olds 62 9.5% 696 6.5% 
75 – 84 year olds 33 5.1% 457 4.3% 
85+ year olds 9 1.4% 193 1.8% 
Country of birth     
Australia 379 58.5% 6,290 56.3% 
Overseas 269 41.5% 4,881 43.7% 
Total 651  12,292  
a. Data source: Community Profile, 2016 Census, ABS. Population data is reported at the individual level. 
b. Count of 0-17 year olds excluded in the calculation of proportions for each age group. 
 
As shown in the table above, the resident sample was representative of the population as per the 
spread across gender, country of birth and most of the age groups. Some minor under-representation 
was observed among 20 – 24 year olds and 25 – 34 year olds, and some minor over-representation 





Table 8: Resident sample representativeness according to location (SA1), relative to individual and 
household-level population dataa. 










2114402 18 2.8% 490 4.0% 199 3.2% 
2114405 16 2.5% 383 3.1% 171 2.8% 
2114406 16 2.5% 465 3.8% 196 3.2% 
2114407 15 2.3% 406 3.3% 189 3.0% 
2114454 22 3.4% 621 5.1% 285 4.6% 
2114404 38 5.8% 821 6.7% 475 7.7% 
2114403 24 3.7% 588 4.8% 356 5.7% 
2114401 16 2.5% 409 3.3% 187 3.0% 
2114459 13 2.0% 291 2.4% 158 2.5% 
2114457 44 6.8% 959 7.8% 536 8.6% 
2114458 17 2.6% 346 2.8% 184 3.0% 
2114439 26 4.0% 378 3.1% 146 2.4% 
2114441 31 4.8% 656 5.3% 339 5.5% 
2111902 22 3.4% 410 3.3% 265 4.3% 
2111903 40 6.1% 376 3.1% 214 3.4% 
2111904 17 2.6% 238 1.9% 122 2.0% 
2113910 28 4.3% 472 3.8% 223 3.6% 
2113901 20 3.1% 314 2.6% 126 2.0% 
2114422 17 2.6% 299 2.4% 130 2.1% 
2114421 13 2.0% 288 2.3% 160 2.6% 
2114420 34 5.2% 431 3.5% 189 3.0% 
2113905 31 4.8% 621 5.1% 269 4.3% 
2113903 34 5.2% 676 5.5% 368 5.9% 
2114411 39 6.0% 432 3.5% 248 4.0% 
2114419 21 3.2% 470 3.8% 250 4.0% 
2114442 39 6.0% 452 3.7% 223 3.6% 
Total 651  12,292  6,208  
a. Data source: 2016 Census, ABS. Population data is reported at the individual level (i.e. total count of 






As shown in the table above, the resident sample was representative of the population according to 
the spread across SA1’s. 
3.2.5. Escalations 
An agreed escalation procedure was put in place at the start of the project in order to deal with any 
sensitive contacts encountered during fieldwork. There were two cases that required escalation during 
the fieldwork period. They are as follows: 
1. 15/06/2018 - an interviewer attended North Richmond Community Health and requested to 
pick up printed participant information materials. The interviewer misunderstood instructions 
related to the dissemination of printed participant information material. The printed materials 
were not at the Community Health Centre, they were being distributed in field. Confusion 
ensued. The North Richmond Community Health Centre filed a complaint with the department 
regarding this incident. Colmar Brunton responded by discussing the incident with the 
fieldworker in question and with the Fieldwork Supervisor. At this stage, all interviewers had 
the printed materials so the incident could not reoccur. Colmar Brunton requested that the 
department pass on their apologies for the confusion and inconvenience caused.  
2. 19/06/2018 – a resident lodged a complaint with the department regarding the conduct of an 
interviewer in field. Details of the complaint are as follows: the complainee was conducting an 
interview with a respondent in an apartment complex. After the complainee had finished 
interviewing the resident, they knocked on the door of the complainant. The complainant 
became distressed by the interviewers’ presence. The complainee explained why they were 
there and then moved on when it became clear the complainant did not wish to participate. 
The interviewer went outside and was buzzed in again by a resident of another unit in the 
same apartment complex. The complainant came out and again became distressed by the 
interviewers presence. The interviewer again explained the purpose of her visit. When she 
closed the interaction with the complainant the interviewer asked, ‘are you okay, do you need 
a hug?’ 
Later that day, the respondent filed a complaint with the department. The project team took 
the following actions: the individual interviewer was counselled by Paul Hoger (Director of 
Q&A Market Research) on the importance of buzzing in at each unit in an apartment complex, 
the importance of providing an escalation option to community members who become 
distressed, and on the inappropriateness of the ‘are you alright, do you need a hug’ comment. 
The complainee was taken off the project and conducted no further fieldwork for the study. 
Colmar Brunton facilitated a re-brief session with fieldworkers and covered off the main topics 
of appropriate conduct in field and how to escalate a situation if a community member 
becomes distressed. The department liaised with the complainant regarding the complaint 









3.3. Data processing and weighting 
3.3.1. Data processing 
Practices to ensure high quality data commenced at the set-up phase of the project. The following 
steps were taken. 
 Once the survey had been programmed, a number of checks occurred prior to the 
commencement of fieldwork. The Q&A Market Research analyst who was responsible for 
the survey build conducted the first test and Colmar Brunton’s Senior Account Manager 
conducted a second test. 
 The survey was programmed with built in consistency and validity checks. 
 Dummy datafiles were also checked to ensure all routing and filters were functioning as 
intended. Once the internal checks had been finalised, the department conducted a check of 
the dummy datafile and provided approval on the content prior to the commencement of 
fieldwork.  
 An interim data file was produced after sufficient surveys had been completed. This was 
checked by Colmar Brunton Senior Account Manager. 
 A full data cleaning and validation process occurred at the end of the project. 
 Two resident respondents mistakenly completed the business survey (interviewer selected 
‘business’ before handing over the tablet to them to complete in one of the priority 
languages). The two cases were retained in the datafile – they can be identified by a flag 
variable (Incorrectflag=1). 
 Extreme values were identified on Q5B, Q6B and Q26. These values are retained as raw 
data in the datafile (not transformed). The department may decide to delete or replace these 
values depending on their preferred method. 
 The file was weighted in accordance with the requirements set-out by the department. The 
weighting strategy is described in 3.3.2 below. 
 The required derived variables were computed and included in the datafile.  
 The final data file was delivered in SPSS file format. All syntax and weighting variables were 
provided with the data file. 
3.3.2. Weighting 
Weights were calculated for the resident sub-cohort only (ComBusiSamp=1) (n = 650). One 
respondent identified as ‘other’ gender. This respondent was coded as SYSMISS for the weight 
variable. 
Weights were calculated using the following auxiliary variables: gender (Q17 = 1 ‘male’; 2 ‘female’) 
and age group (recage = 1 '18-19 yrs'; 2 '20-24 yrs'; 3 '25-29 yrs'; 4 '30-34 yrs'; 5 '35-39 yrs'; 6 '40-44 
yrs'; 7 '45-49 yrs'; 8 '50-59 yrs'; 9 '60-69 yrs'; 10 '70-79 yrs'; 11 '80+yrs'). 
Population-level data confined to the population parameters of the study (i.e. the 26 SA1’s) were used 
to calculate weights. An interlocking weight structure was used to generate accurate population 
weights for each gender x age group combination thus ensuring strong alignment to the population 






Colmar Brunton developed codeframes for the following open-ended questions.  
 S3 - What is your position in this business? (Single response) 
 Q7B - Thinking about the last time someone approached you on a street in your local 
area to sell you drugs, what type of drugs were you offered? (Single response) 
 Q8 - What, if anything, concerns you about drug-related activity in your local area? 
(Multiple response) 
 Q11A - Do you know the location of the Medically Supervised Injecting Room (MSIR) 
trial? (Single response) 
 Q14 - Do you have any further comments you would like to make about the Medically 
Supervised Injecting Room trial? (Multiple response) 
 Q15 - Do you have any further comments you would like to make about drug-related 
activity in your local area? (Multiple response) 
The codeframes for these questions are appended to this report. In order to conduct the coding, the 
following steps were taken: 
Develop codeframe 
• Two Colmar Brunton researchers separately and independently reviewed open-ended 
responses and derived themes. 
• The two researchers met and discussed themes and agreed on final codeframes. 
• The department reviewed and approved the codeframes. 
First validation 
• One researcher read open-ended responses for the first 50 cases and coded for theme 
endorsement using the codeframes. 
• The department reviewed the 50 coded cases and provided feedback. Feedback was 
incorporated into the coding strategy going forward. 
Coding 
• After incorporating the feedback from the department, one Colmar Brunton researcher read 
each open-ended response and coded for theme endorsement using the codeframes. 





4. Research schedule 
The following table provides a summary of the key research tasks and their completion dates.   
Table 9: Research schedule. 
5. Recommendations for future surveys 
The Victorian Government Contact Centre telephone number was recorded on the Call Back Cards 
that were deposited in residents’ letter boxes. If residents contacted the Contact Centre and 
expressed interested in completing the survey, the operator was instructed to patch the call through to 
Q&A Market Research survey hotline so that the survey could be completed via CATI. A very small 
number of respondents completed the survey via the call-back procedure (n = 21). It is recommended 
that for future waves of household surveys, the direct telephone line of the survey provider be 
recorded on the call back card. This may increase responses from community members who are not 
at home during the normal fieldwork hours of operation. 
Task Dates 
Research proposal submitted  18th of May, 2018 
Project commissioned  30th of May, 2018 
Project scoping meeting 31st of May, 2018 
Survey finalised 6th of June, 2018 
Participant information material finalised 13th of June, 2018 
Ethics approval granted 5th of June, 2018 
Ministerial approval received 8th of June, 2018 
Survey program testing and finalisation 14th of June, 2018 
Resident survey field researcher training 13th of June, 2018 
Business survey field researcher training 18th of June, 2018 
Resident survey fieldwork 15th – 29th of June, 2018 
Business survey fieldwork 19th of June – 3rd of July, 2018 
Data processing, coding, checking, weighting 4th July – 31st of July 
Data file delivered 31st of July 
Draft technical report delivered 10th of August, 2018 
Feedback on technical report received 28th of August, 2018 






6.1. Appendix A – Personnel 
Kirstin 
 
Dr Kirstin Couper, Research Director, Colmar 
Brunton (Melbourne) 
Kirstin is the Head of the Government research team for Colmar Brunton 
in Melbourne. Kirstin joined Colmar Brunton in Melbourne from Ipsos 
MORI in London, where she was a member of the Local Government 
senior management team; responsible for directing studies for central 
and local government across England. 
Since the completion of her PhD Kirstin has worked for research 
agencies in Social and Government research for over 13 years. She 
specialises in the design of bespoke research studies to meet specific 
research objectives. Her experience in random sampling spans her work 
in London and Melbourne. In London she worked on the National Study 
of Adult Learning for the Department of Education and Skills, and the 
Universal Credit study for the Department of Work and Pensions. Both 
required random probability sampling approaches to be designed and 
required consideration of ensuring the non-response bias, particularly 
among non-English speaking groups, was minimised. In Melbourne she 
is currently directing a large national study of youth for a non-
governmental organisation, which focuses on youth mental health. 
Emily 
 
Emily Bariola, Senior Account Manager, 
Colmar Brunton (Melbourne) 
Emily is a Senior Account Manager in the Social & Government research 
team in Victoria. She joined Colmar Brunton in June, 2018. She has a 
Bachelor of Arts with an Honours degree in Psychology and is currently 
completing her PhD in Psychology. Emily has worked as a researcher 
for ten years, with her research spanning behavioural science, public 
health and social epidemiology. She has worked across university, not-
for-profit, government and commercial sectors and has extensive 
experience working on both agency and client sides of the research 
process. Emily uses both quantitative and qualitative methodologies to 
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6.3. Appendix C – Participant Information Materials 













6.3.2. Participant Approach Letter (Residents) 
 
Dear Householder 
Monitor of community attitudes to drug activity in the inner-eastern area of Melbourne 
The Department of Health and Human Services has engaged Colmar Brunton to conduct a survey 
about community attitudes to drug activity in the inner-eastern area of Melbourne that are of public 
interest and for research purposes only. It is expected that this knowledge will inform policy, 
planning and research. 
 
The survey involves answering some general questions about yourself as well as some questions 
relating to drug activity in your area. The survey will take approximately ten minutes to complete. 
Questions regarding this survey can be directed to Kirstin Couper at 
Kirstin.Couper@colmarbrunton.com or by calling the Victorian Government Contact Centre on 1300 
366 356 (then select menu option 1). 
 
Participants will remain completely anonymous and all information provided will remain confidential. 
In addition, data collected through this survey will be analysed and reported in group form only and, 
therefore, no personal information will be identifiable in the results of the study. Your participation is 
also completely voluntary. By completing this questionnaire, you are expressing your consent to 
participate. However, you are free to withdraw from the questionnaire at any time. 
 
The study is being conducted in accordance with the National Health and Medical Research Council 
Act 1992 (Commonwealth), the Health Records Act 2001 (Victoria), the Privacy and Data Protection 
Act 2014 (Victoria) and the Statutory Guidelines on Research under the Health Records Act 2001 
(Victoria). The study also complies with the Department of Health and Human Services’ Privacy 
Policy which is available at: https://www.dhhs.vic.gov.au/privacy. An information brochure that 
explains the steps taken to safeguard your privacy is attached to this letter. 
 
This study adheres to the Guidelines of the ethical review process of The University of Queensland 
and the National Statement on Ethical Conduct in Human Research. Whilst you are free to discuss 
your participation in this study with project staff (contactable on 1300 366 356), if you would like to 
speak to an officer of the University not involved in the study, you may contact the Ethics 
Coordinators on +617 3365 3924 / +617 3443 1656 or email humanethics@research.uq.edu.au. 
 
Thank you for your assistance. Your participation in this survey is important in helping  to inform 











Nếu quý vị cần thông dịch viên, xin hãy gọi cho Dịch vụ Thông Phiên dịch Quốc gia (TIS Quốc gia) theo 
số 131 450 và yêu cầu họ gọi cho (Victorian Government Contact Centre) theo số (1300 366 356). Giờ 
làm việc của chúng tôi là (8:30am to  5:00pm  Monday to Friday, except for Public Holidays). 
 
Cantonese 
若你需要口譯員，請撥打TIS National電話131 450並請他們轉接 (Victorian Government Contact Centre) 的
電話 (1300 366 356)。我們的工作時間是 (8:30am to  5:00pm  Monday to Friday, except for Public Holidays)。 
 
Mandarin 
如果您需要口译员，请拨打TIS National 的电话131 450，请他们打电话 给(Victorian Government Contact 




Αν χρειάζεστε διερμηνέα, καλέστε την TIS National στο 131 450 και ζητήστε να καλέσουν το (Victorian 
Government Contact Centre) στον αριθμό (1300 366 356). Οι ώρες λειτουργίας μας είναι (8:30am 
to  5:00pm  Monday to Friday, except for Public Holidays). 
 
Hakka 
如果您需要口译员，请拨打TIS National 的电话131 450，请他们打电话 给(Victorian Government 
Contact Centre)，电话号码： (1300 366 356)。我们的营业 时间是 (8:30am to  5:00pm  Monday to 










Monitor of community attitudes to drug activity in the inner-eastern area of Melbourne 
 
The Department of Health and Human Services has engaged Colmar Brunton to conduct a survey 
about community attitudes to drug activity in the inner-eastern area of Melbourne that are of public 
interest and for research purposes only. It is expected that this knowledge will inform policy, planning 
and research. 
 
The survey involves answering some general questions about yourself and the business you work in, 
as well as some questions relating to drug activity in your area.. The survey will take approximately 
ten minutes to complete. Questions regarding this survey can be directed to Kirstin Couper at 
Kirstin.Couper@colmarbrunton.com or by calling the Victorian Government Contact Centre on 1300 
366 356 (then select menu option 1).  
 
Participants will remain completely anonymous and all information provided will remain confidential. In 
addition, data collected through this survey will be analysed and reported in group form only and, 
therefore, no personal information will be identifiable in the results of the study. Your participation is 
also completely voluntary. By completing this questionnaire, you are expressing your consent to 
participate. However, you are free to withdraw from the questionnaire at any time. 
 
The study is being conducted in accordance with the National Health and Medical Research Council 
Act 1992 (Commonwealth), the Health Records Act 2001 (Victoria), the Privacy and Data Protection 
Act 2014 (Victoria) and the Statutory Guidelines on Research under the Health Records Act 2001 
(Victoria). The study also complies with the Department of Health and Human Services’ Privacy Policy 
which is available at: https://www.dhhs.vic.gov.au/privacy. An information brochure that explains the 
steps taken to safeguard your privacy is  attached to this letter. 
 
This study adheres to the Guidelines of the ethical review process of The University of Queensland 
and the National Statement on Ethical Conduct in Human Research. Whilst you are free to discuss 
your participation in this study with project staff (contactable on 1300 366 356), if you would like to 
speak to an officer of the University not involved in the study, you may contact the Ethics 
Coordinators on +617 3365 3924 / +617 3443 1656 or email humanethics@research.uq.edu.au. 
 
Thank you for your assistance. Your participation in this survey is important in helping to inform policy, 











Nếu quý vị cần thông dịch viên, xin hãy gọi cho Dịch vụ Thông Phiên dịch Quốc gia (TIS Quốc gia) theo 
số 131 450 và yêu cầu họ gọi cho (Victorian Government Contact Centre) theo số (1300 366 356). Giờ 
làm việc của chúng tôi là (8:30am to  5:00pm  Monday to Friday, except for Public Holidays). 
 
Cantonese 
若你需要口譯員，請撥打TIS National電話131 450並請他們轉接 (Victorian Government Contact Centre) 的
電話 (1300 366 356)。我們的工作時間是 (8:30am to  5:00pm  Monday to Friday, except for Public Holidays)。 
 
Mandarin 
如果您需要口译员，请拨打TIS National 的电话131 450，请他们打电话 给(Victorian Government Contact 




Αν χρειάζεστε διερμηνέα, καλέστε την TIS National στο 131 450 και ζητήστε να καλέσουν το (Victorian 
Government Contact Centre) στον αριθμό (1300 366 356). Οι ώρες λειτουργίας μας είναι (8:30am 
to  5:00pm  Monday to Friday, except for Public Holidays). 
 
Hakka 
如果您需要口译员，请拨打TIS National 的电话131 450，请他们打电话 给(Victorian Government 
Contact Centre)，电话号码： (1300 366 356)。我们的营业 时间是 (8:30am to  5:00pm  Monday to 






6.3.4. Call Back Card (Residents) 
Have Your Say 
Survey of community attitudes to drug activity in your local area 
 
We visited today to ask you if you were willing to participate in a survey of community attitudes to drug activity in your area. Sorry we missed you.  
It will be possible to complete the 10 minute survey with an interviewer in English / Mandarin or Cantonese / Greek / Vietnamese / Hakka. If you would like more 
information or to arrange a time to participate by phone, please call 1300 366 356. 













Σας πισκεφτήκαμε σήμερα  να σας ρωτήσ αν ήσαστ πρόθυμο να συμμετάσχετε σε μια έρευνα της στάσης της Κοινότητας στη δραστηριότητα των ναρκωτικών στην περιοχή 
σας. ς  ς .  
Eίναι δυνατόν να ολοκληρωθεί η έρευνα 10 λεπτ με μια συνέντευξη στα Ελληνικά. Αν επιθυμείτε περισσότερες πληροφορίες ή για να κανονίσουμε μια ώρα για να συμμετ από το 
τηλέφωνο, παρακαλώ καλέστε στo 1300 366 356. Σας ευχαριστούμε για τη βοήθειά σας.  
 
Vietnamese 
Chúng tôi đã đến thăm hôm nay để hỏi bạn có sẵn sàng tham gia vào một cuộc khảo sát về thái độ của cộng đồng đối với hoạt động ma túy trong khu vực của bạn hay không. Xin lỗi, 
chúng tôi không thấy bạn ở nhà. Bạn có thể hoàn thành bản khảo sát (chỉ là 10 phút) với người phỏng vấn bằng tiếng Việt. Nếu bạn muốn biết thêm thông tin hoặc sắp xếp thời gian để 










6.4. Appendix D – Codeframes 
Table 10: Codeframes for S3, Q7B, Q8, Q11A, Q14 and Q15 
Codeframes  
S3 - What is your position in this business? SR 
Owner 
Manager 
Employee (not manager) 
Q7B - Thinking about the last time someone approached you on a street in your local area to sell 








Unsure of type/didn't specify 
Q8 - What, if anything, concerns you about drug-related activity in your local area? MR 
Violence and crime (e.g. theft, burglary, property damage) 
Safety concerns for children (own children) 
Safety concerns for children (general & school) 
Safety concerns for self and others 
Safety concerns for drug users 
Unpredictability of drug users 
Aggressiveness of users (e.g. aggressiveness, yelling) 
Discarded syringes in public spaces (e.g. being injured by needle, fear of injury, general discomfort with waste) 
Public visibility of drug use/drug deals 
Lack of Government regulation / police presence 
Bad for business 
Begging (e.g. money, cigarettes, food) 
General concern about MSIR 
Spread of infectious diseases 







Table 10: Codeframes for S3, Q7B, Q8, Q11A, Q14 and Q15 
Codeframes 
Q11A - Do you know the location of the Medically Supervised Injecting Room (MSIR) trial? SR 
Exact (building or street, or surrounding area) 
Approximate (suburb, or nearby streets, vague explanation of health centre/school) 
Incorrect 
Q14 - Do you have any further comments you would like to make about the Medically Supervised 
Injecting Room trial? MR 
Negative comments 
General negative opinion 
Normalisation of drug use 
MSIR should not be located near school/near children 
MSIR should not be located near residential / community areas 
MSIR should be located near a hospital 
Increase drug-related activity in area (use and dealing) 
Safety concerns 
Need to ensure increased security/police presence 
Not enough consultation with community 
Zero tolerance approach preferred 
Other harm minimisation approach preferred (e.g. rehab, education) 
Non-endorsement of Ice use in MSIR 
MSIR should be in a different location (unspecified) 
MSIR will not help/only a short term solution 
MSIR is politically motivated/driven 
Other negative comment 
Affirmative comments 
General support for MSIR 
Saves lives of users 
Reduce spread of infectious diseases 
Get drug users off the street 
Increased safety for community (e.g. reduced syringe waste, reduced anti-social behaviour in public space, 
reduced crime) 
Recommend introduction of multiple MSIR's 
Other positive comment 
Neutral comments 
No comment 









Q15 - Do you have any further comments you would like to make about drug-related activity in 
your local area? MR 
More security in local area (e.g., police presence, security cameras) 
Need for rehabilitation services/support services 
Concern about MSIR proximity to school/children 
Zero tolerance approach preferred 
Need for further government and council intervention (e.g. clean up the area, more community consultation) 
Need to reduce crime rates 
Legalise marijuana use 
Public visibility of drug use/drug deal  
Safety concerns for children (own children and general youth) 
Safety concerns for self and others 
Increase drug-related activity in area (use and dealing) 
Unpredictability of drug users 
Aggressiveness of users (e.g. aggressiveness, yelling) 
Public visibility of drug affected individuals 
Drug use is a big problem  
Wants drug use to stop 
Cannot stop drug use 
Difficult to fix the problem 
Support for MSIR 
Other comment 





6.5. Appendix E – Escalation Procedure 
There are four separate escalation procedures that should be adhered to, in the event any of these 
situations arise throughout data collection. They are: 
(i) Requests for more information about the survey or complaints about the survey. 
(ii) Requests for information about the Safe Injecting Room or complaints about the Safe 
Injecting Room. 
(iii) Duty of care protocol for distressed respondents (or other household members). 
(iv) Interviewer safety when in housing estate 
Requests for more information about the survey or complaints about the 
survey. 
If a respondent would like further information about the survey or if they have complaints about the 
survey, interviewers should recommend the respondent calls the Victorian Government Contact 
Centre on 1300 366 356 to log their query or complaint. 
Requests for information about the Safe Injecting Room or complaints 
about the Safe Injecting Room. 
If a respondent requests further information about the Safe Injecting Room or complains about the 
Safe Injecting Room, interviewers should recommend the respondent calls the Victorian Government 
Contact Centre on 1300 366 356 for more information. 
Duty of care protocol for distressed respondents (or other household 
members). 
If a respondent (or other household member present at the time of the interview) becomes distressed 
at any time during the interview process, the interviewer may rely on the following script.  
‘I am sorry you are going through a hard time. You could try discussing your concerns with staff at 
Lifeline or Beyondblue. You can have a confidential chat with a person who is specially trained in 
supporting people who are going through a tough time. Numbers to call are: 
Lifeline. (https://www.lifeline.org.au/). Phone: 13 11 14 
Beyondblue. (https://www.beyondblue.org.au/). Phone: 1300 224 636’ 
Interviewer safety when in housing estate 
Before collecting data in the housing estates, it is important that the Housing Office is notified in 
advance and that your name and contact details are provided to the Office ahead of time. Before 
starting the shift in the housing estate, you must sign in at the Housing Office. 
If at anytime you feel unsafe – you should contact the security control room on 9428 9725 and they 





6.6. Appendix F – Methods to Ensure Data Quality 
Project-based quality assurance 
CBSR’s philosophy is to work as a team with our clients. An important element of such a relationship 
is to seek input and feedback from our clients throughout a project. This enables any potential issues 
to be dealt with collaboratively and early on, preventing them from becoming major problems.  To 
supplement this process and enable formal tracking of their views, clients are sent a feedback form 
after the completion of each project, in which to record their satisfaction with the implementation and 
outcomes of the project and the research consultants who worked with them on it. These forms are 
monitored, and targets (such as overall satisfaction with the project) are set at both an individual and 
office level.  
Our research executives are members of the Australian/New Zealand Market Research Society and 
are signatories to the Code of Ethics of our industry. Moreover, Colmar Brunton is a founding member 
of the Association of Market and Social Research Organisations (AMSRO). Colmar Brunton endorses 
and fully supports AMSRO aims. 
Privacy issues and data security 
We are required to work in accordance with the ESOMAR International Code of Conduct for Market 
Research, the Australian Market & Social Research Privacy Principles (which subsume the National 
Privacy Principles) and the AMSRS Code of Professional Behaviour, to which our researchers are 
signatories.   
At all times, we respect the confidentiality of our informants and our clients. We therefore guarantee 
this confidentiality according to our industry standards and the Department’s privacy legislation.  In 
particular, confidentiality provisions apply to the supply of unit record data. 
In addition, we accept that CBSR, if commissioned, will be bound by Public Service regulations with 
respect to confidentiality. We recognise that all information gathered in relation to the project is the 
property of the Department. We recognise that we are not at liberty to disclose any related information 
to any other party. 
Quality assurance accreditations 
Colmar Brunton puts a real and applied focus on quality. 
 We have a QMS system in place and have ISO 20252 accreditation. 
 We abide by the AMSRS Code of Professional Behaviour and Privacy Principles; and 
 We have created a position in our company dedicated to keeping up to date with best 







The current status of our ISO 20252 accreditation process is in the table 
below. 
Office Audit Status 
Canberra Passed Audit April 2009 
Brisbane Passed Audit April 2009 
Adelaide Passed Audit April 2009 
Sydney Passed Audit June 2009 







6.7. Appendix G - Quality Assurance 
Colmar Brunton is committed to helping its clients achieve and sustain market success by providing 
superior market research and strategic direction.  
A critical foundation of our commitment to our clients is the implementation of Quality Assurance in all 
relevant areas of its operations. We have implemented and achieved certification for our Quality 
Management System AS-ISO 20252 for all areas of our operations. 
Colmar Brunton (and its field company, Your Source) also operates under the Australian Market & 
Social Research Society (AMSRS) Professional Code of Behaviour and the Market & Social 
Research Privacy Principles administered by the Association of Market & Social Research (AMSRO) 
Secretariat. 
 
In accordance with our Quality Management System (QMS) this proposal has been reviewed and 
approved by: 
 
NAME   David Spicer 
ROLE   Research Director 
Colmar Brunton  
 
DATE   5th December 2019 









All methodologies and findings outlined in this proposal are provided solely for use by the client.  
Copyright is reserved by Colmar Brunton. 
In accordance with Article 15 of the ICC/ESOMAR International Code of Marketing Research, this document remains the 
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1. Executive summary 
This technical report provides an overview of the research design, methodology and data preparation 
processes employed for the Review of the trial of the Medically Supervised Injecting Room (MSIR), 
Survey of Residents and Businesses, Wave II (hereafter referred to as the MSIR Survey of Residents 
and Businesses). The study is an initiative of the Victorian Government Department of Health and 
Human Services (the department). 
In May 2019, the department contracted independent social research agency Colmar Brunton to 
conduct the Data Collection component of the MSIR Survey of Residents and Businesses. Colmar 
Brunton engaged Q&A Market Research as a sub-contractor to conduct the fieldwork for the project. 
The purpose of the MSIR Survey of Residents and Businesses was to collect representative data on 
the experiences and attitudes of the community within a defined geographical area surrounding the 
MSIR, approximately one year following its operational commencement. The survey covered topics 
including: witnessing public injecting; discarded needles and syringes; being offered drugs for 
purchase; experiences of drug activity; and attitudes towards the MSIR. The survey was administered 
to community members who live in the local area (resident survey) and community members who 
work in the local area (business survey). The methodology was designed to ensure that the sample 
was representative of the local community. 
The aim was to survey a representative sample of 500 residents and 300 businesses within a 
predefined geographical area surrounding the MSIR approximately one year following its operational 
commencement. A total of n = 844 community members completed the survey (n = 543 residents; 
and n = 301 businesses). 
 
2. Background 
The Victorian Government is committed to addressing drug problems within the state of Victoria. 
Forming part of this commitment, the Government’s Drug Rehabilitation Plan will invest $87 million to 
address drug harms, including 100 new rehabilitation beds, trialling a medically supervised injecting 
centre and boosting training in the alcohol and other drug workforce. 
The Drug Rehabilitation Plan includes a trial of a medically supervised injecting room at North 
Richmond Community Health. The Drugs, Poisons and Controlled Substances Amendment (Medically 
Supervised Injecting Centre) Act 2017 allows for the licence of a Medically Supervised Injecting Room 
trial for a two year period. The objects of the Act are:  
(a) to reduce the number of avoidable deaths and the harm caused by overdoses of drugs of 
dependence;  
(b) to deliver more effective health services for clients of the licensed medically supervised 





treatment, rehabilitation support, healthcare, mental health treatment and support and 
counselling;  
(c) to reduce attendance by ambulance services, paramedic services and emergency 
services and attendances at hospitals due to overdoses of drugs of dependence;   
(d) to reduce the number of discarded needles and syringes in public places and the 
incidence of injecting of drugs of dependence in public places in the vicinity of the licensed 
medically supervised injecting centre;  
(e) to improve the amenity of the neighbourhood for residents and businesses in the vicinity of 
the licensed medically supervised injecting centre; and  
(f) to assist in reducing the spread of blood borne diseases in respect of clients of the licensed 
medically supervised injecting centre including, but not limited to, HIV and hepatitis C.  
An independent panel, supported by the department, is conducting a review of the MSIR to inform 
potential extension of the trial period. One of the components of the review is the MSIR Survey of 
Residents and Businesses. 
On the 23rd of May, the department contracted independent social research agency Colmar Brunton 
to conduct the data collection component of Wave II of the MSIR Survey of Residents and 
Businesses. Colmar Brunton engaged Q&A Market Research as a sub-contractor to conduct the 
fieldwork for the project. 
The purpose of the MSIR Survey of Residents and Businesses was to collect data on the experiences 
and attitudes of a representative sample of the community, approximately one year into the MSIR trail 
and to ensure that this data is comparable to baseline data captured prior to the commencement of 
the trial. The survey covered topics including: witnessing public injecting; discarded needles and 




The methodology for Wave II of the MSIR Survey of Residents and Businesses was designed by the 
department. The sampling approach was co-designed by the department, Colmar Brunton and Q&A 
Market Research. A summary of the method is provided below. 
3.1. Preparation 
3.1.1. Scoping 
The initial scoping session was held on the 30th of May, 2019. Emily Bariola represented Colmar 
Brunton at this meeting. Josephine Norman, Katherine Scarcebrook and Shannon Fox attended from 





The following topics were covered during the scoping meeting:   
• Confirmation of the objectives of the survey; 
• Roles of individuals in Colmar Brunton, Q&A Market Research and the department’s project 
teams; 
• Confirmation of the project schedule; 
• Confirmation of the participant communication material; 
• Confirmation of the methodology including the sampling, recruitment, face-to-face fieldwork 
and computer-assisted telephone interviewing (CATI) fieldwork; 
• Discussion of the ethics application process; 
• Discussion of the fieldwork briefing agenda; 
• The setup of an online portal to provide real-time updates of fieldwork progress; and 
• Reporting requirements. 
3.1.2. Ethics approval 
An ethics application for this study was submitted to The University of Queensland Human Research 
Ethics Committee (HREC). Approval was obtained on 19th of June 2019 (approval number: 
2019001002). The department managed this process and were responsible for providing updates to 
the committee when required.  
3.1.3. Sampling 
The study population parameters consisted of the boundaries of 26 Statistical Area Level 1s (SA1s), 
confined to the Melbourne suburbs of Richmond, Abbotsford and East Melbourne (refer to Table 1). 
These parameters approximated a 500m radius of the location of the MSIR (North Richmond 
Community Health, 23 Lennox Street, Richmond). A graphical representation of the sampling frame is 






Figure 1: MSIR Survey of Residents and Businesses sampling frame. 
Sampling for the resident survey 
Household selection 
The total count and proportion of private dwellings in each SA1 are listed below in Table 1. This 
population data was sourced from the Australian Bureau of Statistics (ABS), 2016 Census. The total 
number of eligible households within the sampling frame was N = 6,208. 
In preparation for the fieldwork for the first wave of this study (2018), Q&A Market Research fieldwork 
officers conducted a residential address indexation exercise. This involved physically walking the 
streets of the sample frame and logging all discoverable and accessible households into an electronic 
database to be used during fieldwork. This data was made available for the conduct of the second 
wave of the study.  
Minimum quota targets were set for each SA1. Quotas for each SA1 were determined according to 
population data at the household level (ABS, 2016 Census). Minimum quota targets are listed in 
Table 1. Total number of households to be approached in each SA1 was determined by multiplying 
each SA1 quota target by 5. A factor of 5 was selected as it was determined that an average of 5 
households would need to be approached in order to achieve a completed survey (based on 
response rates achieved in the first wave of the study). In wave 2, these numbers were sufficient in 
achieving quota targets in all SA1s with the exception of two SA1s: 2114459 (required a factor of 8) 





Then, using a geo-mapping tool, a number of start points (i.e. the first addresses to be approached in 
each SA1) were randomly selected in each SA1. The number of start points (and subsequently the 
number of runs1 per SA1) were determined according to the size of the SA1 (i.e. the more households 
in the SA1 – the more start points were selected). A single address was never included in more than 
one run. Start points that resulted in a high degree of overlap were discarded (thus preventing 
clustering of participating households). The number of start points ranged between 2 and 4 across the 
SA1s. From each start point, run sheets were drawn and each household to be approached was 
selected using the right shoulder to the curb approach2 and every nth household was selected. The 
value of n was determined according to the number of accessible households identified in the address 
indexation exercise in each SA1. n ranged between 2 and 4 across the SA1s, with a higher n for 
SA1s where more households were accessible.  
The run sheets excluded premises determined to be non-eligible (i.e. commercial properties, vacant 
properties and inaccessible properties). All residences were attempted in the order of the run sheets. 
Each selected household was approached up to three times, depending on the conversion rate in that 
particular SA1. In the event of a high conversion rate, each household would need to be approached 
only one time (in some instances a household may not be approached at all if the conversion rate was 
high). If residents were not home at the point of initial contact, a calling card was left to allow the 
residents to initiate contact. 
Fieldwork shifts were allocated to ensure good representation across each SA1. Fieldwork shifts were 
divided into 2-3 hour blocks, with one SA1 run per block. For the next 2-3 hour block of fieldwork, the 
team would progress to a new run within the same SA1, or to a different SA1 altogether, and so on 
until they finished their shift. The time of day and day of the week (weekday/weekend) of the visits 
were staggered for subsequent allocation (i.e. subsequent visits) of the same SA1. Each SA1 was 
visited between five and six times during fieldwork. On return visits to SA1s, fieldworkers would 
attempt second calls (i.e. visits) within the run before continuing to approach addresses from the end 
point of the last visit to that SA1s run (as per the run sheets). Households that were left a calling card 
were also approached subsequent times. Each household was visited up to three times, unless the 
quota for the SA1 was already achieved. 
Minimum target quotas that were set by SA1 relative to household-level population data were 
monitored closely to ensure proportionate representation was achieved. Minimum quota targets were 
achieved for each SA1. 
This sampling approach allowed us to achieve a representative sample of the community according to 
age, gender, country of birth and location/SA1. As the sample is proportionately representative by key 
demographic variables, we are able to conclude that the data is representative of the views of the 





1 A run refers to a discrete selection of households within an SA1. Households within a run are 
approached consecutively to participate in the study. 
2 The interviewer commenced at their start point and then progressed with their right shoulder to 










Table 1. Count and proportion of private dwellings and businesses in sample universe. 
 Private dwellings - 
populationa 
Private dwellings –        
quota targets 











2114402 199 3.2% 16 3.2% 0 0.0% 
2114405 171 2.8% 14 2.8% 0 0.0% 
2114406 196 3.2% 16 3.2% 1 0.1% 
2114407 189 3.0% 15 3.0% 0 0.0% 
2114454 285 4.6% 23 4.6% 97 9.8% 
2114404 475 7.7% 39 7.7% 25 2.5% 
2114403 356 5.7% 29 5.7% 24 2.4% 
2114401 187 3.0% 15 3.0% 98 9.9% 
2114459 158 2.5% 13 2.5% 7 0.7% 
2114457 536 8.6% 43 8.6% 14 1.4% 
2114458 184 3.0% 15 3.0% 55 5.6% 
2114439 146 2.4% 12 2.4% 84 8.5% 
2114441 339 5.5% 28 5.5% 86 8.7% 
2111902 265 4.3% 22 4.3% 28 2.8% 
2111903 214 3.4% 17 3.4% 11 1.1% 
2111904 122 2.0% 10 2.0% 31 3.1% 
2113910 223 3.6% 18 3.6% 64 6.5% 
2113901 126 2.0% 10 2.0% 71 7.2% 
2114422 130 2.1% 11 2.1% 53 5.4% 
2114421 160 2.6% 13 2.6% 27 2.7% 
2114420 189 3.0% 15 3.0% 9 0.9% 
2113905 269 4.3% 22 4.3% 109 11.1% 
2113903 368 5.9% 30 5.9% 33 3.3% 
2114411 248 4.0% 20 4.0% 25 2.5% 
2114419 250 4.0% 20 4.0% 13 1.3% 
2114442 223 3.6% 18 3.6% 21 2.1% 
Total 6,208  500  986  
a. Data source: 2016 Census, ABS. 
b. Data source: Discoverable businesses located within the sample frame.  Refer to Sampling for Business 





Resident respondent selection 
Respondents within an eligible household were selected using a conditional-replacement next-
birthday method. This means that at the point of initial approach, the householder with the next 
birthday was invited to participate. In order for the next-birthday householder to participate, the 
following inclusion criteria must have been satisfied: 
• They were contactable during the fieldwork period; 
• They were aged 18 years or over; 
• They had been living in the area for at least two months; 
• They had the ability to participate in English or one of the five priority languages: Mandarin, 
Cantonese, Hakka, Vietnamese, or Greek; and 
• They provided informed consent. 
In the event that the next-birthday household member could not complete for any of these reasons, 
the person with the subsequent birthday was invited to participate. If the next-birthday person refused, 
the household was excluded from the sample and the next household in the run sheet was sampled. 
Only a single person per household completed the survey. The target sample size for the resident 
sample was n = 500. 
Sampling for the business survey 
Business selection 
The list of businesses used in the first wave of the study that had a call outcome that identified they 
were an active business and were in the target area (sample universe) were used this wave. A 
description of how this list of businesses were sourced is described in the Technical Report prepared 
for the first wave. As per the first wave of the study, the sample universe was confined to businesses 
located within the study population parameters (i.e. the 26 SA1s). Additional inclusion and exclusion 
criteria were then applied. Businesses located along Bridge Road and Wellington Parade were 
excluded, while businesses located on both sides of Victoria Street (between Powlett Street, SA1: 
2111904; and Johnston Street, SA1: 2114422) were included. Upon applying these criteria, the list of 
discoverable business telephone numbers was 885.3 A further 53 discoverable businesses were 
added to this list. These were discovered via a comprehensive check of the Yellow Pages and an 
additional Google maps check. Additionally, during fieldwork, for all of the businesses that had a 
disconnected phone number, a secondary google maps review was conducted in order to identify new 
businesses at the address. As a result of this, an additional 48 numbers were added to the list. As a 
result of these inclusions, the total number of discoverable business numbers located within the 
sample frame was N = 986. The total count and proportion of discoverable business in each SA1 are 
listed above in Table 1. 
Business respondent selection 
 
3 The total number of discoverable businesses in 2018 was 890. 5 businesses were excluded 





Initially, a random sampling strategy was to be utilised for the business survey. However, throughout 
the field period, the sample was exhausted. As such, all discoverable businesses within the sampling 
frame were approached to participate in the survey (N = 986). Business respondents were 
approached to participate via telephone. In order for respondents to be selected, the following 
inclusion criteria must have been satisfied: 
• They were contactable during the fieldwork period; 
• They were aged 18 years or over; 
• They had been working in the area for at least two months; 
• They were a senior staff member (e.g. business owner or manager). If the business owner or 
manager were not available, the most senior staff member available at the time of the call 
was invited to participate; 
• They had the ability to participate in English or one of the five priority languages: Mandarin, 
Cantonese, Hakka, Vietnamese, or Greek; and 
• They provided informed consent. 
Only a single person per business was invited to complete the survey. The target sample size for the 
business sample was n = 300. 
3.1.4. Participation of people from non-English speaking 
backgrounds 
The department identified five languages other than English that were most commonly spoken (based 
on lowest English proficiency) within the area that the survey was being conducted. They were 
Vietnamese, Cantonese, Mandarin, Greek and Hakka. In order to enable participation of people from 
non-English speaking backgrounds, the survey was translated into these five priority languages. Both 
the resident survey and the business survey were translated into the five priority languages. 
Translated surveys were facilitated by the following ways: 
On the occasion that a fieldworker approached a resident who had difficulty communicating in 
English, the fieldworker would directly ask whether they spoke English. If the resident’s response was 
not in English, the fieldworker would probe further as to the resident’s spoken language. If required, 
fieldworkers would also use translated cards in order to establish whether the resident spoke one of 
the five priority languages (these translated cards provided an introduction and a brief overview of the 
survey). If the resident did speak one of the priority languages, the fieldworker would show the 
respondent the translated survey preamble and they would gain consent at this point.  If consent was 
established, the interviewer would hand the tablet to the participant and they would self-complete the 
survey. 
For translated surveys completed via CATI, fieldworkers were typically advised by the gatekeeper 
(person that first answered the phone call) that the eligible respondent spoke a language other than 
English. The fieldworker would then arrange a call back appointment with an interviewer who speaks 
the priority language. Alternatively, the interviewer would tell the gatekeeper that they would call back 






3.1.5. Data collection procedures 
During the scoping stage, the methodology and data collection procedures were discussed with the 
department and the most suitable approach was agreed upon. The procedures for the resident survey 
and for the business survey are described below. 
 
Data collection procedure for the resident survey 
A total of 17 Q&A Market Research interviewers conducted the fieldwork for the resident survey (13 
face-to-face interviewers and 4 telephone interviewers). Face-to-face fieldwork was conducted via 
household door knocking between the hours of 10am and 6pm on weekdays and 9am and 6pm on 
weekends. Fieldwork shifts were allocated across the 26 SA1s to ensure a relatively proportionate 
number of residents were able to complete the survey, relative to general population spread. 
Fieldworkers conducted data collection in pairs (they attended households individually). Fieldworkers 
used a live call sheet loaded on an app (hard copies were available as well) to track recruitment. On 
the call sheet they were able to record the recruitment status of every household in the sampling 
frame (e.g. refusal, not eligible, inaccessible, non-contact, completed survey, unknown eligibility, etc). 
Order of sampling per residence: 
• Fieldworkers knocked on the door or pressed the intercom button of each private dwelling that 
was approached. Fieldworkers remained on the doorstep throughout all interactions with 
residents. At no point did fieldworkers cross the threshold. 
• When a resident was available at the time of initial approach, the fieldworker would introduce 
themselves, and the study (refer to preamble to the survey in Appendix B). They would then 
screen for eligibility, as per the study inclusion criteria (described above in 3.1.3). If eligible, 
the resident would be invited to participate in the survey. All respondents were provided with 
the Participant Information Form (refer to Appendix C) prior to participating. Consent was 
obtained verbally and evidence of consent was recorded on the tablet and included in the final 
datafile. 
• If contact was made but the eligible resident was unable to complete the survey at the time of 
initial approach, the fieldworker would collect the resident’s contact name and number and 
arrange a re-appointment (either via call back to complete the survey via CATI or in person to 
complete the survey face-to-face at their door step). 
• If no contact was made at the address, a call back card was left in the letter box (refer to 
Appendix C). Residents had the option of calling the Q&A Market Research survey hotline if 
they wished to participate in the survey. In the Housing Estate, call back cards were pushed 
under the door of households, as fieldworkers were not able to gain access to letterboxes. 
This approach was endorsed by the Richmond Housing Office. 







The survey was administered by one of three modes: 
• English, interviewer-administered, face-to-face, Computer-Assisted Personal-
Interviewing (CAPI). If the respondent was able to complete the survey at the time the 
fieldworker visited the household, and in English, then the survey was interviewer-
administered, face-to-face. The fieldworker would read the survey text from a tablet and 
record the responses on the tablet. 
• One of the priority languages, self-administered, Computer-Assisted Self-Interviewing 
(CASI). If the respondent was able to complete the survey at the time the fieldworker visited 
the household, was unable to complete the survey in English, but was able to complete the 
survey in one of the priority languages (Mandarin, Cantonese, Greek, Vietnamese or Hakka) - 
the survey was self-completed on the tablet. 
• English or one of the priority languages, Computer-Assisted Telephone Interviewing 
(CATI). If a respondent indicated they would be willing to participate but they were unable to 
complete at the time the fieldworker visited the household, the fieldworker arranged a CATI 
call back. Surveys completed via CATI could be completed in English or in one of the priority 
languages. 
Data collection procedure for the business survey 
A total of 7 Q&A Market Research interviewers conducted the telephone interviewing for the business 
survey. Fieldwork was conducted between the hours of 9am and 5pm on weekdays. All discoverable 
businesses within the sampling frame were approached to participate in the survey. 
Fieldworkers used a live call sheet to track recruitment. On the call sheet they were able to record the 
recruitment status of every business in the sampling frame (e.g. refusal, not eligible, non-contact, 
disconnected, completed survey, unknown eligibility, etc.). 
Order of sampling per business: 
• Interviewer called the business telephone number. 
• If the call was answered, the interviewer would introduce themselves, and the study (refer to 
preamble to the survey in Appendix B). They would then screen for eligibility, as per the study 
inclusion criteria (described above in 3.1.3. Sampling). If eligible, the owner/employee would 
be invited to participate in the survey. If respondents requested further information about the 
study, they were sent the Participant Information Form (refer to Appendix C) via email. 
Consent was obtained verbally and evidence of consent was recorded and included in the 
final datafile. 
• If contact was made and the respondent was not able to complete the survey at the time of 







3.1.6. Survey programming and testing 
The department delivered a final survey instrument to Colmar Brunton on the 29th of May. 
Colmar Brunton reformatted and edited the survey instrument to include instructions for survey 
scripting. The department reviewed this document, provided feedback and final approval on content. 
The final survey is appended to this report (refer to Appendix B). 
The final version of the survey was then sent to Q&A Market Research analysts for the electronic 
survey build. All routing and validations were programmed into the electronic interface of the survey.  
The survey tool was translated into five priority languages (Mandarin, Cantonese, Hakka, Vietnamese 
and Greek).  
Once the survey had been programmed, a number of checks occurred prior to the commencement of 
fieldwork. The Q&A Market Research analyst who was responsible for the survey build conducted the 
first test and a Colmar Brunton researcher conducted a second test. Dummy datafiles were also 
checked to ensure all routing and filters were functioning as intended. 
3.2. Data collection 
3.2.1. Training the field team 
Training the field team for the resident survey 
A total of 13 Q&A Market Research interviewers conducted the face-to-face fieldwork for the Resident 
Survey. All fieldworkers had substantial experience in the conduct of social research fieldwork and all 
were accredited with The Australian Market & Social Research Society (AMSRS). The fieldwork team 
attended a face-to-face briefing at Colmar Brunton Melbourne office on the 4th of June, prior to the 
commencement of fieldwork. The briefing was facilitated by Paul Hoger (Q&A Market Research) and 
Emily Bariola (Colmar Brunton), with assistance from Katherine Scarcebrook and Shannon Fox (from 
the department). A total of 10 face-to-face fieldwork interviewers attended the briefing session. Three 
face-to-face fieldwork interviewers did not attend the face to face briefing.  They were given a full 
briefing by phone before commencing their first shift.  They were also placed with an interviewer that 
had attended the briefing for their first shift. The fieldworkers who conducted the telephone interviews 
for the resident survey were also briefed separately. 
The briefing provided an overview of the rationale for the trial, contextual information about the MSIR, 
the sampling approach, recruitment strategy, participant introductory script, the survey tool, ethical 
requirements, timelines, escalation processes and interviewer safety. 
A detailed fieldwork protocol document was produced to ensure that members of the field team and 






Prior to the commencement of fieldwork, interviewers were provided with the following materials: 
• Q&A Market Research ID on lanyard, to be worn at all times; 
• A tablet (for survey administration) and portable battery charger; 
• A map of the fieldwork area; 
• Interview protocol; 
• Survey tool (refer to Appendix B); 
• Live contact sheet link (used to record contact/recruitment data); and 
• Printed copies of the Call Back Card and Participant Information Form (refer to Appendix C). 
Fieldworkers were encouraged to dress appropriately for cold weather and to carry a light if 
conducting fieldwork in the late afternoon/early evening. 
In the event respondents requested further information about the survey or the MSIR, or had a 
complaint about the survey or the MSIR, interviewers were instructed to direct respondents to the 
Victorian Government Contact Centre. 
The Richmond Housing Office was notified about the survey and approval to visit the Richmond 
Housing Estates. The Office was also provided with the names and phone numbers of the 
fieldworkers who were conducting the fieldwork in the Richmond Housing Estates. Interviewers were 
provided with the Security Control Room contact number and were instructed to call security should 
they feel unsafe at any time.  
Colmar Brunton maintained regular contact with fieldwork supervisors throughout data collection in 
order to monitor progress of fieldwork and also provide support/advice to the field team, when 
required.  
 
Training the field team for the business survey 
A total of 7 Q&A Market Research interviewers conducted the CATI data collection for the business 
survey. As was the case for the face-to-face interviewers, all CATI interviewers who worked on this 
project had substantial experience in the conduct of social research fieldwork and all were accredited 
with the AMSRS. The fieldwork team and fieldwork supervisors dialled into a teleconference briefing 
on 11th July prior to the commencement of fieldwork for the business survey. The briefing was 
facilitated by Brodie Black and Heidi Berry (Q&A Market Research) and was also attended by Emily 
Bariola (Colmar Brunton) and Katherine Scarcebrook (DHHS). 3 business fieldwork interviewers 
initially attended the teleconference, 4 were subsequently briefed. The fieldworkers who conducted 
the telephone interviews for the resident survey were also briefed separately. 
This briefing provided an overview of the rationale for the trail, contextual information about the MSIR, 
sampling approach, recruitment strategy, participant introductory script, the survey tool, ethical 
requirements, timelines and escalation processes. 
A detailed fieldwork protocol document was produced to ensure that members of the field team and 
supervisors had the required reference material. 
Prior to the commencement of fieldwork, fieldworkers were provided with the following materials: 
• Interview protocol; 





• Live contact sheet link (used to record contact/recruitment data); and 
• Electronic copies of the Participant Information Form (refer to Appendix C). 
In the event respondents requested further information or wished to lodge a complaint about the 




Recruitment for the resident survey 
Fieldwork for the resident survey commenced on the 4th of July and ended on the 10th of August.  
A total of n = 543 residents completed the survey. n = 527 respondents completed the survey face-to-
face and n = 16 completed the survey via CATI (these respondents responded to the call back card 
that was left in their letter box). Average survey completion times were 10.7 minutes and 27.5 minutes 
for the surveys completed face-to-face and via CATI, respectively. Table 2 provides an overview of 






Table 2: Resident survey recruitment outcomes. 
Recruitment outcomes Count 
Proportion of 
population 
Completed total (C) 543 8.7% 
Completed face-to-face 527 8.5% 
Completed CATI 16 0.3% 
Non-contact (eligible, non-interview) total (NC) 0 0.0% 
Refusal (eligible, non-interview) total (R) 191 3.1% 
Other (eligible, non-interview) total (O) 286 4.6% 
Other - language barrier 87 1.4% 
Other - unable to complete due to illness or disability 2 0.0% 
Other - broken appointment 58 0.9% 
Other - other non-response 139 2.2% 
Unknown eligibility, non-interview total (UE) 5,148 82.9% 
Unknown eligibility - not attempted (selected) 132 2.1% 
Unknown eligibility - not attempted (not selected) 3,205 51.6% 
Unknown eligibility - inaccessible 199 3.2% 
Unknown eligibility - received call back carda 1,612 26.0% 
Not eligible, non-interview total 40 0.6% 
Not eligible - out of sample (aged <18 years; lived in the area <2 
months) 
40 0.6% 
Total populationb 6,208  
Response Rate (RR) - Proportion of cases interviewed of all eligible cases    
C / (C) + (NC+R+O) + (UE) 
- 8.8% 
Co-operation Rate (COOP) - Proportion of cases interviewed of eligible 
cases contacted      C / (C)+(R+O) 
- 53.2% 
Refusal Rate (REF) - Proportion of eligible sample that refused 
R / ((C)+(NC+R+O) + (UE)) 
- 3.1% 
Contact Rate (CON) - Proportion of eligible sample where a household was 






a. Households that received a call back card in the letter box, but did not respond are included in this tally. 
b. Data source: Count of Private Dwellings, 2016 Census, Australian Bureau of Statistics (ABS). 
 
The overall response rate (proportion of cases interviewed of all eligible cases) for the resident survey 
was 8.8%. The co-operation rate (proportion of cases interviewed of eligible cases contacted) was 
53.2%. 
Several reasons for non-completion due to language barrier were recorded. It was noted that 
fieldworkers encountered individuals that spoke languages not covered by the survey methodology 
(i.e. other than English, Greek, Vietnamese, Hakka, Mandarin, Cantonese). It was also noted that 
some individuals who were from non-English speaking backgrounds had no/insufficient English to 
determine their language. 
 
Recruitment for the business survey 
Fieldwork for the business survey commenced on the 11th of July and ended on the 31st of July.  A 
total of n = 301 respondents completed the business survey (all via CATI). The sample was 
exhausted, meaning all discoverable businesses were approached to participate. The average survey 
completion time was 10.7 minutes. 
Table 3 provides an overview of the recruitment outcomes for the business survey. The overall 
response rate (proportion of cases interviewed of all eligible cases) for the business survey was 
47.0%. The co-operation rate (proportion of cases interviewed of eligible cases contacted) was 
71.7%. 
Response rates for each sampling unit (SA1) 
Response rates for the resident survey and the business survey for each SA1 are presented in Table 
4. 
For the resident sample, response rates were relatively evenly spread across each of the SA1s, 









Table 3. Business survey recruitment outcomes. 
Recruitment outcomes Count 
Proportion of 
population 
Completed totala (C) 301 30.5% 
Completed face-to-face - - 
Completed CATI 301 30.5% 
Non-contact (eligible, non-interview) total (NC) 3 0.3% 
Refusal (eligible, non-interview) total (R) 101 10.2% 
Other (eligible, non-interview) total (O) 18 1.8% 
Other - language barrier 17 1.7% 
Other - unable to complete due to illness or disability 1 0.1% 
Other - broken appointment 0 0.0% 
Other - other non-response 0 0.0% 
Unknown eligibility, non-interview total (UE) 218 22.1% 
Unknown eligibility - not attempted 0 0.0% 
Unknown eligibility - non-contact (always ringing, always voicemail) 218 22.1% 
Unknown eligibility - business number, unknown if eligible person 0 0.0% 
Not eligible, non-interview total 345 35.0% 
Not eligible - out of sample (aged <18 years; worked in the area <2 months) 15 1.5% 
Not eligible - number out of service or disconnected 203 20.6% 
Not eligible - other ineligible 127 12.9% 
Total populationa 986  
Response Rate (RR) - Proportion of cases interviewed of all eligible cases                         
C / (C) + (NC+R+O) + (UE) 
- 47.0% 
Co-operation Rate (COOP) - Proportion of cases interviewed of eligible cases contacted      
C / (C)+(R+O) 
- 71.7% 
Refusal Rate (REF) - Proportion of eligible sample that refused                                          
R / ((C)+(NC+R+O) + (UE)) 
- 15.8% 
Contact Rate (CON) - Proportion of eligible sample where a business was reached      
(C+R+O) / (C+R+O+NC+UE) 
- 65.5% 





Table 4. Response ratesa for the resident and business surveys, by SA1. 
SA1 
Resident survey response 
rate 
Business survey response 
rate 
2114402 8.0% - 
2114405 8.8% - 
2114406 9.2% 0.0% 
2114407 11.7% - 
2114454 9.9% 63.1% 
2114404 8.6% 46.2% 
2114403 8.3% 73.3% 
2114401 8.6% 41.9% 
2114459 10.3% 60.0% 
2114457 8.7% 44.4% 
2114458 8.7% 54.3% 
2114439 9.0% 50.0% 
2114441 8.6% 50.0% 
2111902 8.3% 46.2% 
2111903 9.9% 0.0% 
2111904 8.3% 47.6% 
2113910 8.5% 44.7% 
2113901 8.0% 47.3% 
2114422 7.7% 22.9% 
2114421 7.5% 50.0% 
2114420 7.9% 25.0% 
2113905 9.3% 39.7% 
2113903 8.2% 63.6% 
2114411 8.6% 38.9% 
2114419 10.4% 25.0% 
2114442 8.1% 54.5% 
Total 8.8% 47.0% 
a. Response Rate (RR) - Proportion of cases interviewed of all eligible cases. 







3.2.3. Survey outcomes 
The count and proportion of respondents who completed the resident and the business surveys by 
SA1 are presented below in Table 5. 
Table 5. Count and proportion of respondents by SA1. 
 Resident survey Business survey 
SA1 Count Proportion of total Count Proportion of total 
2114402 16 2.9% - - 
2114405 15 2.8% - - 
2114406 18 3.3% 0 0.0% 
2114407 22 4.1% - - 
2114454 28 5.2% 41 13.6% 
2114404 41 7.6% 6 2.0% 
2114403 29 5.3% 11 3.7% 
2114401 16 2.9% 31 10.3% 
2114459 16 2.9% 3 1.0% 
2114457 45 8.3% 4 1.3% 
2114458 16 2.9% 19 6.3% 
2114439 13 2.4% 25 8.3% 
2114441 29 5.3% 28 9.3% 
2111902 22 4.1% 6 2.0% 
2111903 20 3.7% 0 0.0% 
2111904 10 1.8% 10 3.3% 
2113910 20 3.7% 17 5.6% 
2113901 10 1.8% 26 8.6% 
2114422 10 1.8% 8 2.7% 
2114421 12 2.2% 9 3.0% 
2114420 15 2.8% 2 0.7% 
2113905 25 4.6% 27 9.0% 
2113903 30 5.5% 14 4.7% 
2114411 21 3.9% 7 2.3% 
2114419 26 4.8% 1 0.3% 
2114442 18 3.3% 6 2.0% 
Total 543  301  






The count and proportion of surveys completed in each of the survey languages are presented below 
in Table 6. 
Table 6. Count and proportion of surveys completed in each of the survey languages. 
 Resident survey Business survey 






English 508 93.6% 296 98.3% 
Vietnamese 19 3.5% 5 1.7% 
Mandarin 12 2.2% 0 0.0% 
Cantonese 3 0.6% 0 0.0% 
Greek 1 0.2% 0 0.0% 
Hakka 0 0.0% 0 0.0% 
Total 543  301  
 
A relatively small proportion of respondents completed the translated versions of the survey (6.4% of 
the resident sample and 1.7% of the business sample). It was noted by the field team that the majority 
of the respondents who were from non-English speaking backgrounds were able to complete the 
survey in English, hence the low proportion of completions in the surveys translated into languages 
other than English. 
3.2.4. Sample representativeness for the resident survey 
An assessment of sample representativeness for the resident survey, relative to population data is 
presented below in Table 7. The representativeness of the business sample was not assessed as 











Table 7: Resident sample representativeness according to demographic characteristics, relative to 
individual-level population data. 
 Sample Populationa 
Demographic characteristic Count Proportion of 
total 
Count Proportion of 
totalb 
Gender     
Male 273 50.5% 5,975 48.6% 
Female 268 49.5% 6,314 51.4% 
Other - - - - 
Age group     
0 – 17 year olds - - 1,473 - 
18 – 19 year olds 8 1.5% 197 1.8% 
20 – 24 year olds 42 7.7% 1,072 10.0% 
25 – 34 year olds 122 22.5% 3,779 35.2% 
35 – 44 year olds 112 20.6% 1,801 16.8% 
45 – 54 year olds 80 14.7% 1,394 13.0% 
55 – 64 year olds 92 16.9% 1,143 10.7% 
65 – 74 year olds 47 8.7% 696 6.5% 
75 – 84 year olds 34 6.3% 457 4.3% 
85+ year olds 6 1.1% 193 1.8% 
Country of birth     
Australia 324 59.9% 6,290 56.3% 
Overseas 217 40.1% 4,881 43.7% 
Total 543  12,292  
a. Data source: Community Profile, 2016 Census, ABS. Population data is reported at the individual level. 
b. Count of 0-17 year olds excluded in the calculation of proportions for each age group. 
 
As shown in the table above, the demographic spread of the sample closely approximates the 
demographic spread of the population, indicating the sample is representative of the population. 
Some minor under-representation was observed among 25 – 34 year olds, and some minor over-
representation was observed among 55 – 64 year olds. A weighting variable was created to account 
for any minor dis-representation and is included in the datafile provided to the department. Weighting 
factors are within acceptable range (0.39 and 2.26), providing confirmation that the sample is 





Table 8: Resident sample representativeness according to location (SA1), relative to individual and 
household-level population dataa. 










2114402 16 2.9% 490 4.0% 199 3.2% 
2114405 15 2.8% 383 3.1% 171 2.8% 
2114406 18 3.3% 465 3.8% 196 3.2% 
2114407 22 4.1% 406 3.3% 189 3.0% 
2114454 28 5.2% 621 5.1% 285 4.6% 
2114404 41 7.6% 821 6.7% 475 7.7% 
2114403 29 5.3% 588 4.8% 356 5.7% 
2114401 16 2.9% 409 3.3% 187 3.0% 
2114459 16 2.9% 291 2.4% 158 2.5% 
2114457 45 8.3% 959 7.8% 536 8.6% 
2114458 16 2.9% 346 2.8% 184 3.0% 
2114439 13 2.4% 378 3.1% 146 2.4% 
2114441 29 5.3% 656 5.3% 339 5.5% 
2111902 22 4.1% 410 3.3% 265 4.3% 
2111903 20 3.7% 376 3.1% 214 3.4% 
2111904 10 1.8% 238 1.9% 122 2.0% 
2113910 20 3.7% 472 3.8% 223 3.6% 
2113901 10 1.8% 314 2.6% 126 2.0% 
2114422 10 1.8% 299 2.4% 130 2.1% 
2114421 12 2.2% 288 2.3% 160 2.6% 
2114420 15 2.8% 431 3.5% 189 3.0% 
2113905 25 4.6% 621 5.1% 269 4.3% 
2113903 30 5.5% 676 5.5% 368 5.9% 
2114411 21 3.9% 432 3.5% 248 4.0% 
2114419 26 4.8% 470 3.8% 250 4.0% 
2114442 18 3.3% 452 3.7% 223 3.6% 
Total 543  12,292  6,208  
a. Data source: 2016 Census, ABS. Population data is reported at the individual level (i.e. total count of 






As shown in the table above, the resident sample was representative of the population according to 
the spread across SA1s. 
3.2.5. Escalations 
An agreed escalation procedure was put in place at the start of the project in order to deal with any 
sensitive contacts encountered during fieldwork. There was only one incident that required escalation 
throughout fieldwork. This is described below.  
An employee of Neighbourhood House in Richmond contacted the department and made a formal 
complaint regarding the conduct of the survey. They were contacted via telephone and invited to 
participate in the business version of the survey. They felt they were contacted too many times to 
participate. A review of the call log revealed that on the 15th of July an interviewer called the 
Neighbourhood House and spoke to complainant. Complainant said the head office Manager needs 
to approve before they can participate. Complainant provided email address so interviewer can send 
participant information so they can supply to head office management. The call centre supervisor 
doesn’t recall being asked to send the email by the interviewer. Unfortunately, the participant 
information was not passed on to complainant. An interviewer then attempted to call back on three 
occasions to speak to complainant (not realising that a participant information sheet was not passed 
on to complainant). On the third call, interviewer spoke to complainant – and they again reiterated that 
they need clearance from management.  The complainant then proceeded to lodge a complaint with 
the department/ 
In response to the complaint, Colmar Brunton provided the department with details of the call log, as 
well as the exact survey script interviewers use when recruiting via telephone. Colmar Brunton 
explained that miscommunication occurred and multiple calls were made and perceived as 
unnecessary by complainant because the participant information sheet was not sent. The department 
progressed this by following up with complainant. 
3.3. Data processing and weighting 
3.3.1. Data processing 
Practices to ensure high quality data commenced at the set-up phase of the project. The following 
steps were taken. 
• Once the survey had been programmed, a number of checks occurred prior to the 
commencement of fieldwork. The Q&A Market Research analyst who was responsible for 
the survey build conducted the first test and a Colmar Brunton researcher conducted a 
second test. 
• The survey was programmed with built in consistency and validity checks. 
• Dummy datafiles were also checked to ensure all routing and filters were functioning as 
intended. Once the internal checks had been finalised, the department conducted a check 
of the dummy datafile and provided approval on the content prior to the commencement 
of fieldwork.  
• An interim data file was produced after sufficient surveys had been completed. This was 
checked by a Colmar Brunton researcher. 





• One resident respondent mistakenly completed the business survey. This case was 
retained in the datafile – and can be identified by a flag variable (Incorrectflag=1). 
• The file was weighted in accordance with the requirements set-out by the department. 
The weighting strategy is described in 3.3.2 below. 
• The required derived variables were computed and included in the datafile.  
• The final data file was delivered in SPSS file format. All syntax and weighting variables 
were provided with the data file. 
3.3.2. Weighting 
Weights were calculated for the resident sub-cohort only (ComBusiSamp=1) (n = 543). Two 
respondents chose not to respond to the gender question. As no gender information was provided by 
these two respondents, these two cases were coded as 1 for the weight variable. Applying a weight of 
1 means that survey responses for these two cases are not weighted up or down. 
Weights were calculated using the following auxiliary variables: gender (Q17 = 1 ‘male’; 2 ‘female’) 
and age group (recage = 1 '18-19 yrs'; 2 '20-24 yrs'; 3 '25-29 yrs'; 4 '30-34 yrs'; 5 '35-39 yrs'; 6 '40-44 
yrs'; 7 '45-49 yrs'; 8 '50-59 yrs'; 9 '60-69 yrs'; 10 '70-79 yrs'; 11 '80+yrs'). 
Population-level data confined to the population parameters of the study (i.e. the 26 SA1s) were used 
to calculate weights. An interlocking weight structure was used to generate accurate population 
weights for each gender x age group combination thus ensuring strong alignment to the population 
level data.  Data source: Community Profile, 2016 Census, ABS. 
3.3.3. Coding 
Colmar Brunton developed codeframes for the following open-ended questions.  
• S3 - What is your position in this business? (Single response). 
• Q7B - Thinking about the last time someone approached you on a street in your local 
area to sell you drugs, what type of drugs were you offered? (Single response). 
• Q8 - What, if anything, concerns you about drug-related activity in your local area? 
(Multiple response). 
• Q11A - Do you know the location of the Medically Supervised Injecting Room (MSIR) 
trial? (Single response). 
• Q11B - Please describe what you understand about what happens in the Medically 
Supervised Injecting Room. (Multiple response). 
• Q13A - Do you think the Medically Supervised Injecting Room has contributed to any 
changes in the area? This could include positive and negative changes. (Yes/No). Q13B - 
Can you describe the changes that you have noticed? (Multiple response). 
• Q14 - Do you have any further comments you would like to make about the Medically 
Supervised Injecting Room trial? (Multiple response). 
• Q15 - Do you have any further comments you would like to make about drug-related 





The codeframes for these questions are appended to this report. In order to conduct the coding, the 
following steps were taken: 
Develop codeframe 
• One Colmar Brunton researcher reviewed open-ended responses and derived themes. 
• Two researchers met and discussed themes and reviewed responses and agreed on final 
codeframes. 
• The department reviewed and approved the codeframes. 
First validation 
• One researcher read open-ended responses for 100 resident cases and 75 business 
cases and coded for theme endorsement using the codeframes. 
• The department reviewed the 175 coded cases and provided feedback. Feedback was 
incorporated into the coding strategy going forward. 
Coding 
• After incorporating the feedback from the department, one Colmar Brunton researcher 
read each open-ended response and coded for theme endorsement using the 






4. Research schedule 
The following table provides a summary of the key research tasks and their completion dates.   
Table 9: Research schedule. 
  
Task Dates 
Research proposal submitted  7th of May, 2019 
Project commissioned  23rd of May, 2019 
Project scoping meeting 30th of May, 2019 
Survey finalised 21st of June, 2019 
Participant information material finalised 21st of June, 2019 
Ethics approval granted 19th of June, 2019 
Resident survey field researcher training 4th of June, 2019 
Business survey field researcher training 11th of July, 2019 
Resident survey fieldwork 4th July – 10th August, 2019 
Business survey fieldwork 11th July – 31st July, 2019 
Data processing, coding, checking, weighting 19th November, 2019 
Final data file delivered 19th November, 2019 
Draft technical report delivered 11th October 2019 
Feedback on technical report received 4th November, 2019 






5.1. Appendix A – Personnel 
David 
 
David Spicer, Research Director, Colmar 
Brunton (Melbourne) 
BA (hons) Psychology. Member of the Australasian Evaluation Society 
and Market and Social Research Society. 
David is the Head of the Government research team for Colmar Brunton 
in Melbourne. 
With a background in psychology, social research and evaluation, David 
has over 18 years’ experience in the design and implementation of 
evaluation projects for a broad range of public and private sector clients. 
He has designed and managed many projects with a focus on the 
evaluation of programs, communications, products and services.  
David has led a number of research and evaluation projects relevant to 
this project including: 
• The development of program logics and evaluation frameworks 
in many sectors including justice, aged care and Indigenous 
services;  
• Research and evaluation to assess initiatives in a number of 
workplace contexts including work with the Department of 
Premier and Cabinet, Department of Education ad the Diversity 
Council of Australia 
• A range of other research and evaluation experience including: 
• Outcome/impact evaluations for state and federal government in 
a range of sectors including occupational health and safety; and 
primary and secondary healthcare;  
• The development of performance monitoring frameworks and 
systems in the healthcare sector;  
• Research and evaluation with potentially sensitive populations 
such as the frail aged, Aboriginal peoples, people from Culturally 
and Linguistically Diverse backgrounds, illegal immigrants and 
incarcerated offenders. 
Emily Emily Bariola, Senior Consultant, Colmar 
Brunton (Melbourne) 
Emily is a Senior Account Manager in the Social & Government research 
team in Victoria. She joined Colmar Brunton in June, 2018. She has a 
Bachelor of Arts with an Honours degree in Psychology. Emily has 
worked as a researcher for ten years, with her research spanning 
behavioural science, public health and social epidemiology. She has 
worked across university, not-for-profit, government and commercial 
sectors and has extensive experience working on both agency and client 





qualitative methodologies to answer research questions and has 
expertise designing longitudinal surveys, large national cross-sectional 
surveys, and qualitative studies. She is passionate about evidence-
based practice and enjoys translating research knowledge into practice 
for her clients. 
Emily has conducted several research studies examining drug, alcohol 
and tobacco use among specific populations (including marginalised 
communities and Australian youth). She has a strong working 






























































5.3. Appendix C – Participant Information Materials 











































5.4. Appendix D – Codeframes 
Table 10: Codeframes for S3, Q7B, Q8, Q11A, Q11B, Q13B, Q14 and Q15 
Codeframes 
S3 - What is your position in this business? SR 
Owner 
Manager 
Employee (not manager) 
Q7B - Thinking about the last time someone approached you on a street in your local area to sell 








Unsure of type/didn't specify 
Q8 - What, if anything, concerns you about drug-related activity in your local area? MR 
Violence and crime (e.g. theft, burglary, property damage, trespassing) 
Safety concerns for children (own children) 
Safety concerns for children (general & school) 
Safety concerns for self and others 
Safety concerns for drug users (incl. health concerns e.g. users suffering for their habit) 
Unpredictability of drug users 
Aggressiveness of users (e.g. aggressiveness, yelling) 
Antisocial/bad behaviour/attitude of users 
Discarded syringes in public spaces (e.g. being injured by needle, fear of injury, general discomfort with waste) 
Public visibility of drug use/drug deals 
Blood, faeces, urine, rubbish etc. left by drug users 
Lack of Government regulation / police presence 
Bad for business 
Begging (e.g. money, cigarettes, food) 
General concern about MSIR 
Affirmative towards MSIR, with suggestions for improvement 
Spread of infectious diseases 







Table 10: Codeframes for S3, Q7B, Q8, Q11A, Q11B, Q13B, Q14 and Q15 
Codeframes 
Q11A - Do you know the location of the Medically Supervised Injecting Room (MSIR) trial? SR 
Exact (building or street, or surrounding area) 
Approximate (suburb, or nearby streets) 
Incorrect 
Don't know (not allocated to Q11A_RC_97 by fieldworker) 
Q11B. Please describe what you understand about what happens in the Medically Supervised 
Injecting Room. MR 
People inject themselves with/take drugs 
It's safe/controlled 
There is medical supervision/monitoring 
Overdoses are prevented 
People can get injected with drugs/are given drugs 
Sterile injecting equipment is provided 
Injecting equipment can be discarded safely 
People must register/provide information to staff 
People can access mental health/counselling services 
People can access medical help/health services 
People can access drug rehab/cessation services 
People can access support/treatment/information (NFI) 
There is legal immunity 
Other 
Null response 
Don't know (not allocated to Q11BDK_97 by fieldworker) 
Q13B. Can you describe the changes that you have noticed? MR 
Fewer people injecting in public 
More people injecting in public 
Fewer drug users in the area 
More drug users in the area 
Fewer people overdosing/dying 
More people overdosing/dying 
Fewer syringes in public 
More syringes in public 
Decreased crime/violence/antisocial behaviour 
Increased crime/violence/antisocial behaviour 
Increased homelessness 
More dealers in the area/in public 
Increased police presence 





Table 10: Codeframes for S3, Q7B, Q8, Q11A, Q11B, Q13B, Q14 and Q15 
Codeframes 
People moving out of/avoiding moving into the area 
Businesses closing 
Area no longer hospitable 
Decreased sense of public safety 
General/other positive change 
General/other negative change 
Other 
Did not describe any change 
Q14 - Do you have any further comments you would like to make about the Medically Supervised 
Injecting Room trial? MR 
Negative comments 
General negative opinion 
Normalisation of drug use 
MSIR should not be located near school/near children 
MSIR should not be located near residential/community areas 
MSIR should be located near a hospital 
Increase drug-related activity in area (use and dealing) 
Safety concerns 
Need to ensure increased security/police presence 
Not enough consultation with community 
Not enough information provided to community 
Zero tolerance approach preferred 
Other harm minimisation approach preferred (e.g. rehab, education) 
Non-endorsement of Ice use in MSIR 
MSIR should be in a different location (unspecified) 
MSIR should be in a rural/isolated area 
MSIR should be in an industrial area 
MSIR should be in St Kilda 
MSIR should be in the CBD 
MSIR has not helped 
Only a short term solution 
MSIR is politically motivated/driven 
Not adequately resourced e.g. opening hours too limited/not enough staff/premises 
Drug users not using the MSIR 
Bad for business 
People moving out of the area 
Other negative comment 
Affirmative comments 





Table 10: Codeframes for S3, Q7B, Q8, Q11A, Q11B, Q13B, Q14 and Q15 
Codeframes 
Saves lives of users 
Reduce spread of infectious diseases 
Get drug users off the street 
Increased safety for community (e.g. reduced syringe waste, anti-social behaviour in public space and crime) 
Recommend introduction of multiple MSIRs 
Other positive comment 
Neutral comments 
Require evidence of effectiveness 
No comment 
Other neutral comment 
Q15 - Do you have any further comments you would like to make about drug-related activity in 
your local area? MR 
More security in local area (e.g., police presence, security cameras) 
Police being more rigorous/police need to do their job better incl. want police to arrest more dealers, want harsher 
penalties for dealers/users 
Need for rehabilitation services/support services 
Concern about MSIR proximity to school/children 
Zero tolerance approach preferred 
Wants drug use to stop 
Need for further government and council intervention (e.g. clean up the area, more community consultation) 
Crime rates have increased 
Need to reduce crime rates 
Legalise marijuana use 
Public visibility of drug use/drug deal  
Safety concerns for children (own children and general youth) 
Safety concerns for self and others 
Increase drug-related activity in area (use and dealing) 
Decrease in drug-related activity in area (use and dealing) 
Unpredictability of drug users 
Aggressiveness of users (e.g. aggressiveness, yelling) 
Public visibility of drug affected individuals 
Drug use is a big/widespread problem 
Cannot stop drug use 
Difficult to fix the problem 
Support for MSIR 
Property values decreasing 
Bad for business 
People moving out of/avoiding moving into the area 





5.5. Appendix E – Escalation Procedure 
There are several separate escalation procedures that were adhered to, in the event any of these 
situations arise throughout data collection. They are: 
(i) Requests for more information about the survey or complaints about the survey. 
(ii) Requests for information about the Medically Supervised Injecting Room or complaints 
about the Medically Supervised Injecting Room. 
(iii) Duty of care protocol for distressed respondents (or other household members). 
(iv) Interviewer safety when in housing estate. 
(v) Ineligible respondent would like to participate. 
(vi) Reporting any significant community interactions. 
Requests for more information about the survey or complaints 
about the survey. 
If a respondent would like further information about the survey or if they have complaints about the 
survey, interviewers should recommend the respondent calls the Victorian Government Contact 
Centre on 1300 366 356 to log their query or complaint. 
Requests for information about the Medically Supervised 
Injecting Room or complaints about the Medically 
Supervised Injecting Room. 
If a respondent requests further information about the Medically Supervised Injecting Room or 
complains about the Medically Supervised Injecting Room, interviewers should recommend the 
respondent calls the Victorian Government Contact Centre on 1300 366 356 for more information. 
Duty of care protocol for distressed respondents (or other 
household members). 
If a respondent (or other household member present at the time of the interview) becomes distressed 
at any time during the interview process, the interviewer may rely on the following script.  
‘I am sorry you are going through a hard time. You could try discussing your concerns with staff at 
Lifeline or Beyondblue. You can have a confidential chat with a person who is specially trained in 
supporting people who are going through a tough time. Numbers to call are: 
Lifeline. (https://www.lifeline.org.au/). Phone: 13 11 14 
Beyondblue. (https://www.beyondblue.org.au/). Phone: 1300 224 636’ 
MSIR should be moved 
Other comment 





Interviewer safety when in housing estate 
Before collecting data in the housing estates, it is important that the Housing Office is notified in 
advance and that your name and contact details are provided to the Office ahead of time. Before 
starting the shift in the housing estate, you must sign in at the Housing Office. 
If at anytime you feel unsafe – you should contact the security control room on 9428 9725 and they 
will be able to assist you. 
Ineligible respondent wants to participate 
In the event a community member is determined ineligible after screening (approached at household 
doorstep or patched through to Q&A Survey Hotline), but becomes disgruntled because they really 
wish to participate - interviewers should recommend the respondent calls the Victorian Government 
Contact Centre on 1300 366 356 for more information. 
Reporting any significant community interactions 
Please make a record of any significant community interactions in the interviewer portal. These 
should be fed back to Colmar Brunton on a regular basis. 
 
5.6. Appendix F – Methods to Ensure Data Quality 
Project-based quality assurance 
CBSR’s philosophy is to work as a team with our clients. An important element of such a relationship 
is to seek input and feedback from our clients throughout a project. This enables any potential issues 
to be dealt with collaboratively and early on, preventing them from becoming major problems.  To 
supplement this process and enable formal tracking of their views, clients are sent a feedback form 
after the completion of each project, in which to record their satisfaction with the implementation and 
outcomes of the project and the research consultants who worked with them on it. These forms are 
monitored, and targets (such as overall satisfaction with the project) are set at both an individual and 
office level.  
Our research executives are members of the Australian/New Zealand Market Research Society and 
are signatories to the Code of Ethics of our industry. Moreover, Colmar Brunton is a founding member 
of the Association of Market and Social Research Organisations (AMSRO). Colmar Brunton endorses 
and fully supports AMSRO aims. 
Privacy issues and data security 
We are required to work in accordance with the ESOMAR International Code of Conduct for Market 
Research, the Australian Market & Social Research Privacy Principles (which subsume the National 
Privacy Principles) and the AMSRS Code of Professional Behaviour, to which our researchers are 





At all times, we respect the confidentiality of our informants and our clients. We therefore guarantee 
this confidentiality according to our industry standards and the Department’s privacy legislation.  In 
particular, confidentiality provisions apply to the supply of unit record data. 
In addition, we accept that CBSR, if commissioned, will be bound by Public Service regulations with 
respect to confidentiality. We recognise that all information gathered in relation to the project is the 
property of the Department. We recognise that we are not at liberty to disclose any related information 
to any other party. 
Quality assurance accreditations 
Colmar Brunton puts a real and applied focus on quality. 
 We have a QMS system in place and have ISO 20252 accreditation. 
 We abide by the AMSRS Code of Professional Behaviour and Privacy Principles; and 
 We have created a position in our company dedicated to keeping up to date with best 
practice in research and providing internal systems that facilitate quality management. 
 
 
The current status of our ISO 20252 accreditation process is in the table 
below. 
Office Audit Status 







5.7. Appendix G - Quality Assurance 
 
Colmar Brunton is committed to helping its clients achieve and sustain market success by providing 
superior market research and strategic direction.  
A critical foundation of our commitment to 
our clients is the implementation of Quality 
Assurance in all relevant areas of its 
operations. We have implemented and 
achieved certification for our Quality 
Management System AS-ISO 20252:2012 
for all areas of our operations. 
 
 
Colmar Brunton also operates under the 
Australian Market & Social Research Society 
(AMSRS) Professional Code of Behaviour and 
the Market & Social Research Privacy 
Principles administered by the Association of 
Market & Social Research (AMSRO) 
Secretariat. 
 
In accordance with our Quality Management System (QMS) this proposal has been reviewed and 
approved by: 
 
NAME David Spicer 
ROLE Research Director 
Colmar Brunton  
 
DATE 5th December 2019 
Document version 1.0 
 
All methodologies and findings outlined in this proposal are provided solely for use by the client.  
Copyright is reserved by Colmar Brunton Social Research. 
In accordance with Article 15 of the ICC/ESOMAR International Code of Marketing Research, this document remains the 
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